Effect	NN	O	O
of	IN	O	O
duloxetine	NN	i	IPM
on	IN	O	O
pain	NN	o	OPA
,	,	o	O
function	NN	o	OPH
,	,	o	O
and	CC	o	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
among	IN	O	O
patients	NNS	p	O
with	IN	p	O
chemotherapy-induced	JJ	p	PC
painful	JJ	p	PC
peripheral	JJ	p	PC
neuropathy	NN	p	PC
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

IMPORTANCE	NNP	O	O
There	EX	O	O
are	VBP	O	O
no	DT	O	O
known	JJ	O	O
effective	JJ	O	O
treatments	NNS	O	O
for	IN	O	O
painful	JJ	O	O
chemotherapy-induced	JJ	O	O
peripheral	JJ	O	O
neuropathy	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
duloxetine	NN	i	IPM
,	,	O	O
60	CD	O	O
mg	JJ	O	O
daily	RB	O	O
,	,	O	O
on	IN	O	O
average	JJ	o	OPA
pain	NN	o	OPA
severity	NN	o	OPA
.	.	O	O

DESIGN	NNP	O	O
,	,	O	O
SETTING	NNP	O	O
,	,	O	O
AND	NNP	O	O
PATIENTS	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
crossover	NN	O	O
trial	NN	O	O
at	IN	O	O
8	CD	O	O
National	NNP	O	O
Cancer	NNP	O	O
Institute	NNP	O	O
(	(	O	O
NCI	NNP	O	O
)	)	O	O
-funded	VBD	O	O
cooperative	JJ	O	O
research	NN	O	O
networks	NNS	O	O
that	WDT	O	O
enrolled	VBD	O	O
231	CD	p	PC
patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
25	CD	p	O
years	NNS	p	O
or	CC	p	O
older	JJR	p	O
being	VBG	p	O
treated	VBN	p	O
at	IN	p	O
community	NN	p	O
and	CC	p	O
academic	JJ	p	O
settings	NNS	p	O
between	IN	p	O
April	NNP	p	O
2008	CD	p	O
and	CC	p	O
March	NNP	p	O
2011	CD	p	O
.	.	O	O

Study	NNP	O	O
follow-up	NN	O	O
was	VBD	O	O
completed	VBN	O	O
July	NNP	O	O
2012	CD	O	O
.	.	O	O

Stratified	VBN	O	O
by	IN	O	O
chemotherapeutic	JJ	O	O
drug	NN	O	O
and	CC	O	O
comorbid	NN	O	O
pain	NN	O	O
risk	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
duloxetine	NN	i	IPM
followed	VBN	O	O
by	IN	O	O
placebo	NN	i	IC
or	CC	O	O
placebo	NN	i	IC
followed	VBN	O	O
by	IN	O	O
duloxetine	NN	i	IPM
.	.	O	O

Eligibility	NN	p	O
required	VBD	p	O
that	IN	p	O
patients	NNS	p	O
have	VBP	p	O
grade	VBN	p	PC
1	CD	p	PC
or	CC	p	PC
higher	JJR	p	PC
sensory	NN	p	PC
neuropathy	JJ	p	PC
according	VBG	p	O
to	TO	p	O
the	DT	p	O
NCI	NNP	p	O
Common	NNP	p	O
Terminology	NNP	p	O
Criteria	NNP	p	O
for	IN	p	O
Adverse	NNP	p	O
Events	NNS	p	O
and	CC	p	O
at	IN	p	O
least	JJS	p	O
4	CD	p	PC
on	IN	p	PC
a	DT	p	PC
scale	NN	p	PC
of	IN	p	PC
0	CD	p	PC
to	TO	p	PC
10	CD	p	PC
,	,	p	PC
representing	VBG	p	PC
average	JJ	p	PC
chemotherapy-induced	JJ	p	PC
pain	NN	p	PC
,	,	p	O
after	IN	p	O
paclitaxel	NN	p	O
,	,	p	O
other	JJ	p	O
taxane	NN	p	O
,	,	p	O
or	CC	p	O
oxaliplatin	JJ	p	O
treatment	NN	p	O
.	.	O	O

INTERVENTIONS	VBZ	O	O
The	DT	O	O
initial	JJ	O	O
treatment	NN	O	O
consisted	VBN	O	O
of	IN	O	O
taking	VBG	O	O
1	CD	O	O
capsule	JJ	O	O
daily	RB	O	O
of	IN	O	O
either	CC	O	O
30	CD	O	O
mg	NN	O	O
of	IN	O	O
duloxetine	NN	i	IPM
or	CC	O	O
placebo	NN	i	IC
for	IN	O	O
the	DT	O	O
first	JJ	O	O
week	NN	O	O
and	CC	O	O
2	CD	O	O
capsules	NNS	O	O
of	IN	O	O
either	DT	O	O
30	CD	O	O
mg	NN	O	O
of	IN	O	O
duloxetine	NN	i	IPM
or	CC	O	O
placebo	JJ	i	IC
daily	JJ	O	O
for	IN	O	O
4	CD	O	O
additional	JJ	O	O
weeks	NNS	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
The	DT	O	O
primary	JJ	O	O
hypothesis	NN	O	O
was	VBD	O	O
that	IN	O	O
duloxetine	NN	i	IPM
would	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
placebo	NN	i	IC
in	IN	O	O
decreasing	VBG	O	O
chemotherapy-induced	JJ	o	OPA
peripheral	JJ	o	OPA
neuropathic	JJ	o	OPA
pain	NN	o	OPA
.	.	O	O

Pain	NNP	o	OPA
severity	NN	o	OPA
was	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
the	DT	O	O
Brief	JJ	o	OPA
Pain	NNP	o	OPA
Inventory-Short	NNP	o	OPA
Form	NNP	o	OPA
average	NN	o	OPA
pain	NN	o	OPA
item	NN	o	OPA
with	IN	O	O
0	CD	O	O
representing	VBG	O	O
no	DT	O	O
pain	NN	o	OPA
and	CC	O	O
10	CD	O	O
representing	VBG	O	O
as	RB	O	O
bad	JJ	O	O
as	IN	O	O
can	MD	O	O
be	VB	O	O
imagined	VBN	O	O
.	.	O	O

RESULTS	JJ	O	O
Individuals	NNS	O	O
receiving	VBG	O	O
duloxetine	NN	O	O
as	IN	O	O
their	PRP$	O	O
initial	JJ	O	O
5-week	JJ	O	O
treatment	NN	O	O
reported	VBD	O	O
a	DT	O	O
mean	JJ	O	O
decrease	NN	O	O
in	IN	O	O
average	JJ	o	O
pain	NN	o	O
of	IN	O	O
1.06	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.72-1.40	NNP	O	O
)	)	O	O
vs	VBZ	O	O
0.34	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.01-0.66	NNP	O	O
)	)	O	O
among	IN	O	O
those	DT	O	O
who	WP	O	O
received	VBD	O	O
placebo	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.003	NNP	O	O
;	:	O	O
effect	NN	O	O
size	NN	O	O
,	,	O	O
0.513	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
observed	JJ	O	O
mean	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
average	JJ	o	OPA
pain	NN	o	OPA
score	NN	o	OPA
between	IN	O	O
duloxetine	NN	i	IPM
and	CC	O	O
placebo	NN	i	IC
was	VBD	O	O
0.73	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.26-1.20	NN	O	O
)	)	O	O
.	.	O	O

Fifty-nine	JJ	O	O
percent	NN	O	O
of	IN	O	O
those	DT	O	O
initially	RB	O	O
receiving	VBG	O	O
duloxetine	NN	i	IPM
vs	FW	O	O
38	CD	O	O
%	NN	O	O
of	IN	O	O
those	DT	O	O
initially	RB	O	O
receiving	VBG	O	O
placebo	NN	O	O
reported	VBD	O	O
decreased	JJ	O	O
pain	NN	o	OPA
of	IN	O	O
any	DT	O	O
amount	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
AND	CC	O	O
RELEVANCE	NNP	O	O
Among	IN	O	O
patients	NNS	p	O
with	IN	p	O
painful	JJ	p	PC
chemotherapy-induced	JJ	p	PC
peripheral	JJ	p	PC
neuropathy	NN	p	PC
,	,	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
duloxetine	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
for	IN	O	O
5	CD	O	O
weeks	NNS	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
greater	JJR	O	O
reduction	NN	O	O
in	IN	O	O
pain	NN	o	OPA
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
clinicaltrials.gov	NN	O	O
Identifier	NNP	O	O
:	:	O	O
NCT00489411	NN	O	O
.	.	O	O

Additive	JJ	O	O
IOP-reducing	JJ	o	OPH
effect	NN	O	O
of	IN	O	O
latanoprost	NN	O	O
in	IN	O	O
patients	NNS	p	O
insufficiently	RB	p	PC
controlled	VBN	p	PC
on	IN	p	O
timolol	NN	p	O
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
on	IN	O	O
intraocular	JJ	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
IOP	NNP	o	OPH
)	)	o	OPH
of	IN	O	O
switching	VBG	O	O
from	IN	O	O
timolol	NN	i	IPM
to	TO	O	O
latanoprost	VB	i	IPM
or	CC	O	O
adding	VBG	O	O
latanoprost	NN	i	IPM
to	TO	O	O
timolol	VB	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
open	JJ	p	O
angle	NN	p	PC
glaucoma	NN	p	PC
or	CC	p	PC
ocular	JJ	p	PC
hypertension	NN	p	PC
where	WRB	p	O
IOP	NNP	p	O
is	VBZ	p	O
not	RB	p	O
adequately	RB	p	O
controlled	VBN	p	O
with	IN	p	O
timolol	NN	p	O
.	.	O	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
6-week	JJ	O	O
,	,	O	O
double-masked	JJ	O	O
,	,	O	O
randomised	VBD	O	O
multi-centre	NN	O	O
study	NN	O	O
.	.	O	O

53	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
primary	JJ	p	PC
open	JJ	p	PC
angle	NN	p	PC
glaucoma	NN	p	PC
,	,	p	O
capsular	JJ	p	PC
glaucoma	NN	p	PC
,	,	p	O
or	CC	p	O
ocular	JJ	p	PC
hypertension	NN	p	PC
with	IN	p	O
an	DT	p	O
IOP	NNP	p	O
of	IN	p	O
at	IN	p	O
least	JJS	p	O
21	CD	p	O
mmHg	NN	p	O
on	IN	p	O
current	JJ	p	O
therapy	NN	p	O
were	VBD	O	O
recruited	VBN	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
run-in	JJ	O	O
period	NN	O	O
of	IN	O	O
at	IN	O	O
least	JJS	O	O
2	CD	O	O
weeks	NNS	O	O
on	IN	O	O
timolol	NN	i	IPM
,	,	O	O
5	CD	O	O
mg/ml	NN	O	O
twice	RB	O	O
daily	RB	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
groups	NNS	O	O
.	.	O	O

One	CD	O	O
group	NN	O	O
continued	VBD	O	O
on	IN	O	O
timolol	NN	i	IPM
,	,	O	O
one	CD	O	O
switched	VBN	O	O
from	IN	O	O
timolol	NN	i	IPM
to	TO	O	O
latanoprost	VB	i	IPM
,	,	O	O
50	CD	O	O
microg/ml	NN	O	O
once	RB	O	O
daily	JJ	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
third	JJ	O	O
group	NN	O	O
received	VBD	O	O
latanoprost	RB	i	IPM
in	IN	O	O
addition	NN	O	O
to	TO	O	O
timolol	VB	i	IPM
.	.	O	O

The	DT	O	O
efficacy	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
by	IN	O	O
comparing	VBG	O	O
IOP	NNP	o	OPH
at	IN	O	O
9	CD	O	O
AM	NNP	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
6	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
IOP	NNP	o	OPH
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
6	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
mean	JJ	O	O
+/-	NNP	O	O
SEM	NNP	O	O
)	)	O	O
were	VBD	O	O
24.2	CD	O	O
+/-	JJ	O	O
0.9	CD	O	O
and	CC	O	O
23.8	CD	O	O
+/-	JJ	O	O
1.0	CD	O	O
mmHg	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
16	CD	O	O
)	)	O	O
for	IN	O	O
patients	NNS	O	O
continuing	VBG	O	O
on	IN	O	O
timolol	NN	O	O
,	,	O	O
26.3	CD	O	O
+/-	JJ	O	O
1.2	CD	O	O
and	CC	O	O
19.6	CD	O	O
+/-	JJ	O	O
1.1	CD	O	O
mmHg	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
17	CD	O	O
)	)	O	O
for	IN	O	O
patients	NNS	O	O
switching	VBG	O	O
to	TO	O	O
latanoprost	VB	O	O
,	,	O	O
and	CC	O	O
23.2	CD	O	O
+/-	JJ	O	O
1.0	CD	O	O
and	CC	O	O
17.5	CD	O	O
+/-	JJ	O	O
0.8	CD	O	O
mmHg	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
17	CD	O	O
)	)	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
combined	JJ	O	O
treatment	NN	O	O
.	.	O	O

Adding	VBG	O	O
latanoprost	NN	O	O
to	TO	O	O
timolol	VB	O	O
reduced	VBN	O	O
IOP	NNP	o	OPH
with	IN	O	O
5.9	CD	O	O
+/-	JJ	O	O
0.9	CD	O	O
mmHg	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
switching	VBG	O	O
from	IN	O	O
timolol	NN	O	O
to	TO	O	O
latanoprost	VB	O	O
reduced	VBN	O	O
IOP	NNP	o	OPH
with	IN	O	O
5.0	CD	O	O
+/-	JJ	O	O
0.9	CD	O	O
mmHg	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
caused	VBD	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
a	DT	O	O
significant	JJ	O	O
IOP	NNP	o	OPH
reduction	NN	O	O
of	IN	O	O
about	RB	O	O
25	CD	O	O
%	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
effect	NN	O	O
of	IN	O	O
latanoprost	NN	O	O
was	VBD	O	O
additive	JJ	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
timolol	NN	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
good	JJ	O	O
effect	NN	O	O
on	IN	O	O
IOP	NNP	o	OPH
reduction	NN	O	O
was	VBD	O	O
also	RB	O	O
achieved	VBN	O	O
by	IN	O	O
switching	VBG	O	O
from	IN	O	O
timolol	NN	O	O
to	TO	O	O
latanoprost	VB	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
a	DT	O	O
switch	NN	O	O
in	IN	O	O
many	JJ	O	O
patients	NNS	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
alternative	NN	O	O
to	TO	O	O
combination	NN	O	O
treatment	NN	O	O
.	.	O	O

Parent-implemented	JJ	O	O
enhanced	VBD	i	IE
milieu	NNS	i	IE
teaching	VBG	i	IE
with	IN	O	O
preschool	JJ	p	PA
children	NNS	p	PA
who	WP	p	O
have	VBP	p	O
intellectual	JJ	p	PC
disabilities	NNS	p	PC
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
enhanced	JJ	i	IE
milieu	NN	i	IE
teaching	NN	i	IE
(	(	i	IE
EMT	NNP	i	IE
)	)	i	IE
implemented	VBN	O	O
by	IN	O	O
parents	NNS	O	O
and	CC	O	O
therapists	NNS	O	O
versus	VBP	O	O
therapists	VBZ	O	O
only	RB	O	O
on	IN	O	O
the	DT	O	O
language	NN	O	O
skills	NNS	O	O
of	IN	O	O
preschool	NN	p	O
children	NNS	p	O
with	IN	p	O
intellectual	JJ	p	PC
disabilities	NNS	p	PC
(	(	p	PC
IDs	NNP	p	PC
)	)	p	PC
,	,	p	O
including	VBG	p	O
children	NNS	p	O
with	IN	p	O
Down	NNP	p	PC
syndrome	NN	p	PC
and	CC	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
.	.	O	O

METHOD	NNP	O	O
Seventy-seven	JJ	p	PSS
children	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
2	CD	O	O
treatments	NNS	O	O
(	(	O	O
parent	NN	i	IE
+	NNP	i	IE
therapist	NN	i	IE
EMT	NNP	i	IE
or	CC	O	O
therapist-only	RB	i	IE
EMT	NNP	i	IE
)	)	O	O
and	CC	O	O
received	VBD	O	O
36	CD	O	O
intervention	NN	O	O
sessions	NNS	O	O
.	.	O	O

Children	NNP	O	O
were	VBD	O	O
assessed	VBN	O	O
before	RB	O	O
,	,	O	O
immediately	RB	O	O
after	IN	O	O
,	,	O	O
6	CD	O	O
months	NNS	O	O
after	IN	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
after	IN	O	O
intervention	NN	O	O
.	.	O	O

Separate	JJ	O	O
linear	JJ	O	O
regressions	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
for	IN	O	O
each	DT	O	O
standardized	JJ	O	O
and	CC	O	O
observational	JJ	O	O
measure	NN	O	O
at	IN	O	O
each	DT	O	O
time	NN	O	O
point	NN	O	O
.	.	O	O

RESULTS	JJ	O	O
Parents	NNS	O	O
in	IN	O	O
the	DT	O	O
parent	NN	O	O
+	NNP	O	O
therapist	NN	O	O
group	NN	O	O
demonstrated	VBD	O	O
greater	JJR	O	O
use	NN	O	O
of	IN	O	O
EMT	NNP	o	OPH
strategies	NNS	o	OPH
at	IN	O	O
home	NN	O	O
than	IN	O	O
untrained	JJ	O	O
parents	NNS	O	O
in	IN	O	O
the	DT	O	O
therapist-only	JJ	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
these	DT	O	O
effects	NNS	O	O
maintained	VBD	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

Effect	JJ	O	O
sizes	NN	O	O
for	IN	O	O
observational	JJ	o	OOt
measures	NNS	o	OOt
ranged	VBD	O	O
from	IN	O	O
d	NN	O	O
=	$	O	O
0.10	CD	O	O
to	TO	O	O
d	VB	O	O
=	JJ	O	O
1.32	CD	O	O
favoring	VBG	O	O
the	DT	O	O
parent	NN	O	O
+	NNP	O	O
therapist	NN	O	O
group	NN	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
largest	JJS	O	O
effect	NN	O	O
sizes	VBZ	O	O
found	VBD	O	O
12	CD	O	O
months	NNS	O	O
after	IN	O	O
intervention	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Findings	NNS	O	O
from	IN	O	O
this	DT	O	O
study	NN	O	O
indicate	VBP	O	O
generally	RB	O	O
that	IN	O	O
there	EX	O	O
are	VBP	O	O
benefits	NNS	O	O
to	TO	O	O
training	VBG	O	O
parents	NNS	O	O
to	TO	O	O
implement	VB	O	O
naturalistic	JJ	O	O
language	NN	O	O
intervention	NN	O	O
strategies	NNS	O	O
with	IN	O	O
preschool	JJ	p	PA
children	NNS	p	PA
who	WP	p	O
have	VBP	p	O
ID	NNP	p	O
and	CC	p	O
significant	JJ	p	O
language	NN	p	O
impairments	NNS	p	O
.	.	O	O

Development	NNP	O	O
of	IN	O	O
renal	JJ	O	O
disease	NN	O	O
in	IN	O	O
people	NNS	p	O
at	IN	p	O
high	JJ	p	O
cardiovascular	JJ	p	O
risk	NN	p	O
:	:	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
HOPE	NNP	O	O
randomized	VBD	O	O
study	NN	O	O
.	.	O	O

In	IN	O	O
people	NNS	p	O
with	IN	p	O
diabetes	NNS	p	O
,	,	O	O
renal	JJ	O	O
disease	NN	O	O
tends	VBZ	O	O
to	TO	O	O
progress	VB	O	O
from	IN	O	O
microalbuminuria	NN	O	O
to	TO	O	O
clinical	JJ	O	O
proteinuria	NN	O	O
to	TO	O	O
renal	JJ	O	O
insufficiency	NN	O	O
.	.	O	O

Little	JJ	O	O
evidence	NN	O	O
has	VBZ	O	O
been	VBN	O	O
published	VBN	O	O
for	IN	O	O
the	DT	O	O
nondiabetic	JJ	O	O
population	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
retrospectively	RB	O	O
analyzed	VBD	O	O
changes	NNS	O	O
of	IN	O	O
proteinuria	NN	O	O
over	IN	O	O
4.5	CD	O	O
yr	NNS	O	O
in	IN	O	O
the	DT	O	O
HOPE	NNP	O	O
(	(	O	O
Heart	NNP	O	O
Outcomes	NNP	O	O
and	CC	O	O
Prevention	NNP	O	O
Evaluation	NNP	O	O
)	)	O	O
study	NN	O	O
,	,	O	O
which	WDT	O	O
compared	VBN	O	O
ramipril	NN	i	IPM
's	POS	i	IPM
effects	NNS	O	O
to	TO	O	O
placebo	VB	i	IC
in	IN	O	O
9297	CD	O	O
participants	NNS	O	O
,	,	O	O
including	VBG	O	O
3577	CD	O	O
with	IN	O	O
diabetes	NNS	O	O
and	CC	O	O
1956	CD	O	O
with	IN	O	O
microalbuminuria	NN	O	O
.	.	O	O

This	DT	O	O
report	NN	O	O
is	VBZ	O	O
restricted	VBN	O	O
to	TO	O	O
7674	CD	p	O
participants	NNS	p	O
with	IN	p	O
albuminuria	NNS	p	O
data	NNS	p	O
at	IN	p	O
baseline	NN	p	O
and	CC	p	O
at	IN	p	O
follow-up	JJ	p	O
.	.	O	O

Inclusion	NN	O	O
criteria	NNS	O	O
were	VBD	O	O
known	VBN	O	O
vascular	JJ	O	O
disease	NN	O	O
or	CC	O	O
diabetes	VBZ	O	O
plus	CC	O	O
one	CD	O	O
other	JJ	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
factor	NN	O	O
,	,	O	O
exclusion	NN	O	O
criteria	NNS	O	O
included	VBD	O	O
heart	NN	O	O
failure	NN	O	O
or	CC	O	O
known	VBN	O	O
impaired	JJ	O	O
left	VBD	O	O
ventricular	JJ	O	O
function	NN	O	O
,	,	O	O
dipstick-positive	JJ	O	O
proteinuria	NN	O	O
(	(	O	O
>	JJ	O	O
1+	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
serum	JJ	O	O
creatinine	NN	O	O
>	$	O	O
2.3	CD	O	O
mg/dl	NN	O	O
(	(	O	O
200	CD	O	O
microM	NN	O	O
)	)	O	O
.	.	O	O

Baseline	NNP	O	O
microalbuminuria	NN	O	O
predicted	VBD	O	O
subsequent	JJ	O	O
clinical	JJ	o	OPH
proteinuria	NN	o	OPH
for	IN	O	O
the	DT	O	O
study	NN	O	O
participants	NNS	O	O
overall	JJ	O	O
(	(	O	O
adjusted	VBN	O	O
odds	NNS	O	O
ratio	VBP	O	O
[	CD	O	O
OR	NNP	O	O
]	NNP	O	O
,	,	O	O
17.5	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
12.6	CD	O	O
to	TO	O	O
24.4	CD	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
participants	NNS	O	O
without	IN	O	O
diabetes	NNS	O	O
(	(	O	O
OR	NNP	O	O
,	,	O	O
16.7	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
8.6	CD	O	O
to	TO	O	O
32.4	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
participants	NNS	O	O
with	IN	O	O
diabetes	NNS	O	O
(	(	O	O
OR	NNP	O	O
,	,	O	O
18.2	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
12.4	CD	O	O
to	TO	O	O
26.7	CD	O	O
)	)	O	O
.	.	O	O

Any	DT	O	O
progression	NN	o	OPH
of	IN	o	OPH
albuminuria	NNS	o	OPH
(	(	O	O
defined	VBN	O	O
as	IN	O	O
new	JJ	O	O
microalbuminuria	NNS	O	O
or	CC	O	O
new	JJ	O	O
clinical	JJ	O	O
proteinuria	NN	O	O
)	)	O	O
occurred	VBD	O	O
in	IN	O	O
1859	CD	O	O
participants	NNS	O	O
;	:	O	O
1542	CD	O	O
developed	VBD	O	O
new	JJ	O	O
microalbuminuria	NNS	o	OPH
,	,	O	O
and	CC	O	O
317	CD	O	O
participants	NNS	O	O
developed	VBD	O	O
clinical	JJ	o	OPH
proteinuria	NN	o	OPH
.	.	O	O

Ramipril	NNP	i	IPM
reduced	VBD	O	O
the	DT	O	O
risk	NN	O	O
for	IN	O	O
any	DT	O	O
progression	NN	o	OPH
(	(	O	O
OR	NNP	O	O
,	,	O	O
0.87	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.78	CD	O	O
to	TO	O	O
0.97	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.0146	CD	O	O
)	)	O	O
.	.	O	O

People	NNS	O	O
without	IN	O	O
and	CC	O	O
with	IN	O	O
diabetes	NNS	O	O
who	WP	O	O
are	VBP	O	O
at	IN	O	O
high	JJ	O	O
risk	NN	O	O
for	IN	O	O
cardiovascular	JJ	O	O
disease	NN	O	O
are	VBP	O	O
also	RB	O	O
at	IN	O	O
risk	NN	O	O
for	IN	O	O
a	DT	O	O
progressive	JJ	O	O
rise	NN	O	O
in	IN	O	O
albuminuria	NN	o	OPH
.	.	O	O

Microalbuminuria	NNP	O	O
itself	PRP	O	O
predicts	VBZ	O	O
clinical	JJ	O	O
proteinuria	NNS	O	O
in	IN	O	O
nondiabetic	JJ	p	O
and	CC	p	O
in	IN	p	O
diabetic	JJ	p	O
people	NNS	p	O
.	.	O	O

Ramipril	JJ	i	IPM
prevents	NNS	O	O
or	CC	O	O
delays	VBZ	O	O
the	DT	O	O
progression	NN	o	OPH
of	IN	o	OPH
albuminuria	NN	o	OPH
.	.	O	O

An	DT	O	O
open-label	JJ	O	O
extension	NN	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autistic	JJ	p	O
disorder	NN	p	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
long-term	JJ	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
in	IN	O	O
treating	VBG	O	O
irritability	NN	O	O
and	CC	O	O
related	JJ	O	O
behaviors	NNS	O	O
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autistic	JJ	p	O
disorders	NNS	p	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
6	CD	O	O
month	NN	O	O
(	(	O	O
26	CD	O	O
week	NN	O	O
)	)	O	O
open-label	NN	O	O
extension	NN	O	O
(	(	O	O
OLE	NNP	O	O
)	)	O	O
study	NN	O	O
,	,	O	O
patients	NNS	p	O
(	(	p	O
5-17	JJ	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
,	,	p	O
who	WP	p	O
completed	VBD	p	O
the	DT	p	O
previous	JJ	p	O
fixed-dose	JJ	p	O
,	,	p	O
6	CD	p	O
week	NN	p	O
,	,	p	O
double-blind	JJ	p	O
[	NNP	p	O
DB	NNP	p	O
]	NNP	p	O
phase	NN	p	O
)	)	O	O
were	VBD	O	O
flexibly	RB	O	O
dosed	VBN	O	O
with	IN	O	O
risperidone	NN	i	IPM
based	VBN	O	O
on	IN	O	O
body	NN	O	O
weight	NN	O	O
.	.	O	O

The	DT	O	O
maximum	JJ	O	O
allowed	VBD	O	O
dose	NN	O	O
was	VBD	O	O
1.25	CD	O	O
mg/day	NN	O	O
for	IN	O	O
those	DT	O	O
weighing	VBG	O	O
20	CD	O	O
to	TO	O	O
<	VB	O	O
45	CD	O	O
kg	NN	O	O
,	,	O	O
and	CC	O	O
1.75	CD	O	O
mg/day	NN	O	O
for	IN	O	O
those	DT	O	O
weighing	VBG	O	O
?	.	O	O
45	CD	O	O
kg	NN	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
primarily	RB	O	O
assessed	VBD	O	O
risperidone	NN	i	O
's	POS	O	O
safety	NN	o	O
;	:	O	O
efficacy	NN	o	O
was	VBD	O	O
assessed	VBN	O	O
as	IN	O	O
a	DT	O	O
secondary	JJ	O	O
end-point	NN	O	O
.	.	O	O

RESULTS	VB	O	O
Fifty-six	NNP	p	O
(	(	p	O
71	CD	p	O
%	NN	p	O
)	)	p	O
out	IN	p	O
of	IN	p	O
79	CD	p	O
enrolled	JJ	p	O
patients	NNS	p	O
completed	VBD	p	O
the	DT	p	O
OLE	NNP	p	O
;	:	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
discontinuations	NNS	O	O
were	VBD	O	O
for	IN	O	O
insufficient	JJ	O	O
response	NN	O	O
(	(	O	O
7	CD	O	O
[	RB	O	O
9	CD	O	O
%	NN	O	O
]	NN	O	O
)	)	O	O
or	CC	O	O
adverse	JJ	o	O
events	NNS	o	O
(	(	o	O
AE	NNP	O	O
)	)	O	O
(	(	O	O
5	CD	O	O
[	RB	O	O
6	CD	O	O
%	NN	O	O
]	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
(	(	O	O
?	.	O	O
5	CD	O	O
%	NN	O	O
frequency	NN	O	O
in	IN	O	O
the	DT	O	O
total	JJ	O	O
group	NN	O	O
)	)	O	O
AEs	NNP	O	O
were	VBD	O	O
increased	VBN	O	O
appetite	RB	o	O
(	(	O	O
11	CD	O	O
%	NN	O	O
[	JJ	O	O
n=9	JJ	O	O
]	NN	O	O
)	)	O	O
;	:	O	O
increased	VBN	O	O
weight	NN	o	O
and	CC	o	O
vomiting	NN	o	O
(	(	O	O
9	CD	O	O
%	NN	O	O
[	JJ	O	O
n=7	JJ	O	O
]	NNP	O	O
each	DT	O	O
)	)	O	O
;	:	O	O
sedation	NN	o	O
,	,	o	O
pyrexia	NN	o	O
,	,	o	O
and	CC	o	O
upper	JJ	o	O
respiratory	NN	o	O
tract	NN	o	O
infection	NN	o	O
(	(	O	O
8	CD	O	O
%	NN	O	O
[	JJ	O	O
n=6	JJ	O	O
]	NNP	O	O
each	DT	O	O
)	)	O	O
;	:	O	O
nasopharyngitis	NN	o	O
(	(	O	O
6	CD	O	O
%	NN	O	O
[	JJ	O	O
n=5	JJ	O	O
]	NN	O	O
)	)	O	O
;	:	O	O
and	CC	O	O
somnolence	NN	o	O
and	CC	o	O
fatigue	NN	o	O
(	(	O	O
5	CD	O	O
%	NN	O	O
[	JJ	O	O
n=4	JJ	O	O
]	NNP	O	O
each	DT	O	O
)	)	O	O
.	.	O	O

Extrapyramidal	JJ	O	O
AEs	NNP	o	O
were	VBD	O	O
reported	VBN	O	O
in	IN	O	O
6	CD	O	O
(	(	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
.	.	O	O

Increase	NNP	O	O
in	IN	o	O
mean	JJ	o	O
weight	NN	o	O
(	(	O	O
11-15	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
body	NN	o	O
mass	NN	o	O
index	NN	o	O
(	(	O	O
5-10	CD	O	O
%	NN	O	O
)	)	O	O
occurred	VBD	O	O
;	:	O	O
one	CD	O	O
patient	NN	O	O
discontinued	VBN	O	O
because	IN	O	O
of	IN	O	O
weight	JJ	o	O
increase	NN	O	O
.	.	O	O

One	CD	O	O
potentially	RB	O	O
prolactin-related	JJ	o	O
AE	NNP	o	O
(	(	o	O
irregular	JJ	o	O
menstruation	NN	o	O
)	)	o	O
was	VBD	O	O
reported	VBN	O	O
.	.	O	O

The	DT	O	O
risperidone	NN	i	O
high-dose	JJ	O	O
group	NN	O	O
had	VBD	O	O
the	DT	O	O
greatest	JJS	O	O
mean	JJ	O	O
improvement	NN	O	O
in	IN	o	O
sleep	JJ	o	O
visual	JJ	o	O
analog	NN	o	O
scale	NN	o	O
(	(	O	O
24.6	CD	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
groups	NNS	O	O
showed	VBD	O	O
additional	JJ	O	O
improvement	NN	O	O
in	IN	O	O
efficacy	NN	o	O
scale	JJ	o	O
scores	NNS	o	O
during	IN	O	O
the	DT	O	O
OLE	NNP	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
During	IN	O	O
this	DT	O	O
OLE	NNP	O	O
,	,	O	O
safety	NN	O	O
findings	NNS	O	O
with	IN	O	O
risperidone	NN	i	O
treatment	NN	O	O
(	(	O	O
maximum	JJ	O	O
weight-based	JJ	O	O
dose	NN	O	O
of	IN	O	O
1.25	CD	O	O
mg/day	NN	O	O
or	CC	O	O
1.75	CD	O	O
mg/day	NN	O	O
)	)	O	O
were	VBD	O	O
consistent	JJ	O	O
with	IN	O	O
those	DT	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
DB	NNP	O	O
phase	NN	O	O
,	,	O	O
and	CC	O	O
with	IN	O	O
the	DT	O	O
current	JJ	O	O
safety	NN	O	O
information	NN	O	O
for	IN	O	O
risperidone	NN	i	O
in	IN	O	O
autistic	JJ	O	O
,	,	O	O
psychiatric	JJ	O	O
,	,	O	O
and	CC	O	O
behavioral	JJ	O	O
disorders	NNS	O	O
.	.	O	O

Patients	NNS	O	O
experienced	VBD	O	O
some	DT	O	O
additional	JJ	O	O
improvement	NN	O	O
in	IN	O	O
irritability	NN	o	O
and	CC	o	O
related	JJ	o	O
behaviors	NNS	o	O
.	.	O	O

CLINICAL	JJ	O	O
TRIALS	NNP	O	O
REGISTRY	NNP	O	O
This	DT	O	O
phase-4	JJ	O	O
study	NN	O	O
is	VBZ	O	O
registered	VBN	O	O
at	IN	O	O
ClinicalTrials.gov	NNP	O	O
(	(	O	O
NCT00576732	NNP	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	O	O
cross-over	JJ	O	O
trial	NN	O	O
of	IN	O	O
the	DT	O	O
impact	NN	O	O
on	IN	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
of	IN	O	O
continuing	VBG	O	O
dexamethasone	JJ	i	IPM
beyond	IN	O	O
24	CD	O	O
h	NN	O	O
following	VBG	O	O
adjuvant	JJ	p	O
chemotherapy	NN	p	O
for	IN	p	O
breast	NN	p	O
cancer	NN	p	O
.	.	O	O

Uncertainty	NN	O	O
remains	VBZ	O	O
about	IN	O	O
the	DT	O	O
optimal	JJ	O	O
anti-emetic	JJ	O	O
regimen	NNS	O	O
for	IN	O	O
control	NN	O	O
of	IN	O	O
delayed	JJ	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
after	IN	O	O
adjuvant	JJ	O	O
chemotherapy	NN	O	O
for	IN	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Many	JJ	O	O
patients	NNS	O	O
receive	VBP	O	O
dexamethasone	NN	i	O
but	CC	O	O
complain	NN	O	O
of	IN	O	O
insomnia	NN	O	O
,	,	O	O
anxiety/agitation	NN	O	O
,	,	O	O
and	CC	O	O
indigestion	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
chemotherapy	NN	O	O
for	IN	O	O
breast	NN	p	O
cancer	NN	p	O
prefer	VBP	O	O
treatment	NN	O	O
with	IN	O	O
dexamethasone	NN	i	O
or	CC	O	O
placebo	NN	i	O
for	IN	O	O
prophylaxis	NN	O	O
against	IN	O	O
delayed	VBN	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
compare	VB	O	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
(	(	o	O
QOL	NNP	o	O
)	)	o	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatments	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
cross-over	JJ	O	O
trial	NN	O	O
,	,	O	O
we	PRP	O	O
compared	VBN	O	O
oral	JJ	O	O
dexamethasone	NN	i	O
(	(	O	O
4	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
2	CD	O	O
days	NNS	O	O
)	)	O	O
versus	VBP	O	O
placebo	NN	i	O
for	IN	O	O
chemotherapy-na?ve	JJ	p	O
patients	NNS	p	O
with	IN	p	O
breast	JJ	p	O
cancer	NN	p	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
intravenous	JJ	O	O
granisetron	NN	i	O
and	CC	O	O
dexamethasone	NN	i	O
pre-chemotherapy	NN	O	O
and	CC	O	O
oral	JJ	O	O
granisetron	NN	i	O
on	IN	O	O
day	NN	O	O
2	CD	O	O
.	.	O	O

Primary	JJ	O	O
endpoints	NNS	O	O
were	VBD	O	O
:	:	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
patient	NN	o	O
preference	NN	o	O
;	:	O	O
(	(	O	O
ii	NN	O	O
)	)	O	O
difference	NN	O	O
between	IN	O	O
cycles	NNS	O	O
in	IN	O	O
change	NN	o	O
of	IN	o	O
QOL	NNP	o	O
from	IN	O	O
days	NNS	O	O
1	CD	O	O
to	TO	O	O
8	CD	O	O
.	.	O	O

Median	JJ	O	O
age	NN	p	O
of	IN	p	O
the	DT	p	O
94	CD	p	O
women	NNS	p	O
was	VBD	p	O
51	CD	p	O
years	NNS	p	O
(	(	p	O
range	VB	p	O
27-76	JJ	p	O
)	)	p	O
:	:	O	O
79	CD	O	O
received	VBD	O	O
fluorouracil/epirubicin/cyclophosphamide	NN	i	O
and	CC	O	O
15	CD	O	O
received	VBD	O	O
doxorubicin/cyclophosphamide	NN	i	O
.	.	O	O

Thirteen	JJ	O	O
withdrew	VBD	O	O
pre-cycle	JJ	O	O
2	CD	O	O
with	IN	O	O
no	DT	O	O
differences	NNS	O	O
between	IN	O	O
arms	NNS	O	O
.	.	O	O

Of	IN	O	O
80	CD	O	O
patients	NNS	O	O
stating	VBG	O	O
a	DT	O	O
preference	NN	O	O
,	,	O	O
31	CD	O	O
preferred	JJ	O	O
placebo	NN	i	O
(	(	O	O
39	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
28-50	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
37	CD	O	O
(	(	O	O
46	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
35-58	CD	O	O
%	NN	O	O
)	)	O	O
preferred	VBD	O	O
dexamethasone	NN	i	O
;	:	O	O
12	CD	O	O
had	VBD	O	O
no	DT	O	O
preference	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
in	IN	O	O
intensity	NN	o	O
of	IN	o	O
vomiting	VBG	o	O
,	,	o	O
nausea	NN	o	O
,	,	o	O
or	CC	o	O
time	NN	o	O
to	TO	o	O
onset	VB	o	O
of	IN	o	O
vomiting	VBG	o	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
greater	JJR	O	O
decrease	NN	O	O
in	IN	O	O
global	JJ	o	O
QOL	NNP	o	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.06	CD	O	O
)	)	O	O
when	WRB	O	O
patients	NNS	O	O
received	VBD	O	O
dexamethasone	NN	i	O
.	.	O	O

No	DT	O	O
other	JJ	o	O
symptom/QOL	NN	O	O
domains	NNS	O	O
differed	VBD	O	O
significantly	RB	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
patient	JJ	o	O
preference	NN	o	O
,	,	o	O
QOL	NNP	o	O
,	,	o	O
or	CC	o	O
symptoms	NNS	o	O
regardless	RB	O	O
of	IN	O	O
whether	IN	O	O
dexamethasone	NN	i	O
or	CC	O	O
placebo	NN	i	O
was	VBD	O	O
used	VBN	O	O
after	IN	O	O
adjuvant	JJ	O	O
chemotherapy	NN	O	O
.	.	O	O

Chronic	NNP	O	O
vasodilator	NN	O	O
therapy	NN	O	O
with	IN	O	O
flosequinan	NN	i	IPM
in	IN	O	O
congestive	JJ	p	PC
heart	NN	p	PC
failure	NN	p	PC
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
long-term	JJ	o	OPH
effect	NN	o	OPH
of	IN	O	O
flosequinan	NN	i	IPM
,	,	O	O
a	DT	O	O
new	JJ	O	O
orally	RB	O	O
administered	VBN	O	O
arterial	JJ	O	O
and	CC	O	O
venous	JJ	O	O
dilator	NN	O	O
,	,	O	O
on	IN	O	O
the	DT	O	O
clinical	JJ	O	O
course	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
moderate	JJ	p	O
to	TO	p	O
severe	VB	p	O
congestive	JJ	p	O
heart	NN	p	O
failure	NN	p	O
.	.	O	O

Seventeen	JJ	p	O
patients	NNS	p	O
on	IN	p	O
chronic	JJ	p	O
digitalis	NN	p	O
and	CC	p	O
diuretic	JJ	p	O
therapy	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
flosequinan	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
9	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
8	CD	O	O
)	)	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
fashion	NN	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
symptomatology	NN	o	OPH
,	,	o	O
exercise	NN	o	OPH
performance	NN	o	OPH
,	,	O	O
and	CC	O	O
left	VBD	o	OPH
ventricular	JJ	o	OPH
function	NN	o	OPH
were	VBD	O	O
assessed	VBN	O	O
serially	RB	O	O
during	IN	O	O
the	DT	O	O
two-month	JJ	O	O
treatment	NN	O	O
period	NN	O	O
.	.	O	O

During	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
therapy	NN	O	O
,	,	O	O
a	DT	O	O
modest	JJ	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
symptom	NN	o	OPH
scores	NNS	o	OPH
and	CC	O	O
functional	JJ	o	OPH
classification	NN	o	OPH
of	IN	O	O
the	DT	O	O
flosequinan-treated	JJ	O	O
patients	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

Flosequinan	NNP	i	IPM
evoked	VBD	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
maximal	JJ	o	OPH
exercise	NN	o	OPH
capacity	NN	o	OPH
.	.	O	O

While	IN	O	O
long-term	JJ	O	O
flosequinan	JJ	i	IPM
administration	NN	O	O
also	RB	O	O
effected	VBD	O	O
a	DT	O	O
progressive	JJ	O	O
increase	NN	O	O
in	IN	O	O
resting	VBG	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
,	,	O	O
it	PRP	O	O
did	VBD	O	O
not	RB	O	O
consistently	RB	O	O
improve	VB	O	O
indices	NNS	O	O
of	IN	O	O
left	JJ	o	OPH
ventricular	JJ	o	OPH
systolic	JJ	o	OPH
function	NN	o	OPH
.	.	O	O

The	DT	O	O
addition	NN	O	O
of	IN	O	O
chronic	JJ	O	O
vasodilator	NN	O	O
therapy	NN	O	O
with	IN	O	O
flosequinan	NN	i	IPM
to	TO	O	O
standard	VB	O	O
digitalis-diuretic	JJ	O	O
regimens	NNS	O	O
is	VBZ	O	O
capable	JJ	O	O
of	IN	O	O
inducing	VBG	O	O
clinical	JJ	O	O
improvement	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
moderate	JJ	p	O
to	TO	p	O
severe	VB	p	O
chronic	JJ	p	O
heart	NN	p	O
failure	NN	p	O
.	.	O	O

Trials	NNS	O	O
involving	VBG	O	O
larger	JJR	O	O
patient	JJ	O	O
populations	NNS	O	O
will	MD	O	O
be	VB	O	O
necessary	JJ	O	O
to	TO	O	O
confirm	VB	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
preliminary	JJ	O	O
study	NN	O	O
and	CC	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
clinical	JJ	O	O
improvement	NN	O	O
,	,	O	O
subpopulations	NNS	O	O
benefited	VBD	O	O
,	,	O	O
role	NN	O	O
in	IN	O	O
heart	NN	O	O
failure	NN	O	O
therapeutics	NNS	O	O
,	,	O	O
and	CC	O	O
so	RB	O	O
forth	JJ	O	O
.	.	O	O

Role	NNP	O	O
of	IN	O	O
posterior	JJ	i	IPH
tibial	JJ	i	IPH
nerve	NN	i	IPH
stimulation	NN	i	IPH
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
refractory	JJ	O	O
monosymptomatic	JJ	O	O
nocturnal	JJ	O	O
enuresis	NN	O	O
:	:	O	O
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
We	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
early	JJ	O	O
clinical	JJ	O	O
and	CC	O	O
urodynamic	JJ	O	O
results	NNS	O	O
of	IN	O	O
posterior	JJ	i	O
tibial	JJ	i	O
nerve	NN	i	O
stimulation	NN	i	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
refractory	JJ	p	PC
monosymptomatic	JJ	p	PC
nocturnal	JJ	p	PC
enuresis	NN	p	PC
.	.	O	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
We	PRP	O	O
randomly	VBP	O	O
assigned	VBD	O	O
28	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
refractory	JJ	p	O
monosymptomatic	JJ	p	O
nocturnal	JJ	p	O
enuresis	NN	p	O
to	TO	O	O
2	CD	O	O
equal	JJ	O	O
groups	NNS	O	O
.	.	O	O

Group	NNP	O	O
1	CD	O	O
received	VBD	O	O
a	DT	O	O
weekly	JJ	O	O
session	NN	O	O
of	IN	O	O
posterior	JJ	i	O
tibial	JJ	i	O
nerve	NN	i	O
stimulation	NN	i	O
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
and	CC	O	O
group	NN	O	O
2	CD	O	O
was	VBD	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
.	.	O	O

Evaluation	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
posterior	JJ	O	O
tibial	JJ	O	O
nerve	NN	O	O
stimulation	NN	O	O
to	TO	O	O
compare	VB	O	O
clinical	JJ	O	O
and	CC	O	O
urodynamic	JJ	O	O
findings	NNS	O	O
.	.	O	O

Another	DT	O	O
clinical	JJ	O	O
assessment	NN	O	O
was	VBD	O	O
done	VBN	O	O
3	CD	O	O
months	NNS	O	O
after	IN	O	O
the	DT	O	O
first	JJ	O	O
followup	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
2	CD	O	O
groups	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
in	IN	O	O
baseline	JJ	O	O
clinical	JJ	O	O
and	CC	O	O
urodynamic	JJ	O	O
data	NNS	O	O
.	.	O	O

Overall	NNP	O	O
,	,	O	O
13	CD	O	O
patients	NNS	O	O
(	(	O	O
46.4	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
detrusor	VBN	o	OPH
overactivity	NN	o	OPH
and	CC	O	O
14	CD	O	O
(	(	O	O
50	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
decreased	VBN	O	O
bladder	NN	o	OPH
capacity	NN	o	OPH
.	.	O	O

After	IN	O	O
treatment	NN	O	O
11	CD	O	O
group	NN	O	O
1	CD	O	O
patients	NNS	O	O
(	(	O	O
78.6	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
a	DT	O	O
partial	JJ	O	O
or	CC	O	O
full	JJ	O	O
response	NN	o	OOt
to	TO	O	O
posterior	VB	O	O
tibial	JJ	O	O
nerve	NN	O	O
stimulation	NN	O	O
but	CC	O	O
only	RB	O	O
2	CD	O	O
(	(	O	O
14.3	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
group	NN	O	O
2	CD	O	O
had	VBD	O	O
a	DT	O	O
partial	JJ	O	O
response	NN	o	OOt
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
.	.	O	O

Also	RB	O	O
,	,	O	O
the	DT	O	O
average	JJ	O	O
number	NN	o	OOt
of	IN	o	OOt
wet	JJ	o	OOt
nights	NNS	o	OOt
in	IN	O	O
group	NN	O	O
1	CD	O	O
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
at	IN	O	O
baseline	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
urodynamic	JJ	o	OPH
parameters	NNS	o	OPH
significantly	RB	O	O
improved	VBN	O	O
in	IN	O	O
group	NN	O	O
1	CD	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
wet	JJ	o	OOt
nights	NNS	o	OOt
and	CC	o	O
urodynamic	JJ	o	OPH
parameters	NNS	o	OPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
significantly	RB	O	O
in	IN	O	O
group	NN	O	O
2	CD	O	O
.	.	O	O

At	IN	O	O
3-month	JJ	O	O
followup	NN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
a	DT	O	O
partial	JJ	O	O
or	CC	O	O
full	JJ	O	O
response	NN	o	OOt
in	IN	O	O
group	NN	O	O
1	CD	O	O
had	VBD	O	O
decreased	VBN	O	O
from	IN	O	O
11	CD	O	O
(	(	O	O
78.6	CD	O	O
%	NN	O	O
)	)	O	O
to	TO	O	O
6	CD	O	O
(	(	O	O
42.9	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
change	NN	O	O
was	VBD	O	O
evident	JJ	O	O
in	IN	O	O
group	NN	O	O
2	CD	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Posterior	NNP	i	O
tibial	JJ	i	O
nerve	NN	i	O
stimulation	NN	i	O
can	MD	O	O
be	VB	O	O
a	DT	O	O
viable	JJ	O	O
treatment	NN	O	O
option	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	p	O
with	IN	p	O
refractory	JJ	p	O
monosymptomatic	JJ	p	O
nocturnal	JJ	p	O
enuresis	NN	p	O
.	.	O	O

However	RB	O	O
,	,	O	O
deterioration	NN	O	O
in	IN	O	O
some	DT	O	O
responders	NNS	O	O
with	IN	O	O
time	NN	O	O
suggests	VBZ	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
maintenance	NN	O	O
protocols	NNS	O	O
.	.	O	O

A	DT	O	O
multi-component	JJ	i	IE
social	JJ	i	IE
skills	NNS	i	IE
intervention	NN	i	IE
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
Asperger	NNP	p	PC
syndrome	NN	p	PC
:	:	O	O
the	DT	O	O
Junior	NNP	i	IE
Detective	NNP	i	IE
Training	NNP	i	IE
Program	NNP	i	IE
.	.	O	O

BACKGROUND	NNP	O	O
The	DT	O	O
study	NN	O	O
aimed	VBN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
a	DT	O	O
new	JJ	O	O
multi-component	JJ	i	IE
social	JJ	i	IE
skills	NNS	i	IE
intervention	NN	i	IE
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
Asperger	NNP	p	PC
syndrome	NN	p	PC
(	(	p	PC
AS	IN	p	PC
)	)	p	PC
:	:	O	O
The	DT	O	O
Junior	NNP	O	O
Detective	NNP	O	O
Training	NNP	O	O
Program	NNP	O	O
.	.	O	O

This	DT	O	O
7-week	JJ	O	O
program	NN	O	O
included	VBD	O	O
a	DT	O	O
computer	NN	O	O
game	NN	O	O
,	,	O	O
small	JJ	O	O
group	NN	O	O
sessions	NNS	O	O
,	,	O	O
parent	NN	O	O
training	NN	O	O
sessions	NNS	O	O
and	CC	O	O
teacher	NN	O	O
handouts	NNS	O	O
.	.	O	O

METHOD	NNP	O	O
Forty-nine	JJ	p	PSS
children	NNS	p	PA
with	IN	p	O
AS	NNP	p	PC
were	VBD	O	O
recruited	VBN	O	O
to	TO	O	O
participate	VB	O	O
and	CC	O	O
randomly	VB	O	O
assigned	VBN	O	O
to	TO	O	O
intervention	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
26	CD	O	O
)	)	O	O
or	CC	O	O
wait-list	JJ	O	O
control	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
23	CD	O	O
)	)	O	O
conditions	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Relative	NNP	O	O
to	TO	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
wait-list	JJ	O	O
group	NN	O	O
,	,	O	O
program	NN	O	O
participants	NNS	O	O
showed	VBD	O	O
greater	JJR	O	O
improvements	NNS	o	OME
in	IN	o	OME
social	JJ	o	OME
skills	NNS	o	OME
over	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
,	,	O	O
as	IN	O	O
indicated	VBN	O	O
by	IN	O	O
parent-report	JJ	O	O
measures	NNS	O	O
.	.	O	O

Teacher-report	NNP	O	O
data	NNS	O	O
also	RB	O	O
confirmed	VBD	O	O
that	IN	O	O
children	NNS	O	O
receiving	VBG	O	O
the	DT	O	O
intervention	NN	O	O
made	VBD	O	O
significant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
social	JJ	o	OME
functioning	NN	o	OME
from	IN	O	O
pre-	JJ	O	O
to	TO	O	O
post-treatment	JJ	O	O
.	.	O	O

Treatment	NNP	O	O
group	NN	O	O
participants	NNS	O	O
were	VBD	O	O
better	RBR	O	O
able	JJ	O	O
to	TO	O	O
suggest	VB	O	O
appropriate	JJ	O	O
emotion-management	JJ	o	OME
strategies	NNS	o	OME
for	IN	O	O
story	NN	O	O
characters	NNS	O	O
at	IN	O	O
post-intervention	NN	O	O
than	IN	O	O
at	IN	O	O
pre-intervention	NN	O	O
,	,	O	O
whereas	NNS	O	O
control	VBP	O	O
participants	NNS	O	O
were	VBD	O	O
not	RB	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
improvements	NNS	O	O
made	VBN	O	O
by	IN	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
and	CC	O	O
control	NN	O	O
conditions	NNS	O	O
on	IN	O	O
facial	JJ	o	OME
expression	NN	o	OME
and	CC	o	O
body-posture	NN	o	OME
recognition	NN	o	OME
measures	NNS	o	OME
.	.	O	O

Follow-up	NNP	O	O
data	NN	O	O
suggested	VBD	O	O
that	IN	O	O
treatment	NN	O	O
gains	NNS	O	O
were	VBD	O	O
maintained	VBN	O	O
by	IN	O	O
children	NNS	O	O
at	IN	O	O
5-months	JJ	O	O
post-intervention	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
Junior	NNP	i	IE
Detective	NNP	i	IE
Training	NNP	i	IE
Program	NNP	i	IE
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
enhancing	VBG	O	O
the	DT	O	O
social	JJ	o	OME
skills	NNS	o	OME
and	CC	o	O
emotional	JJ	o	OME
understanding	NN	o	OME
of	IN	O	O
children	NNS	p	PA
with	IN	p	O
AS	NNP	p	PC
.	.	O	O

Limitations	NNS	O	O
and	CC	O	O
suggestions	NNS	O	O
for	IN	O	O
future	JJ	O	O
research	NN	O	O
are	VBP	O	O
discussed	VBN	O	O
.	.	O	O

Prevention	NN	O	O
of	IN	O	O
spinal	JJ	O	O
anesthesia-induced	JJ	O	O
hypotension	NN	O	O
in	IN	O	O
the	DT	p	O
elderly	JJ	p	O
:	:	O	O
comparison	NN	O	O
between	IN	O	O
preanesthetic	JJ	O	O
administration	NN	O	O
of	IN	O	O
crystalloids	NNS	i	IPM
,	,	O	O
colloids	NNS	i	IPM
,	,	O	O
and	CC	O	O
no	DT	i	O
prehydration	NN	i	O
.	.	O	O

The	DT	O	O
practice	NN	O	O
of	IN	O	O
routinely	RB	O	O
prehydrating	VBG	O	O
patients	NNS	O	O
by	IN	O	O
infusing	VBG	O	O
a	DT	O	O
crystalloid	NN	i	IPM
or	CC	O	O
colloid	JJ	i	IPM
solution	NN	i	IPM
(	(	O	O
up	IN	O	O
to	TO	O	O
1.0	CD	O	O
L/70	NNP	O	O
kg	NN	O	O
)	)	O	O
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
spinal	JJ	O	O
anesthesia-induced	JJ	O	O
hypotension	NN	O	O
has	VBZ	O	O
been	VBN	O	O
challenged	VBN	O	O
recently	RB	O	O
,	,	O	O
after	IN	O	O
several	JJ	O	O
reports	NNS	O	O
of	IN	O	O
failure	NN	O	O
to	TO	O	O
demonstrate	VB	O	O
its	PRP$	O	O
efficacy	NN	O	O
in	IN	O	O
young	JJ	O	O
women	NNS	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
incidence	NN	o	OPH
and	CC	o	OPH
frequency	NN	o	OPH
of	IN	o	OPH
hypotension	NN	o	OPH
and	CC	o	OPH
vasopressor	NN	o	OPH
therapy	NN	o	OPH
after	IN	O	O
spinal	JJ	O	O
anesthesia	NN	O	O
and	CC	O	O
no	DT	i	O
prehydration	NN	i	O
with	IN	O	O
crystalloid	NN	i	IPM
and	CC	O	O
colloid	JJ	i	IPM
prehydration	NN	i	IPM
in	IN	p	O
elderly	JJ	p	O
patients	NNS	p	O
.	.	O	O

Eighty-five	JJ	p	O
ASA	NNP	p	O
grade	NN	p	O
I	PRP	p	O
or	CC	p	O
II	NNP	p	O
patients	NNS	p	O
(	(	p	O
aged	VBN	p	O
60-89	CD	p	O
yr	NN	p	O
)	)	p	O
for	IN	p	O
elective	JJ	p	O
total	JJ	p	O
hip	NN	p	O
replacement	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
500	CD	O	O
mL	NN	O	O
crystalloid	JJ	i	IPM
solution	NN	i	IPM
(	(	O	O
Hartmanns	NNP	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
29	CD	O	O
)	)	O	O
,	,	O	O
500	CD	O	O
mL	NN	O	O
colloid	NN	i	IPM
(	(	O	O
Haemaccel	NNP	i	IPM
,	,	O	O
n	JJ	O	O
=	NNP	O	O
28	CD	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
no	DT	i	IC
prehydration	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
28	CD	O	O
)	)	O	O
over	IN	O	O
10	CD	O	O
min	NNS	O	O
prior	RB	O	O
to	TO	O	O
spinal	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

Hypotension	NNP	o	OPH
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
a	DT	O	O
30	CD	O	O
%	NN	O	O
decrease	NN	O	O
from	IN	O	O
baseline	JJ	O	O
systolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	O	O
BP	NNP	O	O
)	)	O	O
or	CC	O	O
systolic	JJ	O	O
<	$	O	O
90	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
,	,	O	O
and	CC	O	O
was	VBD	O	O
treated	VBN	O	O
with	IN	O	O
ephedrine	JJ	O	O
3-mg	JJ	O	O
boluses	NNS	O	O
.	.	O	O

Although	IN	O	O
absolute	JJ	o	OPH
systolic	JJ	o	OPH
BP	NNP	o	OPH
readings	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
colloid	NN	i	O
group	NN	O	O
between	IN	O	O
6	CD	O	O
and	CC	O	O
30	CD	O	O
min	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
hypotension	NN	o	OPH
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
ephedrine	NN	o	OA
use	NN	o	OA
,	,	o	OA
incidence	NN	o	OA
of	IN	o	OA
nausea/vomiting	NN	o	OA
,	,	O	O
and	CC	O	O
median	JJ	o	OOt
total	NN	o	OOt
dose	NN	o	OOt
of	IN	o	OOt
ephedrine	NN	o	OOt
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
all	DT	O	O
groups	NNS	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
,	,	O	O
in	IN	O	O
elderly	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
elective	JJ	p	O
procedures	NNS	p	O
,	,	O	O
withholding	VBG	O	O
prehydration	NN	O	O
is	VBZ	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
any	DT	O	O
greater	JJR	O	O
degree	NN	O	O
of	IN	O	O
hypotension	NN	o	OPH
or	CC	O	O
need	NN	o	OOt
for	IN	o	OOt
vasopressor	NN	o	OOt
therapy	NN	o	OOt
compared	VBN	O	O
with	IN	O	O
crystalloid	NN	i	O
or	CC	O	O
colloid	JJ	i	O
prehydration	NN	i	O
.	.	O	O

Teacher	DT	O	O
and	CC	O	O
child	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
achieving	VBG	O	O
IEP	NNP	O	O
goals	NNS	O	O
of	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
encouraging	VBG	O	O
that	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
show	VBP	O	O
a	DT	O	O
strong	JJ	O	O
response	NN	O	O
to	TO	O	O
early	JJ	O	O
intervention	NN	O	O
,	,	O	O
yet	RB	O	O
more	JJR	O	O
research	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
for	IN	O	O
understanding	VBG	O	O
the	DT	O	O
variability	NN	O	O
in	IN	O	O
responsiveness	NN	O	O
to	TO	O	O
specialized	JJ	O	O
programs	NNS	O	O
.	.	O	O

Treatment	NNP	O	O
predictor	NN	O	O
variables	NNS	O	O
from	IN	O	O
47	CD	p	O
teachers	NNS	p	O
and	CC	p	O
children	NNS	p	O
who	WP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
the	DT	O	O
COMPASS	NNP	i	IE
intervention	NN	i	IE
(	(	O	O
Ruble	JJ	O	O
et	NN	O	O
al	NN	O	O
.	.	O	O

in	IN	O	O
The	DT	O	O
collaborative	JJ	O	O
model	NN	O	O
for	IN	O	O
promoting	VBG	O	O
competence	NN	O	O
and	CC	O	O
success	NN	O	O
for	IN	O	O
students	NNS	O	O
with	IN	O	O
ASD	NNP	O	O
.	.	O	O

Springer	NNP	O	O
,	,	O	O
New	NNP	O	O
York	NNP	O	O
,	,	O	O
2012a	CD	O	O
)	)	O	O
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

Predictors	NNS	O	O
evaluated	VBD	O	O
against	IN	O	O
child	NN	O	O
IEP	NNP	O	O
goal	NN	O	O
attainment	NN	O	O
included	VBD	O	O
child	NN	O	O
,	,	O	O
teacher	NN	O	O
,	,	O	O
intervention	NN	O	O
practice	NN	O	O
,	,	O	O
and	CC	O	O
implementation	NN	O	O
practice	NN	O	O
variables	NNS	O	O
based	VBN	O	O
on	IN	O	O
an	DT	O	O
implementation	NN	O	O
science	NN	O	O
framework	NN	O	O
(	(	O	O
Dunst	NNP	O	O
and	CC	O	O
Trivette	NNP	O	O
in	IN	O	O
J	NNP	O	O
Soc	NNP	O	O
Sci	NNP	O	O
8:143-148	CD	O	O
,	,	O	O
2012	CD	O	O
)	)	O	O
.	.	O	O

Findings	NNS	O	O
revealed	VBD	O	O
one	CD	O	O
child	NN	O	O
(	(	O	O
engagement	NN	O	O
)	)	O	O
,	,	O	O
one	CD	O	O
teacher	NN	O	O
(	(	O	O
exhaustion	NN	O	O
)	)	O	O
,	,	O	O
two	CD	O	O
intervention	NN	O	O
quality	NN	O	O
(	(	O	O
IEP	NNP	O	O
quality	NN	O	O
for	IN	O	O
targeted	VBN	O	O
and	CC	O	O
not	RB	O	O
targeted	JJ	O	O
elements	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
no	DT	O	O
implementation	NN	O	O
quality	NN	O	O
variables	NNS	O	O
accounted	VBD	O	O
for	IN	O	O
variance	NN	O	O
in	IN	O	O
child	NN	O	O
outcomes	NNS	O	O
when	WRB	O	O
analyzed	VBN	O	O
separately	RB	O	O
.	.	O	O

When	WRB	O	O
the	DT	O	O
four	CD	O	O
significant	JJ	O	O
variables	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
against	IN	O	O
each	DT	O	O
other	JJ	O	O
in	IN	O	O
a	DT	O	O
single	JJ	O	O
regression	NN	O	O
analysis	NN	O	O
,	,	O	O
IEP	NNP	O	O
quality	NN	O	O
accounted	VBD	O	O
for	IN	O	O
one	CD	O	O
quarter	NN	O	O
of	IN	O	O
the	DT	O	O
variance	NN	O	O
in	IN	O	O
child	NN	O	O
outcomes	NNS	O	O
.	.	O	O

Recurrent	JJ	O	O
epithelial	JJ	O	O
ovarian	JJ	O	O
carcinoma	NN	O	O
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
phase	NN	O	O
III	NNP	O	O
study	NN	O	O
of	IN	O	O
pegylated	VBN	i	IPM
liposomal	JJ	i	IPM
doxorubicin	NN	i	IPM
versus	NN	O	O
topotecan	JJ	i	IPM
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
pegylated	JJ	i	IPM
liposomal	JJ	i	IPM
doxorubicin	NN	i	IPM
(	(	i	IPM
PLD	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
topotecan	JJ	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
epithelial	JJ	p	PC
ovarian	JJ	p	PC
carcinoma	NN	p	PC
that	WDT	p	O
recurred	VBD	p	PC
after	IN	p	PC
or	CC	p	O
did	VBD	p	PC
n't	RB	p	PC
respond	VB	p	PC
to	TO	p	PC
first-line	JJ	p	PC
,	,	p	PC
platinum-based	JJ	p	PC
chemotherapy	NN	p	PC
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Patients	NNPS	p	O
with	IN	p	O
measurable	JJ	p	O
and	CC	p	O
assessable	JJ	p	O
disease	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
PLD	NNP	i	IPM
50	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
as	IN	O	O
a	DT	O	O
1-hour	JJ	O	O
infusion	NN	O	O
every	DT	O	O
4	CD	O	O
weeks	NNS	O	O
or	CC	O	O
topotecan	JJ	i	IPM
1.5	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/d	NN	O	O
for	IN	O	O
5	CD	O	O
consecutive	JJ	O	O
days	NNS	O	O
every	DT	O	O
3	CD	O	O
weeks	NNS	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
stratified	VBN	O	O
prospectively	RB	O	O
for	IN	O	O
platinum	NN	O	O
sensitivity	NN	O	O
and	CC	O	O
for	IN	O	O
the	DT	O	O
presence	NN	O	O
or	CC	O	O
absence	NN	O	O
of	IN	O	O
bulky	JJ	O	O
disease	NN	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
474	CD	p	PSS
patients	NNS	p	O
were	VBD	O	O
treated	VBN	O	O
(	(	O	O
239	CD	O	O
PLD	NNP	i	IPM
and	CC	O	O
235	CD	O	O
topotecan	JJ	i	IPM
)	)	O	O
.	.	O	O

They	PRP	O	O
comprised	VBD	O	O
the	DT	O	O
intent-to-treat	JJ	O	O
population	NN	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OMO
progression-free	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
similar	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
arms	NNS	O	O
(	(	O	O
P	NNP	O	O
=.095	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OOt
response	NN	o	OOt
rates	NNS	o	OOt
for	IN	O	O
PLD	NNP	i	IPM
and	CC	O	O
topotecan	JJ	i	IPM
were	VBD	O	O
19.7	CD	O	O
%	NN	O	O
and	CC	O	O
17.0	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
=.390	NNP	O	O
)	)	O	O
.	.	O	O

Median	JJ	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
times	NNS	o	OMO
were	VBD	O	O
60	CD	O	O
weeks	NNS	O	O
for	IN	O	O
PLD	NNP	i	IPM
and	CC	O	O
56.7	CD	O	O
weeks	NNS	O	O
for	IN	O	O
topotecan	JJ	i	IPM
.	.	O	O

Data	NNP	O	O
analyzed	VBD	O	O
in	IN	O	O
platinum-sensitive	JJ	O	O
patients	NNS	O	O
demonstrated	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
benefit	NN	O	O
from	IN	O	O
PLD	NNP	i	IPM
for	IN	O	O
progression-free	JJ	O	O
survival	NN	O	O
(	(	O	O
P	NNP	O	O
=.037	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
medians	NNS	O	O
of	IN	O	O
28.9	CD	O	O
for	IN	O	O
PLD	NNP	i	IPM
versus	FW	O	O
23.3	CD	O	O
weeks	NNS	O	O
for	IN	O	O
topotecan	JJ	i	IPM
.	.	O	O

For	IN	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
,	,	O	O
PLD	NNP	i	IPM
was	VBD	O	O
significantly	RB	O	O
superior	JJ	O	O
to	TO	O	O
topotecan	VB	i	IPM
(	(	O	O
P	NNP	O	O
=.008	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
median	NN	O	O
of	IN	O	O
108	CD	O	O
weeks	NNS	O	O
versus	RB	O	O
71.1	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
platinum-refractory	JJ	O	O
subgroup	NN	O	O
demonstrated	VBD	O	O
a	DT	O	O
nonstatistically	RB	O	O
significant	JJ	O	O
survival	JJ	O	O
trend	NN	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
topotecan	JJ	i	IPM
(	(	O	O
P	NNP	O	O
=.455	NNP	O	O
)	)	O	O
.	.	O	O

Severe	JJ	o	OA
hematologic	JJ	o	OA
toxicity	NN	o	OA
was	VBD	O	O
more	RBR	O	O
common	JJ	O	O
with	IN	O	O
topotecan	JJ	i	IPM
and	CC	O	O
was	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
dosage	NN	O	O
modification	NN	O	O
,	,	O	O
or	CC	O	O
growth	NN	O	O
factor	NN	O	O
or	CC	O	O
blood	NN	O	O
product	NN	O	O
utilization	NN	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
comparable	JJ	O	O
efficacy	NN	o	OOt
,	,	O	O
favorable	JJ	O	O
safety	NN	o	OOt
profile	NN	O	O
,	,	O	O
and	CC	O	O
convenient	NN	O	O
dosing	VBG	O	O
support	NN	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
PLD	NNP	i	IPM
as	IN	O	O
a	DT	O	O
valuable	JJ	O	O
treatment	NN	O	O
option	NN	O	O
in	IN	O	O
this	DT	O	O
patient	JJ	O	O
population	NN	O	O
.	.	O	O

Raising	VBG	O	O
high-density	NN	O	O
lipoprotein	NN	O	O
in	IN	O	O
humans	NNS	O	O
through	IN	O	O
inhibition	NN	O	O
of	IN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
transfer	NN	O	O
protein	NN	O	O
:	:	O	O
an	DT	O	O
initial	JJ	O	O
multidose	NN	O	O
study	NN	O	O
of	IN	O	O
torcetrapib	NN	i	IPM
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
ability	NN	O	O
of	IN	O	O
the	DT	O	O
potent	NN	O	O
cholesteryl	NN	i	IPM
ester	NN	i	IPM
transfer	NN	i	IPM
protein	NN	i	IPM
(	(	i	IPM
CETP	NNP	i	IPM
)	)	i	IPM
inhibitor	NN	i	IPM
torcetrapib	NN	i	IPM
(	(	O	O
CP-529,414	NNP	O	O
)	)	O	O
to	TO	O	O
raise	VB	O	O
high-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
(	(	O	O
HDL-C	NNP	O	O
)	)	O	O
levels	NNS	O	O
in	IN	O	O
healthy	JJ	p	PC
young	JJ	p	PC
subjects	NNS	p	PC
was	VBD	O	O
tested	VBN	O	O
in	IN	O	O
this	DT	O	O
initial	JJ	O	O
phase	NN	O	O
1	CD	O	O
multidose	NN	O	O
study	NN	O	O
.	.	O	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Five	NNP	p	O
groups	NNS	p	O
of	IN	p	O
8	CD	p	O
subjects	NNS	p	O
each	DT	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
(	(	O	O
n=2	NN	O	O
)	)	O	O
or	CC	O	O
torcetrapib	NN	i	IPM
(	(	O	O
n=6	JJ	O	O
)	)	O	O
at	IN	O	O
10	CD	O	O
,	,	O	O
30	CD	O	O
,	,	O	O
60	CD	O	O
,	,	O	O
and	CC	O	O
120	CD	O	O
mg	NNS	O	O
daily	RB	O	O
and	CC	O	O
120	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
14	CD	O	O
days	NNS	O	O
.	.	O	O

Torcetrapib	NN	i	IPM
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
,	,	O	O
with	IN	O	O
all	DT	O	O
treated	JJ	O	O
subjects	NNS	O	O
completing	VBG	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
correlation	NN	O	O
of	IN	O	O
plasma	JJ	o	OPH
drug	NN	o	OPH
levels	NNS	o	OPH
with	IN	O	O
inhibition	NN	O	O
(	(	O	O
EC50=43	NNP	O	O
nM	RB	O	O
)	)	O	O
was	VBD	O	O
as	IN	O	O
expected	VBN	O	O
based	VBN	O	O
on	IN	O	O
in	IN	O	O
vitro	JJ	O	O
potency	NN	O	O
(	(	O	O
IC50	NNP	O	O
approximately	RB	O	O
50	CD	O	O
nM	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
increases	VBZ	O	O
in	IN	O	O
CETP	NNP	O	O
mass	NN	O	O
were	VBD	O	O
consistent	JJ	O	O
with	IN	O	O
the	DT	O	O
proposed	VBN	O	O
mechanism	NN	O	O
of	IN	O	O
inhibition	NN	O	O
.	.	O	O

CETP	NNP	O	O
inhibition	NN	O	O
increased	VBD	O	O
with	IN	O	O
escalating	VBG	O	O
dose	NN	O	O
,	,	O	O
leading	VBG	O	O
to	TO	O	O
elevations	NNS	O	O
of	IN	O	O
HDL-C	NNP	O	O
of	IN	O	O
16	CD	O	O
%	NN	O	O
to	TO	O	O
91	CD	O	O
%	NN	O	O
.	.	O	O

Total	JJ	o	OPH
plasma	JJ	o	OPH
cholesterol	NN	o	OPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
significantly	RB	O	O
because	IN	O	O
of	IN	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
nonHDL-C	JJ	o	OPH
,	,	O	O
including	VBG	O	O
a	DT	O	O
21	CD	O	O
%	NN	O	O
to	TO	O	O
42	CD	O	O
%	NN	O	O
lowering	NN	O	O
of	IN	O	O
low-density	NN	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
at	IN	O	O
the	DT	O	O
higher	JJR	O	O
doses	NNS	O	O
.	.	O	O

Apolipoprotein	NNP	o	OPH
A-I	NNP	o	OPH
and	CC	o	OPH
E	NNP	o	OPH
were	VBD	O	O
elevated	VBN	O	O
27	CD	O	O
%	NN	O	O
and	CC	O	O
66	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
apoB	NN	o	OPH
was	VBD	O	O
reduced	VBN	O	O
26	CD	O	O
%	NN	O	O
with	IN	O	O
120	CD	O	O
mg	NNS	O	O
twice	RB	O	O
daily	RB	O	O
.	.	O	O

Cholesteryl	NNP	o	OPH
ester	NN	o	OPH
content	NN	o	OPH
decreased	VBN	O	O
and	CC	O	O
triglyceride	VB	o	OPH
increased	VBN	O	O
in	IN	O	O
the	DT	O	O
nonHDL	JJ	O	O
plasma	NN	O	O
fraction	NN	O	O
,	,	O	O
with	IN	O	O
contrasting	VBG	O	O
changes	NNS	O	O
occurring	VBG	O	O
in	IN	O	O
HDL	NNP	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
These	DT	O	O
effects	NNS	O	O
of	IN	O	O
CETP	NNP	O	O
inhibition	NN	O	O
resemble	VBP	O	O
those	DT	O	O
observed	VBN	O	O
in	IN	O	O
partial	JJ	O	O
CETP	NNP	O	O
deficiency	NN	O	O
.	.	O	O

This	DT	O	O
work	NN	O	O
serves	VBZ	O	O
as	IN	O	O
a	DT	O	O
prelude	NN	O	O
to	TO	O	O
further	JJ	O	O
studies	NNS	O	O
in	IN	O	O
subjects	NNS	O	O
with	IN	O	O
low	JJ	O	O
HDL	NNP	O	O
,	,	O	O
or	CC	O	O
combinations	NNS	O	O
of	IN	O	O
dyslipidemia	NN	O	O
,	,	O	O
in	IN	O	O
assessing	VBG	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
CETP	NNP	O	O
in	IN	O	O
atherosclerosis	NN	O	O
.	.	O	O

Levobunolol	NNP	i	IPM
compared	VBN	O	O
with	IN	O	O
timolol	NN	i	IPM
:	:	O	O
a	DT	O	O
four-year	JJ	O	O
study	NN	O	O
.	.	O	O

Fifty-one	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
raised	VBN	p	PC
intraocular	JJ	p	PC
pressure	NN	p	PC
(	(	p	PC
IOP	NNP	p	PC
)	)	p	PC
were	VBD	O	O
treated	VBN	O	O
for	IN	O	O
up	IN	O	O
to	TO	O	O
four	CD	O	O
years	NNS	O	O
with	IN	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
ophthalmic	JJ	O	O
solutions	NNS	O	O
:	:	O	O
0.5	CD	O	O
%	NN	O	O
levobunolol	NN	i	IPM
,	,	O	O
1	CD	O	O
%	NN	O	O
levobunolol	NN	i	IPM
,	,	O	O
or	CC	O	O
0.5	CD	O	O
%	NN	O	O
timolol	NN	i	IPM
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
as	IN	O	O
a	DT	O	O
double-masked	JJ	O	O
,	,	O	O
randomised	JJ	O	O
trial	NN	O	O
in	IN	O	O
which	WDT	O	O
medications	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
twice	RB	O	O
daily	RB	O	O
to	TO	O	O
both	DT	O	O
eyes	NNS	O	O
.	.	O	O

Levobunolol	NNP	i	IPM
and	CC	O	O
timolol	NN	i	IPM
were	VBD	O	O
equally	RB	O	O
effective	JJ	O	O
in	IN	O	O
reducing	VBG	O	O
overall	JJ	o	OPH
mean	JJ	o	OPH
IOP	NNP	o	OPH
;	:	O	O
reductions	NNS	O	O
were	VBD	O	O
greater	JJR	O	O
than	IN	O	O
8.8	CD	O	O
mmHg	NNS	O	O
in	IN	O	O
all	DT	O	O
three	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
showed	VBD	O	O
levobunolol	NNS	i	IPM
to	TO	O	O
be	VB	O	O
as	IN	O	O
safe	JJ	O	O
and	CC	O	O
effective	JJ	O	O
as	IN	O	O
timolol	NN	i	IPM
in	IN	O	O
the	DT	O	O
long-term	JJ	O	O
control	NN	O	O
of	IN	O	O
raised	VBN	O	O
IOP	NNP	O	O
.	.	O	O

A	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
,	,	O	O
multicenter	NN	O	O
study	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	O	O
cardiovascular	JJ	o	OA
effects	NNS	o	OA
of	IN	O	O
skeletal	JJ	i	IPH
myoblast	NN	i	IPH
implantation	NN	i	IPH
by	IN	O	O
catheter	NN	O	O
delivery	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
heart	NN	p	PC
failure	NN	p	PC
after	IN	p	O
myocardial	JJ	p	PC
infarction	NN	p	PC
.	.	O	O

BACKGROUND	NNP	O	O
We	PRP	O	O
sought	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	O	O
preliminary	JJ	O	O
efficacy	NN	o	OOt
of	IN	O	O
transcatheter	NN	O	O
intramyocardial	JJ	O	O
administration	NN	O	O
of	IN	O	O
myoblasts	NNS	i	IPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
heart	NN	p	PC
failure	NN	p	PC
(	(	p	PC
HF	NNP	p	PC
)	)	p	PC
.	.	O	O

METHODS	NNP	O	O
MARVEL	NNP	O	O
is	VBZ	O	O
a	DT	O	O
randomized	JJ	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
image-guided	JJ	O	O
,	,	O	O
catheter-based	JJ	O	O
intramyocardial	JJ	O	O
injection	NN	O	O
of	IN	O	O
placebo	NN	i	IC
or	CC	O	O
myoblasts	NNS	i	IPM
(	(	O	O
400	CD	O	O
or	CC	O	O
800	CD	O	O
million	CD	O	O
)	)	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
class	NN	p	PC
II	NNP	p	PC
to	TO	p	PC
IV	NNP	p	PC
HF	NNP	p	PC
and	CC	p	O
ejection	NN	p	O
fraction	NN	p	O
<	VBD	p	O
35	CD	p	O
%	NN	p	O
.	.	O	O

Primary	JJ	O	O
end	NN	O	O
points	NNS	O	O
were	VBD	O	O
frequency	NN	o	OA
of	IN	o	OA
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	o	O
safety	NN	o	OPH
)	)	o	O
and	CC	O	O
changes	NNS	o	OPH
in	IN	o	OPH
6-minute	JJ	o	OPH
walk	NN	o	OPH
test	NN	o	OPH
and	CC	O	O
Minnesota	NNP	o	OOt
Living	NNP	o	OOt
With	IN	o	OOt
HF	NNP	o	OOt
score	NN	o	OOt
(	(	o	O
efficacy	NN	o	OOt
)	)	o	O
.	.	O	O

Of	IN	p	O
330	CD	p	PSS
patients	NNS	p	O
intended	VBN	p	O
for	IN	p	O
enrollment	NN	p	O
,	,	p	O
23	CD	p	PSS
were	VBD	p	O
randomized	VBN	p	O
(	(	p	O
MARVEL-1	NNP	p	O
)	)	p	O
before	IN	p	O
stopping	VBG	p	O
the	DT	p	O
study	NN	p	O
for	IN	p	O
financial	JJ	p	O
reasons	NNS	p	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
similar	JJ	O	O
numbers	NNS	O	O
of	IN	O	O
events	NNS	O	O
occurred	VBN	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
:	:	O	O
8	CD	O	O
(	(	O	O
placebo	NN	i	IC
)	)	O	O
,	,	O	O
7	CD	O	O
(	(	O	O
low	JJ	O	O
dose	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
8	CD	O	O
(	(	O	O
high	JJ	O	O
dose	NN	O	O
)	)	O	O
,	,	O	O
without	IN	O	O
deaths	NNS	O	O
.	.	O	O

Ventricular	JJ	o	OPH
tachycardia	NN	o	OPH
responsive	NN	o	OPH
to	TO	O	O
amiodarone	VB	O	O
was	VBD	O	O
more	RBR	O	O
frequent	JJ	O	O
in	IN	O	O
myoblast-treated	JJ	i	IPM
patients	NNS	O	O
:	:	O	O
1	CD	O	O
(	(	O	O
placebo	NN	i	IC
)	)	O	O
,	,	O	O
3	CD	O	O
(	(	O	O
low	JJ	O	O
dose	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
4	CD	O	O
(	(	O	O
high	JJ	O	O
dose	NN	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
trend	NN	O	O
toward	IN	O	O
improvement	NN	O	O
in	IN	O	O
functional	JJ	o	OME
capacity	NN	o	OME
was	VBD	O	O
noted	VBN	O	O
in	IN	O	O
myoblast-treated	JJ	i	IPM
groups	NNS	O	O
(	(	O	O
?6-minute	JJ	O	O
walk	NN	O	O
test	NN	O	O
of	IN	O	O
-3.6	NNP	O	O
vs	FW	O	O
+95.6	NNP	O	O
vs	FW	O	O
+85.5	NNP	O	O
m	FW	O	O
[	NNP	O	O
placebo	NN	O	O
vs	NN	O	O
low	JJ	O	O
dose	NN	O	O
vs	NN	O	O
high	JJ	O	O
dose	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.50	NNP	O	O
]	NNP	O	O
)	)	O	O
without	IN	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
Minnesota	NNP	o	O
Living	NNP	o	O
With	IN	o	O
HF	NNP	o	O
scores	NNS	o	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
HF	NNP	p	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	O
postinfarction	NN	p	O
cardiomyopathy	NN	p	O
,	,	O	O
transcatheter	JJ	O	O
administration	NN	O	O
of	IN	O	O
myoblasts	NNS	i	O
in	IN	O	O
doses	NNS	O	O
of	IN	O	O
400	CD	O	O
to	TO	O	O
800	CD	O	O
million	CD	O	O
cells	NNS	O	O
is	VBZ	O	O
feasible	JJ	O	O
and	CC	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
important	JJ	O	O
clinical	JJ	O	O
benefits	NNS	O	O
.	.	O	O

Ventricular	JJ	O	O
tachycardia	NN	O	O
may	MD	O	O
be	VB	O	O
provoked	VBN	O	O
by	IN	O	O
myoblast	JJ	i	O
injection	NN	O	O
but	CC	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
transient	NN	O	O
and	CC	O	O
treatable	JJ	O	O
problem	NN	O	O
.	.	O	O

A	DT	O	O
large-scale	JJ	O	O
outcome	JJ	O	O
trial	NN	O	O
of	IN	O	O
myoblast	JJ	i	O
administration	NN	O	O
in	IN	O	O
HF	NNP	p	O
patients	NNS	p	O
with	IN	p	O
postinfarction	NN	p	O
cardiomyopathy	NN	p	O
is	VBZ	O	O
feasible	JJ	O	O
and	CC	O	O
warranted	VBD	O	O
.	.	O	O

A	DT	O	O
selective	JJ	O	O
angiotensin	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	,	O	O
Valsartan	NNP	i	IPM
,	,	O	O
produced	VBD	O	O
regression	NN	O	O
of	IN	O	O
left	JJ	p	PC
ventricular	JJ	p	PC
hypertrophy	NN	p	PC
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
reduction	NN	O	O
of	IN	O	O
arterial	JJ	O	O
stiffness	NN	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
whether	IN	O	O
a	DT	O	O
selective	JJ	i	IPM
angiotensin	NN	i	IPM
II	NNP	i	IPM
receptor	NN	i	IPM
blocker	NN	i	IPM
(	(	i	IPM
ARB	NNP	i	IPM
)	)	i	IPM
would	MD	O	O
have	VB	O	O
a	DT	O	O
regressive	JJ	O	O
effect	NN	O	O
on	IN	O	O
left	NN	O	O
ventricular	JJ	O	O
hypertrophy	NN	O	O
(	(	O	O
LVH	NNP	O	O
)	)	O	O
in	IN	O	O
patients	NNS	p	O
on	IN	p	O
continuous	JJ	p	O
ambulatory	JJ	p	O
peritoneal	JJ	p	O
dialysis	NN	p	O
(	(	p	O
CAPD	NNP	p	O
)	)	p	O
.	.	O	O

In	IN	O	O
a	DT	O	O
double-blind	NN	O	O
study	NN	O	O
,	,	O	O
24	CD	p	PSS
CAPD	NNP	p	O
patients	NNS	p	O
with	IN	p	O
LVH	NNP	p	O
[	NNP	p	O
left	VBD	p	O
ventricular	JJ	p	O
mass	NN	p	O
index	NN	p	O
(	(	p	O
LVMi	NNP	p	O
)	)	p	O
>	VBD	p	O
110	CD	p	O
g/m2	NN	p	O
for	IN	p	O
women	NNS	p	PSE
and	CC	p	PSE
LVMi	NNP	p	PSE
>	NNP	p	PSE
137	CD	p	PSE
g/m2	NN	p	PSE
for	IN	p	PSE
men	NNS	p	PSE
]	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
12	CD	O	O
months	NNS	O	O
'	POS	O	O
administration	NN	O	O
of	IN	O	O
either	CC	O	O
the	DT	O	O
ARB	NNP	i	IPM
valsartan	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
or	CC	O	O
a	DT	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
target	NN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
BP	NNP	o	OPH
)	)	o	OPH
was	VBD	O	O
140/90	CD	O	O
mmHg	NN	O	O
or	CC	O	O
lower	JJR	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
following	JJ	O	O
parameters	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
before	RB	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
:	:	O	O
aortic	JJ	o	O
and	CC	o	O
large-artery	JJ	o	O
compliance	NN	o	O
and	CC	O	O
arterial	JJ	o	OPH
wave	NN	o	OPH
reflections	NNS	o	OPH
[	VBP	o	OPH
pulse	JJ	o	OPH
wave	VBP	o	OPH
velocity	NN	o	OPH
(	(	o	OPH
PWV	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
augmentation	NN	o	OPH
index	NN	o	OPH
(	(	o	OPH
AI	NNP	o	OPH
)	)	o	OPH
application	NN	o	OPH
tonometry	NN	o	OPH
]	NNP	o	OPH
and	CC	O	O
cardiac	JJ	o	OPH
echocardiography	NN	o	OPH
.	.	O	O

Periodically	RB	O	O
recorded	VBN	O	O
were	VBD	O	O
body	JJ	o	OPH
weight	NN	o	OPH
,	,	o	OPH
BP	NNP	o	OPH
(	(	o	OPH
mercury	NN	o	OPH
sphygmomanometer	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
serum	JJ	o	OPH
creatinine	NN	o	OPH
,	,	o	OPH
electrolytes	VBZ	o	OPH
,	,	o	OPH
complete	JJ	o	OPH
blood	NN	o	OPH
cell	NN	o	OPH
counts	NNS	o	OPH
,	,	o	OPH
urine	JJ	o	OPH
volume	NN	o	OPH
,	,	o	OPH
drainage	NN	o	OPH
volume	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
weekly	JJ	o	OPH
creatinine	NN	o	OPH
clearance	NN	o	OPH
.	.	O	O

Two-way	JJ	O	O
analysis	NN	O	O
of	IN	O	O
variance	NN	O	O
for	IN	O	O
repeated	JJ	O	O
measurements	NNS	O	O
was	VBD	O	O
used	VBN	O	O
for	IN	O	O
statistical	JJ	O	O
analysis	NN	O	O
.	.	O	O

Systolic	NNP	o	O
and	CC	o	O
diastolic	JJ	o	O
BP	NNP	o	O
were	VBD	O	O
both	DT	O	O
reduced	VBN	O	O
in	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
ARB	NNP	i	O
.	.	O	O

The	DT	O	O
LVMi	NNP	o	O
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
in	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
ARB	NNP	i	O
(	(	O	O
to	TO	O	O
121	CD	O	O
+/-	JJ	O	O
4	CD	O	O
from	IN	O	O
145	CD	O	O
+/-	JJ	O	O
5	CD	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
those	DT	O	O
receiving	VBG	O	O
placebo	NN	i	O
(	(	O	O
to	TO	O	O
137	CD	O	O
+/-	JJ	O	O
3	CD	O	O
from	IN	O	O
152	CD	O	O
+/-	JJ	O	O
3	CD	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
decrease	NN	O	O
in	IN	O	O
LVMi	NNP	o	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
PWV	NNP	o	OOt
and	CC	O	O
AI	NNP	o	O
.	.	O	O

In	IN	O	O
CAPD	NNP	O	O
patients	NNS	O	O
with	IN	O	O
LVH	NNP	O	O
,	,	O	O
ARB	NNP	i	O
reduced	VBD	O	O
LVMi	NNP	o	O
in	IN	O	O
association	NN	O	O
with	IN	O	O
alterations	NNS	O	O
in	IN	O	O
arterial	JJ	O	O
hemodynamics	NNS	O	O
.	.	O	O

Antioxidant	JJ	i	IPM
supplementation	NN	i	O
and	CC	O	O
exercise-induced	JJ	O	O
oxidative	JJ	O	O
stress	NN	O	O
in	IN	O	O
the	DT	p	O
60-year-old	JJ	p	PA
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
antipyrine	NN	i	O
hydroxylates	NNS	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
12	CD	O	O
weeks	NNS	O	O
of	IN	O	O
antioxidant	JJ	i	IPM
supplementation	NN	i	IPM
on	IN	O	O
exercise-induced	JJ	O	O
oxidative	JJ	O	O
stress	NN	O	O
were	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
older	JJR	p	O
adults	NNS	p	O
(	(	p	O
60	CD	p	O
(	(	p	O
SE	NNP	p	O
1	CD	p	O
)	)	p	O
years	NNS	p	O
;	:	p	O
BMI	NNP	p	O
26	CD	p	O
(	(	p	O
SE	NNP	p	O
1	CD	p	O
)	)	p	O
kg/m	NN	p	O
(	(	p	O
2	CD	p	O
)	)	p	O
)	)	p	O
.	.	O	O

Subjects	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
in	IN	O	O
two	CD	O	O
groups	NNS	O	O
:	:	O	O
supplementation	NN	O	O
(	(	O	O
n	JJ	O	O
11	CD	O	O
)	)	O	O
with	IN	O	O
100	CD	O	O
mg	NNS	O	O
dl-alpha-tocopheryl	JJ	i	IPM
acetate	NN	i	IPM
,	,	O	O
200	CD	O	O
mg	NN	O	O
ascorbic	JJ	i	IPM
acid	NN	i	IPM
,	,	O	O
and	CC	O	O
2	CD	O	O
mg	NN	O	O
beta-carotene	NN	i	IPM
,	,	O	O
and	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
9	CD	O	O
)	)	O	O
.	.	O	O

Before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
12	CD	O	O
week	NN	O	O
supplementation	NN	O	O
period	NN	O	O
,	,	O	O
subjects	NNS	O	O
cycled	VBD	O	O
for	IN	O	O
45	CD	O	O
min	NN	O	O
at	IN	O	O
submaximal	JJ	O	O
intensity	NN	O	O
(	(	O	O
50	CD	O	O
%	NN	O	O
maximal	JJ	O	O
workload	NN	O	O
capacity	NN	O	O
)	)	O	O
.	.	O	O

Antipyrine	NNP	i	IPM
was	VBD	O	O
used	VBN	O	O
as	IN	O	O
marker	NN	O	O
for	IN	O	O
oxidative	JJ	O	O
stress	NN	O	O
.	.	O	O

Antipyrine	NNP	O	O
reacts	VBZ	O	O
quickly	RB	O	O
with	IN	O	O
hydroxyl	JJ	O	O
radicals	NNS	O	O
to	TO	O	O
form	VB	O	O
para-	JJ	O	O
and	CC	O	O
ortho-hydroxyantipyrine	JJ	O	O
.	.	O	O

The	DT	O	O
latter	JJ	O	O
metabolite	NN	O	O
is	VBZ	O	O
not	RB	O	O
formed	VBN	O	O
in	IN	O	O
man	NN	O	O
through	IN	O	O
the	DT	O	O
mono-oxygenase	JJ	O	O
pathway	NN	O	O
of	IN	O	O
cytochrome	JJ	O	O
P450	NNP	O	O
.	.	O	O

Daily	NNP	O	O
supplementation	NN	O	O
significantly	RB	O	O
increased	VBD	O	O
plasma	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
alpha-tocopherol	NN	O	O
and	CC	O	O
beta-carotene	NN	O	O
in	IN	O	O
the	DT	O	O
supplemented	VBN	O	O
group	NN	O	O
(	(	O	O
Delta	NNP	O	O
14.4	CD	O	O
(	(	O	O
SE	NNP	O	O
3.2	CD	O	O
)	)	O	O
and	CC	O	O
0.4	CD	O	O
(	(	O	O
se	VB	O	O
0.1	CD	O	O
)	)	O	O
micromol/l	NN	O	O
;	:	O	O
P	NNP	O	O
<	VBZ	O	O
0.001	CD	O	O
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
,	,	O	O
within	IN	O	O
and	CC	O	O
between	IN	O	O
groups	NNS	O	O
,	,	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
exercise-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
ratios	NNS	O	O
para-	JJ	o	OPH
and	CC	o	OPH
ortho-hydroxyantipyrine	JJ	o	OPH
to	TO	o	OPH
antipyrine	VB	o	OPH
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
supplementation	NN	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
exercise-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
thiobarbituric	JJ	o	OPH
acid	NN	o	OPH
reactive	JJ	o	OPH
substances	NNS	o	OPH
in	IN	o	OPH
plasma	NN	o	OPH
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
in	IN	O	O
60-year-old	JJ	p	O
subjects	NNS	p	O
antioxidant	JJ	i	IPM
supplementation	NN	i	IPM
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
exercise-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
oxidative	JJ	O	O
stress	NN	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
free	JJ	o	OOt
radical	JJ	o	OOt
products	NNS	o	OOt
of	IN	o	OOt
antipyrine	NN	o	OOt
.	.	O	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
intensive	JJ	i	IE
early	JJ	i	IE
intervention	NN	i	IE
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
pervasive	JJ	p	PC
developmental	JJ	p	PC
disorder	NN	p	PC
.	.	O	O

Young	NNP	p	PA
children	NNS	p	PA
with	IN	p	O
pervasive	JJ	p	PC
developmental	JJ	p	PC
disorder	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
intensive	VB	i	IC
treatment	NN	i	IC
or	CC	O	O
parent	NN	i	IE
training	NN	i	IE
.	.	O	O

The	DT	O	O
intensive	JJ	i	O
treatment	NN	i	O
group	NN	O	O
(	(	O	O
7	CD	p	PSS
with	IN	p	O
autism	NN	p	PC
,	,	p	O
8	CD	p	PSS
with	IN	p	O
pervasive	JJ	p	O
developmental	JJ	p	O
disorder	NN	p	O
not	RB	p	O
otherwise	RB	p	O
specified	VBN	p	O
--	:	p	O
NOS	NNP	p	O
)	)	O	O
averaged	VBD	O	O
24.52	CD	O	O
hours	NNS	O	O
per	IN	O	O
week	NN	O	O
of	IN	O	O
individual	JJ	O	O
treatment	NN	O	O
for	IN	O	O
one	CD	O	O
year	NN	O	O
,	,	O	O
gradually	RB	O	O
reducing	VBG	O	O
hours	NNS	O	O
over	IN	O	O
the	DT	O	O
next	JJ	O	O
1	CD	O	O
to	TO	O	O
2	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
parent	NN	i	IE
training	NN	i	IE
group	NN	O	O
(	(	O	O
7	CD	p	PSS
with	IN	p	O
autism	NN	p	O
,	,	p	O
6	CD	p	PSS
with	IN	p	O
pervasive	JJ	p	PC
developmental	JJ	p	PC
disorder	NN	p	PC
NOS	NNP	p	O
)	)	O	O
received	VBD	O	O
3	CD	O	O
to	TO	O	O
9	CD	O	O
months	NNS	O	O
of	IN	O	O
parent	NN	i	IE
training	NN	i	IE
.	.	O	O

The	DT	O	O
groups	NNS	O	O
appeared	VBD	O	O
similar	JJ	O	O
at	IN	O	O
intake	NN	O	O
on	IN	O	O
all	DT	O	O
measures	NNS	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
at	IN	O	O
follow-up	JJ	O	O
the	DT	O	O
intensive	JJ	i	O
treatment	NN	i	O
group	NN	O	O
outperformed	VBD	O	O
the	DT	O	O
parent	NN	i	IE
training	VBG	i	IE
group	NN	O	O
on	IN	O	O
measures	NNS	O	O
of	IN	O	O
intelligence	NN	o	OME
,	,	o	OME
visual-spatial	JJ	o	OME
skills	NNS	o	OME
,	,	o	OME
language	NN	o	OME
,	,	o	OME
and	CC	o	OME
academics	NNS	o	OME
,	,	O	O
though	IN	O	O
not	RB	O	O
adaptive	JJ	o	OME
functioning	NN	o	OME
or	CC	O	O
behavior	NN	o	OME
problems	NNS	o	OME
.	.	O	O

Children	NNP	p	PA
with	IN	p	O
pervasive	JJ	p	PC
developmental	JJ	p	PC
disorder	NN	p	PC
NOS	NNP	O	O
may	MD	O	O
have	VB	O	O
gained	VBN	O	O
more	JJR	O	O
than	IN	O	O
those	DT	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

The	DT	O	O
role	NN	O	O
of	IN	O	O
somatostatin	NN	i	IPM
(	(	i	IPM
octreotide	JJ	i	IPM
)	)	i	IPM
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
melatonin	JJ	o	OPH
secretion	NN	o	OPH
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
and	CC	p	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
primary	JJ	p	PC
hypothyroidism	NN	p	PC
.	.	p	O

Somatostatin	NNP	i	IPM
has	VBZ	O	O
been	VBN	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
pineal	JJ	O	O
gland	NN	O	O
of	IN	O	O
several	JJ	O	O
animal	JJ	O	O
species	NNS	O	O
,	,	O	O
which	WDT	O	O
suggests	VBZ	O	O
that	IN	O	O
it	PRP	O	O
may	MD	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
melatonin	JJ	o	OPH
secretion	NN	o	OPH
.	.	O	O

Whether	NNP	O	O
somatostatin	NN	i	IPM
has	VBZ	O	O
regulatory	JJ	O	O
influence	NN	O	O
on	IN	O	O
melatonin	NN	o	OPH
secretion	NN	o	OPH
in	IN	O	O
man	NN	O	O
has	VBZ	O	O
never	RB	O	O
been	VBN	O	O
unequivocally	RB	O	O
shown	VBN	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
the	DT	O	O
nocturnal	JJ	o	OPH
melatonin	NN	o	OPH
secretion	NN	o	OPH
in	IN	O	O
8	CD	p	PSS
healthy	JJ	p	O
volunteers	NNS	p	O
,	,	p	O
and	CC	p	O
6	CD	p	PSS
women	NNS	p	PSE
with	IN	p	O
untreated	JJ	p	O
primary	JJ	p	PC
hypothyroidism	NN	p	PC
,	,	O	O
a	DT	O	O
disease	NN	O	O
state	NN	O	O
that	WDT	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
nocturnal	JJ	O	O
secretion	NN	O	O
of	IN	O	O
melatonin	NN	O	O
.	.	O	O

The	DT	O	O
participants	NNS	O	O
were	VBD	O	O
given	VBN	O	O
subcutaneous	JJ	O	O
injections	NNS	O	O
at	IN	O	O
18:00	CD	O	O
h	NN	O	O
and	CC	O	O
23:00	CD	O	O
h	NN	O	O
of	IN	O	O
either	DT	O	O
saline	NN	i	IPM
or	CC	O	O
octreotide	NN	i	IPM
(	(	i	IPM
Sandostatin	NNP	i	IPM
;	:	O	O
each	DT	O	O
injection	NN	O	O
50	CD	O	O
microg	NN	O	O
)	)	O	O
.	.	O	O

During	IN	O	O
the	DT	O	O
nights	NNS	O	O
when	WRB	O	O
the	DT	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
were	VBD	O	O
given	VBN	O	O
octreotide	RB	i	IPM
,	,	O	O
melatonin	JJ	o	OPH
secretion	NN	o	OPH
was	VBD	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
recorded	VBN	O	O
during	IN	O	O
administration	NN	O	O
of	IN	O	O
saline	NN	i	IPM
.	.	O	O

Also	RB	O	O
the	DT	O	O
urinary	JJ	o	OPH
excretion	NN	o	OPH
of	IN	o	OPH
melatonin	NN	o	OPH
was	VBD	O	O
of	IN	O	O
similar	JJ	O	O
magnitude	NN	O	O
at	IN	O	O
these	DT	O	O
two	CD	O	O
occasions	NNS	O	O
.	.	O	O

By	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
GH	NNP	o	OPH
secretion	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
the	DT	O	O
nights	NNS	O	O
the	DT	O	O
healthy	JJ	O	O
controls	NNS	O	O
were	VBD	O	O
given	VBN	O	O
octreotide	RB	i	IPM
(	(	O	O
GH	NNP	O	O
AUC	NNP	O	O
22.6+/-5.4	JJ	O	O
mU/l	NN	O	O
x	NNP	O	O
h	NN	O	O
during	IN	O	O
octreotide	JJ	i	IPM
and	CC	O	O
126.6+/-21.9	JJ	O	O
mU/l	NN	O	O
x	NNP	O	O
h	NN	O	O
during	IN	O	O
saline	NN	i	IPM
;	:	O	O
p	CC	O	O
<	VB	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
patients	NNS	p	O
with	IN	p	O
hypothyroidism	NN	p	PC
also	RB	O	O
showed	VBD	O	O
similar	JJ	O	O
nocturnal	JJ	o	OPH
melatonin	NN	o	OPH
secretion	NN	o	OPH
during	IN	O	O
octreotide	NN	i	IPM
and	CC	O	O
saline	NN	i	IPM
.	.	O	O

Urinary	JJ	o	OPH
excretion	NN	o	OPH
of	IN	o	OPH
melatonin	NN	o	OPH
also	RB	O	O
remained	VBD	O	O
unchanged	JJ	O	O
,	,	O	O
as	IN	O	O
did	VBD	O	O
GH	NNP	O	O
secretion	NN	O	O
.	.	O	O

The	DT	O	O
total	JJ	o	OPH
nocturnal	JJ	o	OPH
secretion	NN	o	OPH
of	IN	o	OPH
TSH	NNP	o	OPH
was	VBD	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
significantly	RB	O	O
reduced	VBN	O	O
by	IN	O	O
octreotide	NN	i	IPM
(	(	O	O
TSH	NNP	O	O
AUC	NNP	O	O
562+/-136	JJ	O	O
mU/l	NN	O	O
x	NNP	O	O
h	NN	O	O
during	IN	O	O
octreotide	JJ	i	IPM
and	CC	O	O
851+/-185	JJ	O	O
mU/l	NN	O	O
x	NNP	O	O
h	NN	O	O
during	IN	O	O
saline	NN	i	IC
;	:	O	O
p	CC	O	O
<	VB	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
thus	RB	O	O
suggesting	VBG	O	O
that	IN	O	O
100	CD	O	O
microg	NN	O	O
of	IN	O	O
octreotide	NN	i	IPM
should	MD	O	O
be	VB	O	O
sufficient	JJ	O	O
to	TO	O	O
inhibit	VB	O	O
also	RB	O	O
the	DT	O	O
pinealocytes	NNS	O	O
if	IN	O	O
their	PRP$	O	O
function	NN	O	O
were	VBD	O	O
regulated	VBN	O	O
by	IN	O	O
somatostatin	NN	i	IPM
.	.	O	O

Since	IN	O	O
exogenous	JJ	O	O
somatostatin	NN	i	IPM
--	:	O	O
in	IN	O	O
the	DT	O	O
form	NN	O	O
of	IN	O	O
octreotide	NN	i	IPM
--	:	O	O
fails	VBZ	O	O
to	TO	O	O
influence	VB	O	O
nocturnal	JJ	o	OPH
secretion	NN	o	OPH
and	CC	o	O
urinary	JJ	o	OPH
excretion	NN	o	OPH
of	IN	o	OPH
melatonin	NN	o	OPH
in	IN	O	O
normal	JJ	p	O
subjects	NNS	p	O
and	CC	p	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
primary	JJ	p	O
hypothyroidism	NN	p	PC
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
reasonable	JJ	O	O
to	TO	O	O
assume	VB	O	O
that	DT	O	O
endogenous	JJ	O	O
somatostatin	NN	i	IPM
may	MD	O	O
not	RB	O	O
be	VB	O	O
an	DT	O	O
important	JJ	O	O
regulator	NN	O	O
of	IN	O	O
melatonin	JJ	O	O
secretion	NN	O	O
in	IN	O	O
man	NN	O	O
.	.	O	O

[	JJ	O	O
Effects	NNS	O	O
of	IN	O	O
auditory	JJ	i	IE
integrative	JJ	i	IE
training	NN	i	IE
on	IN	O	O
autistic	JJ	p	PC
children	NNS	p	PC
]	VBP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
explore	VB	O	O
the	DT	O	O
short-term	JJ	O	O
treatment	NN	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
auditory	JJ	i	IE
integrative	JJ	i	IE
training	NN	i	IE
on	IN	O	O
autistic	JJ	p	O
children	NNS	p	O
and	CC	O	O
provide	VB	O	O
them	PRP	O	O
with	IN	O	O
clinical	JJ	O	O
support	NN	O	O
for	IN	O	O
rehabilitative	JJ	O	O
treatment	NN	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	p	PC
total	NN	p	PC
of	IN	p	PC
81	CD	p	PC
cases	NNS	p	PC
of	IN	p	PC
autistic	JJ	p	PC
children	NNS	p	PC
were	VBD	O	O
selected	VBN	O	O
through	IN	O	O
the	DT	O	O
standard	NN	O	O
of	IN	O	O
DSM-4	NNP	O	O
and	CC	O	O
clinical	JJ	O	O
case	NN	O	O
study	NN	O	O
was	VBD	O	O
used	VBN	O	O
.	.	O	O

They	PRP	O	O
were	VBD	O	O
divided	VBN	O	O
randomly	RB	O	O
into	IN	O	O
experimental	JJ	O	O
group	NN	O	O
and	CC	O	O
control	VB	O	O
one	CD	O	O
,	,	O	O
and	CC	O	O
respectively	RB	O	O
received	VBD	O	O
auditory	JJ	i	IE
integrative	JJ	i	IE
training	NN	i	IE
and	CC	O	O
no	DT	O	O
training	NN	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
multiple	JJ	O	O
therapies	NNS	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
investigated	VBN	O	O
using	VBG	O	O
clinical	JJ	o	OPH
manifestation	NN	o	OPH
and	CC	O	O
Autism	NNP	o	OOt
Behavior	NNP	o	OOt
Checklist	NNP	o	OOt
(	(	o	OOt
ABC	NNP	o	OOt
)	)	o	OOt
and	CC	O	O
intelligence	NN	o	OOt
quotient	NN	o	OOt
(	(	o	OOt
IQ	NNP	o	OOt
)	)	o	OOt
before	IN	O	O
and	CC	O	O
after	IN	O	O
six	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
through	IN	O	O
the	DT	O	O
changes	NNS	o	O
of	IN	o	O
clinical	JJ	o	O
manifestations	NNS	o	O
and	CC	O	O
scores	NNS	O	O
of	IN	O	O
ABC	NNP	o	OA
and	CC	O	O
IQ	NNP	o	OOt
.	.	O	O

The	DT	O	O
changes	NNS	O	O
of	IN	O	O
scores	NNS	O	O
of	IN	O	O
IQ	NNP	o	OOt
were	VBD	O	O
determined	VBN	O	O
with	IN	O	O
Gesell	NNP	O	O
and	CC	O	O
WPPSI	NNP	O	O
or	CC	O	O
WISC-R	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
Compared	VBD	O	O
with	IN	O	O
40	CD	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
after	IN	O	O
the	DT	O	O
six	CD	O	O
months	NNS	O	O
of	IN	O	O
the	DT	O	O
auditory	JJ	i	IE
integrative	JJ	i	IE
training	NN	i	IE
,	,	O	O
41	CD	O	O
of	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
had	VBD	O	O
greatly	RB	O	O
improved	VBN	O	O
in	IN	O	O
many	JJ	O	O
aspects	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
disorders	NNS	o	OOt
of	IN	o	OOt
their	PRP$	o	OOt
language	NN	o	OOt
,	,	o	OOt
social	JJ	o	OOt
interactions	NNS	o	OOt
and	CC	o	OOt
typical	JJ	o	OOt
behavior	NN	o	OOt
symptoms	NNS	o	OOt
while	IN	O	O
they	PRP	O	O
had	VBD	O	O
not	RB	O	O
changed	VBN	O	O
in	IN	O	O
their	PRP$	O	O
abnormal	JJ	o	OOt
behaviors	NNS	o	OOt
.	.	O	O

The	DT	O	O
scores	NNS	o	OOt
of	IN	o	OOt
IQ	NNP	o	OOt
or	CC	o	OOt
DQ	NNP	o	OOt
had	VBD	O	O
increased	VBN	O	O
and	CC	O	O
scores	NNS	O	O
of	IN	O	O
ABC	NNP	o	OOt
had	VBD	O	O
dropped	VBN	O	O
.	.	O	O

The	DT	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
greatly	RB	O	O
significant	JJ	O	O
in	IN	O	O
statistics	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
decreasing	VBG	O	O
level	NN	O	O
of	IN	O	O
both	DT	O	O
ABC	NNP	o	OOt
scores	NNS	o	OOt
and	CC	O	O
the	DT	O	O
increasing	VBG	O	O
level	NN	O	O
of	IN	O	O
the	DT	O	O
IQ	NNP	o	OOt
scores	NNS	o	OOt
were	VBD	O	O
negatively	RB	O	O
correlated	VBN	O	O
with	IN	O	O
age	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
decreasing	VBG	O	O
level	NN	O	O
of	IN	O	O
ABC	NNP	o	OOt
scores	NNS	o	OOt
was	VBD	O	O
in	IN	O	O
line	NN	O	O
regression	NN	O	O
(	(	O	O
positive	JJ	O	O
correlation	NN	O	O
)	)	O	O
with	IN	O	O
base	NN	O	O
IQ	NNP	O	O
.	.	O	O

CONCLUSION	NNP	O	O
The	DT	O	O
treatment	NN	O	O
of	IN	O	O
auditory	JJ	i	IE
integrative	JJ	i	IE
training	NN	i	IE
(	(	i	IE
AIT	NNP	i	IE
)	)	i	IE
could	MD	O	O
greatly	RB	O	O
improve	VB	O	O
on	IN	O	O
language	NN	o	OOt
disorders	NNS	o	OOt
,	,	O	O
the	DT	O	O
difficulties	NNS	o	OPH
of	IN	o	OPH
social	JJ	o	OPH
interactions	NNS	o	OPH
,	,	o	OPH
typical	JJ	o	OPH
behavior	NN	o	OPH
symptoms	NNS	o	OPH
and	CC	O	O
developmental	JJ	o	OOt
levels	NNS	o	OOt
,	,	O	O
therefore	IN	O	O
it	PRP	O	O
is	VBZ	O	O
positive	JJ	O	O
to	TO	O	O
the	DT	O	O
autistic	JJ	p	O
children	NNS	p	O
in	IN	O	O
its	PRP$	O	O
short-term	JJ	O	O
treatment	NN	O	O
effect	NN	O	O
.	.	O	O

The	DT	O	O
immediate	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
adjunctive	JJ	O	O
doxycycline	NN	i	IPM
in	IN	O	O
treatment	NN	O	O
of	IN	O	O
localized	VBN	p	PC
juvenile	NN	p	PC
periodontitis	NN	p	PC
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
on	IN	O	O
the	DT	O	O
immediate	JJ	o	OOt
clinical	JJ	o	OOt
and	CC	o	OOt
microbiological	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
doxycycline	NN	i	IPM
(	(	O	O
100	CD	O	O
mg	NN	O	O
for	IN	O	O
14	CD	O	O
days	NNS	O	O
)	)	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
benefit	NN	O	O
of	IN	O	O
adjunctive	JJ	O	O
medication	NN	O	O
in	IN	O	O
16	CD	p	PSS
patients	NNS	p	PSS
with	IN	p	O
localized	JJ	p	PC
juvenile	NN	p	PC
periodontitis	NN	p	PC
.	.	O	O

Measurements	NNS	O	O
of	IN	O	O
gingival	NN	o	OPH
fluid	NN	o	OPH
flow	NN	o	OPH
,	,	o	OPH
probing	VBG	o	OPH
depths	NNS	o	OPH
,	,	o	OPH
bleeding	VBG	o	OPH
on	IN	o	OPH
probing	VBG	o	OPH
and	CC	o	OPH
suppuration	NN	o	OPH
were	VBD	O	O
determined	VBN	O	O
at	IN	O	O
2	CD	O	O
periodontal	JJ	O	O
sites	NNS	O	O
with	IN	O	O
and	CC	O	O
2	CD	O	O
without	IN	O	O
radiographic	JJ	O	O
attachment	JJ	O	O
loss	NN	O	O
,	,	O	O
at	IN	O	O
weeks	NNS	O	O
0	CD	O	O
,	,	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
and	CC	O	O
8	CD	O	O
.	.	O	O

Subgingival	JJ	o	OPH
bacterial	JJ	o	OPH
samples	NNS	o	OPH
were	VBD	O	O
taken	VBN	O	O
with	IN	O	O
curettes	NNS	O	O
from	IN	O	O
the	DT	O	O
same	JJ	O	O
sites	NNS	O	O
.	.	O	O

Spirochaetes	NNS	o	O
were	VBD	O	O
searched	VBN	O	O
for	IN	O	O
by	IN	O	O
dark-field	JJ	o	O
microscopy	NN	o	O
.	.	O	O

Actinobacillus	CC	O	O
actinomycetemcomitans	NNS	O	O
,	,	O	O
pigmented	VBN	O	O
and	CC	O	O
non-pigmented	JJ	O	O
Bacteroides	NNP	O	O
spp.	NN	O	O
,	,	O	O
Capnocytophaga	NNP	O	O
,	,	O	O
Fusobacterium	NNP	O	O
and	CC	O	O
Actinomyces	NNP	O	O
spp	NN	O	O
.	.	O	O

were	VBD	O	O
cultured	VBN	O	O
on	IN	O	O
various	JJ	O	O
selective	JJ	O	O
and	CC	O	O
non-selective	JJ	O	O
media	NNS	O	O
.	.	O	O

Bacterial	JJ	O	O
species	NNS	O	O
found	VBN	O	O
at	IN	O	O
least	JJS	O	O
in	IN	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
and	CC	O	O
comprising	VBG	O	O
on	IN	O	O
average	JJ	O	O
5	CD	O	O
%	NN	O	O
or	CC	O	O
more	JJR	O	O
of	IN	O	O
the	DT	O	O
cultivable	JJ	O	O
flora	NNS	O	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
analysis	NN	O	O
.	.	O	O

Neither	CC	O	O
short-term	JJ	o	OOt
clinical	JJ	o	OOt
nor	CC	o	OOt
microbiological	JJ	o	OOt
efficacy	NN	o	OOt
beyond	IN	O	O
that	DT	O	O
of	IN	O	O
a	DT	O	O
course	NN	O	O
of	IN	O	O
mechanical	JJ	O	O
debridement	NN	O	O
alone	RB	O	O
was	VBD	O	O
found	VBN	O	O
by	IN	O	O
using	VBG	O	O
systemic	JJ	O	O
medication	NN	O	O
with	IN	O	O
doxycycline	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
localized	JJ	p	PC
juvenile	NN	p	PC
periodontitis	NN	p	PC
.	.	O	O

Efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
selamectin	NN	i	IPM
against	IN	O	O
fleas	NNS	O	O
and	CC	O	O
heartworms	NNS	O	O
in	IN	O	O
dogs	NNS	p	O
and	CC	p	O
cats	NNS	p	O
presented	VBD	p	O
as	IN	p	O
veterinary	JJ	p	O
patients	NNS	p	O
in	IN	p	O
North	NNP	p	O
America	NNP	p	O
.	.	O	O

A	NNP	O	O
series	NN	O	O
of	IN	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
,	,	O	O
masked	VBD	O	O
field	NN	O	O
studies	NNS	O	O
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
selamectin	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
flea	NN	O	O
infestations	NNS	O	O
on	IN	O	O
dogs	NNS	p	O
and	CC	p	O
cats	NNS	p	O
,	,	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
heartworm	NN	O	O
infection	NN	O	O
in	IN	O	O
dogs	NNS	p	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
observations	NNS	O	O
were	VBD	O	O
made	VBN	O	O
on	IN	O	O
the	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
of	IN	O	O
selamectin	NN	i	IPM
treatment	NN	O	O
on	IN	O	O
dogs	NNS	p	PC
and	CC	p	PC
cats	NNS	p	PC
showing	VBG	p	PC
signs	NNS	p	PC
of	IN	p	PC
flea	NN	p	PC
allergy	NN	p	PC
dermatitis	NN	p	PC
(	(	p	PC
FAD	NNP	p	PC
)	)	p	PC
.	.	O	O

In	IN	O	O
all	DT	O	O
studies	NNS	O	O
selamectin	VBP	i	IPM
was	VBD	O	O
applied	VBN	O	O
topically	RB	O	O
,	,	O	O
once	RB	O	O
per	IN	O	O
month	NN	O	O
,	,	O	O
in	IN	O	O
unit	NN	O	O
doses	NNS	O	O
providing	VBG	O	O
a	DT	O	O
minimum	JJ	O	O
dosage	NN	O	O
of	IN	O	O
6mgkg	CD	O	O
(	(	O	O
-1	NN	O	O
)	)	O	O
.	.	O	O

Dogs	NNS	p	O
and	CC	p	O
cats	NNS	p	O
with	IN	p	O
naturally	RB	p	O
occurring	VBG	p	O
flea	NN	p	PC
infestations	NNS	p	PC
,	,	p	O
some	DT	p	O
of	IN	p	O
which	WDT	p	O
also	RB	p	O
had	VBD	p	O
signs	NNS	p	O
associated	VBN	p	O
with	IN	p	O
FAD	NNP	p	O
,	,	O	O
were	VBD	O	O
assigned	VBN	O	O
randomly	RB	O	O
to	TO	O	O
receive	VB	O	O
three	CD	O	O
months	NNS	O	O
of	IN	O	O
topical	JJ	O	O
treatment	NN	O	O
with	IN	O	O
selamectin	NN	i	IPM
(	(	O	O
220	CD	p	O
dogs	NNS	p	O
,	,	p	O
189	CD	p	O
cats	NNS	p	O
)	)	p	O
or	CC	O	O
a	DT	O	O
positive-control	JJ	O	O
product	NN	O	O
(	(	O	O
dogs	NNS	O	O
:	:	O	O
fenthion	NN	i	IPM
,	,	O	O
n=81	RB	O	O
;	:	O	O
cats	NNS	O	O
:	:	O	O
pyrethrins	NNS	i	IPM
,	,	O	O
n=66	NN	O	O
)	)	O	O
.	.	O	O

Selamectin	NNP	i	IPM
was	VBD	O	O
administered	VBN	O	O
on	IN	O	O
days	NNS	O	O
0	CD	O	O
,	,	O	O
30	CD	O	O
,	,	O	O
and	CC	O	O
60	CD	O	O
.	.	O	O

Day	NNP	O	O
0	CD	O	O
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
the	DT	O	O
day	NN	O	O
that	IN	O	O
the	DT	O	O
animal	NN	O	O
first	RB	O	O
received	VBD	O	O
treatment	NN	O	O
.	.	O	O

Flea	NN	O	O
burdens	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
flea	NN	o	O
comb	NN	o	O
counts	NNS	o	O
and	CC	O	O
clinical	JJ	o	O
evaluations	NNS	o	O
of	IN	o	O
FAD	NNP	o	O
were	VBD	O	O
performed	VBN	O	O
before	IN	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
on	IN	O	O
days	NNS	O	O
14	CD	O	O
,	,	O	O
30	CD	O	O
,	,	O	O
60	CD	O	O
,	,	O	O
and	CC	O	O
90	CD	O	O
.	.	O	O

On	IN	O	O
days	NNS	O	O
30	CD	O	O
,	,	O	O
60	CD	O	O
,	,	O	O
and	CC	O	O
90	CD	O	O
,	,	O	O
mean	JJ	o	OPH
flea	NN	o	OPH
counts	NNS	o	OPH
in	IN	O	O
selamectin-treated	JJ	i	IPM
dogs	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
92.1	CD	O	O
,	,	O	O
99.0	CD	O	O
,	,	O	O
and	CC	O	O
99.8	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
mean	JJ	o	OPH
flea	NN	o	OPH
counts	NNS	o	OPH
in	IN	O	O
fenthion-treated	JJ	O	O
dogs	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
81.5	CD	O	O
,	,	O	O
86.8	CD	O	O
,	,	O	O
and	CC	O	O
86.1	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
day	NN	O	O
0	CD	O	O
counts	NNS	O	O
.	.	O	O

Also	RB	O	O
,	,	O	O
on	IN	O	O
days	NNS	O	O
30	CD	O	O
,	,	O	O
60	CD	O	O
,	,	O	O
and	CC	O	O
90	CD	O	O
,	,	O	O
mean	JJ	o	OPH
flea	NN	o	OPH
counts	NNS	o	OPH
in	IN	O	O
selamectin-treated	JJ	O	O
cats	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
92.5	CD	O	O
,	,	O	O
98.3	CD	O	O
,	,	O	O
and	CC	O	O
99.3	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
mean	JJ	o	OPH
flea	NN	o	OPH
counts	NNS	o	OPH
in	IN	O	O
pyrethrin-treated	JJ	O	O
cats	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
66.4	CD	O	O
,	,	O	O
73.9	CD	O	O
,	,	O	O
and	CC	O	O
81.3	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
day	NN	O	O
0	CD	O	O
counts	NNS	O	O
.	.	O	O

Selamectin	NNP	i	IPM
also	RB	O	O
was	VBD	O	O
beneficial	JJ	O	O
in	IN	O	O
alleviating	VBG	O	O
signs	NNS	O	O
in	IN	O	O
dogs	NNS	p	O
and	CC	p	O
cats	NNS	p	O
diagnosed	VBD	p	O
clinically	RB	p	O
with	IN	p	O
FAD	NNP	p	O
.	.	O	O

A	NNP	O	O
total	NN	O	O
of	IN	O	O
397	CD	p	O
dogs	NNS	p	O
free	JJ	p	O
of	IN	p	O
adult	NN	p	O
heartworm	NN	p	O
infection	NN	p	O
from	IN	p	O
four	CD	p	O
heartworm-endemic	JJ	p	O
areas	NNS	p	O
of	IN	p	O
the	DT	p	O
USA	NNP	p	O
were	VBD	O	O
allocated	VBN	O	O
randomly	RB	O	O
to	TO	O	O
six	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
selamectin	NN	i	O
(	(	O	O
n=298	JJ	O	O
)	)	O	O
or	CC	O	O
ivermectin	NN	i	IPM
(	(	O	O
n=99	JJ	O	O
)	)	O	O
.	.	O	O

Selamectin	NNP	i	O
achieved	VBD	O	O
a	DT	O	O
heartworm	JJ	o	OPH
prevention	NN	o	OPH
rate	NN	o	OPH
of	IN	O	O
100	CD	O	O
%	NN	O	O
,	,	O	O
with	IN	O	O
all	DT	O	O
dogs	NNS	O	O
testing	VBG	O	O
negative	JJ	O	O
for	IN	O	O
microfilariae	NN	O	O
and	CC	O	O
adult	NN	O	O
heartworm	NN	O	O
antigen	NN	O	O
on	IN	O	O
days	NNS	O	O
180	CD	O	O
and	CC	O	O
300	CD	O	O
.	.	O	O

Selamectin	NNP	i	O
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
673	CD	p	O
dogs	NNS	p	O
and	CC	p	O
347	CD	p	O
cats	NNS	p	O
having	VBG	O	O
an	DT	O	O
age	NN	O	O
range	NN	O	O
of	IN	O	O
6	CD	O	O
weeks	NNS	O	O
to	TO	O	O
19	CD	O	O
years	NNS	O	O
(	(	O	O
3954	CD	O	O
doses	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
animals	NNS	p	O
included	VBD	p	O
19	CD	p	O
purebred	VBD	p	O
or	CC	p	O
crossbred	JJ	p	O
Collies	NNS	p	O
(	(	p	O
Bearded	NNP	p	O
,	,	p	O
Border	NNP	p	O
,	,	p	O
and	CC	p	O
unspecified	JJ	p	O
)	)	p	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
serious	JJ	O	O
adverse	JJ	o	OA
events	NNS	o	OA
.	.	O	O

Results	NNS	O	O
of	IN	O	O
these	DT	O	O
studies	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
selamectin	NN	i	O
was	VBD	O	O
highly	RB	O	O
effective	JJ	o	OOt
in	IN	O	O
the	DT	O	O
control	NN	O	O
of	IN	O	O
flea	NN	O	O
infestations	NNS	O	O
in	IN	O	O
dogs	NNS	p	O
and	CC	p	O
cats	NNS	p	O
without	IN	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
simultaneous	JJ	O	O
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
environment	NN	O	O
or	CC	O	O
of	IN	O	O
in-contact	JJ	O	O
animals	NNS	O	O
and	CC	O	O
also	RB	O	O
was	VBD	O	O
beneficial	JJ	O	O
in	IN	O	O
alleviating	VBG	O	O
signs	NNS	o	O
associated	VBN	o	O
with	IN	o	O
FAD	NNP	o	O
.	.	O	O

Selamectin	NNP	i	O
also	RB	O	O
was	VBD	O	O
100	CD	O	O
%	NN	O	O
effective	JJ	O	O
in	IN	O	O
preventing	VBG	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
canine	NN	O	O
heartworms	NNS	o	O
and	CC	O	O
was	VBD	O	O
safe	JJ	o	OOt
for	IN	O	O
topical	JJ	O	O
use	NN	O	O
in	IN	O	O
dogs	NNS	p	O
and	CC	p	O
cats	NNS	p	O
.	.	O	O

Randomized	VBN	O	O
phase	NN	O	O
II	NNP	O	O
study	NN	O	O
of	IN	O	O
two	CD	O	O
different	JJ	O	O
schedules	NNS	O	O
of	IN	O	O
gemcitabine	NN	i	IPM
and	CC	O	O
oral	JJ	O	O
S-1	NNP	i	IPM
in	IN	O	O
chemo-na?ve	JJ	p	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
non-small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
.	.	O	O

INTRODUCTION	NNP	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	O
and	CC	O	O
safety	NN	o	O
and	CC	O	O
to	TO	O	O
compare	VB	O	O
dosing	VBG	O	O
schedules	NNS	O	O
of	IN	O	O
gemcitabine	NN	i	O
combined	VBN	O	O
with	IN	O	O
S-1	NNP	i	O
in	IN	O	O
chemo-na?ve	JJ	p	O
non-small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
patients	NNS	p	O
.	.	O	O

METHODS	NNP	O	O
Patients	NNPS	p	O
with	IN	p	O
chemo-na?ve	JJ	p	O
stage	NN	p	O
IIIB/IV	NNP	p	O
non-small	NN	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
into	IN	O	O
two	CD	O	O
treatment	NN	O	O
arms	NNS	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
given	VBN	O	O
oral	JJ	O	O
S-1	NNP	i	IPM
(	(	O	O
60	CD	O	O
mg/m/d	NN	O	O
,	,	O	O
twice	RB	O	O
a	DT	O	O
day	NN	O	O
)	)	O	O
from	IN	O	O
days	NNS	O	O
1	CD	O	O
to	TO	O	O
14	CD	O	O
with	IN	O	O
gemcitabine	NN	i	IPM
(	(	O	O
1000	CD	O	O
mg/m/d	NN	O	O
)	)	O	O
on	IN	O	O
days	NNS	O	O
1	CD	O	O
and	CC	O	O
8	CD	O	O
(	(	O	O
arm	VB	O	O
A	NNP	O	O
)	)	O	O
or	CC	O	O
on	IN	O	O
days	NNS	O	O
8	CD	O	O
and	CC	O	O
15	CD	O	O
(	(	O	O
arm	NN	O	O
B	NNP	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
cycle	NN	O	O
was	VBD	O	O
repeated	VBN	O	O
every	DT	O	O
21	CD	O	O
days	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
80	CD	p	O
patients	NNS	p	O
were	VBD	p	O
entered	VBN	p	O
in	IN	p	O
this	DT	p	O
trial	NN	p	O
.	.	p	O

The	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
response	NN	o	O
rate	NN	o	O
.	.	O	O

The	DT	O	O
response	NN	o	O
rates	NNS	o	O
of	IN	O	O
arm	NN	O	O
A	NNP	O	O
and	CC	O	O
arm	NN	O	O
B	NNP	O	O
were	VBD	O	O
22.0	CD	O	O
and	CC	O	O
28.9	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.606	CD	O	O
)	)	O	O
.	.	O	O

Median	JJ	O	O
time	NN	o	O
to	TO	o	O
treatment	NN	o	O
failure	NN	o	O
in	IN	O	O
arm	NN	O	O
A	NN	O	O
was	VBD	O	O
3.6	CD	O	O
months	NNS	O	O
and	CC	O	O
4.8	CD	O	O
months	NNS	O	O
in	IN	O	O
arm	NN	O	O
B	NNP	O	O
.	.	O	O

Median	JJ	O	O
time	NN	o	O
to	TO	o	O
progression	NN	o	O
in	IN	O	O
arm	NN	O	O
A	NN	O	O
was	VBD	O	O
4.1	CD	O	O
months	NNS	O	O
and	CC	O	O
5.5	CD	O	O
months	NNS	O	O
in	IN	O	O
arm	NN	O	O
B	NNP	O	O
.	.	O	O

Median	JJ	O	O
survival	JJ	o	O
time	NN	o	O
in	IN	O	O
arm	NN	O	O
A	NN	O	O
and	CC	O	O
arm	NN	O	O
B	NNP	O	O
was	VBD	O	O
15.5	CD	O	O
months	NNS	O	O
and	CC	O	O
18.8	CD	O	O
months	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
toxicity	NN	o	O
profile	NN	o	O
was	VBD	O	O
relatively	RB	O	O
mild	JJ	O	O
and	CC	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
very	RB	O	O
much	RB	O	O
between	IN	O	O
two	CD	O	O
arms	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
combination	NN	O	O
of	IN	O	O
gemcitabine	NN	i	IPM
and	CC	O	O
S-1	NNP	i	IPM
was	VBD	O	O
determined	VBN	O	O
to	TO	O	O
be	VB	O	O
feasible	JJ	o	O
and	CC	O	O
effective	JJ	o	O
for	IN	O	O
advanced	JJ	O	O
non-small	JJ	O	O
cell	NN	O	O
lung	NN	O	O
cancer	NN	O	O
.	.	O	O

We	PRP	O	O
selected	VBD	O	O
arm	NN	O	O
B	NNP	O	O
for	IN	O	O
further	JJ	O	O
studies	NNS	O	O
because	IN	O	O
of	IN	O	O
its	PRP$	O	O
higher	JJR	O	O
response	NN	o	O
rate	NN	o	O
and	CC	o	O
survival	NN	o	O
data	NNS	o	O
.	.	O	O

Custom-fit	NNP	O	O
minimally	RB	O	O
invasive	JJ	O	O
total	JJ	i	O
knee	NN	i	IS
arthroplasty	NN	i	IS
:	:	O	O
effect	NN	O	O
on	IN	O	O
blood	NN	o	OPH
loss	NN	o	OPH
and	CC	O	O
early	JJ	o	OPH
clinical	JJ	o	OPH
outcomes	NNS	o	OPH
.	.	O	O

PURPOSE	NNP	O	O
Recently	NNP	O	O
,	,	O	O
new	JJ	O	O
custom-fit	JJ	O	O
pin	NN	O	O
guides	NNS	O	O
in	IN	O	O
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
(	(	p	O
TKA	NNP	i	IS
)	)	p	O
have	VBP	O	O
been	VBN	O	O
introduced	VBN	O	O
.	.	O	O

Use	NN	O	O
of	IN	O	O
these	DT	O	O
guides	NNS	O	O
may	MD	O	O
reduce	VB	O	O
operating	NN	O	O
time	NN	O	O
.	.	O	O

Use	NN	O	O
of	IN	O	O
the	DT	O	O
guides	NNS	O	O
combined	VBN	O	O
with	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
intramedullary	JJ	O	O
alignment	NN	O	O
jigs	NNS	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
reduced	VB	O	O
blood	NN	o	OPH
loss	NN	o	OPH
and	CC	O	O
improved	VBN	O	O
early	JJ	o	OPH
outcomes	NNS	o	OPH
.	.	O	O

Our	PRP$	O	O
aim	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
blood	NN	o	O
loss	NN	o	O
and	CC	O	O
early	JJ	o	OPH
clinical	JJ	o	OPH
outcomes	NNS	o	OPH
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
minimally	RB	p	O
invasive	JJ	p	O
TKA	NNP	p	O
using	VBG	O	O
custom-fit	JJ	i	IPH
magnetic	JJ	i	IPH
resonance	NN	i	IPH
imaging	NN	i	IPH
(	(	i	IPH
MRI	NNP	i	IPH
)	)	i	IPH
-based	VBD	i	IPH
pin	NN	i	IPH
guides	NNS	i	IPH
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
prospective	JJ	O	O
study	NN	O	O
in	IN	O	O
80	CD	p	O
patients	NNS	p	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
divided	VBN	O	O
randomly	RB	O	O
into	IN	O	O
2	CD	O	O
equal	JJ	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
one	CD	O	O
group	NN	O	O
,	,	O	O
intramedullary	JJ	i	IPH
alignment	NN	i	IPH
jigs	NNS	i	IPH
were	VBD	O	O
used	VBN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
second	JJ	O	O
group	NN	O	O
,	,	O	O
custom-fit	JJ	i	IPH
MRI-based	JJ	i	IPH
pin	NN	i	IPH
guides	NNS	i	IPH
were	VBD	O	O
used	VBN	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
the	DT	O	O
same	JJ	O	O
cemented	VBD	i	IS
posterior-stabilized	JJ	i	IS
implant	NN	i	IS
through	IN	O	O
a	DT	O	O
mini-midvastus	JJ	O	O
approach	NN	O	O
.	.	O	O

The	DT	O	O
volume	NN	O	O
in	IN	O	O
the	DT	O	O
drain	NN	O	O
bottles	NNS	O	O
was	VBD	O	O
recorded	VBN	O	O
after	IN	O	O
48	CD	O	O
h.	JJ	O	O
Hb	NNP	o	OPH
loss	NN	o	OPH
was	VBD	O	O
estimated	VBN	O	O
by	IN	O	O
subtracting	VBG	O	O
the	DT	O	O
postoperative	NN	O	O
from	IN	O	O
the	DT	O	O
preoperative	JJ	O	O
Hb	NNP	O	O
level	NN	O	O
.	.	O	O

Transfusion	NN	o	OPH
requirements	NNS	o	OPH
and	CC	O	O
surgical	JJ	o	OOt
time	NN	o	OOt
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

Outcome	JJ	O	O
measures	NNS	O	O
were	VBD	O	O
Knee	NNP	o	OPH
Society	NNP	o	OPH
Scores	NNP	o	OPH
(	(	o	OPH
KSS	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
knee	JJ	o	OPH
flexion	NN	o	OPH
,	,	o	OPH
knee	VB	o	OPH
swelling	VBG	o	OPH
and	CC	o	OPH
pain	NN	o	OPH
.	.	O	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
lower	JJR	O	O
mean	JJ	O	O
drainage	NN	o	OPH
of	IN	o	OPH
blood	NN	o	OPH
in	IN	O	O
the	DT	O	O
custom-fit	JJ	i	IPH
group	NN	O	O
(	(	O	O
391	CD	O	O
ml	NN	O	O
vs.	FW	O	O
603	CD	O	O
ml	NN	O	O
;	:	O	O
p	CC	O	O
<	VB	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
estimated	VBN	O	O
loss	NN	o	OPH
of	IN	o	OPH
Hb	NNP	o	OPH
(	(	O	O
3.6	CD	O	O
g/dl	NN	O	O
vs.	FW	O	O
4.1	CD	O	O
g/dl	NN	O	O
;	:	O	O
n.s	CC	O	O
.	.	O	O

)	)	O	O
and	CC	O	O
in	IN	O	O
transfusion	NN	O	O
requirements	NNS	O	O
(	(	O	O
7.5	CD	O	O
%	NN	O	O
vs.	FW	O	O
10	CD	O	O
%	NN	O	O
;	:	O	O
n.s.	CC	O	O
)	)	O	O
.	.	O	O

Surgical	JJ	o	O
time	NN	o	O
was	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
the	DT	O	O
custom-fit	JJ	i	O
group	NN	O	O
(	(	O	O
12	CD	O	O
min	NN	O	O
less	JJR	O	O
;	:	O	O
p	NN	O	O
=	VBZ	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

KSS	NNP	o	O
measured	VBD	O	O
at	IN	O	O
week	NN	O	O
2	CD	O	O
,	,	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
showed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

Knee	NNP	o	OPH
flexion	NN	o	OPH
measured	VBN	O	O
on	IN	O	O
days	NNS	O	O
7	CD	O	O
,	,	O	O
10	CD	O	O
and	CC	O	O
at	IN	O	O
week	NN	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
and	CC	O	O
knee	VB	o	OPH
swelling	VBG	o	OPH
and	CC	O	O
pain	NN	o	OPH
measured	VBN	O	O
on	IN	O	O
days	NNS	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
10	CD	O	O
and	CC	O	O
at	IN	O	O
week	NN	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
showed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Using	VBG	O	O
custom-fit	JJ	i	O
pin	NN	i	O
guides	NNS	i	O
reduces	NNS	O	O
blood	NN	o	O
drainage	NN	o	O
,	,	O	O
but	CC	O	O
not	RB	O	O
the	DT	O	O
estimated	VBN	O	O
Hb	NNP	o	O
loss	NN	o	O
in	IN	O	O
minimally	RB	O	O
invasive	JJ	O	O
TKA	NNP	O	O
and	CC	O	O
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
transfusion	NN	o	O
rate	NN	o	O
.	.	O	O

Surgical	JJ	o	O
time	NN	o	O
is	VBZ	O	O
reduced	VBN	O	O
.	.	O	O

There	EX	O	O
is	VBZ	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
early	JJ	o	OPH
clinical	JJ	o	OPH
outcomes	NNS	o	OPH
.	.	O	O

LEVEL	NN	O	O
OF	IN	O	O
EVIDENCE	NNP	O	O
Therapeutic	NNP	O	O
study	NN	O	O
,	,	O	O
Level	NNP	O	O
I	PRP	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
weight	NN	i	IPH
training	NN	i	IPH
on	IN	O	O
bone	JJ	o	OPH
mineral	JJ	o	OPH
density	NN	o	OPH
and	CC	O	O
bone	NN	o	OPH
turnover	NN	o	OPH
in	IN	O	O
postmenopausal	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
survivors	NNS	p	O
with	IN	p	O
bone	JJ	p	O
loss	NN	p	O
:	:	O	O
a	DT	O	O
24-month	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

SUMMARY	VB	O	O
This	DT	O	O
study	NN	O	O
examined	VBD	O	O
whether	IN	O	O
24	CD	O	O
months	NNS	O	O
of	IN	O	O
weight	JJ	i	IPH
training	NN	i	IPH
exercises	NNS	i	IPH
enhanced	VBD	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
risedronate	NN	O	O
,	,	O	O
calcium	NN	O	O
,	,	O	O
and	CC	O	O
vitamin	NN	O	O
D	NNP	O	O
in	IN	O	O
maintaining	VBG	O	O
or	CC	O	O
improving	VBG	O	O
bone	JJ	o	OPH
mineral	JJ	o	OPH
density	NN	o	OPH
(	(	o	OPH
BMD	NNP	o	OPH
)	)	o	OPH
in	IN	O	O
223	CD	p	O
postmenopausal	NN	p	O
breast	NN	p	O
cancer	NN	p	O
survivors	NNS	p	O
.	.	O	O

Subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
>	NNP	O	O
or	CC	O	O
=50	CD	O	O
%	NN	O	O
adherent	NN	O	O
to	TO	O	O
exercise	VB	O	O
had	VBN	O	O
no	DT	O	O
improvement	NN	O	O
in	IN	O	O
BMD	NNP	o	OPH
but	CC	O	O
were	VBD	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
lose	VB	O	O
BMD	NNP	o	OPH
.	.	O	O

INTRODUCTION	NNP	O	O
This	DT	O	O
study	NN	O	O
examined	VBD	O	O
whether	IN	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
postmenopausal	NN	p	O
breast	NN	p	O
cancer	NN	p	O
survivors	NNS	p	O
(	(	p	O
BCS	NNP	p	O
)	)	p	O
with	IN	p	O
bone	NN	p	O
loss	NN	p	O
taking	VBG	O	O
24	CD	O	O
months	NNS	O	O
of	IN	O	O
risedronate	NN	i	IPM
,	,	O	O
calcium	NN	i	IPM
,	,	O	O
and	CC	O	O
vitamin	NN	i	IPM
D	NNP	i	IPM
had	VBD	O	O
increased	VBN	O	O
bone	RB	o	O
mineral	JJ	o	O
density	NN	o	O
(	(	o	O
BMD	NNP	o	O
)	)	o	O
at	IN	O	O
the	DT	O	O
total	JJ	O	O
hip	NN	O	O
,	,	O	O
femoral	JJ	O	O
neck	NN	O	O
,	,	O	O
L1-L4	NNP	O	O
spine	NN	O	O
,	,	O	O
total	JJ	O	O
radius	NN	O	O
and	CC	O	O
33	CD	O	O
%	NN	O	O
radius	NN	O	O
,	,	O	O
and	CC	O	O
decreased	VBD	O	O
bone	NN	o	OPH
turnover	NN	o	OPH
;	:	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
subjects	NNS	O	O
who	WP	O	O
also	RB	O	O
participated	VBD	O	O
in	IN	O	O
strength/weight	JJ	i	IPH
training	NN	i	IPH
(	(	i	IPH
ST	NNP	i	IPH
)	)	i	IPH
exercises	NNS	i	IPH
had	VBD	O	O
greater	JJR	O	O
increases	NNS	O	O
in	IN	O	O
BMD	NNP	o	OPH
and	CC	O	O
greater	JJR	O	O
decreases	NNS	O	O
in	IN	O	O
bone	NN	o	OPH
turnover	NN	o	OPH
;	:	O	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
subjects	NNS	O	O
who	WP	O	O
also	RB	O	O
exercised	VBD	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
preserve	VB	O	O
(	(	O	O
at	IN	O	O
least	JJS	O	O
maintain	NN	O	O
)	)	O	O
BMD	NNP	o	OPH
.	.	O	O

METHODS	NNP	O	O
Postmenopausal	NNP	p	O
BCS	NNP	p	O
(	(	p	O
223	CD	p	O
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
exercise	VB	i	IPH
plus	JJ	i	IE
medication	NN	i	IPM
or	CC	O	O
medication	NN	i	IPM
only	RB	O	O
groups	NNS	O	O
.	.	O	O

Both	DT	O	O
groups	NNS	O	O
received	VBD	O	O
24	CD	O	O
months	NNS	O	O
of	IN	O	O
1,200	CD	O	O
mg	NN	O	O
of	IN	O	O
calcium	NN	i	IPM
and	CC	O	O
400	CD	O	O
IU	NNP	O	O
of	IN	O	O
vitamin	NNP	i	IPM
D	NNP	i	IPM
daily	RB	O	O
and	CC	O	O
35	CD	O	O
mg	NN	O	O
of	IN	O	O
risedronate	JJ	i	IPM
weekly	JJ	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
exercise	NN	i	IPH
group	NN	O	O
additionally	RB	O	O
had	VBD	O	O
ST	NNP	i	IPH
exercises	NNS	i	IPH
twice	RB	O	O
weekly	RB	O	O
.	.	O	O

RESULTS	NNP	O	O
After	IN	O	O
24	CD	O	O
months	NNS	O	O
,	,	O	O
women	NNS	O	O
who	WP	O	O
took	VBD	O	O
medications	NNS	i	IPH
without	IN	O	O
exercising	VBG	i	IPH
had	VBD	O	O
significant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
BMD	NNP	o	OPH
at	IN	O	O
the	DT	O	O
total	JJ	O	O
hip	NN	O	O
(	(	O	O
+1.81	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
spine	NN	O	O
(	(	O	O
+2.85	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
significant	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
Alkphase	NNP	o	OPH
B	NNP	o	OPH
(	(	O	O
-8.7	NNP	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
serum	JJ	o	OPH
NTx	NNP	o	OPH
(	(	O	O
-16.7	NNP	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Women	NNS	O	O
who	WP	O	O
also	RB	O	O
exercised	VBD	i	O
had	VBD	O	O
additional	JJ	O	O
increases	NNS	O	O
in	IN	O	O
BMD	NNP	o	OPH
at	IN	O	O
the	DT	O	O
femoral	JJ	O	O
neck	NN	O	O
(	(	O	O
+0.29	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
total	JJ	O	O
hip	NN	O	O
(	(	O	O
+0.34	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
spine	NN	O	O
(	(	O	O
+0.23	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
total	JJ	O	O
radius	NN	O	O
(	(	O	O
+0.30	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
additional	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
Alkphase	NNP	o	OPH
B	NNP	o	OPH
(	(	O	O
-2.4	NNP	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
Serum	NNP	o	OPH
NTx	NNP	o	OPH
(	(	O	O
-6.5	NNP	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Additional	JJ	O	O
changes	NNS	O	O
in	IN	O	O
BMD	NNP	o	OPH
and	CC	o	O
bone	NN	o	OPH
turnover	NN	o	OPH
with	IN	O	O
exercise	NN	O	O
were	VBD	O	O
not	RB	O	O
significant	JJ	O	O
.	.	O	O

Subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
>	NNP	O	O
or	CC	O	O
=50	CD	O	O
%	NN	O	O
adherent	NN	O	O
to	TO	O	O
exercise	VB	i	O
were	VBD	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
lose	VB	O	O
BMD	NNP	o	OPH
at	IN	O	O
the	DT	O	O
total	JJ	O	O
hip	NN	O	O
(	(	O	O
chi-square	JJ	O	O
[	NN	O	O
1	CD	O	O
]	NNP	O	O
=	NNP	O	O
4.66	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
and	CC	O	O
femoral	JJ	O	O
neck	NN	O	O
(	(	O	O
chi-square	JJ	O	O
[	NN	O	O
1	CD	O	O
]	NNP	O	O
=	NNP	O	O
4.63	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Strength/weight	NNP	i	O
training	NN	i	O
exercises	NNS	i	O
may	MD	O	O
prevent	VB	O	O
loss	NN	O	O
of	IN	O	O
BMD	NNP	o	OPH
in	IN	O	O
postmenopausal	NN	O	O
BCS	NNP	O	O
at	IN	O	O
risk	NN	O	O
for	IN	O	O
bone	NN	O	O
loss	NN	O	O
.	.	O	O

Clinical	JJ	o	OA
effects	NNS	o	OA
of	IN	O	O
root	NN	O	O
instrumentation	NN	O	O
using	VBG	O	O
conventional	JJ	O	O
steel	NN	O	O
or	CC	O	O
non-tooth	JJ	O	O
substance	NN	O	O
removing	VBG	O	O
plastic	NN	O	O
curettes	NNS	O	O
during	IN	O	O
supportive	JJ	O	O
periodontal	JJ	O	O
therapy	NN	O	O
(	(	O	O
SPT	NNP	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
root	NN	O	O
instrumentation	NN	O	O
has	VBZ	O	O
been	VBN	O	O
accepted	VBN	O	O
as	IN	O	O
the	DT	O	O
most	RBS	O	O
important	JJ	O	O
cause-related	JJ	O	O
treatment	NN	O	O
of	IN	O	O
periodontal	JJ	O	O
diseases	NNS	O	O
,	,	O	O
repeated	VBD	O	O
scaling	NN	O	O
and	CC	O	O
root	NN	O	O
planing	NN	O	O
may	MD	O	O
over	VB	O	O
time	NN	O	O
result	NN	O	O
in	IN	O	O
substantive	JJ	O	O
loss	NN	O	O
of	IN	O	O
tooth	JJ	O	O
substance	NN	O	O
and	CC	O	O
increased	JJ	O	O
sensitivity	NN	O	O
of	IN	O	O
the	DT	O	O
teeth	NN	O	O
.	.	O	O

In	IN	O	O
an	DT	O	O
effort	NN	O	O
to	TO	O	O
minimize	VB	O	O
these	DT	O	O
side	JJ	O	O
effects	NNS	O	O
of	IN	O	O
therapy	NN	O	O
,	,	O	O
non-root	JJ	O	O
substance	NN	O	O
removing	VBG	O	O
curettes	NNS	O	O
have	VBP	O	O
been	VBN	O	O
developed	VBN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
clinical	JJ	o	OPH
effects	NNS	o	OPH
of	IN	O	O
such	JJ	O	O
plastic	NN	O	O
curettes	NNS	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
of	IN	O	O
the	DT	O	O
periodontal	JJ	O	O
infection	NN	O	O
has	VBZ	O	O
not	RB	O	O
yet	RB	O	O
been	VBN	O	O
established	VBN	O	O
.	.	O	O

The	DT	O	O
aims	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
were	VBD	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
root	NN	O	O
instrumentation	NN	O	O
using	VBG	O	O
plastic	NN	i	IOt
curettes	NNS	i	IOt
(	(	O	O
Universal	NNP	O	O
Perio	NNP	O	O
Soft	NNP	O	O
Scaler	NNP	O	O
,	,	O	O
Hawe-Neos	NNP	O	O
Dental	NNP	O	O
,	,	O	O
Bioggio	NNP	O	O
,	,	O	O
TI	NNP	O	O
,	,	O	O
Switzerland	NNP	O	O
)	)	O	O
versus	VBP	O	O
conventional	JJ	i	IOt
steel	NN	i	IOt
curettes	NNS	i	IOt
on	IN	O	O
the	DT	O	O
periodontal	JJ	O	O
conditions	NNS	O	O
during	IN	O	O
supportive	JJ	O	O
periodontal	JJ	O	O
therapy	NN	O	O
.	.	O	O

40	CD	p	PSS
subjects	NNS	p	O
participated	VBN	O	O
in	IN	O	O
this	DT	O	O
parallel	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double	JJ	O	O
blind	NN	O	O
,	,	O	O
prospective	JJ	O	O
longitudinal	JJ	O	O
clinical	JJ	O	O
study	NN	O	O
following	VBG	O	O
active	JJ	O	O
peridontal	JJ	O	O
therapy	NN	O	O
.	.	O	O

20	CD	p	PSS
subjects	NNS	p	O
served	VBD	p	O
as	IN	p	O
a	DT	p	O
control	NN	p	O
group	NN	p	O
and	CC	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
conventional	JJ	i	IOt
steel	NN	i	IOt
curettes	NNS	i	IOt
during	IN	O	O
a	DT	O	O
supportive	JJ	p	O
periodontal	NN	p	O
care	NN	p	O
visit	NN	O	O
(	(	O	O
SPT	NNP	p	O
)	)	O	O
.	.	O	O

The	DT	O	O
other	JJ	O	O
20	CD	p	PSS
subjects	NNS	p	O
,	,	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
,	,	O	O
were	VBD	O	O
treated	VBN	O	O
using	VBG	O	O
plastic	NN	i	IOt
curettes	NNS	i	IOt
during	IN	O	O
a	DT	O	O
similar	JJ	O	O
SPT	NNP	O	O
visit	NN	O	O
.	.	O	O

Clinical	JJ	O	O
parameters	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
bleeding	VBG	o	OPH
on	IN	o	OPH
probing	VBG	o	OPH
(	(	o	OPH
BOP	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
probing	VBG	o	OPH
pocket	NN	o	OPH
depth	NN	o	OPH
(	(	o	OPH
PPD	NNP	o	OPH
)	)	o	OPH
,	,	O	O
were	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
3-6	JJ	O	O
months	NNS	O	O
later	RB	O	O
at	IN	O	O
the	DT	O	O
next	JJ	O	O
regular	JJ	O	O
SPT	NNP	O	O
visit	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
the	DT	O	O
BOP	NNP	o	OPH
percentage	NN	o	OPH
was	VBD	O	O
determined	VBN	O	O
10	CD	O	O
days	NNS	O	O
following	VBG	O	O
baseline	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
2	CD	O	O
treatment	NN	O	O
modalities	NNS	O	O
regarding	VBG	O	O
BOP	NNP	o	OPH
and	CC	o	O
PPD	NNP	o	OPH
at	IN	O	O
any	DT	O	O
observation	NN	O	O
time	NN	O	O
.	.	O	O

Both	DT	O	O
treatments	NNS	O	O
were	VBD	O	O
effective	JJ	O	O
in	IN	O	O
reducing	VBG	O	O
the	DT	O	O
BOP	NNP	o	OPH
percentage	NN	o	OPH
which	WDT	O	O
ranged	VBD	O	O
from	IN	O	O
17-42	CD	O	O
%	NN	O	O
at	IN	O	O
baseline	NN	O	O
by	IN	O	O
about	IN	O	O
40	CD	O	O
%	NN	O	O
after	IN	O	O
10	CD	O	O
days	NNS	O	O
(	(	O	O
mean	JJ	O	O
BOP	NNP	o	OPH
baseline	NN	O	O
:	:	O	O
26	CD	O	O
%	NN	O	O
,	,	O	O
mean	JJ	O	O
BOP	NNP	o	OPH
after	IN	O	O
10	CD	O	O
days	NNS	O	O
:	:	O	O
16	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
clinical	JJ	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
non-root	JJ	i	IOt
substance	NN	i	IOt
removing	VBG	i	IOt
curettes	NNS	i	IOt
may	MD	O	O
be	VB	O	O
valuable	JJ	O	O
instruments	NNS	O	O
for	IN	O	O
periodontally	RB	O	O
treated	JJ	O	O
patients	NNS	O	O
during	IN	O	O
maintenance	NN	O	O
care	NN	O	O
,	,	O	O
thus	RB	O	O
minimizing	VBG	O	O
trauma	NN	O	O
on	IN	O	O
the	DT	O	O
hard	JJ	O	O
structures	NNS	O	O
of	IN	O	O
the	DT	O	O
teeth	NN	O	O
.	.	O	O

Superior	JJ	O	O
visual	JJ	O	O
search	NN	O	O
in	IN	O	O
adults	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
suggested	VBN	O	O
that	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
perform	NN	O	O
better	RBR	O	O
than	IN	O	O
matched	VBN	O	O
controls	NNS	O	O
on	IN	O	O
visual	JJ	O	O
search	NN	O	O
tasks	NNS	O	O
and	CC	O	O
that	IN	O	O
this	DT	O	O
stems	VBZ	O	O
from	IN	O	O
a	DT	O	O
superior	JJ	O	O
visual	JJ	O	O
discrimination	NN	O	O
ability	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
assessed	VBD	O	O
whether	IN	O	O
these	DT	O	O
findings	NNS	O	O
generalize	VBP	O	O
from	IN	O	O
children	NNS	O	O
to	TO	O	O
adults	NNS	p	O
with	IN	p	O
autism	NN	p	O
.	.	O	O

Experiments	NNS	O	O
1	CD	O	O
and	CC	O	O
2	CD	O	O
showed	VBD	O	O
that	IN	O	O
,	,	O	O
like	IN	O	O
children	NNS	O	O
,	,	O	O
adults	NNS	p	O
with	IN	p	O
autism	NN	p	O
were	VBD	O	O
superior	JJ	O	O
to	TO	O	O
controls	NNS	O	O
at	IN	O	O
searching	VBG	o	OME
for	IN	o	OME
targets	NNS	o	OME
.	.	O	O

Experiment	NN	O	O
3	CD	O	O
showed	VBD	O	O
that	IN	O	O
increases	NNS	O	O
in	IN	O	O
target-distractor	JJ	O	O
similarity	NN	O	O
slowed	VBD	O	O
the	DT	O	O
visual	JJ	o	OME
search	NN	o	OME
performance	NN	o	OME
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
significantly	RB	O	O
more	RBR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
autism	NN	O	O
group	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
the	DT	O	O
adults	NNS	O	O
with	IN	O	O
autism	NN	O	O
have	VBP	O	O
a	DT	O	O
superior	JJ	O	O
visual	JJ	o	OPH
discrimination	NN	o	OPH
ability	NN	o	OPH
.	.	O	O

Thus	RB	O	O
,	,	O	O
these	DT	O	O
experiments	NNS	O	O
replicate	VBP	O	O
in	IN	O	O
adults	NNS	O	O
previous	JJ	O	O
findings	NNS	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

Superior	NNP	O	O
unique	JJ	o	OME
item	NN	o	OME
detection	NN	o	OME
in	IN	O	O
adults	NNS	O	O
with	IN	O	O
autism	NN	O	O
,	,	O	O
stemming	VBG	O	O
from	IN	O	O
enhanced	VBN	O	O
discrimination	NN	O	O
,	,	O	O
is	VBZ	O	O
discussed	VBN	O	O
in	IN	O	O
the	DT	O	O
light	NN	O	O
of	IN	O	O
the	DT	O	O
possible	JJ	O	O
role	NN	O	O
of	IN	O	O
stimulus	JJ	O	O
processing	NN	O	O
disturbances	NNS	O	O
in	IN	O	O
the	DT	O	O
disorder	NN	O	O
in	IN	O	O
general	JJ	O	O
.	.	O	O

Local	JJ	O	O
immunotherapy	NN	O	O
by	IN	O	O
inhalation	NN	O	O
of	IN	O	O
a	DT	O	O
powder	NN	O	O
extract	NN	O	O
in	IN	O	O
asthma	NN	O	O
due	JJ	O	O
to	TO	O	O
house	NN	O	O
dust	NN	O	O
mite	NN	O	O
Dermatophagoides	NNP	O	O
pteronyssinus	NN	O	O
:	:	O	O
a	DT	O	O
double-blind	JJ	O	O
comparison	NN	O	O
with	IN	O	O
parenteral	JJ	O	O
immunotherapy	NN	O	O
.	.	O	O

To	TO	O	O
verify	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
the	DT	O	O
tolerability	NN	o	OOt
of	IN	O	O
local	JJ	i	IPM
immunotherapy	NN	i	IPM
(	(	O	O
LI	NNP	O	O
)	)	O	O
by	IN	O	O
inhalation	NN	O	O
of	IN	O	O
a	DT	O	O
powder	NN	i	IPM
extract	NN	i	IPM
of	IN	i	IPM
house	NN	i	IPM
dust	NN	i	IPM
mite	NN	i	IPM
(	(	i	IPM
HDM	NNP	i	IPM
)	)	i	IPM
,	,	O	O
in	IN	O	O
comparison	NN	O	O
with	IN	O	O
parenteral	JJ	i	IPM
immunotherapy	NN	i	IPM
(	(	i	IPM
PI	NNP	i	IPM
)	)	i	IPM
by	IN	O	O
injection	NN	O	O
,	,	O	O
10	CD	p	O
patients	NNS	p	O
with	IN	p	O
asthma	NNS	p	O
due	JJ	p	O
to	TO	p	O
HDM	NNP	p	O
were	VBD	O	O
studied	VBN	O	O
in	IN	O	O
a	DT	O	O
blind	JJ	O	O
fashion	NN	O	O
.	.	O	O

5	CD	O	O
patients	NNS	O	O
(	(	O	O
Group	NNP	O	O
A	NNP	O	O
)	)	O	O
underwent	NN	O	O
LI	NNP	O	O
and	CC	O	O
subcutaneous	JJ	O	O
injections	NNS	O	O
of	IN	O	O
placebo	NN	i	IC
,	,	O	O
5	CD	O	O
patients	NNS	O	O
(	(	O	O
Group	NNP	O	O
B	NNP	O	O
)	)	O	O
underwent	NN	O	O
PI	NNP	O	O
and	CC	O	O
inhalation	NN	O	O
of	IN	O	O
lactose	NN	i	IPM
for	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
groups	NNS	O	O
each	DT	O	O
inhalation	NN	O	O
was	VBD	O	O
preceded	VBN	O	O
by	IN	O	O
premedication	NN	O	O
with	IN	O	O
disodium	NN	i	IPM
cromoglycate	NN	i	IPM
(	(	i	IPM
DSCG	NNP	i	IPM
)	)	i	IPM
(	(	O	O
40	CD	O	O
mg	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
Group	NNP	O	O
A	NNP	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
symptoms	NNS	o	OPH
score	NN	o	OPH
and	CC	O	O
in	IN	O	O
peak	JJ	o	OPH
expiratory	NN	o	OPH
flow	NN	o	OPH
(	(	o	OPH
PEF	NNP	o	OPH
)	)	o	OPH
-derived	VBD	o	OPH
parameters	NNS	o	OPH
was	VBD	O	O
observed	VBN	O	O
already	RB	O	O
after	IN	O	O
3	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
patients	NNS	O	O
lost	VBD	O	O
the	DT	O	O
late	JJ	O	O
component	NN	O	O
of	IN	O	O
the	DT	O	O
bronchial	JJ	o	OPH
response	NN	o	OPH
to	TO	O	O
the	DT	O	O
challenge	NN	O	O
with	IN	O	O
HDM	NNP	O	O
.	.	O	O

No	NNP	O	O
significant	JJ	O	O
variation	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
bronchial	JJ	o	OPH
responsiveness	NN	o	OPH
to	TO	O	O
methacholine	VB	O	O
and	CC	O	O
ultrasonically	RB	O	O
nebulized	VBN	O	O
distilled	JJ	O	O
water	NN	O	O
(	(	O	O
UNDW	NNP	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
immunologic	JJ	o	OPH
humoral	JJ	o	OPH
and	CC	o	OPH
cellular	JJ	o	OPH
parameters	NNS	o	OPH
in	IN	o	OPH
peripheral	JJ	o	OPH
blood	NN	o	OPH
after	IN	O	O
treatment	NN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

No	DT	O	O
local	JJ	o	OA
important	JJ	o	OA
adverse	JJ	o	OA
reactions	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
Group	NNP	O	O
A	NNP	O	O
and	CC	O	O
no	DT	O	O
systemic	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
LI	NNP	O	O
is	VBZ	O	O
as	RB	O	O
effective	JJ	O	O
as	IN	O	O
PI	NNP	O	O
,	,	O	O
but	CC	O	O
more	RBR	O	O
rapid	JJ	O	O
in	IN	O	O
its	PRP$	O	O
action	NN	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
asthma	NNS	O	O
due	JJ	O	O
to	TO	O	O
HDM	NNP	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
LI	NNP	O	O
is	VBZ	O	O
locally	RB	O	O
well	RB	O	O
tolerated	VBN	O	O
,	,	O	O
providing	VBG	O	O
DSCG	NNP	O	O
is	VBZ	O	O
inhaled	VBN	O	O
before	IN	O	O
each	DT	O	O
therapeutic	JJ	O	O
inhalation	NN	O	O
,	,	O	O
and	CC	O	O
does	VBZ	O	O
not	RB	O	O
induce	VB	O	O
systemic	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
.	.	O	O

Systemic	NNP	o	OPH
hemodynamic	NN	o	OPH
,	,	o	OPH
neurohormonal	JJ	o	OPH
,	,	o	OPH
and	CC	o	OPH
renal	JJ	o	OPH
effects	NNS	o	OPH
of	IN	O	O
a	DT	O	O
steady-state	JJ	O	O
infusion	NN	O	O
of	IN	O	O
human	JJ	i	IPM
brain	NN	i	IPM
natriuretic	JJ	i	IPM
peptide	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
hemodynamically	RB	p	PC
decompensated	VBN	p	PC
heart	NN	p	PC
failure	NN	p	PC
.	.	O	O

BACKGROUND	NNP	O	O
Human	NNP	i	IPM
brain	NN	i	IPM
natriuretic	JJ	i	IPM
peptide	NN	i	IPM
(	(	i	IPM
hBNP	NN	i	IPM
)	)	i	IPM
is	VBZ	O	O
a	DT	O	O
promising	JJ	O	O
agent	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
decompensated	JJ	O	O
cardiac	JJ	O	O
failure	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
systemic	JJ	o	OPH
hemodynamic	NN	o	OPH
,	,	o	O
neurohormonal	JJ	o	OPH
,	,	o	O
and	CC	o	O
renal	JJ	o	OPH
effects	NNS	o	OPH
of	IN	O	O
hBNP	NNS	i	IPM
have	VBP	O	O
been	VBN	O	O
incompletely	RB	O	O
studied	VBN	O	O
in	IN	O	O
human	JJ	O	O
heart	NN	O	O
failure	NN	O	O
.	.	O	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
The	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
continuous	JJ	O	O
4-hour	JJ	O	O
infusion	NN	O	O
of	IN	O	O
hBNP	NN	i	IPM
were	VBD	O	O
determined	VBN	O	O
in	IN	O	O
16	CD	p	PSS
decompensated	JJ	p	PC
heart	NN	p	PC
failure	NN	p	PC
patients	NNS	p	O
in	IN	O	O
an	DT	O	O
invasive	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
during	IN	O	O
three	CD	O	O
4-hour	JJ	O	O
study	NN	O	O
periods	NNS	O	O
:	:	O	O
baseline	NN	O	O
,	,	O	O
treatment	NN	O	O
(	(	O	O
placebo	JJ	i	IC
[	NNP	O	O
n	NN	O	O
=	VBD	O	O
4	CD	O	O
]	NNP	O	O
versus	NN	O	O
hBNP	NN	i	IPM
0.025	CD	O	O
or	CC	O	O
0.05	CD	O	O
microgram/kg/min	NNS	O	O
[	JJ	O	O
n	JJ	O	O
=	NN	O	O
12	CD	O	O
]	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
post-treatment	NN	O	O
.	.	O	O

Urinary	JJ	O	O
volume	NN	O	O
losses	NNS	O	O
were	VBD	O	O
replaced	VBN	O	O
hourly	RB	O	O
to	TO	O	O
separate	VB	O	O
the	DT	O	O
vasodilatory	NN	O	O
and	CC	O	O
diuretic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
hBNP	NN	i	IPM
.	.	O	O

Two	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
hBNP	NN	i	IPM
group	NN	O	O
were	VBD	O	O
excluded	VBN	O	O
from	IN	O	O
the	DT	O	O
analysis	NN	O	O
because	IN	O	O
of	IN	O	O
adverse	JJ	o	OA
events	NNS	o	OA
.	.	O	O

hBNP	NN	i	IPM
significantly	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
reduced	VBD	O	O
right	JJ	o	OPH
atrial	JJ	o	OPH
pressure	NN	o	OPH
and	CC	o	OPH
pulmonary	JJ	o	OPH
capillary	JJ	o	OPH
wedge	NN	o	OPH
pressure	NN	o	OPH
by	IN	O	O
approximately	RB	O	O
30	CD	O	O
%	NN	O	O
and	CC	O	O
40	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

hBNP	NN	i	IPM
also	RB	O	O
significantly	RB	O	O
lowered	VBN	O	O
systemic	JJ	o	OPH
vascular	JJ	o	OPH
resistance	NN	o	OPH
from	IN	O	O
1722	CD	O	O
+/-	JJ	O	O
139	CD	O	O
to	TO	O	O
1101	CD	O	O
+/-	JJ	O	O
83	CD	O	O
dynes.s.cm-5	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
unloading	JJ	O	O
effects	NNS	O	O
of	IN	O	O
hBNP	NN	i	IPM
produced	VBD	O	O
a	DT	O	O
28	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
cardiac	JJ	o	OPH
index	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
with	IN	O	O
no	DT	O	O
change	NN	O	O
in	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
.	.	O	O

Compared	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
,	,	O	O
hBNP	VB	i	IPM
decreased	VBN	O	O
plasma	JJ	o	OPH
norepinephrine	NN	o	OPH
and	CC	o	OPH
aldosterone	NN	o	OPH
.	.	O	O

Renal	JJ	o	OPH
hemodynamics	NNS	o	OPH
were	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
hBNP	NN	i	IPM
;	:	O	O
however	RB	O	O
,	,	O	O
most	JJS	O	O
patients	NNS	O	O
were	VBD	O	O
resistant	JJ	O	O
to	TO	O	O
its	PRP$	O	O
natriuretic	JJ	o	OPH
effect	NN	o	OPH
.	.	O	O

CONCLUSIONS	NNP	O	O
1	CD	O	O
)	)	O	O
The	DT	O	O
predominant	JJ	O	O
hemodynamic	JJ	o	OPH
effects	NNS	o	OPH
of	IN	O	O
hBNP	NN	i	IPM
were	VBD	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
cardiac	JJ	o	OPH
preload	NN	o	OPH
and	CC	o	OPH
systemic	JJ	o	OPH
vascular	JJ	o	OPH
resistance	NN	o	OPH
.	.	O	O

2	CD	O	O
)	)	O	O
hBNP	NN	i	IPM
also	RB	O	O
improved	VBD	O	O
cardiac	JJ	o	OPH
output	NN	o	OPH
without	IN	O	O
increasing	VBG	O	O
heart	NN	o	OPH
rate	NN	o	OPH
.	.	O	O

3	CD	O	O
)	)	O	O
Plasma	NNP	o	OPH
norepinephrine	NN	o	OPH
and	CC	o	OPH
aldosterone	NN	o	OPH
levels	NNS	o	OPH
decreased	VBN	O	O
during	IN	O	O
hBNP	JJ	i	IPM
infusion	NN	O	O
.	.	O	O

4	CD	O	O
)	)	O	O
hBNP	NN	i	IPM
is	VBZ	O	O
pharmacologically	RB	O	O
active	JJ	O	O
and	CC	O	O
has	VBZ	O	O
potential	VBN	O	O
in	IN	O	O
the	DT	O	O
therapy	NN	O	O
for	IN	O	O
decompensated	JJ	O	O
heart	NN	O	O
failure	NN	O	O
.	.	O	O

Protection	NN	O	O
of	IN	O	O
man	NN	O	O
from	IN	O	O
natural	JJ	O	O
infection	NN	O	O
with	IN	O	O
influenza	JJ	O	O
A2	NNP	O	O
Hong	NNP	O	O
Kong	NNP	O	O
virus	NN	O	O
by	IN	O	O
amantadine	NN	i	IPM
:	:	O	O
a	DT	O	O
controlled	JJ	O	O
field	NN	O	O
trial	NN	O	O
.	.	O	O

Prophylactic	JJ	O	O
administration	NN	O	O
of	IN	O	O
amantadine	NN	i	IPM
in	IN	O	O
doses	NNS	O	O
of	IN	O	O
100	CD	O	O
mg.	NN	O	O
twice	RB	O	O
a	DT	O	O
day	NN	O	O
offered	VBN	O	O
statistically	RB	O	O
significant	JJ	O	O
protection	NN	O	O
against	IN	O	O
influenza	JJ	O	O
A2	NNP	O	O
infection	NN	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
field	NN	O	O
trial	NN	O	O
involving	VBG	O	O
391	CD	p	PSS
medical	JJ	p	PC
student	NN	p	PC
volunteers	NNS	p	PC
during	IN	p	O
the	DT	p	O
influenza	JJ	p	O
A2	NNP	p	O
Hong	NNP	p	O
Kong	NNP	p	O
epidemic	VBP	p	O
in	IN	p	O
Helsinki	NNP	p	O
in	IN	p	O
the	DT	p	O
winter	NN	p	O
of	IN	p	O
1969	CD	p	O
.	.	O	O

Serologically	RB	o	OPH
verified	JJ	o	OPH
influenza	NN	o	OPH
,	,	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
complement	JJ	o	OPH
fixation	NN	o	OPH
and/or	NN	o	OPH
haemagglutination	NN	o	OPH
inhibition	NN	o	OPH
,	,	O	O
occurred	VBD	O	O
in	IN	O	O
27	CD	O	O
out	IN	O	O
of	IN	O	O
192	CD	O	O
students	NNS	O	O
in	IN	O	O
the	DT	O	O
amantadine	NN	i	IPM
group	NN	O	O
against	IN	O	O
57	CD	O	O
out	IN	O	O
of	IN	O	O
199	CD	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
,	,	O	O
giving	VBG	O	O
a	DT	O	O
protection	NN	O	O
rate	NN	O	O
of	IN	O	O
52	CD	O	O
%	NN	O	O
.	.	O	O

RESPECT-PTSD	JJ	O	O
:	:	O	O
re-engineering	JJ	O	O
systems	NNS	O	O
for	IN	O	O
the	DT	O	O
primary	JJ	O	O
care	NN	O	O
treatment	NN	O	O
of	IN	O	O
PTSD	NNP	p	PC
,	,	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Although	IN	O	O
collaborative	JJ	O	O
care	NN	O	O
is	VBZ	O	O
effective	JJ	O	O
for	IN	O	O
treating	VBG	O	O
depression	NN	O	O
and	CC	O	O
other	JJ	O	O
mental	JJ	O	O
disorders	NNS	O	O
in	IN	O	O
primary	JJ	O	O
care	NN	O	O
,	,	O	O
there	EX	O	O
have	VBP	O	O
been	VBN	O	O
no	DT	O	O
randomized	JJ	O	O
trials	NNS	O	O
of	IN	O	O
collaborative	JJ	O	O
care	NN	O	O
specifically	RB	O	O
for	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
Posttraumatic	NNP	p	PC
stress	NN	p	PC
disorder	NN	p	PC
(	(	p	PC
PTSD	NNP	p	PC
)	)	p	PC
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
compare	VB	O	O
a	DT	O	O
collaborative	JJ	O	O
approach	NN	O	O
,	,	O	O
the	DT	O	O
Three	NNP	i	IPS
Component	NNP	i	IPS
Model	NNP	i	IPS
(	(	i	IPS
3CM	CD	i	IPS
)	)	i	IPS
,	,	O	O
with	IN	O	O
usual	JJ	i	IC
care	NN	i	IC
for	IN	O	O
treating	VBG	O	O
PTSD	NNP	O	O
in	IN	O	O
primary	JJ	O	O
care	NN	O	O
.	.	O	O

DESIGN	VB	O	O
The	DT	O	O
study	NN	O	O
was	VBD	O	O
a	DT	O	O
two-arm	JJ	O	O
,	,	O	O
parallel	JJ	O	O
randomized	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

PTSD	JJ	p	O
patients	NNS	p	O
were	VBD	p	O
recruited	VBN	p	O
from	IN	p	O
five	CD	p	O
primary	JJ	p	O
care	NN	p	O
clinics	NNS	p	O
at	IN	p	O
four	CD	p	O
Veterans	NNS	p	O
Affairs	NNP	p	O
healthcare	NN	p	O
facilities	NNS	p	O
and	CC	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
usual	JJ	i	IC
care	NN	i	IC
or	CC	O	O
usual	JJ	i	IE
care	NN	i	IE
plus	CC	i	IE
3CM	CD	i	IE
.	.	O	O

Blinded	VBN	O	O
assessors	NNS	O	O
collected	VBD	O	O
data	NNS	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
3-month	JJ	O	O
and	CC	O	O
6-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

PARTICIPANTS	JJ	O	O
Participants	NNS	p	O
were	VBD	p	O
195	CD	p	PSS
Veterans	NNPS	p	O
.	.	O	O

Their	PRP$	p	O
average	JJ	p	O
age	NN	p	O
was	VBD	p	O
45	CD	p	PA
years	NNS	p	PA
,	,	p	O
91	CD	p	O
%	NN	p	O
were	VBD	p	O
male	JJ	p	O
,	,	p	O
58	CD	p	O
%	NN	p	O
were	VBD	p	O
white	JJ	p	O
,	,	p	O
40	CD	p	O
%	NN	p	O
served	VBN	p	O
in	IN	p	O
Iraq	NNP	p	O
or	CC	p	O
Afghanistan	NNP	p	O
,	,	p	O
and	CC	p	O
42	CD	p	O
%	NN	p	O
served	VBD	p	O
in	IN	p	O
Vietnam	NNP	p	O
.	.	O	O

INTERVENTION	NNP	O	O
All	NNP	O	O
participants	NNS	O	O
received	VBD	O	O
usual	JJ	O	O
care	NN	O	O
.	.	O	O

Participants	NNS	O	O
assigned	VBD	O	O
to	TO	O	O
3CM	CD	i	IPS
also	RB	O	O
received	VBD	O	O
telephone	NN	i	IE
care	NN	i	IE
management	NN	i	IE
.	.	O	O

Care	NN	O	O
managers	NNS	O	O
received	VBD	O	O
supervision	NN	O	O
from	IN	O	O
a	DT	O	O
psychiatrist	NN	O	O
.	.	O	O

MAIN	NNP	O	O
MEASURES	NNP	O	O
PTSD	NNP	o	OPH
symptom	NN	o	OPH
severity	NN	o	OPH
was	VBD	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
.	.	O	O

Depression	NNP	o	OPH
,	,	o	OME
functioning	NN	o	OPH
,	,	o	O
perceived	VBD	o	OPH
quality	NN	o	OPH
of	IN	o	OPH
care	NN	o	OPH
,	,	o	OOt
utilization	NN	o	OOt
,	,	o	O
and	CC	o	O
costs	NNS	o	OOt
were	VBD	O	O
secondary	JJ	O	O
outcomes	NNS	O	O
.	.	O	O

KEY	JJ	O	O
RESULTS	NNP	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
between	IN	O	O
3CM	CD	O	O
and	CC	O	O
usual	JJ	O	O
care	NN	O	O
in	IN	O	O
symptoms	NNS	o	O
or	CC	O	O
functioning	VBG	o	O
.	.	O	O

Participants	NNS	O	O
assigned	VBD	O	O
to	TO	O	O
3CM	CD	i	IE
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
mental	JJ	o	OME
health	NN	o	OME
visit	NN	o	OME
,	,	o	O
fill	VB	o	OOt
an	DT	o	OOt
antidepressant	JJ	o	OOt
prescription	NN	o	OOt
,	,	O	O
and	CC	O	O
have	VBP	O	O
adequate	VBN	o	OOt
antidepressant	JJ	o	OOt
refills	NNS	o	OOt
.	.	O	O

3CM	CD	i	IE
participants	NNS	O	O
also	RB	O	O
had	VBD	O	O
more	RBR	O	O
mental	JJ	o	OME
health	NN	o	OME
visits	NNS	o	OME
and	CC	O	O
higher	JJR	O	O
outpatient	NN	o	OOt
pharmacy	NN	o	OOt
costs	NNS	o	OOt
.	.	O	O

CONCLUSIONS	NNP	O	O
Results	NNP	O	O
suggest	VBP	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
careful	JJ	O	O
examination	NN	O	O
of	IN	O	O
the	DT	O	O
way	NN	O	O
that	IN	O	O
collaborative	JJ	O	O
care	NN	O	O
models	NNS	O	O
are	VBP	O	O
implemented	VBN	O	O
for	IN	O	O
treating	VBG	O	O
PTSD	NNP	O	O
,	,	O	O
and	CC	O	O
for	IN	O	O
additional	JJ	O	O
supports	NNS	O	O
to	TO	O	O
encourage	VB	O	O
primary	JJ	O	O
care	NN	O	O
providers	NNS	O	O
to	TO	O	O
manage	VB	O	O
PTSD	NNP	O	O
.	.	O	O

[	NN	O	O
Improving	VBG	O	O
wound	IN	o	OPH
healing	VBG	o	OPH
after	IN	p	PC
nose	JJ	p	PC
surgery	NN	p	PC
by	IN	O	O
combined	JJ	O	O
administration	NN	O	O
of	IN	O	O
xylometazoline	NNP	i	IPM
and	CC	O	O
dexpanthenol	JJ	i	IPM
]	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
the	DT	O	O
examination	NN	O	O
of	IN	O	O
efficacy	NN	o	OOt
and	CC	O	O
tolerability	NN	o	OOt
of	IN	O	O
an	DT	O	O
application-form	NN	O	O
of	IN	O	O
the	DT	O	O
new	JJ	O	O
combination	NN	O	O
of	IN	O	O
Xylometazoline	NN	i	IPM
with	IN	O	O
Dexpanthenol	NNP	i	IPM
(	(	i	IPM
Nasic	NNP	i	IPM
)	)	i	IPM
versus	FW	O	O
Xylometazoline	NNP	i	IPM
alone	RB	i	O
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Randomized	NNP	O	O
verum	NN	O	O
controlled	VBD	O	O
parallel-group-comparison	NN	O	O
of	IN	O	O
two	CD	O	O
weeks	NNS	O	O
treatment	NN	O	O
of	IN	O	O
a	DT	O	O
nasal-spray	JJ	O	O
.	.	O	O

61	CD	p	O
inpatients	NNS	p	O
with	IN	p	O
the	DT	p	O
diagnosis	NN	p	O
Rhinitis	NNP	p	O
following	VBG	p	O
nasal	JJ	p	O
operation	NN	p	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
and	CC	O	O
30	CD	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
verum	NN	i	IPM
and	CC	O	O
placebo	NN	i	IC
each	DT	O	O
.	.	O	O

The	DT	O	O
assessment	NN	O	O
of	IN	O	O
nasal-breathing-resistance	NN	o	OPH
according	VBG	o	OOt
to	TO	o	OOt
scores	NNS	o	OOt
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
target-parameter	NN	O	O
.	.	O	O

Confirmatory	NNP	O	O
statistical	JJ	O	O
analysis	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
according	VBG	O	O
to	TO	O	O
Wilcoxon-Mann-Whitney-U	JJ	O	O
two-sided	JJ	O	O
at	IN	O	O
alpha	JJ	O	O
<	NN	O	O
or	CC	O	O
=	$	O	O
0.05	CD	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
The	DT	O	O
superiority	NN	O	O
of	IN	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
Xylometazoline-Dexpanthenol	JJ	i	IPM
nasal-spray	JJ	O	O
versus	NN	O	O
Xylometazoline	NNP	i	IPM
nasal	NN	O	O
spray	NN	O	O
could	MD	O	O
be	VB	O	O
proven	VBN	O	O
for	IN	O	O
the	DT	O	O
target-parameter	NN	O	O
as	IN	O	O
clinically	RB	O	O
relevant	JJ	O	O
and	CC	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

The	DT	O	O
clinically	RB	O	O
proven	JJ	O	O
efficacy	NN	o	OOt
is	VBZ	O	O
emphasized	VBN	O	O
by	IN	O	O
good	JJ	O	O
tolerability	NN	o	OOt
of	IN	O	O
both	DT	O	O
treatments	NNS	O	O
.	.	O	O

Due	NNP	O	O
to	TO	O	O
easy	VB	O	O
handling	NN	O	O
of	IN	O	O
the	DT	O	O
nasal-spray	JJ	O	O
a	DT	O	O
good	JJ	O	O
compliance	NN	o	OOt
was	VBD	O	O
confirmed	VBN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Distinct	NNP	O	O
improvement	NN	o	OPH
of	IN	O	O
symptoms	NNS	O	O
in	IN	O	O
patients	NNS	p	O
following	VBG	p	O
nasal	JJ	p	O
operations	NNS	p	O
underlines	VBP	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
both	DT	O	O
medications	NNS	O	O
.	.	O	O

With	IN	O	O
respect	NN	O	O
to	TO	O	O
the	DT	O	O
tolerability	NN	o	OOt
therapy	NN	O	O
with	IN	O	O
the	DT	O	O
combination	NN	O	O
is	VBZ	O	O
more	RBR	O	O
beneficial	JJ	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
alternative	JJ	O	O
therapy	NN	O	O
.	.	O	O

The	DT	O	O
result	NN	O	O
of	IN	O	O
this	DT	O	O
controlled	VBN	O	O
clinical	JJ	O	O
study	NN	O	O
confirms	VBZ	O	O
that	IN	O	O
the	DT	O	O
combination	NN	O	O
Xylometazoline-Dexpanthenol	NNP	i	IPM
is	VBZ	O	O
an	DT	O	O
enlargement	NN	O	O
and	CC	O	O
improvement	NN	O	O
of	IN	O	O
effective	JJ	O	O
medicinal	JJ	O	O
treatment	NN	O	O
of	IN	O	O
rhinitis	NN	p	O
following	VBG	p	O
nasal	JJ	p	O
operation	NN	p	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
therapy	VB	O	O
with	IN	O	O
Xylometazoline	NNP	i	IPM
alone	RB	O	O
.	.	O	O

[	JJ	O	O
Double-blind	NNP	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
effectiveness	NN	o	OOt
and	CC	O	O
tolerability	NN	o	OOt
of	IN	O	O
10	CD	O	O
and	CC	O	O
30	CD	O	O
mg	NN	O	O
ketorolac	NN	i	IPM
tromethamine	NN	i	IPM
suppositories	NNS	O	O
in	IN	O	O
post-cholecystectomy	JJ	p	PC
pain	NN	p	PC
]	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
tolerability	NN	o	OOt
of	IN	O	O
ketorolac	NN	i	IPM
tromethamine	NN	i	IPM
10	CD	O	O
mg	NN	O	O
and	CC	O	O
30	CD	O	O
mg	NN	O	O
suppositories	NNS	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
placebo	VB	i	IC
,	,	O	O
after	IN	O	O
single	JJ	O	O
dose	JJ	O	O
administration	NN	O	O
in	IN	O	O
patients	NNS	p	O
suffering	VBG	p	O
from	IN	p	O
post-operative	JJ	p	PC
pain	NN	p	PC
after	IN	p	O
cholecystectomy	NN	p	PC
.	.	O	O

DESIGN	NNP	O	O
Double-blind	NNP	O	O
,	,	O	O
randomized	VBD	O	O
,	,	O	O
controlled	VBD	O	O
study	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Anaesthesia	NNP	O	O
Service	NNP	O	O
.	.	O	O

PATIENTS	NNP	O	O
99	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
severe	JJ	p	PC
pain	NN	p	PC
following	VBG	p	PC
surgery	NN	p	PC
.	.	O	O

INTERVENTIONS	NNP	O	O
Cholecystectomy	NNP	O	O
.	.	O	O

MEASUREMENTS	NNP	O	O
AND	CC	O	O
MAIN	NNP	O	O
RESULTS	NNP	O	O
The	DT	O	O
analgesia	JJ	O	O
activity	NN	O	O
of	IN	O	O
ketorolac	NN	i	IPM
tromethamine	NN	i	IPM
10	CD	O	O
mg	NN	O	O
and	CC	O	O
30	CD	O	O
mg	NN	O	O
suppositories	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
after	IN	O	O
single	JJ	O	O
dose	JJ	O	O
administration	NN	O	O
by	IN	O	O
assessing	VBG	O	O
pain	NN	o	OPA
intensity	NN	o	OPA
and	CC	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
using	VBG	O	O
a	DT	O	O
4	CD	o	OPA
point	NN	o	OPA
scale	NN	o	OPA
(	(	o	OPA
VRS	NNP	o	OPA
)	)	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
period	NN	O	O
overall	JJ	O	O
assessment	NN	O	O
of	IN	O	O
safety	NN	o	OOt
and	CC	O	O
efficacy	NN	o	OOt
were	VBD	O	O
recorded	VBN	O	O
by	IN	O	O
physician	JJ	O	O
and	CC	O	O
patient	JJ	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
in	IN	O	O
both	DT	O	O
active	JJ	O	O
groups	NNS	O	O
after	IN	O	O
30	CD	O	O
'	POS	O	O
and	CC	O	O
until	IN	O	O
4	CD	O	O
hours	NNS	O	O
,	,	O	O
pain	VBP	o	OPA
intensity	NN	o	OPA
decreased	VBN	O	O
significantly	RB	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
the	DT	O	O
baseline	NN	O	O
.	.	O	O

However	RB	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
groups	NNS	O	O
of	IN	O	O
p	NN	O	O
<	NN	O	O
0.02	CD	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0.01	CD	O	O
and	CC	O	O
p	VB	O	O
<	JJ	O	O
0.05	CD	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
favour	NN	O	O
of	IN	O	O
the	DT	O	O
30	CD	O	O
mg	NN	O	O
dose	NN	O	O
respectively	RB	O	O
at	IN	O	O
30	CD	O	O
'	''	O	O
,	,	O	O
6	CD	O	O
and	CC	O	O
8	CD	O	O
hours	NNS	O	O
after	IN	O	O
administration	NN	O	O
.	.	O	O

All	PDT	O	O
the	DT	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
placebo	JJ	i	IC
suppositories	NNS	O	O
required	VBN	O	O
another	DT	O	O
rescue	NN	o	OOt
analgesic	JJ	o	OOt
drug	NN	o	OOt
and	CC	O	O
withdrew	NN	O	O
from	IN	O	O
the	DT	O	O
trial	NN	O	O
.	.	O	O

Three	CD	O	O
patients	NNS	O	O
complained	VBD	O	O
adverse	JJ	o	OA
events	NNS	o	OA
not	RB	O	O
related	VBN	O	O
to	TO	O	O
treatment	NN	O	O
:	:	O	O
two	CD	O	O
on	IN	O	O
placebo	NN	O	O
and	CC	O	O
one	CD	O	O
on	IN	O	O
ketorolac	NN	O	O
10	CD	O	O
mg	NN	O	O
.	.	O	O

The	DT	O	O
systemic	JJ	o	OOt
and	CC	o	OOt
local	JJ	o	OOt
tolerability	NN	o	OOt
of	IN	O	O
the	DT	O	O
drug	NN	O	O
was	VBD	O	O
good	JJ	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
shows	VBZ	O	O
that	IN	O	O
ketorolac	$	i	IPM
30	CD	O	O
mg	NN	O	O
suppositories	NNS	O	O
are	VBP	O	O
effective	JJ	O	O
in	IN	O	O
clinical	JJ	O	O
conditions	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
after	IN	p	PC
surgery	NN	p	PC
,	,	O	O
in	IN	O	O
which	WDT	O	O
pain	NN	O	O
control	NN	O	O
must	MD	O	O
be	VB	O	O
achieved	VBN	O	O
within	IN	O	O
the	DT	O	O
shortest	JJ	O	O
time	NN	O	O
interval	NN	O	O
and	CC	O	O
maintained	VBD	O	O
or	CC	O	O
improved	VBN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
route	NN	O	O
of	IN	O	O
administration	NN	O	O
.	.	O	O

Safety	NN	o	OOt
,	,	o	OOt
tolerability	NN	o	OOt
,	,	o	OOt
and	CC	o	OOt
immunogenicity	NN	o	OOt
after	IN	O	O
1	CD	O	O
and	CC	O	O
2	CD	O	O
doses	NNS	O	O
of	IN	O	O
zoster	NN	i	IPM
vaccine	NN	i	IPM
in	IN	O	O
healthy	JJ	p	O
adults	NNS	p	O
?60	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
.	.	O	O

BACKGROUND	NNP	O	O
Incidence	NNP	O	O
and	CC	O	O
severity	NN	O	O
of	IN	O	O
herpes	NNS	O	O
zoster	NNP	O	O
(	(	O	O
HZ	NNP	O	O
)	)	O	O
and	CC	O	O
postherpetic	JJ	O	O
neuralgia	JJ	O	O
increase	NN	O	O
with	IN	O	O
age	NN	O	O
,	,	O	O
associated	VBN	O	O
with	IN	O	O
age-related	JJ	O	O
decrease	NN	O	O
in	IN	O	O
immunity	NN	O	O
to	TO	O	O
varicella-zoster	JJ	O	O
virus	NN	O	O
(	(	O	O
VZV	NNP	O	O
)	)	O	O
.	.	O	O

One	CD	O	O
dose	NN	O	O
of	IN	O	O
zoster	NN	i	O
vaccine	NN	i	O
(	(	i	O
ZV	NNP	i	O
)	)	i	O
has	VBZ	O	O
demonstrated	VBN	O	O
substantial	JJ	O	O
protection	NN	O	O
against	IN	O	O
HZ	NNP	O	O
;	:	O	O
this	DT	O	O
study	NN	O	O
examined	VBD	O	O
impact	NN	O	O
of	IN	O	O
a	DT	O	O
second	JJ	O	O
dose	NN	O	O
of	IN	O	O
ZV	NNP	i	O
.	.	O	O

METHODS	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
double-blind	NN	O	O
,	,	O	O
multicenter	NN	O	O
study	NN	O	O
with	IN	O	O
210	CD	p	O
subjects	NNS	p	O
?60	CD	p	O
years	NNS	p	O
old	JJ	p	O
compared	VBN	O	O
immunity	NN	o	O
and	CC	o	O
safety	NN	o	O
profiles	NNS	o	O
after	IN	O	O
one	CD	O	O
and	CC	O	O
two	CD	O	O
doses	NNS	O	O
of	IN	O	O
ZV	NNP	i	O
,	,	O	O
separated	VBN	O	O
by	IN	O	O
6	CD	O	O
weeks	NNS	O	O
,	,	O	O
vs.	FW	O	O
placebo	NN	O	O
.	.	O	O

Immunogenicity	NNP	O	O
was	VBD	o	O
evaluated	VBN	O	O
using	VBG	O	O
VZV	NNP	o	O
interferon-gamma	JJ	o	O
(	(	o	O
IFN-?	NNP	o	O
)	)	o	O
enzyme-linked	JJ	o	O
immunospot	NN	o	O
(	(	o	O
ELISPOT	NNP	o	O
)	)	o	O
assay	NN	o	O
and	CC	o	O
VZV	NNP	o	O
glycoprotein	VBD	o	O
enzyme-linked	JJ	o	O
immunosorbent	NN	o	O
antibody	NN	o	O
(	(	o	O
gpELISA	NN	o	O
)	)	o	O
assay	NN	o	O
.	.	O	O

Adverse	JJ	O	O
experiences	NNS	o	O
(	(	o	O
AEs	NNP	o	O
)	)	o	O
were	VBD	O	O
recorded	VBN	O	O
on	IN	O	O
a	DT	O	O
standardized	JJ	O	O
Vaccination	NNP	O	O
Report	NNP	O	O
Card	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
No	NNP	O	O
serious	JJ	O	O
vaccine-related	JJ	o	O
AEs	NNP	o	O
occurred	VBD	O	O
.	.	O	O

VZV	NNP	o	O
IFN-?	NNP	O	O
ELISPOT	NNP	o	O
geometric	JJ	o	O
mean	NN	o	O
count	NN	o	O
(	(	o	O
GMC	NNP	o	O
)	)	o	O
of	IN	o	O
spot-forming	JJ	o	O
cells	NNS	o	O
per	IN	o	O
10	CD	o	O
(	(	o	O
6	CD	o	O
)	)	o	O
peripheral	JJ	o	O
blood	NN	o	O
mononuclear	JJ	o	O
cells	NNS	o	O
increased	VBN	O	O
in	IN	O	O
the	DT	O	O
ZV	NNP	i	O
group	NN	O	O
from	IN	O	O
16.9	CD	O	O
prevaccination	NN	O	O
to	TO	O	O
49.5	CD	O	O
and	CC	O	O
32.8	CD	O	O
at	IN	O	O
2	CD	O	O
and	CC	O	O
6	CD	O	O
weeks	NNS	O	O
postdose	RB	O	O
1	CD	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Two	CD	O	O
weeks	NNS	O	O
,	,	O	O
6	CD	O	O
weeks	NNS	O	O
and	CC	O	O
6	CD	O	O
months	NNS	O	O
postdose	RB	O	O
2	CD	O	O
,	,	O	O
GMC	NNP	O	O
was	VBD	O	O
44.3	CD	O	O
,	,	O	O
42.9	CD	O	O
,	,	O	O
and	CC	O	O
36.5	CD	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

GMC	NNP	o	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
did	VBD	O	O
not	RB	O	O
change	NN	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
peak	JJ	O	O
ELISPOT	NNP	o	O
response	NN	o	O
occurred	VBD	O	O
?2	NNP	O	O
weeks	NNS	O	O
after	IN	O	O
each	DT	O	O
ZV	NNP	i	O
dose	NN	O	O
.	.	O	O

The	DT	O	O
gpELISA	NN	O	O
geometric	JJ	o	O
mean	NN	o	O
titers	NNS	o	O
(	(	o	O
GMTs	NNP	o	O
)	)	o	O
in	IN	O	O
the	DT	O	O
ZV	NNP	i	O
group	NN	O	O
were	VBD	O	O
higher	JJR	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
at	IN	O	O
6	CD	O	O
weeks	NNS	O	O
after	IN	O	O
each	DT	O	O
dose	NN	O	O
.	.	O	O

Correlation	NN	O	O
between	IN	O	O
the	DT	O	O
IFN-?	NNP	o	O
ELISPOT	NNP	o	O
and	CC	o	O
gpELISA	NN	o	O
assays	NNS	o	O
was	VBD	O	O
poor	JJ	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
ZV	NNP	i	O
was	VBD	O	O
generally	RB	O	O
well-tolerated	JJ	O	O
and	CC	O	O
immunogenic	JJ	O	O
in	IN	O	O
adults	NNS	O	O
?60	CD	O	O
years	NNS	O	O
old	JJ	O	O
.	.	O	O

A	DT	O	O
second	JJ	O	O
dose	NN	O	O
of	IN	O	O
ZV	NNP	i	O
was	VBD	O	O
generally	RB	O	O
safe	JJ	o	O
,	,	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
boost	VB	O	O
VZV-specific	NNP	O	O
immunity	NN	o	O
beyond	IN	O	O
levels	NNS	O	O
achieved	VBN	O	O
postdose	RB	O	O
1	CD	O	O
.	.	O	O

Necessary	NNP	O	O
but	CC	O	O
not	RB	O	O
sufficient	JJ	O	O
:	:	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
screening	NN	O	O
and	CC	O	O
feedback	NN	O	O
on	IN	O	O
outcomes	NNS	O	O
of	IN	O	O
primary	JJ	p	O
care	NN	p	O
patients	NNS	p	O
with	IN	p	O
untreated	JJ	p	PC
anxiety	NN	p	PC
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
consider	VB	O	O
the	DT	O	O
impact	NN	O	O
on	IN	O	O
primary	JJ	O	O
care	NN	O	O
patient	JJ	O	O
outcomes	NNS	O	O
of	IN	O	O
using	VBG	O	O
both	DT	O	O
a	DT	O	O
screener	NN	O	O
to	TO	O	O
determine	VB	O	O
elevated	VBN	O	O
anxiety	NN	O	O
levels	NNS	O	O
among	IN	O	O
patients	NNS	p	O
with	IN	p	O
previously	RB	p	O
undetected	VBN	p	PC
anxiety	NN	p	PC
and	CC	O	O
a	DT	O	O
physician	JJ	O	O
intervention	NN	O	O
to	TO	O	O
inform	VB	O	O
physicians	NNS	O	O
of	IN	O	O
their	PRP$	O	O
patients	NNS	O	O
'	POS	O	O
conditions	NNS	O	O
.	.	O	O

DESIGN	NNP	O	O
Participating	VBG	O	O
physicians	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
either	CC	O	O
the	DT	O	O
demonstration	NN	i	IE
or	CC	O	O
the	DT	O	O
control	NN	O	O
arm	NN	O	O
,	,	O	O
and	CC	O	O
patients	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
study	NN	O	O
arm	NN	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
randomization	NN	O	O
of	IN	O	O
their	PRP$	O	O
physicians	NNS	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
for	IN	O	O
change	NN	O	O
in	IN	O	O
outcome	JJ	O	O
measures	NNS	O	O
during	IN	O	O
the	DT	O	O
five-month	JJ	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

SETTING	VB	O	O
A	DT	O	O
mixed-model	JJ	O	O
health	NN	O	O
maintenance	NN	O	O
organization	NN	O	O
serving	VBG	O	O
approximately	RB	O	O
110,000	CD	O	O
enrollees	NNS	O	O
in	IN	O	O
central	JJ	O	O
Colorado	NNP	O	O
.	.	O	O

PATIENTS/PARTICIPANTS	NNP	O	O
573	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
unrecognized	VBN	p	O
and	CC	p	O
untreated	JJ	p	PC
anxiety	NN	p	PC
identified	VBN	p	O
from	IN	p	O
the	DT	p	O
approximately	RB	p	O
8,000	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
completed	VBD	p	O
the	DT	p	O
waiting	VBG	p	O
room	NN	p	O
screening	NN	p	O
questionnaire	NN	p	O
.	.	O	O

INTERVENTIONS	VBZ	O	O
A	DT	O	O
physician	JJ	i	IE
intervention	NN	i	IE
served	VBD	O	O
the	DT	O	O
dual	JJ	O	O
function	NN	O	O
of	IN	O	O
1	CD	O	O
)	)	O	O
providing	VBG	O	O
an	DT	O	O
educational	JJ	O	O
demonstration	NN	O	O
of	IN	O	O
anxiety	NN	O	O
in	IN	O	O
the	DT	O	O
primary	JJ	O	O
care	NN	O	O
setting	VBG	O	O
and	CC	O	O
2	CD	O	O
)	)	O	O
providing	VBG	O	O
a	DT	O	O
reporting	NN	O	O
system	NN	O	O
for	IN	O	O
summarizing	VBG	O	O
the	DT	O	O
anxiety	NN	O	O
symptom	NN	O	O
levels	NNS	O	O
and	CC	O	O
functioning	VBG	O	O
status	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
enrolled	VBN	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

MEASUREMENTS	NNP	O	O
AND	CC	O	O
MAIN	NNP	O	O
RESULTS	NNP	O	O
Patient	NNP	O	O
outcomes	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
as	IN	O	O
changes	NNS	O	O
in	IN	O	O
global	JJ	o	OME
anxiety	NN	o	OME
scores	NNS	o	OME
,	,	o	O
functioning	VBG	o	OME
and	CC	o	OME
well-being	JJ	o	OME
,	,	o	O
and	CC	O	O
patients	NNS	o	OME
'	POS	o	OME
reports	NNS	o	OME
of	IN	o	OME
global	JJ	o	OME
improvements	NNS	o	OME
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
this	DT	O	O
method	NN	O	O
of	IN	O	O
reporting	VBG	O	O
symptoms	NNS	O	O
and	CC	O	O
functioning	VBG	O	O
status	NN	O	O
to	TO	O	O
primary	VB	O	O
care	NN	O	O
physicians	NNS	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
change	VBP	O	O
patient	JJ	O	O
outcomes	NNS	O	O
.	.	O	O

Improvement	NN	O	O
in	IN	O	O
outcomes	NNS	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
more	RBR	O	O
closely	RB	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
patient	NN	O	O
's	POS	O	O
severity	NN	O	O
of	IN	O	O
psychological	JJ	O	O
distress	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
cuff	NN	O	O
inflation	NN	O	O
on	IN	O	O
self-recorded	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
continuously	RB	O	O
recorded	VBN	O	O
'Finapres	NNS	o	OPH
'	POS	o	OPH
finger	NN	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
in	IN	O	O
ten	JJ	p	O
normotensive	JJ	p	O
and	CC	p	O
seven	CD	p	O
hypertensive	JJ	p	O
subjects	NNS	p	O
induced	VBN	O	O
by	IN	O	O
self-inflation	NN	i	IPH
of	IN	i	IPH
the	DT	i	IPH
cuff	NN	i	IPH
or	CC	O	O
just	RB	i	IPH
wearing	VBG	i	IPH
the	DT	i	IPH
inflated	JJ	i	IPH
cuff	NN	i	IPH
were	VBD	O	O
studied	VBN	O	O
.	.	O	O

Inflating	VBG	i	IPH
the	DT	i	IPH
cuff	NN	i	IPH
caused	VBD	O	O
an	DT	O	O
instantaneous	JJ	O	O
rise	NN	O	O
in	IN	O	O
systolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
of	IN	O	O
13	CD	O	O
and	CC	O	O
12	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
(	(	O	O
hypertensive	JJ	O	O
and	CC	O	O
normotensive	JJ	O	O
subjects	NNS	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Wearing	VBG	O	O
the	DT	O	O
inflated	JJ	i	IPH
cuff	NN	i	IPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
.	.	O	O

Thus	VB	O	O
the	DT	O	O
rise	NN	O	O
in	IN	O	O
pressure	NN	o	OPH
was	VBD	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
muscular	JJ	O	O
activity	NN	O	O
required	VBN	O	O
for	IN	O	O
cuff	NN	i	IPH
inflation	NN	i	IPH
.	.	O	O

Systolic	NNP	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
took	VBD	O	O
on	IN	O	O
average	JJ	O	O
7	CD	O	O
s	NN	O	O
and	CC	O	O
at	IN	O	O
most	JJS	O	O
21	CD	O	O
s	NN	O	O
to	TO	O	O
return	VB	O	O
to	TO	O	O
baseline	VB	O	O
level	NN	O	O
after	IN	O	O
stopping	VBG	O	O
cuff	NN	O	O
inflation	NN	O	O
.	.	O	O

Since	IN	O	O
first	JJ	O	O
Korotkoff	NNP	O	O
sounds	NNS	O	O
may	MD	O	O
already	RB	O	O
be	VB	O	O
heard	VBN	O	O
after	IN	O	O
10-15	JJ	O	O
s	NN	O	O
when	WRB	O	O
following	VBG	O	O
recommended	VBD	O	O
procedures	NNS	O	O
,	,	O	O
self-recorded	JJ	o	OPH
systolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
may	MD	O	O
be	VB	O	O
recorded	VBN	O	O
as	IN	O	O
too	RB	O	O
high	JJ	O	O
when	WRB	O	O
subjects	NNS	O	O
inflate	VBP	O	O
their	PRP$	O	O
cuff	NN	O	O
at	IN	O	O
too	RB	O	O
low	JJ	O	O
a	DT	O	O
pressure	NN	O	O
or	CC	O	O
deflate	VB	O	O
it	PRP	O	O
too	RB	O	O
fast	RB	O	O
.	.	O	O

Conscious	JJ	O	O
analgesia/sedation	NN	O	O
with	IN	O	O
remifentanil	NN	i	IPM
and	CC	O	O
propofol	NN	i	IPM
versus	NN	O	O
total	JJ	O	O
intravenous	JJ	O	O
anesthesia	NN	O	O
with	IN	O	O
fentanyl	NN	i	IPM
,	,	O	O
midazolam	NN	i	IPM
,	,	O	O
and	CC	O	O
propofol	NN	i	IPM
for	IN	O	O
outpatient	JJ	p	O
colonoscopy	NN	p	PC
.	.	O	O

BACKGROUND	NNP	O	O
This	DT	O	O
study	NN	O	O
tested	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
,	,	O	O
for	IN	O	O
colonoscopy	NN	O	O
,	,	O	O
analgesia/sedation	NN	O	O
with	IN	O	O
remifentanil	NN	i	IPM
and	CC	O	O
propofol	NN	i	IPM
might	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
compared	VBN	O	O
with	IN	O	O
anesthesia	NN	O	O
by	IN	O	O
intravenous	JJ	O	O
administration	NN	O	O
of	IN	O	O
midazolam	NN	i	IPM
,	,	O	O
fentanyl	NN	i	IPM
,	,	O	O
and	CC	O	O
propofol	NN	i	IPM
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
,	,	O	O
100	CD	p	PSS
adult	NN	p	O
patients	NNS	p	O
received	VBD	O	O
either	RB	O	O
conscious	JJ	O	O
analgesia/sedation	NN	O	O
(	(	O	O
Sedation	NNP	O	O
group	NN	O	O
)	)	O	O
or	CC	O	O
total	JJ	O	O
intravenous	JJ	O	O
anesthesia	NN	O	O
(	(	O	O
TIVA	NNP	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

Analgesia/sedation	NN	O	O
was	VBD	O	O
achieved	VBN	O	O
by	IN	O	O
infusion	NN	O	O
of	IN	O	O
remifentanil	NN	i	IPM
(	(	O	O
0.20	CD	O	O
to	TO	O	O
0.25	CD	O	O
microg/kg/min	NN	O	O
)	)	O	O
and	CC	O	O
propofol	NN	i	IPM
in	IN	O	O
titrated	JJ	O	O
doses	NNS	O	O
.	.	O	O

TIVA	NNP	O	O
was	VBD	O	O
induced	VBN	O	O
by	IN	O	O
intravenous	JJ	O	O
administration	NN	O	O
of	IN	O	O
fentanyl	NN	i	IPM
(	(	O	O
2	CD	O	O
microg/kg	NN	O	O
)	)	O	O
,	,	O	O
midazolam	FW	i	IPM
(	(	O	O
0.05	CD	O	O
mg/kg	NN	O	O
)	)	O	O
and	CC	O	O
propofol	NN	i	IPM
(	(	O	O
dosage	NN	O	O
titrated	VBN	O	O
)	)	O	O
.	.	O	O

Cardiorespiratory	JJ	o	OPH
parameters	NNS	o	OPH
and	CC	O	O
bispectral	JJ	o	OPH
index	NN	o	OPH
were	VBD	O	O
monitored	VBN	O	O
and	CC	O	O
recorded	VBN	O	O
.	.	O	O

The	DT	O	O
quality	NN	O	O
of	IN	O	O
the	DT	O	O
analgesia	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
a	DT	O	O
Numerical	JJ	o	OOt
Pain	NN	o	OOt
Rating	NNP	o	OOt
Scale	NNP	o	OOt
(	(	o	OOt
NRS	NNP	o	OOt
)	)	o	OOt
;	:	o	OOt
recovery	NN	o	OOt
level	NN	o	OOt
and	CC	O	O
return	NN	o	OOt
of	IN	o	OOt
psychomotor	NN	o	OOt
efficiency	NN	o	OOt
were	VBD	O	O
evaluated	VBN	O	O
with	IN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
the	DT	O	O
Aldrete	NNP	o	OOt
scale	NN	o	OOt
and	CC	O	O
a	DT	O	O
Modified	NNP	o	OPH
Post	NNP	o	OPH
Anesthesia	NNP	o	OPH
Discharge	NNP	o	OPH
Scoring	NNP	o	OPH
(	(	o	OPH
MPADS	NNP	o	OPH
)	)	o	OPH
system	NN	o	OPH
.	.	O	O

RESULTS	VB	O	O
Both	DT	O	O
groups	NNS	O	O
of	IN	O	O
50	CD	O	O
patients	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
demographic	VB	O	O
data	NNS	O	O
,	,	O	O
initial	JJ	O	O
parameters	NNS	O	O
,	,	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
colonoscopy	NN	p	PC
.	.	O	O

All	DT	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
TIVA	NNP	O	O
group	NN	O	O
found	VBD	O	O
the	DT	O	O
colonoscopy	NN	O	O
painless	NN	O	O
(	(	O	O
NRS	NNP	O	O
score	RB	O	O
0	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
Sedation	NNP	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
average	JJ	O	O
pain	NN	o	OPA
intensity	NN	o	OPA
score	NN	o	OPA
was	VBD	O	O
0.4	CD	O	O
(	(	O	O
0.8	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
marked	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
Sedation	NNP	O	O
and	CC	O	O
TIVA	NNP	O	O
groups	NNS	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
the	DT	O	O
time	NN	O	O
from	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
procedure	NN	O	O
until	IN	O	O
the	DT	O	O
maximum	JJ	o	OOt
MPADS	NNP	o	OOt
score	NN	o	OOt
was	VBD	O	O
reached	VBN	O	O
:	:	O	O
respectively	RB	O	O
,	,	O	O
-6.9	NNP	O	O
(	(	O	O
4.0	CD	O	O
)	)	O	O
versus	NN	O	O
25.7	CD	O	O
(	(	O	O
8.4	CD	O	O
)	)	O	O
minutes	NNS	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
TIVA	NNP	O	O
group	NN	O	O
,	,	O	O
changes	NNS	O	O
in	IN	O	O
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
and	CC	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
and	CC	o	OPH
signs	NNS	o	OPH
of	IN	o	OPH
respiratory	NN	o	OPH
depression	NN	o	OPH
were	VBD	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Combined	NNP	O	O
administration	NN	O	O
of	IN	O	O
remifentanil	NN	i	IPM
and	CC	O	O
propofol	NN	i	IPM
for	IN	O	O
colonoscopy	NN	O	O
provides	VBZ	O	O
sufficient	JJ	O	O
analgesia	NN	o	OPH
,	,	O	O
satisfactory	JJ	O	O
hemodynamic	JJ	o	OPH
stability	NN	o	OPH
,	,	O	O
minor	JJ	O	O
respiratory	NN	o	OPH
depression	NN	o	OPH
,	,	O	O
and	CC	O	O
rapid	JJ	o	OPH
recovery	NN	o	OPH
,	,	O	O
and	CC	O	O
allows	VBZ	O	O
patients	NNS	O	O
to	TO	O	O
be	VB	O	O
discharged	VBN	O	O
approximately	RB	O	O
15	CD	O	O
minutes	NNS	O	O
after	IN	O	O
the	DT	O	O
procedure	NN	O	O
.	.	O	O

Teaching	VBG	O	O
emotion	NN	i	IPS
recognition	NN	i	IPS
skills	NNS	O	O
to	TO	O	O
young	JJ	p	PC
children	NNS	p	PA
with	IN	p	PC
autism	NN	p	PC
:	:	O	O
a	DT	O	O
randomised	JJ	O	O
controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
an	DT	O	O
emotion	NN	i	IPS
training	NN	i	IPS
programme	NN	i	IPS
.	.	O	O

BACKGROUND	NNP	O	O
Children	NNP	p	O
with	IN	p	O
autism	NN	p	O
have	VBP	O	O
difficulties	NNS	O	O
in	IN	O	O
emotion	NN	O	O
recognition	NN	O	O
and	CC	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
interventions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
designed	VBN	O	O
to	TO	O	O
target	VB	O	O
these	DT	O	O
problems	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
few	JJ	O	O
emotion	NN	i	IPS
training	NN	i	IPS
interventions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
trialled	VBN	O	O
with	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
and	CC	p	O
co-morbid	JJ	p	O
ID	NNP	p	O
.	.	O	O

This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
an	DT	O	O
emotion	NN	i	IE
training	NN	i	IE
programme	NN	i	IE
for	IN	O	O
a	DT	O	O
group	NN	O	O
of	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
with	IN	p	O
a	DT	p	O
range	NN	p	O
of	IN	p	O
intellectual	JJ	p	O
ability	NN	p	O
.	.	O	O

METHODS	NNP	O	O
Participants	NNPS	p	O
were	VBD	p	O
55	CD	p	PSS
children	NNS	p	O
with	IN	p	O
autistic	JJ	p	O
disorder	NN	p	O
,	,	p	O
aged	VBN	p	O
4-7	CD	p	O
years	NNS	p	O
(	(	p	O
FSIQ	NNP	p	O
42-107	CD	p	O
)	)	p	O
.	.	O	O

Children	NNP	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
an	DT	O	O
intervention	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
28	CD	O	O
)	)	O	O
or	CC	O	O
control	VB	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
27	CD	O	O
)	)	O	O
.	.	O	O

Participants	NNS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
watched	VBD	O	O
a	DT	O	O
DVD	NNP	O	O
designed	VBN	O	O
to	TO	O	O
teach	VB	O	O
emotion	NN	i	IPS
recognition	NN	i	IPS
skills	NNS	i	IPS
to	TO	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
(	(	O	O
the	DT	i	O
Transporters	NNPS	i	IE
)	)	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
watched	VBD	O	O
a	DT	O	O
DVD	NNP	O	O
of	IN	O	O
Thomas	NNP	i	IC
the	DT	i	IC
Tank	NNP	i	IC
Engine	NNP	i	IC
.	.	O	O

Participants	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
on	IN	O	O
their	PRP$	O	O
ability	NN	O	O
to	TO	O	O
complete	VB	O	O
basic	JJ	o	OME
emotion	NN	o	OME
recognition	NN	o	OME
tasks	NNS	o	OME
,	,	o	O
mindreading	VBG	o	OME
and	CC	o	O
theory	NN	o	OME
of	IN	o	OME
mind	NN	o	OME
(	(	o	OME
TOM	NNP	o	OME
)	)	o	OME
tasks	NNS	o	OME
before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
4-week	JJ	O	O
intervention	NN	O	O
period	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
3-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Analyses	NNP	O	O
controlled	VBD	O	O
for	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
chronological	JJ	O	O
age	NN	O	O
,	,	O	O
verbal	JJ	O	O
intelligence	NN	O	O
,	,	O	O
gender	NN	O	O
and	CC	O	O
DVD	NNP	O	O
viewing	VBG	O	O
time	NN	O	O
on	IN	O	O
outcomes	NNS	O	O
.	.	O	O

Children	NNP	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
showed	VBD	O	O
improved	JJ	O	O
performance	NN	O	O
in	IN	O	O
the	DT	O	O
recognition	NN	o	OME
of	IN	o	OME
anger	NN	o	OME
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
,	,	O	O
with	IN	O	O
few	JJ	O	O
improvements	NNS	O	O
maintained	VBD	O	O
at	IN	O	O
3-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
generalisation	NN	O	O
of	IN	O	O
skills	NNS	O	O
to	TO	O	O
TOM	NNP	o	OME
or	CC	O	O
social	JJ	o	OME
skills	NNS	o	OME
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	i	IE
Transporters	NNP	i	IPS
programme	NN	O	O
showed	VBD	O	O
limited	JJ	O	O
efficacy	NN	o	OOt
in	IN	O	O
teaching	VBG	O	O
basic	JJ	O	O
emotion	NN	O	O
recognition	NN	O	O
skills	NNS	O	O
to	TO	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
with	IN	O	O
a	DT	O	O
lower	JJR	O	O
range	NN	O	O
of	IN	O	O
cognitive	JJ	O	O
ability	NN	O	O
.	.	O	O

Improvements	NNS	O	O
were	VBD	O	O
limited	VBN	O	O
to	TO	O	O
the	DT	O	O
recognition	NN	O	O
of	IN	O	O
expressions	NNS	O	O
of	IN	O	O
anger	NN	O	O
,	,	O	O
with	IN	O	O
poor	JJ	O	O
maintenance	NN	O	O
of	IN	O	O
these	DT	O	O
skills	NNS	O	O
at	IN	O	O
follow-up	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
provide	VBP	O	O
limited	JJ	O	O
support	NN	O	O
for	IN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
Transporters	NNP	i	IPS
programme	NN	O	O
for	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
of	IN	O	O
a	DT	O	O
lower	JJR	O	O
cognitive	JJ	O	O
range	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
paromomycin	NN	i	IPM
on	IN	O	O
endotoxemia	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
alcoholic	JJ	p	PC
liver	NN	p	PSS
disease	NN	p	PSS
--	:	O	O
a	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
experimental	JJ	O	O
and	CC	O	O
clinical	JJ	O	O
studies	NNS	O	O
support	VBP	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
gut-derived	JJ	O	O
endotoxins	NNS	O	O
might	MD	O	O
be	VB	O	O
of	IN	O	O
relevance	NN	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
and	CC	O	O
course	NN	O	O
of	IN	O	O
alcoholic	JJ	O	O
liver	NN	O	O
disease	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
nonabsorbable	JJ	O	O
,	,	O	O
broad-spectrum	JJ	O	O
antibiotic	NN	O	O
on	IN	O	O
endotoxemia	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
alcoholic	JJ	p	PC
liver	NN	p	PC
disease	NN	p	PC
.	.	O	O

Fifty	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
alcoholic	JJ	p	PC
liver	NN	p	PC
disease	NN	p	PC
(	(	p	O
27	CD	p	PSS
with	IN	p	O
cirrhosis	NN	p	PC
,	,	p	O
23	CD	p	PSS
without	IN	p	O
cirrhosis	NN	p	PC
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
paromomycin	NN	i	IPM
sulfate	NN	i	IPM
(	(	O	O
3	CD	O	O
x	RB	O	O
1	CD	O	O
g/day	NN	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IPM
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
fashion	NN	O	O
for	IN	O	O
at	IN	O	O
least	JJS	O	O
3	CD	O	O
weeks	NNS	O	O
,	,	O	O
and	CC	O	O
if	IN	O	O
possible	JJ	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

Endotoxin	NNP	o	OPH
concentration	NN	o	OPH
,	,	o	O
liver	JJ	o	OPH
function	NN	o	OPH
tests	NNS	o	OPH
,	,	O	O
and	CC	O	O
other	JJ	O	O
laboratory	NN	O	O
parameters	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
in	IN	O	O
weekly	JJ	O	O
intervals	NNS	O	O
.	.	O	O

Endotoxin	NNP	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
also	RB	O	O
determined	VBN	O	O
in	IN	O	O
15	CD	p	PSS
healthy	JJ	p	PC
controls	NNS	p	O
.	.	O	O

Groups	NNP	O	O
receiving	VBG	O	O
paromomycin	NN	i	IPM
or	CC	O	O
placebo	NN	i	IC
were	VBD	O	O
similar	JJ	O	O
for	IN	O	O
clinical	JJ	O	O
and	CC	O	O
biological	JJ	O	O
items	NNS	O	O
collected	VBN	O	O
initially	RB	O	O
.	.	O	O

Mean	JJ	O	O
initial	JJ	O	O
endotoxin	NN	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
elevated	VBN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
(	(	O	O
mean	JJ	O	O
+/-	JJ	O	O
SEM	NNP	O	O
;	:	O	O
paromomycin	NN	i	IPM
,	,	O	O
16.7	CD	O	O
+/-	JJ	O	O
5.3	CD	O	O
pg/ml	NN	O	O
;	:	O	O
placebo	NN	i	IC
,	,	O	O
17.5	CD	O	O
+/-	JJ	O	O
6.9	CD	O	O
pg/ml	NN	O	O
;	:	O	O
healthy	JJ	O	O
controls	NNS	O	O
,	,	O	O
2.3	CD	O	O
+/-	JJ	O	O
0.4	CD	O	O
pg/ml	NN	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
mean	JJ	O	O
endotoxin	NN	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
verum	NN	O	O
group	NN	O	O
after	IN	O	O
1	CD	O	O
week	NN	O	O
(	(	O	O
paromomycin	NN	i	IPM
,	,	O	O
8.0	CD	O	O
+/-	JJ	O	O
1.9	CD	O	O
pg/ml	NN	O	O
;	:	O	O
placebo	NN	i	IC
,	,	O	O
14.6	CD	O	O
+/-	JJ	O	O
3.5	CD	O	O
pg/ml	NN	O	O
;	:	O	O
p	CC	O	O
>	VB	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
paromomycin	JJ	i	IPM
treatment	NN	O	O
had	VBD	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
endotoxin	NN	o	OPH
concentration	NN	o	OPH
or	CC	O	O
liver	JJ	o	OPH
function	NN	o	OPH
tests	NNS	o	OPH
during	IN	O	O
the	DT	O	O
4-week	JJ	O	O
period	NN	O	O
.	.	O	O

The	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
of	IN	O	O
paromomycin	NN	i	IPM
treatment	NN	O	O
on	IN	O	O
endotoxemia	NN	O	O
in	IN	O	O
cirrhotics	NNS	O	O
reported	VBN	O	O
in	IN	O	O
earlier	JJR	O	O
studies	NNS	O	O
could	MD	O	O
not	RB	O	O
be	VB	O	O
reproduced	VBN	O	O
under	IN	O	O
the	DT	O	O
conditions	NNS	O	O
of	IN	O	O
this	DT	O	O
trial	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
alcoholic	JJ	p	PC
liver	NN	p	PC
disease	NN	p	PC
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
soy	JJ	i	IPM
intake	NN	O	O
on	IN	O	O
sex	NN	o	OPH
hormone	NN	o	OPH
metabolism	NN	o	OPH
in	IN	O	O
premenopausal	JJ	p	PC
women	NNS	p	PSE
.	.	O	O

Studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
phytoestrogens	NNS	O	O
in	IN	O	O
soy	JJ	i	IPM
products	NNS	O	O
may	MD	O	O
impart	VB	O	O
hormonal	JJ	O	O
effects	NNS	O	O
that	WDT	O	O
protect	VBP	O	O
women	NNS	O	O
against	IN	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Limited	VBN	O	O
research	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
intake	NN	O	O
of	IN	O	O
soy	NN	i	IPM
products	NNS	O	O
high	JJ	O	O
in	IN	O	O
isoflavonoid	JJ	O	O
phytoestrogens	NNS	O	O
affects	VBZ	O	O
sex	NN	o	OPH
hormone	NN	o	OPH
metabolism	NN	o	OPH
,	,	O	O
but	CC	O	O
it	PRP	O	O
is	VBZ	O	O
unknown	JJ	O	O
whether	IN	O	O
phytoestrogens	NNS	O	O
in	IN	O	O
soy	NNS	O	O
have	VBP	O	O
any	DT	O	O
effect	NN	O	O
on	IN	O	O
menstrual	JJ	O	O
function	NN	O	O
or	CC	O	O
serum	VB	O	O
sex	NN	O	O
hormones	NNS	O	O
in	IN	O	O
women	NNS	p	O
on	IN	O	O
common	JJ	O	O
hormone	NN	O	O
therapies	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
oral	JJ	O	O
contraceptives	NNS	O	O
(	(	O	O
OC	NNP	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
soy	NN	i	IPM
in	IN	O	O
36	CD	p	PSS
premenopausal	JJ	p	PSE
women	NNS	p	PSE
,	,	p	O
20	CD	p	PSS
of	IN	p	PSS
whom	WP	p	PSS
used	VBD	p	PSS
OC	NNP	p	PSS
.	.	O	O

Subjects	NNS	O	O
consumed	VBD	O	O
their	PRP$	O	O
normal	JJ	O	O
diet	NNS	O	O
for	IN	O	O
two	CD	O	O
menstrual	JJ	O	O
cycles	NNS	O	O
and	CC	O	O
added	VBD	O	O
a	DT	O	O
soy	JJ	i	IPM
beverage	NN	i	IPM
containing	VBG	O	O
20	CD	O	O
g	NN	O	O
of	IN	O	O
protein	NN	O	O
and	CC	O	O
38	CD	O	O
mg	NN	O	O
of	IN	O	O
total	JJ	O	O
isoflavones	NNS	O	O
to	TO	O	O
their	PRP$	O	O
usual	JJ	O	O
diet	NN	O	O
for	IN	O	O
another	DT	O	O
two	CD	O	O
menstrual	JJ	O	O
cycles	NNS	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
serum	NN	o	OPH
estrone	NN	o	OPH
,	,	o	OPH
estradiol	NN	o	OPH
,	,	o	OPH
sex	NN	o	OPH
hormone-binding	JJ	o	OPH
globulin	NN	o	OPH
,	,	o	OPH
dehydroepiandrosterone	NN	o	OPH
sulfate	NN	o	OPH
,	,	o	OPH
prolactin	NN	o	OPH
,	,	o	OPH
or	CC	o	OPH
progesterone	NN	o	OPH
concentrations	NNS	o	OPH
with	IN	O	O
soy	JJ	i	IPM
feeding	NN	O	O
in	IN	O	O
the	DT	O	O
non-OC	JJ	O	O
or	CC	O	O
the	DT	O	O
OC	NNP	O	O
group	NN	O	O
.	.	O	O

No	DT	O	O
changes	NNS	O	O
in	IN	O	O
menstrual	JJ	o	OPH
cycle	NN	o	OPH
length	NN	o	OPH
or	CC	o	OPH
the	DT	o	OPH
urinary	JJ	o	OPH
estrogen	NN	o	OPH
metabolite	NNS	o	OPH
ratio	NN	o	OPH
of	IN	o	OPH
2-hydroxyestrone	CD	o	OPH
to	TO	o	OPH
16	CD	o	OPH
alpha-hydroxyestrone	NN	o	OPH
were	VBD	O	O
seen	VBN	O	O
with	IN	O	O
soy	JJ	O	O
feeding	NN	O	O
in	IN	O	O
the	DT	O	O
non-OC	JJ	O	O
or	CC	O	O
the	DT	O	O
OC	NNP	O	O
group	NN	O	O
.	.	O	O

Levels	NNP	O	O
of	IN	O	O
urinary	JJ	o	OPH
estrogen	NN	o	OPH
metabolites	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
non-OC	JJ	O	O
and	CC	O	O
the	DT	O	O
OC	NNP	O	O
group	NN	O	O
.	.	O	O

Thus	RB	O	O
soy	JJ	i	IPM
consumption	NN	O	O
had	VBD	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
menstrual	JJ	o	OPH
cycle	NN	o	OPH
,	,	o	OPH
serum	JJ	o	OPH
sex	NN	o	OPH
hormones	NNS	o	OPH
,	,	o	OPH
or	CC	o	OPH
urinary	JJ	o	OPH
estrogen	NN	o	OPH
metabolite	NN	o	OPH
ratio	NN	o	OPH
in	IN	O	O
premenopausal	NN	p	PSS
OC	NNP	p	PSS
or	CC	O	O
non-OC	JJ	p	PSS
users	NNS	p	PSS
.	.	O	O

A	DT	O	O
pooled	JJ	O	O
analysis	NN	O	O
of	IN	O	O
eastern	JJ	O	O
cooperative	JJ	O	O
oncology	NN	O	O
group	NN	O	O
and	CC	O	O
intergroup	NN	O	O
trials	NNS	O	O
of	IN	O	O
adjuvant	JJ	O	O
high-dose	JJ	O	O
interferon	NN	i	IPM
for	IN	O	O
melanoma	NN	p	PC
.	.	O	O

PURPOSE	NNP	O	O
Nearly	RB	p	O
2000	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
stage	NN	p	O
IIB	NNP	p	O
and	CC	p	O
III	NNP	p	O
melanoma	NNS	p	PC
have	VBP	O	O
participated	VBN	O	O
in	IN	O	O
four	CD	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
trials	NNS	O	O
,	,	O	O
conducted	VBN	O	O
by	IN	O	O
the	DT	O	O
Eastern	NNP	O	O
Cooperative	NNP	O	O
Oncology	NNP	O	O
Group	NNP	O	O
and	CC	O	O
the	DT	O	O
Intergroup	NNP	O	O
,	,	O	O
investigating	VBG	O	O
adjuvant	JJ	O	O
high-dose	JJ	O	O
IFN-alpha	JJ	i	IPM
2b	CD	i	IPM
therapy	NN	O	O
.	.	O	O

The	DT	O	O
objectives	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
were	VBD	O	O
to	TO	O	O
update	VB	O	O
the	DT	O	O
analyses	NNS	O	O
of	IN	O	O
each	DT	O	O
individual	JJ	O	O
trial	NN	O	O
and	CC	O	O
to	TO	O	O
analyze	VB	O	O
prognostic	JJ	O	O
factors	NNS	O	O
and	CC	O	O
treatment	NN	O	O
effects	NNS	O	O
based	VBN	O	O
on	IN	O	O
pooled	JJ	O	O
data	NNS	O	O
.	.	O	O

EXPERIMENTAL	NNP	O	O
DESIGN	NNP	O	O
Survival	NNP	O	O
and	CC	O	O
disease	NN	O	O
status	NN	O	O
were	VBD	O	O
updated	VBN	O	O
to	TO	O	O
April	NNP	O	O
2001	CD	O	O
.	.	O	O

Analysis	NN	O	O
of	IN	O	O
prognostic	JJ	O	O
factors	NNS	O	O
using	VBG	O	O
optimized	JJ	O	O
statistical	JJ	O	O
models	NNS	O	O
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
data	NNS	O	O
from	IN	O	O
patients	NNS	O	O
in	IN	O	O
E1684	NNP	O	O
,	,	O	O
E1690	NNP	O	O
,	,	O	O
E1694	NNP	O	O
,	,	O	O
and	CC	O	O
E2696	NNP	O	O
.	.	O	O

Analysis	NN	O	O
of	IN	O	O
treatment	NN	O	O
effects	NNS	O	O
versus	VBP	O	O
observation	NN	O	O
(	(	O	O
Obs	NNP	O	O
)	)	O	O
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
data	NNS	O	O
from	IN	O	O
713	CD	O	O
patients	NNS	O	O
randomized	VBN	O	O
to	TO	O	O
high-dose	JJ	O	O
IFN-alpha	JJ	i	IPM
2b	CD	i	IPM
(	(	i	IPM
HDI	NNP	i	IPM
)	)	i	IPM
or	CC	O	O
Obs	NNP	i	IPM
in	IN	O	O
Trials	NNP	O	O
E1684	NNP	O	O
and	CC	O	O
E1690	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
Updated	VBD	O	O
analysis	NN	O	O
of	IN	O	O
E1684	NNP	O	O
,	,	O	O
E1690	NNP	O	O
,	,	O	O
and	CC	O	O
E1694	NNP	O	O
confirmed	VBD	O	O
their	PRP$	O	O
original	JJ	O	O
conclusions	NNS	O	O
,	,	O	O
now	RB	O	O
at	IN	O	O
median	JJ	O	O
follow-up	JJ	O	O
intervals	NNS	O	O
of	IN	O	O
2.1-12.6	JJ	O	O
years	NNS	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
two-sided	JJ	O	O
univariate	JJ	O	O
log-rank	JJ	O	O
analysis	NN	O	O
of	IN	O	O
pooled	VBN	O	O
data	NNS	O	O
from	IN	O	O
E1684	NNP	O	O
and	CC	O	O
E1690	NNP	O	O
(	(	O	O
median	JJ	O	O
follow-up	NN	O	O
,	,	O	O
7.2	CD	O	O
years	NNS	O	O
)	)	O	O
,	,	O	O
relapse-free	JJ	o	OMO
survival	NN	o	OMO
(	(	o	OMO
RFS	NNP	o	OMO
)	)	o	OMO
-but	VBZ	O	O
not	RB	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
(	(	o	OMO
OS	NNP	o	OMO
)	)	o	OMO
-was	VBP	O	O
significantly	RB	O	O
prolonged	VBN	O	O
(	(	O	O
two-sided	JJ	O	O
log-rank	NN	O	O
P	NNP	O	O
value	NN	O	O
=	NNP	O	O
0.006	CD	O	O
)	)	O	O
for	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
HDI	NNP	i	IPM
versus	NN	O	O
Obs	NNP	i	IPM
.	.	O	O

Among	IN	O	O
all	DT	O	O
patients	NNS	O	O
,	,	O	O
prognostic	JJ	O	O
factors	NNS	O	O
that	WDT	O	O
significantly	RB	O	O
negatively	RB	O	O
impacted	JJ	O	O
RFS	NNP	O	O
and	CC	O	O
OS	NNP	O	O
included	VBD	O	O
ulceration	NN	O	O
,	,	O	O
recurrent	JJ	O	O
disease	NN	O	O
at	IN	O	O
entry	NN	O	O
,	,	O	O
enrollment	NN	O	O
in	IN	O	O
E1684	NNP	O	O
,	,	O	O
and	CC	O	O
age	NN	O	O
>	VBP	O	O
49	CD	O	O
years	NNS	O	O
.	.	O	O

Multivariate	NNP	O	O
statistical	JJ	O	O
models	NNS	O	O
adjusting	VBG	O	O
for	IN	O	O
these	DT	O	O
factors	NNS	O	O
confirmed	VBD	O	O
the	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
RFS	NNP	o	OMO
benefit	NN	O	O
of	IN	O	O
HDI	NNP	i	IPM
versus	NN	O	O
Obs	NNP	i	IPM
but	CC	O	O
did	VBD	O	O
not	RB	O	O
demonstrate	VB	O	O
a	DT	O	O
significant	JJ	O	O
OS	NNP	o	OMO
benefit	NN	O	O
in	IN	O	O
the	DT	O	O
pooled	JJ	O	O
populations	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
patients	NNS	p	O
with	IN	p	O
high-risk	JJ	p	PC
resected	JJ	p	PC
melanoma	NN	p	PC
,	,	O	O
HDI	NNP	O	O
is	VBZ	O	O
effective	JJ	O	O
adjuvant	JJ	O	O
therapy	NN	O	O
with	IN	O	O
strong	JJ	O	O
evidence	NN	O	O
for	IN	O	O
improved	JJ	O	O
RFS	NNP	o	OMO
and	CC	O	O
evidence	NN	O	O
for	IN	O	O
moderate	JJ	O	O
improvement	NN	O	O
in	IN	O	O
OS	NNP	o	OMO
based	VBN	O	O
on	IN	O	O
two	CD	O	O
prospective	JJ	O	O
randomized	VBN	O	O
studies	NNS	O	O
but	CC	O	O
not	RB	O	O
the	DT	O	O
pooled	JJ	O	O
analysis	NN	O	O
.	.	O	O

Analyses	NNS	O	O
of	IN	O	O
predictors	NNS	O	O
of	IN	O	O
relapse	NN	O	O
and	CC	O	O
response	NN	O	O
are	VBP	O	O
now	RB	O	O
needed	VBN	O	O
to	TO	O	O
improve	VB	O	O
the	DT	O	O
therapeutic	JJ	O	O
value	NN	O	O
of	IN	O	O
this	DT	O	O
modality	NN	O	O
.	.	O	O

Role	NNP	O	O
of	IN	O	O
angiotensin-converting	JJ	i	IPH
enzyme	NN	i	IPH
inhibitors	NNS	i	IPH
in	IN	O	O
early	JJ	O	O
antihypertensive	JJ	O	O
treatment	NN	O	O
in	IN	O	O
non-insulin	JJ	p	PC
dependent	NN	p	PC
diabetes	VBZ	p	PC
mellitus	NN	p	PC
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
captopril	NN	i	IPM
monotherapy	NN	O	O
on	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
and	CC	O	O
metabolism	NN	o	OPH
was	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
a	DT	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
in	IN	O	O
30	CD	p	O
non-insulin	JJ	p	O
dependent	NN	p	O
(	(	p	O
Type	NNP	p	O
II	NNP	p	O
)	)	p	O
diabetic	JJ	p	O
subjects	NNS	p	O
during	IN	O	O
a	DT	O	O
3-week	JJ	O	O
observation	NN	O	O
period	NN	O	O
(	(	O	O
run-in/drug	JJ	O	O
;	:	O	O
placebo/wash-out	NN	O	O
)	)	O	O
on	IN	O	O
a	DT	O	O
metabolic	JJ	O	O
ward	NN	O	O
.	.	O	O

Captopril	NNP	i	IPM
significantly	RB	O	O
reduced	VBD	O	O
both	DT	O	O
systolic	JJ	o	OPH
and	CC	o	OPH
diastolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	O	O
154/90	CD	O	O
+/-	JJ	O	O
5/2	CD	O	O
vs.	FW	O	O
144/86	CD	O	O
+/-	JJ	O	O
4/3	CD	O	O
mmHg	NN	O	O
)	)	O	O
without	IN	O	O
major	JJ	O	O
side	NN	O	O
effects	NNS	O	O
.	.	O	O

Mean	JJ	O	O
run-in	JJ	O	O
postprandial	JJ	o	OPH
blood	NN	o	OPH
glucose	JJ	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
also	RB	O	O
reduced	VBN	O	O
upon	IN	O	O
ACE-inhibition	NNP	O	O
(	(	O	O
9	CD	O	O
a.m.	RB	O	O
:	:	O	O
12.7	CD	O	O
+/-	JJ	O	O
0.4	CD	O	O
vs.	FW	O	O
11.1	CD	O	O
+/-	JJ	O	O
0.4	CD	O	O
mmol/l	NN	O	O
;	:	O	O
1	CD	O	O
p.m.	NN	O	O
:	:	O	O
11.0	CD	O	O
+/-	JJ	O	O
0.3	CD	O	O
vs.	FW	O	O
8.9	CD	O	O
+/-	JJ	O	O
0.3	CD	O	O
mmol/l	NN	O	O
;	:	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
blood	NN	o	OPH
kinin	NN	o	OPH
concentrations	NNS	o	OPH
(	(	O	O
40.0	CD	O	O
+/-	JJ	O	O
2.5	CD	O	O
pmol/l	NN	O	O
)	)	O	O
were	VBD	O	O
approximately	RB	O	O
doubled	VBN	O	O
(	(	O	O
108.8	CD	O	O
+/-	JJ	O	O
23.5	CD	O	O
pmol/l	NN	O	O
;	:	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Body	NNP	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
,	,	o	OPH
fasting	VBG	o	OPH
plasma	JJ	o	OPH
insulin	NN	o	OPH
,	,	o	OPH
serum	JJ	o	OPH
electrolyte	NN	o	OPH
pattern	NN	o	OPH
,	,	o	OPH
uric	JJ	o	OPH
acid	NN	o	OPH
,	,	o	OPH
white	JJ	o	OPH
blood	NN	o	OPH
count	NN	o	OPH
,	,	o	OPH
lipid	JJ	o	OPH
profile	NN	o	OPH
as	RB	O	O
well	RB	O	O
as	IN	O	O
hepatic	JJ	o	OPH
and	CC	o	OPH
renal	JJ	o	OPH
function	NN	o	OPH
parameters	NNS	O	O
remained	VBD	O	O
unaltered	JJ	O	O
throughout	IN	O	O
the	DT	O	O
observation	NN	O	O
period	NN	O	O
.	.	O	O

The	DT	O	O
data	NNS	O	O
are	VBP	O	O
in	IN	O	O
line	NN	O	O
with	IN	O	O
recent	JJ	O	O
experimental	JJ	O	O
studies	NNS	O	O
showing	VBG	O	O
a	DT	O	O
beneficial	JJ	O	O
metabolic	JJ	O	O
effect	NN	O	O
of	IN	O	O
captopril	NN	i	IPM
in	IN	O	O
Type	NNP	O	O
II	NNP	O	O
diabetes	VBZ	O	O
.	.	O	O

ACE	NNP	i	IPH
inhibitors	NNS	i	IPH
might	MD	O	O
therefore	VB	O	O
become	JJ	O	O
first-line	JJ	O	O
drugs	NNS	O	O
in	IN	O	O
early	JJ	O	O
antihypertensive	JJ	O	O
intervention	NN	O	O
in	IN	O	O
Type	NNP	p	O
II	NNP	p	O
diabetic	JJ	p	O
patients	NNS	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
tryptophan	JJ	O	O
depletion	NN	O	O
in	IN	O	O
drug-free	JJ	p	O
adults	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
primary	JJ	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
behavioral	JJ	O	O
and	CC	O	O
biochemical	JJ	O	O
responses	NNS	O	O
to	TO	O	O
acute	VB	O	O
tryptophan	JJ	O	O
depletion	NN	O	O
in	IN	O	O
drug-free	JJ	p	O
adult	NN	p	O
patients	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	O	O

METHODS	NNP	O	O
Twenty	NNP	p	O
drug-free	JJ	p	O
adults	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
(	(	p	O
16	CD	p	O
men	NNS	p	O
and	CC	p	O
4	CD	p	O
women	NNS	p	O
)	)	p	O
(	(	p	O
mean	JJ	p	O
[	NNP	p	O
+/-	NN	p	O
SD	NNP	p	O
]	NNP	p	O
age	NN	p	O
,	,	p	O
30.5	CD	p	O
+/-	JJ	p	O
8.5	CD	p	O
years	NNS	p	O
)	)	p	O
underwent	JJ	O	O
short-term	JJ	O	O
tryptophan	NN	i	IPM
depletion	NN	i	IPM
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
,	,	O	O
randomized	JJ	O	O
crossover	NN	O	O
design	NN	O	O
.	.	O	O

Patients	NNS	O	O
received	VBD	O	O
a	DT	O	O
24-hour	JJ	O	O
,	,	O	O
low-tryptophan	JJ	i	IPM
diet	NN	i	IPM
followed	VBD	O	O
the	DT	O	O
next	JJ	O	O
morning	NN	O	O
by	IN	O	O
an	DT	O	O
amino	NN	i	IPM
acid	NN	i	IPM
drink	NN	i	IPM
.	.	O	O

Behavioral	JJ	O	O
ratings	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
on	IN	O	O
the	DT	O	O
morning	NN	O	O
of	IN	O	O
the	DT	O	O
amino	NN	i	IPM
acid	NN	i	IPM
drink	NN	i	IPM
(	(	O	O
baseline	NN	O	O
)	)	O	O
and	CC	O	O
180	CD	O	O
,	,	O	O
300	CD	O	O
,	,	O	O
and	CC	O	O
420	CD	O	O
minutes	NNS	O	O
after	IN	O	O
the	DT	O	O
drink	NN	O	O
.	.	O	O

Plasma	NNP	o	OPH
free	JJ	o	OPH
and	CC	o	OPH
total	JJ	o	OPH
tryptophan	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
5	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
drink	NN	O	O
.	.	O	O

The	DT	O	O
active	JJ	O	O
and	CC	O	O
sham	JJ	O	O
testing	NN	O	O
sessions	NNS	O	O
were	VBD	O	O
separated	VBN	O	O
by	IN	O	O
7	CD	O	O
days	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Eleven	NNP	O	O
(	(	O	O
65	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
17	CD	O	O
patients	NNS	O	O
who	WP	O	O
completed	VBD	O	O
both	DT	O	O
test	NN	O	O
days	NNS	O	O
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
global	JJ	O	O
worsening	NN	O	O
of	IN	O	O
behavioral	JJ	O	O
symptoms	NNS	O	O
with	IN	O	O
short-term	JJ	O	O
tryptophan	NN	O	O
depletion	NN	O	O
,	,	O	O
but	CC	O	O
none	NN	O	O
of	IN	O	O
the	DT	O	O
17	CD	O	O
patients	NNS	O	O
showed	VBD	O	O
any	DT	O	O
significant	JJ	O	O
change	NN	O	O
in	IN	O	O
clinical	JJ	O	O
status	NN	O	O
from	IN	O	O
baseline	NN	O	O
after	IN	O	O
sham	JJ	O	O
depletion	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

Tryptophan	NNP	O	O
depletion	NN	O	O
led	VBD	O	O
to	TO	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
behaviors	NNS	O	O
such	JJ	O	O
as	IN	O	O
whirling	NN	o	OME
,	,	o	OME
flapping	NN	o	OME
,	,	o	OME
pacing	NN	o	OME
,	,	o	OME
banging	NN	o	OME
and	CC	o	OME
hitting	VBG	o	OME
self	NN	o	OME
,	,	o	OME
rocking	NN	o	OME
,	,	o	OME
and	CC	o	OME
toe	NN	o	OME
walking	NN	o	OME
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
less	JJR	O	O
calm	JJ	o	OME
and	CC	o	OME
happy	JJ	o	OME
and	CC	O	O
more	RBR	O	O
anxious	JJ	o	OME
.	.	O	O

No	DT	O	O
significant	JJ	O	O
change	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
social	JJ	o	OME
relatedness	NN	o	OME
or	CC	o	OME
repetitive	JJ	o	OME
thoughts	NNS	o	OME
and	CC	o	OME
behavior	NN	o	OME
.	.	O	O

Plasma	NNP	o	OPH
total	JJ	o	OPH
and	CC	o	OPH
free	JJ	o	OPH
tryptophan	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
reduced	VBN	O	O
86	CD	O	O
%	NN	O	O
and	CC	O	O
69	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
5	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
tryptophan-deficient	JJ	O	O
amino	NN	O	O
acid	NN	O	O
drink	NN	O	O
.	.	O	O

Patients	NNS	O	O
who	WP	O	O
had	VBD	O	O
a	DT	O	O
significant	JJ	O	O
global	JJ	O	O
exacerbation	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
had	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
baseline	NN	O	O
plasma	IN	o	OPH
total	JJ	o	OPH
tryptophan	NN	o	OPH
levels	NNS	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
and	CC	O	O
Autism	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
scores	NNS	o	OME
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.005	NNP	O	O
)	)	O	O
than	IN	O	O
did	VBD	O	O
patients	NNS	O	O
who	WP	O	O
showed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
change	NN	O	O
in	IN	O	O
symptoms	NNS	O	O
after	IN	O	O
tryptophan	JJ	O	O
depletion	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
previous	JJ	O	O
research	NN	O	O
that	WDT	O	O
has	VBZ	O	O
implicated	VBN	O	O
a	DT	O	O
dysregulation	NN	O	O
in	IN	O	O
serotonin	JJ	O	O
function	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	p	O
with	IN	p	O
autism	NN	p	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
short-term	JJ	O	O
reduction	NN	O	O
of	IN	O	O
serotonin	NN	O	O
precursor	NN	O	O
availability	NN	O	O
may	MD	O	O
exacerbate	VB	O	O
some	DT	O	O
symptoms	NNS	o	OME
characteristic	JJ	O	O
of	IN	O	O
autism	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
.	.	O	O

Continued	JJ	O	O
investigation	NN	O	O
into	IN	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
serotonin	NN	O	O
in	IN	O	O
the	DT	O	O
pathogenesis	NN	O	O
and	CC	O	O
treatment	NN	O	O
of	IN	O	O
autistic	JJ	p	O
disorder	NN	p	O
is	VBZ	O	O
warranted	VBN	O	O
.	.	O	O

To	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
nifedipine	NN	i	IPM
sustained	VBN	i	IPM
release	NN	i	IPM
with	IN	O	O
Ginkgo	NNP	i	IPM
biloba	NN	i	IPM
extract	NN	i	IPM
to	TO	O	O
treat	VB	O	O
patients	NNS	p	O
with	IN	p	O
primary	JJ	p	PC
Raynaud	NNP	p	PC
's	POS	p	PC
phenomenon	NN	p	PC
in	IN	p	O
South	NNP	p	O
Korea	NNP	p	O
;	:	O	O
Korean	NNP	O	O
Raynaud	NNP	O	O
study	NN	O	O
(	(	O	O
KOARA	NNP	O	O
study	NN	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
nifedipine	NN	i	IPM
sustained	VBN	i	IPM
release	NN	i	IPM
(	(	O	O
nifedipine	JJ	i	IPM
SR	NNP	i	IPM
)	)	O	O
compared	VBN	O	O
with	IN	O	O
Ginkgo	NNP	i	IPM
biloba	NN	i	IPM
extract	NN	i	IPM
as	IN	O	O
treatment	NN	O	O
for	IN	O	O
primary	JJ	O	O
Raynaud	NNP	O	O
's	POS	O	O
phenomenon	NN	O	O
(	(	O	O
RP	NNP	O	O
)	)	O	O
in	IN	O	O
Korea	NNP	O	O
.	.	O	O

Primary	NNP	O	O
RP	NNP	O	O
were	VBD	O	O
screened	VBN	O	O
and	CC	O	O
assigned	VBN	O	O
to	TO	O	O
either	CC	O	O
the	DT	O	O
nifedipine	JJ	i	IPM
SR	NNP	i	IPM
group	NN	O	O
(	(	O	O
Group	NNP	O	O
N	NNP	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
Ginkgo	NNP	i	IPM
biloba	NN	i	IPM
extract	NN	i	IPM
group	NN	O	O
(	(	O	O
Group	NNP	O	O
G	NNP	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
ratio	NN	O	O
of	IN	O	O
2:1	CD	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
run-in	JJ	O	O
period	NN	O	O
of	IN	O	O
2	CD	O	O
weeks	NNS	O	O
,	,	O	O
patients	NNS	O	O
received	VBD	O	O
treatment	NN	O	O
for	IN	O	O
8	CD	O	O
weeks	NNS	O	O
.	.	O	O

We	PRP	O	O
observed	VBD	O	O
the	DT	O	O
percent	NN	o	OPH
improvement	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
RP	NNP	o	OPH
attack	NN	o	OPH
rate	NN	o	OPH
between	IN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
8-week	JJ	O	O
treatment	NN	O	O
.	.	O	O

Ninety-three	JJ	p	PSS
subjects	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
.	.	O	O

The	DT	O	O
percent	NN	O	O
improvement	NN	O	O
in	IN	O	O
Group	NNP	O	O
N	NNP	O	O
was	VBD	O	O
50.1	CD	O	O
%	NN	O	O
at	IN	O	O
8	CD	O	O
weeks	NNS	O	O
after	IN	O	O
treatment	NN	O	O
,	,	O	O
while	IN	O	O
it	PRP	O	O
was	VBD	O	O
31.0	CD	O	O
%	NN	O	O
in	IN	O	O
Group	NNP	O	O
G	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
occurred	VBD	O	O
,	,	O	O
and	CC	O	O
almost	RB	O	O
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
mild	JJ	O	O
and	CC	O	O
improved	VBN	O	O
without	IN	O	O
specific	JJ	O	O
treatment	NN	O	O
.	.	O	O

nifedipine	JJ	i	IPM
SR	NNP	i	IPM
was	VBD	O	O
more	RBR	O	O
effective	JJ	o	OOt
than	IN	O	O
Ginkgo	NNP	i	IPM
biloba	NN	i	IPM
extract	NN	i	IPM
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
primary	JJ	O	O
RP	NNP	O	O
in	IN	O	O
Korean	JJ	p	PC
patients	NNS	p	O
.	.	O	O

Both	DT	O	O
drugs	NNS	O	O
were	VBD	O	O
tolerable	JJ	o	OOt
with	IN	O	O
primary	JJ	O	O
RP	NNP	p	O
patients	NNS	p	O
.	.	O	O

Double-blind	NNP	O	O
randomized	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
intercostal	JJ	i	IPM
nerve	NN	i	IPM
blocks	NNS	i	IPM
as	IN	O	O
an	DT	O	O
adjuvant	NN	O	O
to	TO	O	O
subarachnoid	VB	O	O
administered	JJ	O	O
morphine	NN	i	IPM
for	IN	O	O
post-thoracotomy	JJ	p	PC
analgesia	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	NNP	O	O
OBJECTIVES	NNP	O	O
Thoracotomy	NNP	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
pain	NN	O	O
and	CC	O	O
compromised	VBD	O	O
pulmonary	JJ	O	O
function	NN	O	O
.	.	O	O

Intercostal	NNP	i	IPM
nerve	NN	i	IPM
blocks	NNS	i	IPM
(	(	i	IPM
INB	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
subarachnoid	JJ	i	IPM
morphine	NN	i	IPM
(	(	i	IPM
SM	NNP	i	IPM
)	)	i	IPM
act	NN	O	O
on	IN	O	O
different	JJ	O	O
portions	NNS	O	O
of	IN	O	O
the	DT	O	O
pain	NN	O	O
pathway	RB	O	O
.	.	O	O

Each	DT	O	O
is	VBZ	O	O
effective	JJ	O	O
for	IN	O	O
post-thoracotomy	JJ	O	O
pain	NN	o	OPA
relief	NN	O	O
.	.	O	O

The	DT	O	O
combination	NN	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
modalities	NNS	O	O
in	IN	O	O
relieving	VBG	O	O
post-thoracotomy	JJ	o	OPA
pain	NN	o	OPA
and	CC	O	O
improving	VBG	O	O
postoperative	JJ	o	OPH
pulmonary	JJ	o	OPH
function	NN	o	OPH
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
double-blind	NN	O	O
study	NN	O	O
,	,	O	O
20	CD	p	PSS
patients	NNS	p	O
undergoing	JJ	p	O
lateral	JJ	p	PC
thoracotomy	NN	p	PC
for	IN	p	O
lung	NN	p	PC
resection	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
0.5	CD	O	O
mg	NN	O	O
SM	NNP	i	IPM
preoperatively	RB	O	O
and	CC	O	O
INB	NNP	i	IPM
with	IN	O	O
bupivacaine	NN	i	IPM
(	(	O	O
INB+	NNP	O	O
)	)	O	O
prior	RB	O	O
to	TO	O	O
wound	VB	O	O
closure	NN	O	O
or	CC	O	O
0.5	CD	O	O
mg	NNS	O	O
SM	NNP	i	IPM
with	IN	O	O
INB	NNP	i	IPM
using	VBG	O	O
saline	NN	i	IC
(	(	O	O
INB-	NNP	i	O
)	)	O	O
.	.	O	O

Visual	JJ	o	OPA
analog	NN	o	OPA
scale	NN	o	OPA
pain	NN	o	OPA
scores	NNS	o	OPA
at	IN	O	O
rest	NN	O	O
,	,	O	O
with	IN	o	OPH
cough	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
with	IN	o	OPH
movement	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
ipsilateral	JJ	o	OPH
arm	NN	o	OPH
,	,	o	OPH
forced	VBD	o	OPH
expiratory	JJ	o	OPH
volume	NN	o	OPH
in	IN	o	OPH
1	CD	o	OPH
second	JJ	o	OPH
(	(	o	OPH
FEV1	NNP	o	OPH
)	)	o	OPH
,	,	O	O
and	CC	O	O
forced	VBD	o	OPH
vital	JJ	o	OPH
capacity	NN	o	OPH
(	(	o	OPH
FVC	NNP	o	OPH
)	)	o	OPH
were	VBD	O	O
measured	VBN	O	O
at	IN	O	O
4	CD	O	O
,	,	O	O
24	CD	O	O
,	,	O	O
48	CD	O	O
,	,	O	O
and	CC	O	O
72	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
operation	NN	O	O
.	.	O	O

Opioid	NNP	o	OOt
use	NN	o	OOt
was	VBD	O	O
measured	VBN	O	O
during	IN	O	O
the	DT	O	O
initial	JJ	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
operation	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
4	CD	O	O
hours	NNS	O	O
,	,	O	O
the	DT	O	O
INB+	NNP	i	IPM
group	NN	O	O
demonstrated	VBD	O	O
better	JJR	O	O
FEV1	NNP	o	OPH
(	(	O	O
56.6	CD	O	O
%	NN	O	O
vs.	FW	O	O
40.4	CD	O	O
%	NN	O	O
of	IN	O	O
baseline	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
and	CC	O	O
FVC	NNP	o	OPH
values	NNS	O	O
(	(	O	O
54.6	CD	O	O
%	NN	O	O
vs.	FW	O	O
39.6	CD	O	O
%	NN	O	O
of	IN	O	O
baseline	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
and	CC	O	O
less	RBR	O	O
resting	VBG	O	O
and	CC	O	O
cough	JJ	O	O
pain	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
FEV1	NNP	o	OPH
continued	VBD	O	O
to	TO	O	O
decline	VB	O	O
in	IN	O	O
the	DT	O	O
INB+	NNP	i	IPM
group	NN	O	O
at	IN	O	O
24	CD	O	O
hours	NNS	O	O
to	TO	O	O
lower	JJR	O	O
than	IN	O	O
the	DT	O	O
INB-	NNP	i	IPM
group	NN	O	O
although	IN	O	O
pain	NN	o	OPA
scores	NNS	o	OPA
were	VBD	O	O
similar	JJ	O	O
beyond	IN	O	O
4	CD	O	O
hours	NNS	O	O
.	.	O	O

Opioid	JJ	o	OOt
usage	NN	o	OOt
during	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
hours	NNS	O	O
was	VBD	O	O
similar	JJ	O	O
(	(	O	O
INB-	NNP	i	IPM
,	,	O	O
16.7	CD	O	O
mg	NN	O	O
vs.	FW	O	O
INB+	NNP	i	IPM
,	,	O	O
13.2	CD	O	O
mg	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
.7	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
postoperative	JJ	O	O
INB	NNP	i	IPM
provided	VBD	O	O
modest	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
pain	NN	O	O
and	CC	O	O
pulmonary	JJ	O	O
function	NN	O	O
when	WRB	O	O
used	VBN	O	O
as	IN	O	O
an	DT	O	O
adjuvant	NN	O	O
to	TO	O	O
0.5	CD	O	O
mg	NNS	O	O
SM	NNP	i	IPM
for	IN	O	O
post-thoracotomy	JJ	O	O
analgesia	NN	O	O
,	,	O	O
the	DT	O	O
benefits	NNS	O	O
were	VBD	O	O
transient	JJ	O	O
.	.	O	O

The	DT	O	O
authors	NNS	O	O
do	VBP	O	O
not	RB	O	O
recommend	VB	O	O
adding	VBG	O	O
INB	NNP	i	IPM
for	IN	O	O
patients	NNS	O	O
undergoing	JJ	O	O
lateral	JJ	O	O
thoracotomy	NN	O	O
who	WP	O	O
receive	VBP	O	O
0.5	CD	O	O
mg	NN	O	O
SM	NNP	i	IPM
.	.	O	O

Eltrombopag	NNP	i	IPM
for	IN	O	O
management	NN	O	O
of	IN	O	O
chronic	JJ	p	O
immune	NN	p	O
thrombocytopenia	NN	p	O
(	(	O	O
RAISE	NNP	O	O
)	)	O	O
:	:	O	O
a	DT	O	O
6-month	JJ	O	O
,	,	O	O
randomised	VBN	O	O
,	,	O	O
phase	VB	O	O
3	CD	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Eltrombopag	NNP	i	IPM
is	VBZ	O	O
an	DT	O	O
oral	JJ	O	O
thrombopoietin	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
thrombocytopenia	NN	O	O
.	.	O	O

We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
response	NN	o	OPH
to	TO	O	O
once	RB	O	O
daily	JJ	O	O
eltrombopag	NNS	i	IPM
versus	VBP	O	O
placebo	NN	i	IC
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	O
immune	JJ	p	O
thrombocytopenia	NN	p	O
during	IN	O	O
a	DT	O	O
6-month	JJ	O	O
period	NN	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
undertook	VBD	O	O
a	DT	O	O
phase	NN	O	O
3	CD	O	O
,	,	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
in	IN	O	O
adults	NNS	p	O
with	IN	p	O
previously	RB	p	O
treated	VBN	p	O
immune	JJ	p	O
thrombocytopenia	NN	p	O
of	IN	p	O
more	JJR	p	O
than	IN	p	O
6	CD	p	O
months	NNS	p	O
'	POS	p	O
duration	NN	p	O
who	WP	p	O
had	VBD	p	O
baseline	NN	p	O
platelet	NN	p	O
counts	VBZ	p	O
lower	JJR	p	O
than	IN	p	O
30,000	CD	p	O
per	IN	p	O
?L	NN	p	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
(	(	O	O
in	IN	O	O
a	DT	O	O
2:1	CD	O	O
ratio	NN	O	O
)	)	O	O
treatment	NN	O	O
with	IN	O	O
local	JJ	O	O
standard	NN	O	O
of	IN	O	O
care	NN	O	O
plus	CC	O	O
50	CD	O	O
mg	NN	O	O
eltrombopag	NN	i	O
or	CC	O	O
matching	VBG	O	O
placebo	JJ	i	O
once	RB	O	O
daily	JJ	O	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Randomisation	NN	O	O
was	VBD	O	O
done	VBN	O	O
centrally	RB	O	O
with	IN	O	O
a	DT	O	O
computer-generated	JJ	O	O
randomisation	NN	O	O
schedule	NN	O	O
and	CC	O	O
was	VBD	O	O
stratified	VBN	O	O
by	IN	O	O
baseline	JJ	O	O
platelet	NN	O	O
count	NN	O	O
(	(	O	O
?	.	O	O
15,000	CD	O	O
per	IN	O	O
?L	NN	O	O
)	)	O	O
,	,	O	O
use	NN	O	O
of	IN	O	O
treatment	NN	O	O
for	IN	O	O
immune	JJ	O	O
thrombocytopenia	NN	O	O
,	,	O	O
and	CC	O	O
splenectomy	JJ	O	O
status	NN	O	O
.	.	O	O

Patients	NNS	O	O
,	,	O	O
investigators	NNS	O	O
,	,	O	O
and	CC	O	O
those	DT	O	O
assessing	VBG	O	O
data	NNS	O	O
were	VBD	O	O
masked	VBN	O	O
to	TO	O	O
allocation	NN	O	O
.	.	O	O

Dose	JJ	O	O
modifications	NNS	O	O
were	VBD	O	O
made	VBN	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
platelet	NN	O	O
response	NN	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
for	IN	O	O
response	NN	o	O
to	TO	o	O
treatment	NN	o	O
(	(	o	O
defined	VBN	o	O
as	IN	o	O
a	DT	o	O
platelet	NN	o	O
count	NN	o	O
of	IN	o	O
50,000-400,000	CD	O	O
per	IN	O	O
?L	NN	O	O
)	)	O	O
weekly	NN	O	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
6	CD	O	O
weeks	NNS	O	O
and	CC	O	O
at	IN	O	O
least	JJS	O	O
once	RB	O	O
every	DT	O	O
4	CD	O	O
weeks	NNS	O	O
thereafter	RB	O	O
;	:	O	O
the	DT	O	O
primary	JJ	O	O
endpoint	NN	O	O
was	VBD	O	O
the	DT	O	O
odds	NNS	o	OPH
of	IN	o	OPH
response	NN	o	OPH
to	TO	O	O
eltrombopag	VB	i	O
versus	NN	O	O
placebo	NN	i	O
.	.	O	O

Analysis	NN	O	O
was	VBD	O	O
by	IN	O	O
intention	NN	O	O
to	TO	O	O
treat	VB	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
is	VBZ	O	O
registered	VBN	O	O
at	IN	O	O
ClinicalTrials.gov	NNP	O	O
,	,	O	O
number	NN	O	O
NCT00370331	NNP	O	O
.	.	O	O

FINDINGS	NNP	O	O
Between	NNP	p	O
Nov	NNP	p	O
22	CD	p	O
,	,	p	O
2006	CD	p	O
,	,	p	O
and	CC	p	O
July	NNP	p	O
31	CD	p	O
,	,	p	O
2007	CD	p	O
,	,	p	O
197	CD	p	O
patients	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
treatment	NN	O	O
groups	NNS	O	O
and	CC	O	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
intention-to-treat	JJ	O	O
analysis	NN	O	O
(	(	O	O
135	CD	O	O
eltrombopag	NN	i	O
,	,	O	O
62	CD	O	O
placebo	NN	i	O
)	)	O	O
.	.	O	O

106	CD	O	O
(	(	O	O
79	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
eltrombopag	NN	i	O
group	NN	O	O
responded	VBD	o	O
to	TO	O	O
treatment	NN	O	O
at	IN	O	O
least	JJS	O	O
once	RB	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
17	CD	O	O
(	(	O	O
28	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
odds	NNS	O	O
of	IN	o	O
responding	VBG	o	O
were	VBD	O	O
greater	JJR	O	O
in	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
eltrombopag	NN	i	O
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
throughout	IN	O	O
the	DT	O	O
6-month	JJ	O	O
treatment	NN	O	O
period	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
8?2	CD	O	O
,	,	O	O
99	CD	O	O
%	NN	O	O
CI	NNP	O	O
3?59-18?73	CD	O	O
;	:	O	O
p	CC	O	O
<	VB	O	O
0?0001	CD	O	O
)	)	O	O
.	.	O	O

37	CD	O	O
(	(	O	O
59	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
receiving	VBG	O	O
eltrombopag	NN	i	O
reduced	VBD	O	O
concomitant	JJ	o	OPH
treatment	NN	o	OPH
versus	NN	O	O
ten	NN	O	O
(	(	O	O
32	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
receiving	VBG	O	O
placebo	NN	i	O
(	(	O	O
p=0?016	NN	O	O
)	)	O	O
.	.	O	O

24	CD	O	O
(	(	O	O
18	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
receiving	VBG	O	O
eltrombopag	NN	i	O
needed	VBN	O	O
rescue	NN	o	OOt
treatment	NN	o	OOt
compared	VBN	O	O
with	IN	O	O
25	CD	O	O
(	(	O	O
40	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
receiving	VBG	O	O
placebo	NN	i	O
(	(	O	O
p=0?001	NN	O	O
)	)	O	O
.	.	O	O

Three	NNP	O	O
(	(	O	O
2	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
receiving	VBG	O	O
eltrombopag	NN	i	O
had	VBD	O	O
thromboembolic	JJ	o	O
events	NNS	o	O
compared	VBN	O	O
with	IN	O	O
none	NN	O	O
in	IN	O	O
patients	NNS	O	O
on	IN	O	O
placebo	NN	i	O
.	.	O	O

Nine	NNP	O	O
(	(	O	O
7	CD	O	O
%	NN	O	O
)	)	O	O
eltrombopag-treated	JJ	O	O
patients	NNS	O	O
and	CC	O	O
two	CD	O	O
(	(	O	O
3	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
had	VBD	O	O
mild	VBN	O	O
increases	NNS	O	O
in	IN	O	O
alanine	JJ	o	O
aminotransferase	NN	o	O
concentration	NN	o	O
,	,	O	O
and	CC	O	O
five	CD	O	O
(	(	O	O
4	CD	O	O
%	NN	O	O
)	)	O	O
eltrombopag-treated	JJ	i	O
patients	NNS	O	O
(	(	O	O
vs	IN	O	O
none	NN	O	O
allocated	VBN	O	O
to	TO	O	O
placebo	VB	i	O
)	)	O	O
had	VBD	O	O
increases	NNS	O	O
in	IN	O	O
total	JJ	o	O
bilirubin	NN	o	O
.	.	O	O

Four	CD	O	O
(	(	O	O
7	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
taking	VBG	O	O
placebo	NN	i	O
had	VBD	O	O
serious	JJ	o	OA
bleeding	VBG	o	OA
events	NNS	o	OA
,	,	O	O
compared	VBN	O	O
with	IN	O	O
one	CD	O	O
(	(	O	O
<	VB	O	O
1	CD	O	O
%	NN	O	O
)	)	O	O
patient	NN	O	O
treated	VBN	O	O
with	IN	O	O
eltrombopag	NN	i	O
.	.	O	O

INTERPRETATION	NNP	O	O
Eltrombopag	NNP	i	O
is	VBZ	O	O
effective	JJ	O	O
for	IN	O	O
management	NN	O	O
of	IN	O	O
chronic	JJ	O	O
immune	NN	O	O
thrombocytopenia	NN	O	O
,	,	O	O
and	CC	O	O
could	MD	O	O
be	VB	O	O
particularly	RB	O	O
beneficial	JJ	O	O
for	IN	O	O
patients	NNS	O	O
who	WP	O	O
have	VBP	O	O
not	RB	O	O
responded	VBN	O	O
to	TO	O	O
splenectomy	VB	O	O
or	CC	O	O
previous	JJ	O	O
treatment	NN	O	O
.	.	O	O

These	DT	O	O
benefits	NNS	O	O
should	MD	O	O
be	VB	O	O
balanced	VBN	O	O
with	IN	O	O
the	DT	O	O
potential	JJ	O	O
risks	NNS	O	O
associated	VBN	O	O
with	IN	O	O
eltrombopag	JJ	i	O
treatment	NN	O	O
.	.	O	O

FUNDING	NN	O	O
GlaxoSmithKline	NNP	O	O
.	.	O	O

Salbutamol	NNP	i	IPM
or	CC	O	O
mist	NN	i	IPM
in	IN	O	O
acute	JJ	p	O
bronchiolitis	NN	p	O
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
role	NN	O	O
of	IN	O	O
bronchodilators	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
bronchiolitis	NN	O	O
remains	VBZ	O	O
controversial	JJ	O	O
.	.	O	O

METHODS	VB	O	O
A	DT	O	O
double-blind	NN	O	O
,	,	O	O
placebo	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
clinical	JJ	O	O
response	NN	O	O
to	TO	O	O
nebulized	VBN	O	O
salbutamol	NN	i	IPM
.	.	O	O

One	CD	p	O
hundred	CD	p	O
and	CC	p	O
fifty-six	JJ	p	O
infants	NNS	p	O
aged	VBN	p	O
between	IN	p	O
7	CD	p	O
weeks	NNS	p	O
and	CC	p	O
24	CD	p	O
months	NNS	p	O
who	WP	p	O
had	VBD	p	O
had	VBN	p	O
an	DT	p	O
episode	NN	p	O
of	IN	p	O
wheezing	NN	p	O
and	CC	p	O
other	JJ	p	O
signs	NNS	p	O
and	CC	p	O
symptoms	NNS	p	O
of	IN	p	O
bronchiolitis	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
three	CD	O	O
groups	NNS	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
nebulized	VBD	O	O
salbutamol	NN	i	IPM
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
52	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
at	IN	O	O
a	DT	O	O
dose	NN	O	O
of	IN	O	O
0.15	CD	O	O
mg/kg	NNS	O	O
in	IN	O	O
2	CD	O	O
mL	JJ	O	O
saline	NN	i	IC
;	:	O	O
(	(	O	O
ii	NN	O	O
)	)	O	O
saline	NN	i	IC
was	VBD	O	O
nebulized	VBN	O	O
to	TO	O	O
52	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
II	NNP	O	O
and	CC	O	O
(	(	O	O
iii	NN	O	O
)	)	O	O
in	IN	O	O
group	NN	O	O
III	NNP	O	O
52	CD	O	O
patients	NNS	O	O
received	JJ	O	O
mist	NN	i	IPM
in	IN	O	O
a	DT	O	O
tent	NN	O	O
.	.	O	O

All	DT	O	O
three	CD	O	O
groups	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
oxygen	NN	i	IPM
during	IN	O	O
the	DT	O	O
procedures	NNS	O	O
.	.	O	O

Treatment	NNP	O	O
was	VBD	O	O
repeated	VBN	O	O
with	IN	O	O
the	DT	O	O
same	JJ	O	O
agent	NN	O	O
after	IN	O	O
30	CD	O	O
min	NN	O	O
if	IN	O	O
the	DT	O	O
respiratory	NN	O	O
score	NN	O	O
was	VBD	O	O
5	CD	O	O
or	CC	O	O
more	JJR	O	O
.	.	O	O

Respiratory	JJ	o	OPH
rate	NN	o	OPH
,	,	o	O
heart	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
oxygen	NN	o	OPH
saturation	NN	o	OPH
and	CC	o	O
presence	NN	o	OPH
of	IN	o	OPH
cyanosis	NN	o	OPH
,	,	o	OPH
wheezing	VBG	o	OPH
,	,	o	OPH
retractions	NNS	o	OPH
were	VBD	O	O
recorded	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
each	DT	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
respiratory	NN	o	OPH
score	NN	o	OPH
was	VBD	O	O
5.2	CD	O	O
+/-	JJ	O	O
1.8	CD	O	O
,	,	O	O
0.82	CD	O	O
+/-	JJ	O	O
2.4	CD	O	O
and	CC	O	O
1.7	CD	O	O
+/-	JJ	O	O
1.3	CD	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
,	,	O	O
II	NNP	O	O
and	CC	O	O
III	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
decrease	NN	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
other	JJ	O	O
groups	NNS	O	O
.	.	O	O

Heart	NNP	o	OPH
rate	NN	o	OPH
was	VBD	O	O
similar	JJ	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

Oxygen	NNP	o	OPH
saturation	NN	o	OPH
decreased	VBD	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
without	IN	O	O
reaching	VBG	O	O
statistical	JJ	O	O
significance	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Salbutamol	NNP	i	IPM
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	o	OOt
and	CC	O	O
safe	JJ	o	OOt
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
acute	JJ	O	O
bronchiolitis	NN	O	O
.	.	O	O

[	JJ	O	O
Effect	NNP	O	O
of	IN	O	O
liu	NN	i	IPM
wei	NN	i	IPM
di	NN	i	IPM
huang	NN	i	IPM
or	CC	O	O
jin	NN	i	IPM
gui	NN	i	IPM
shen	NN	i	IPM
qi	JJ	i	IPM
decoction	NN	O	O
as	IN	O	O
on	IN	O	O
adjuvant	JJ	O	O
treatment	NN	O	O
in	IN	O	O
small	JJ	p	PC
cell	NN	p	PC
lung	NN	p	PC
cancer	NN	p	PC
]	NNP	O	O
.	.	O	O

Eighty-three	JJ	p	O
patients	NNS	p	O
with	IN	p	O
small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
using	VBG	O	O
a	DT	O	O
traditional	JJ	O	O
Chinese	JJ	O	O
Kidney-tonifying	NNP	i	IPM
decoction	NN	i	IPM
(	(	O	O
Liu	NNP	i	IPM
Wei	NNP	i	IPM
Di	NNP	i	IPM
Huang	NNP	i	IPM
or	CC	O	O
Jin	NNP	i	IPM
Gui	NNP	i	IPM
Shen	NNP	i	IPM
Qi	NNP	i	IPM
medicinal	JJ	O	O
decoction	NN	O	O
)	)	O	O
in	IN	O	O
chemotherapy	NN	O	O
or	CC	O	O
radiotherapy	NN	O	O
courses	NNS	O	O
.	.	O	O

74	CD	p	O
patients	NNS	p	O
were	VBD	O	O
availble	JJ	O	O
to	TO	O	O
be	VB	O	O
analysis	NN	O	O
.	.	O	O

The	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
were	VBD	O	O
well-matched	JJ	O	O
in	IN	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
stage	NN	O	O
and	CC	O	O
performance	NN	O	O
status	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
response	NN	o	OPH
rate	NN	o	OPH
and	CC	o	O
the	DT	o	O
median	JJ	o	OMO
survival	NN	o	OMO
between	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	O	O
CR+PR	NNP	O	O
)	)	O	O
was	VBD	O	O
91.5	CD	O	O
%	NN	O	O
for	IN	O	O
Chinese	JJ	i	IPM
herb	NN	i	IPM
group	NN	O	O
and	CC	O	O
46.9	CD	O	O
%	NN	O	O
for	IN	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
median	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
16	CD	O	O
months	NNS	O	O
for	IN	O	O
the	DT	O	O
traditional	JJ	O	O
Chinese	JJ	O	O
Kidney-tonifying	NNP	i	IPM
decoction	NN	i	IPM
group	NN	O	O
,	,	O	O
and	CC	O	O
10	CD	O	O
months	NNS	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Survival	JJ	o	OMO
curve	NN	o	OMO
(	(	o	OMO
Kaplan-meire	NNP	o	OMO
's	POS	o	OMO
)	)	o	OMO
of	IN	O	O
the	DT	O	O
Chinese	NNP	O	O
herb	NN	O	O
group	NN	O	O
was	VBD	O	O
better	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

10	CD	O	O
patients	NNS	O	O
of	IN	O	O
Chinese	JJ	i	IPM
herb	NN	i	IPM
group	NN	O	O
was	VBD	O	O
alive	JJ	O	O
beyond	IN	O	O
more	JJR	O	O
than	IN	O	O
2	CD	O	O
years	NNS	O	O
.	.	O	O

Until	IN	O	O
now	RB	O	O
,	,	O	O
4	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
Chinese	JJ	i	IPM
herb	NN	i	IPM
group	NN	O	O
,	,	O	O
one	CD	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
are	VBP	O	O
still	RB	O	O
enjoying	VBG	O	O
their	PRP$	O	O
disease-free	JJ	o	OOt
life	NN	o	OOt
for	IN	O	O
more	JJR	O	O
than	IN	O	O
7	CD	O	O
years	NNS	O	O
.	.	O	O

Hematologic	NNP	o	OA
toxicities	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
much	RB	O	O
frequently	RB	O	O
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.005	CD	O	O
and	CC	O	O
0.01/WBC	CD	O	O
and	CC	O	O
BPC	NNP	O	O
)	)	O	O
.	.	O	O

Results	NNS	O	O
of	IN	O	O
animal	JJ	O	O
experiments	NNS	O	O
with	IN	O	O
the	DT	O	O
same	JJ	O	O
traditional	JJ	O	O
medicinal	JJ	O	O
decoctions	NNS	O	O
as	IN	O	O
used	VBN	O	O
in	IN	O	O
clinic	NN	O	O
have	VBP	O	O
showed	VBN	O	O
immuno-enhancement	JJ	o	OPH
activities	NNS	o	OPH
.	.	O	O

These	DT	O	O
results	NNS	O	O
have	VBP	O	O
showed	VBN	O	O
that	IN	O	O
the	DT	O	O
traditional	JJ	O	O
Chinese	JJ	i	IPM
Kidney-tonifying	NNP	i	IPM
decoction	NN	i	IPM
may	MD	O	O
enhance	VB	O	O
non-specific	JJ	O	O
immunology	NN	O	O
activities	NNS	O	O
and	CC	O	O
may	MD	O	O
be	VB	O	O
much	JJ	O	O
useful	JJ	O	O
for	IN	O	O
solid	JJ	p	O
cancer	NN	p	O
patients	NNS	p	O
as	IN	O	O
an	DT	O	O
adjuvant	JJ	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
two	CD	O	O
types	NNS	O	O
of	IN	O	O
teacher	NN	i	IE
training	NN	i	IE
on	IN	O	O
implementation	NN	O	O
of	IN	O	O
Smart	NNP	O	O
Choices	NNPS	O	O
:	:	O	O
a	DT	O	O
tobacco	NN	O	O
prevention	NN	O	O
curriculum	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
implementation	NN	O	O
phase	NN	O	O
of	IN	O	O
a	DT	O	O
four-year	JJ	O	O
research	NN	O	O
project	NN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
strategies	NNS	O	O
to	TO	O	O
increase	VB	O	O
diffusion	NN	o	OME
of	IN	o	OME
Smart	NNP	o	OME
Choices	NNP	o	OME
,	,	O	O
a	DT	O	O
school-based	JJ	O	O
tobacco	NN	O	O
prevention	NN	O	O
program	NN	O	O
.	.	O	O

The	DT	O	O
impact	NN	O	O
on	IN	O	O
curriculum	JJ	O	O
implementation	NN	O	O
of	IN	O	O
two	CD	O	O
approaches	NNS	O	O
to	TO	O	O
teacher	VB	p	O
training	NN	O	O
are	VBP	O	O
compared	VBN	O	O
.	.	O	O

School	JJ	O	O
districts	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
live	JJ	i	IE
workshop	NN	i	IE
training	NN	i	IE
or	CC	O	O
video	NN	i	IE
training	NN	i	IE
condition	NN	i	IE
.	.	O	O

The	DT	O	O
outcome	NN	O	O
of	IN	O	O
the	DT	O	O
evaluation	NN	O	O
was	VBD	O	O
teachers	NNS	o	OME
'	POS	o	OME
implementation	NN	o	OME
of	IN	o	OME
Smart	NNP	o	OME
Choices	NNP	o	OME
.	.	O	O

Results	NNP	O	O
show	VBP	O	O
a	DT	O	O
lower	JJR	O	O
proportion	NN	O	O
of	IN	O	O
video-trained	JJ	i	IE
teachers	NNS	O	O
implemented	VBD	O	O
the	DT	O	O
curriculum	NN	O	O
,	,	O	O
but	CC	O	O
overall	JJ	O	O
completeness	NN	o	OME
and	CC	o	OME
fidelity	NN	o	OME
of	IN	o	OME
implementation	NN	o	OME
for	IN	O	O
those	DT	O	O
teachers	NNS	p	O
who	WP	O	O
did	VBD	O	O
teach	VB	O	O
the	DT	O	O
curriculum	NN	O	O
were	VBD	O	O
comparable	JJ	O	O
for	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

Video-trained	JJ	i	IE
teachers	NNS	p	O
,	,	O	O
however	RB	O	O
,	,	O	O
were	VBD	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
use	VB	O	O
brainstorming	NN	O	O
and	CC	O	O
student	NN	O	O
presentations/role	NN	O	O
plays	NNS	O	O
,	,	O	O
two	CD	O	O
of	IN	O	O
the	DT	O	O
methods	NNS	O	O
prescribed	VBN	O	O
by	IN	O	O
the	DT	O	O
curriculum	NN	O	O
.	.	O	O

Implications	NNS	O	O
of	IN	O	O
the	DT	O	O
results	NNS	O	O
for	IN	O	O
teacher	JJ	p	O
training	NN	O	O
are	VBP	O	O
discussed	VBN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
indomethacin	JJ	i	IPM
phonophoresis	NN	i	IPM
on	IN	O	O
the	DT	O	O
relief	NN	O	O
of	IN	O	O
temporomandibular	JJ	p	O
joint	NN	p	O
pain	NN	p	O
.	.	O	O

The	DT	O	O
pain-relieving	JJ	o	OPA
effect	NN	O	O
of	IN	O	O
indomethacin	JJ	i	IPM
phonophoresis	NN	i	IPM
on	IN	O	O
temporomandibular	NN	O	O
(	(	O	O
TMJ	NNP	O	O
)	)	O	O
joint	NN	O	O
pain	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

Twenty	NNP	p	O
subjects	NNS	p	O
,	,	p	O
who	WP	p	O
have	VBP	p	O
TMJ	NNP	p	O
pain	NN	p	O
,	,	O	O
were	VBD	O	O
included	VBN	O	O
for	IN	O	O
this	DT	O	O
study	NN	O	O
and	CC	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	CC	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
.	.	O	O

Each	DT	O	O
treatment	NN	O	O
consisted	VBN	O	O
of	IN	O	O
the	DT	O	O
application	NN	O	O
of	IN	O	O
ultrasound	JJ	O	O
massage	NN	O	O
(	(	O	O
1.0	CD	O	O
MHz	NNP	O	O
,	,	O	O
0.8	CD	O	O
to	TO	O	O
1.5	CD	O	O
W/cm2	NNP	O	O
continuous	JJ	O	O
output	NN	O	O
)	)	O	O
for	IN	O	O
15	CD	O	O
minutes	NNS	O	O
to	TO	O	O
the	DT	O	O
painful	JJ	O	O
temporomandibular	JJ	O	O
joint	NN	O	O
.	.	O	O

As	IN	O	O
a	DT	O	O
conducting	NN	O	O
medium	NN	O	O
,	,	O	O
1	CD	O	O
%	NN	O	O
indomethacin	JJ	i	IPM
cream	NN	O	O
was	VBD	O	O
used	VBN	O	O
for	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
and	CC	O	O
placebo	NN	i	IC
cream	NN	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
respectively	RB	O	O
.	.	O	O

Pre-	JJ	O	O
and	CC	O	O
post-treatment	JJ	O	O
pain	NN	o	OPA
levels	NNS	o	OPA
and	CC	o	OPA
pain	NN	o	OPA
sensitivity	NN	o	OPA
were	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
visual	JJ	o	OPH
analogue	NN	o	OPH
scales	NNS	o	OPH
(	(	o	OPH
VAS	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
pressure	NN	o	OPA
pain	NN	o	OPA
threshold	NN	o	OPA
(	(	o	OPA
PPT	NNP	o	OPA
)	)	o	OPA
.	.	O	O

Mean	NNP	O	O
data	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
post-treatment	JJ	o	OPH
VAS	NNP	o	OPH
was	VBD	O	O
significantly	RB	O	O
decreased	VBN	O	O
and	CC	O	O
post-treatment	JJ	o	OPA
PPT	NNP	o	OPA
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
,	,	O	O
not	RB	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
indomethacin	JJ	i	IPM
phonophoresis	NN	i	IPM
provides	VBZ	O	O
significant	JJ	O	O
pain	NN	o	OPA
relieving	VBG	O	O
effect	NN	O	O
over	IN	O	O
the	DT	O	O
TMJ	NNP	O	O
pain	NN	O	O
.	.	O	O

Feasibility	NN	O	O
of	IN	O	O
two	CD	O	O
dose-dense	JJ	O	O
FEC	NNP	i	IPM
regimens	VBZ	O	O
with	IN	O	O
growth	NN	O	O
factor	NN	O	O
support	NN	O	O
for	IN	O	O
adjuvant	JJ	O	O
therapy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
early	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
:	:	O	O
results	NNS	O	O
from	IN	O	O
a	DT	O	O
randomised	JJ	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
Central	NNP	O	O
European	NNP	O	O
Cooperative	NNP	O	O
Oncology	NNP	O	O
Group	NNP	O	O
(	(	O	O
CECOG	NNP	O	O
)	)	O	O
.	.	O	O

Addition	NN	O	O
of	IN	O	O
epirubicin	NN	i	IPM
to	TO	O	O
adjuvant	VB	O	O
chemotherapy	NN	O	O
can	MD	O	O
provide	VB	O	O
important	JJ	O	O
benefits	NNS	O	O
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
early	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
,	,	O	O
but	CC	O	O
the	DT	O	O
optimal	JJ	O	O
dose	NN	O	O
remains	VBZ	O	O
unclear	JJ	O	O
.	.	O	O

Further	JJ	O	O
improvements	NNS	O	O
can	MD	O	O
be	VB	O	O
achieved	VBN	O	O
with	IN	O	O
dose-dense	JJ	O	O
regimens	NNS	O	O
,	,	O	O
but	CC	O	O
densification	NN	O	O
of	IN	O	O
fluorouracil/epirubicin/cyclophosphamide	NN	i	IPM
(	(	i	IPM
FEC	NNP	i	IPM
)	)	i	IPM
has	VBZ	O	O
proved	VBN	O	O
difficult	JJ	O	O
,	,	O	O
with	IN	O	O
FEC	NNP	O	O
(	(	O	O
60	CD	O	O
)	)	O	O
providing	VBG	O	O
little	JJ	O	O
benefit	NN	O	O
over	IN	O	O
standard	JJ	O	O
chemotherapy	NN	O	O
and	CC	O	O
FEC	NNP	i	IPM
(	(	O	O
100	CD	O	O
)	)	O	O
associated	VBN	O	O
with	IN	O	O
toxicity	NN	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
feasibility	NN	O	O
of	IN	O	O
two	CD	O	O
intermediate	JJ	O	O
dose-dense	JJ	O	O
FEC	NNP	i	IPH
regimens	NNS	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
six	CD	O	O
cycles	NNS	O	O
of	IN	O	O
FEC	NNP	i	IPM
(	(	O	O
75	CD	O	O
)	)	O	O
or	CC	O	O
FEC	NNP	i	IPM
(	(	O	O
90	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
all	DT	O	O
three	CD	O	O
drugs	NNS	O	O
given	VBN	O	O
on	IN	O	O
day	NN	O	O
1	CD	O	O
of	IN	O	O
each	DT	O	O
14-day	JJ	O	O
cycle	NN	O	O
.	.	O	O

Patients	NNS	O	O
also	RB	O	O
received	VBD	O	O
pegfilgrastim	JJ	i	IPM
6	CD	O	O
mg	NN	O	O
as	IN	O	O
a	DT	O	O
single	JJ	O	O
subcutaneous	JJ	O	O
injection	NN	O	O
on	IN	O	O
day	NN	O	O
2	CD	O	O
of	IN	O	O
each	DT	O	O
cycle	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
efficacy	NN	O	O
endpoint	NN	O	O
was	VBD	O	O
the	DT	O	O
proportion	NN	o	OPH
of	IN	o	OPH
subjects	NNS	o	OPH
receiving	VBG	o	OPH
>	NN	o	OPH
or	CC	o	OPH
=85	CD	o	OPH
%	NN	o	OPH
relative	JJ	o	OPH
dose	JJ	o	OPH
intensity	NN	o	OPH
and	CC	O	O
was	VBD	O	O
achieved	VBN	O	O
by	IN	O	O
96	CD	O	O
%	NN	O	O
and	CC	O	O
88	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
FEC	NNP	O	O
(	(	O	O
75	CD	O	O
)	)	O	O
and	CC	O	O
FEC	NNP	O	O
(	(	O	O
90	CD	O	O
)	)	O	O
arms	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Of	IN	O	O
147	CD	O	O
FEC	NNP	i	IPM
(	(	O	O
75	CD	O	O
)	)	O	O
infusions	NNS	O	O
,	,	O	O
4.1	CD	O	O
%	NN	O	O
were	VBD	O	O
delayed	VBN	O	O
,	,	O	O
while	IN	O	O
9.8	CD	O	O
%	NN	O	O
of	IN	O	O
143	CD	O	O
FEC	NNP	i	IPM
(	(	O	O
90	CD	O	O
)	)	O	O
infusions	NNS	O	O
were	VBD	O	O
delayed	VBN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
reasons	NNS	O	O
for	IN	O	O
delay	NN	O	O
were	VBD	O	O
adverse	JJ	o	OA
events	NNS	o	OA
and	CC	O	O
personal/logistical	JJ	O	O
reasons	NNS	O	O
.	.	O	O

One	CD	O	O
dose	JJ	O	O
reduction	NN	O	O
occurred	VBD	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
(	(	O	O
FEC	NNP	i	IPM
(	(	O	O
90	CD	O	O
)	)	O	O
)	)	O	O
,	,	O	O
related	VBN	O	O
to	TO	O	O
diarrhoea	VB	o	OPH
.	.	O	O

Grade	VB	O	O
3-4	JJ	O	O
haematological	JJ	o	OA
toxicities	NNS	o	OA
were	VBD	O	O
reported	VBN	O	O
in	IN	O	O
two	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
FEC	NNP	i	IPM
(	(	O	O
90	CD	O	O
)	)	O	O
arm	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
incidences	NNS	O	O
of	IN	O	O
febrile	JJ	o	OA
neutropenia	NN	o	OA
during	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
adverse	JJ	O	O
events	NNS	O	O
were	VBD	O	O
increases	NNS	O	O
in	IN	O	O
liver	NN	o	OPH
enzymes	NNS	o	OPH
and	CC	o	OPH
gastrointestinal	JJ	o	OPH
events	NNS	o	OPH
;	:	O	O
no	DT	O	O
event	NN	O	O
resulted	VBD	O	O
in	IN	O	O
discontinuation	NN	O	O
.	.	O	O

Only	RB	O	O
one	CD	O	O
patient	NN	O	O
(	(	O	O
FEC	NNP	i	IPM
(	(	O	O
90	CD	O	O
)	)	O	O
)	)	O	O
experienced	VBD	O	O
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	o	OA
vomiting	VBG	o	OA
and	CC	o	OA
throat	VB	o	OA
oedema	NN	o	OA
)	)	o	OA
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
dose-dense	JJ	O	O
FEC	NNP	i	IPM
(	(	O	O
75	CD	O	O
)	)	O	O
and	CC	O	O
FEC	NNP	i	IPM
(	(	O	O
90	CD	O	O
)	)	O	O
are	VBP	O	O
feasible	JJ	O	O
with	IN	O	O
pegfilgrastim	JJ	O	O
support	NN	O	O
.	.	O	O

These	DT	O	O
regimens	NNS	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
very	RB	O	O
low	JJ	O	O
risk	NN	O	O
of	IN	O	O
Grade	NNP	O	O
3-4	JJ	O	O
toxicity	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
weakness	NN	o	OPH
progression	NN	o	OPH
in	IN	O	O
inclusion	NN	p	O
body	NN	p	O
myositis	NN	p	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
methotrexate	NN	i	IPM
or	CC	O	O
placebo	NN	i	IC
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
whether	IN	O	O
5	CD	O	O
to	TO	O	O
20mg	CD	O	O
per	IN	O	O
week	NN	O	O
oral	JJ	O	O
methotrexate	NN	i	IPM
could	MD	O	O
slow	VB	O	O
down	RP	O	O
disease	NN	o	OPH
progression	NN	o	OPH
in	IN	O	O
44	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
inclusion	NN	p	O
body	NN	p	O
myositis	NN	p	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
over	IN	O	O
48	CD	O	O
weeks	NNS	O	O
.	.	O	O

Mean	NNP	o	OPH
change	NN	o	OPH
of	IN	o	OPH
quantitative	JJ	o	OPH
muscle	NN	o	OPH
strength	NN	o	OPH
testing	VBG	o	OPH
sum	NN	o	OPH
scores	NNS	o	OPH
was	VBD	O	O
the	DT	O	O
primary	JJ	O	O
study	NN	O	O
outcome	JJ	O	O
measure	NN	O	O
.	.	O	O

Quantitative	JJ	o	O
muscle	NN	o	O
strength	NN	o	O
testing	VBG	o	O
sum	NN	o	O
scores	NNS	o	O
declined	VBD	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
,	,	O	O
-0.2	CD	O	O
%	NN	O	O
for	IN	O	O
methotrexate	NN	i	IPM
and	CC	O	O
-3.4	CD	O	O
%	NN	O	O
for	IN	O	O
placebo	NN	i	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
=	NNP	O	O
-2.5	NNP	O	O
%	NN	O	O
to	TO	O	O
+9.1	CD	O	O
%	NN	O	O
for	IN	O	O
difference	NN	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
also	RB	O	O
no	DT	O	O
differences	NNS	O	O
in	IN	O	O
manual	JJ	o	OPH
muscle	NN	o	OPH
testing	VBG	o	OPH
sum	JJ	o	OPH
scores	NNS	o	OPH
,	,	o	OPH
activity	NN	o	OPH
scale	NN	o	OPH
scores	NNS	o	OPH
and	CC	o	OPH
patients	NNS	o	OPH
'	POS	o	OPH
own	JJ	o	OPH
assessments	NNS	o	OPH
after	IN	O	O
48	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Serum	NNP	o	OPH
creatine	JJ	o	OPH
kinase	NN	o	OPH
activity	NN	o	OPH
decreased	VBN	O	O
significantly	RB	O	O
in	IN	O	O
the	DT	O	O
methotrexate	NN	i	IPM
group	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
oral	JJ	O	O
methotrexate	NN	i	IPM
did	VBD	O	O
not	RB	O	O
slow	VB	O	O
down	RP	O	O
progression	NN	o	OPH
of	IN	o	OPH
muscle	NN	o	OPH
weakness	NN	o	OPH
but	CC	O	O
decreased	VBD	O	O
serum	JJ	o	OPH
creatine	JJ	o	OPH
kinase	NN	o	OPH
activity	NN	o	OPH
.	.	O	O

Gastric	NNP	O	O
dysrhythmia	NN	O	O
in	IN	O	O
infants	NNS	p	O
with	IN	p	O
gastrointestinal	JJ	p	PC
diseases	NNS	p	PC
measured	VBN	O	O
by	IN	O	O
epigastric	JJ	O	O
impedance	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Gastrointestinal	NNP	O	O
symptoms	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
association	NN	O	O
with	IN	O	O
myoelectrical	JJ	O	O
dysrhythmia	NN	O	O
,	,	O	O
where	WRB	O	O
different	JJ	O	O
types	NNS	O	O
of	IN	O	O
gastric	JJ	O	O
electrical	JJ	O	O
activity	NN	O	O
have	VBP	O	O
been	VBN	O	O
described	VBN	O	O
.	.	O	O

These	DT	O	O
types	NNS	O	O
of	IN	O	O
gastric	JJ	O	O
myoelectrical	JJ	O	O
activity	NN	O	O
and	CC	O	O
dysrhythmia	NN	O	O
can	MD	O	O
be	VB	O	O
measured	VBN	O	O
by	IN	O	O
electrogastrography	NN	O	O
using	VBG	O	O
cutaneous	JJ	O	O
electrodes	NNS	O	O
.	.	O	O

Epigastric	JJ	i	IPH
impedance	NN	i	IPH
is	VBZ	O	O
a	DT	O	O
non-invasive	JJ	O	O
method	NN	O	O
used	VBN	O	O
to	TO	O	O
study	VB	O	O
gastric	JJ	O	O
emptying	VBG	O	O
time	NN	O	O
and	CC	O	O
gastric	JJ	O	O
phasic	JJ	O	O
activity	NN	O	O
.	.	O	O

At	IN	O	O
present	JJ	O	O
no	DT	O	O
study	NN	O	O
of	IN	O	O
gastric	JJ	O	O
dysrhythmia	NN	O	O
,	,	O	O
measured	VBN	O	O
with	IN	O	O
epigastric	JJ	o	OPH
impedance	NN	o	OPH
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
presented	VBN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
purpose	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
gastric	JJ	O	O
rhythms	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
impedance	NN	O	O
gastrography	NN	O	O
in	IN	O	O
control	NN	O	O
infants	NNS	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
infants	NNS	p	PA
with	IN	p	O
different	JJ	p	O
gastrointestinal	JJ	p	O
diseases	NNS	p	O
,	,	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
of	IN	O	O
their	PRP$	O	O
disease	NN	O	O
.	.	O	O

METHOD	NNP	O	O
21	CD	p	PSS
patients	NNS	p	O
(	(	p	O
age	NN	p	O
0-2	CD	p	PA
months	NNS	p	PA
)	)	p	O
and	CC	p	O
40	CD	p	PSS
healthy	JJ	p	O
infants	NNS	p	O
(	(	p	O
age	NN	p	O
0-2	CD	p	PA
months	NNS	p	PA
)	)	p	O
were	VBD	O	O
investigated	VBN	O	O
.	.	O	O

The	DT	O	O
patients	NNS	p	O
suffered	VBD	p	O
from	IN	p	O
partial	JJ	p	O
or	CC	p	O
total	JJ	p	O
intestinal	JJ	p	O
obstruction	NN	p	O
,	,	p	O
necrotizing	VBG	p	O
enterocolitis	NN	p	O
or	CC	p	O
pyloric	JJ	p	O
stenosis.All	NN	p	O
infants	NNS	p	O
were	VBD	p	O
fasting	VBG	p	O
and	CC	O	O
studied	VBN	O	O
during	IN	O	O
periods	NNS	O	O
of	IN	O	O
at	IN	O	O
least	JJS	O	O
one	CD	O	O
hour	NN	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
in	IN	O	O
the	DT	O	O
acute	NN	O	O
state	NN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
when	WRB	O	O
possible	JJ	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	O	O
pathologic	JJ	O	O
result	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
90	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
.	.	O	O

A	DT	O	O
persistent	JJ	O	O
phasic	JJ	o	OPH
activity	NN	o	OPH
pattern	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
19	CD	O	O
of	IN	O	O
the	DT	O	O
21	CD	O	O
patients	NNS	O	O
,	,	O	O
high	JJ	O	O
frequency	NN	o	OPH
phasic	JJ	o	OPH
activity	NN	o	OPH
in	IN	O	O
11	CD	O	O
of	IN	O	O
the	DT	O	O
21	CD	O	O
patients	NNS	O	O
.	.	O	O

Short-term	JJ	O	O
phasic	JJ	o	OPH
activity	NN	o	OPH
was	VBD	O	O
only	RB	O	O
found	VBN	O	O
in	IN	O	O
13	CD	O	O
out	IN	O	O
of	IN	O	O
40	CD	O	O
of	IN	O	O
the	DT	O	O
normal	JJ	O	O
infants	NNS	O	O
(	(	O	O
32.5	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Using	NNP	O	O
epigastric	JJ	i	IPH
impedance	NN	i	IPH
we	PRP	O	O
found	VBD	O	O
that	IN	O	O
infants	NNS	O	O
with	IN	O	O
partial	JJ	O	O
or	CC	O	O
total	JJ	O	O
intestinal	JJ	O	O
obstruction	NN	O	O
had	VBD	O	O
gastric	JJ	O	O
phasic	JJ	O	O
activity	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
not	RB	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
infants	NNS	O	O
.	.	O	O

The	DT	O	O
origin	NN	O	O
of	IN	O	O
the	DT	O	O
gastric	JJ	O	O
phasic	JJ	O	O
activity	NN	O	O
patterns	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
,	,	O	O
but	CC	O	O
they	PRP	O	O
may	MD	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
electrical	JJ	O	O
control	NN	O	O
activity	NN	O	O
.	.	O	O

Therapeutic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
combined	JJ	O	O
treatment	NN	O	O
using	VBG	O	O
tetracycline-immobilized	JJ	i	IPM
collagen	NN	i	IPM
film	NN	i	IPM
and	CC	i	IPM
root	NN	i	IPM
planing	NN	i	IPM
in	IN	O	O
periodontal	JJ	p	O
furcation	NN	p	O
pockets	NNS	p	O
.	.	O	O

46	CD	p	O
upper	JJ	p	O
and	CC	p	O
lower	JJR	p	O
molars	NNS	p	O
with	IN	p	O
furcation	NN	p	O
grade	NN	p	O
II	NNP	p	O
involvement	NN	p	O
were	VBD	O	O
selected	VBN	O	O
from	IN	O	O
16	CD	p	O
patients	NNS	p	O
with	IN	p	O
periodontal	JJ	p	O
disease	NN	p	O
.	.	O	O

The	DT	O	O
teeth	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
the	DT	O	O
following	VBG	O	O
groups	NNS	O	O
according	VBG	O	O
to	TO	O	O
treatment	NN	O	O
;	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
4	CD	O	O
consecutive	JJ	O	O
administrations	NNS	O	O
of	IN	O	O
tetracycline-immobilized	JJ	i	IPM
cross-linked	JJ	i	IPM
collagen	NN	i	IPM
film	NN	i	IPM
(	(	i	IPM
TC	NNP	i	IPM
film	NN	i	IPM
)	)	i	IPM
at	IN	O	O
intervals	NNS	O	O
of	IN	O	O
1	CD	O	O
week	NN	O	O
(	(	O	O
TC	NNP	O	O
group	NN	O	O
)	)	O	O
;	:	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
1	CD	O	O
root	NN	i	IC
planing	VBG	i	IC
treatment	NN	i	IC
(	(	i	IC
RP	NNP	i	IC
group	NN	O	O
)	)	O	O
;	:	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
combination	NN	O	O
treatment	NN	O	O
(	(	O	O
TC	NNP	i	IC
+	NNP	i	IC
RP	NNP	i	IC
group	NN	O	O
)	)	O	O
;	:	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
no	DT	O	O
treatment	NN	O	O
(	(	O	O
control	VB	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
therapeutic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
each	DT	O	O
treatment	NN	O	O
were	VBD	O	O
compared	VBN	O	O
both	DT	O	O
clinically	RB	O	O
and	CC	O	O
microbiologically	RB	O	O
.	.	O	O

Records	NNS	O	O
of	IN	O	O
plaque	NN	o	OPH
index	NN	o	OPH
,	,	o	OPH
gingival	NN	o	OPH
index	NN	o	OPH
,	,	o	OPH
bleeding	VBG	o	OPH
on	IN	o	OPH
probing	VBG	o	OPH
,	,	o	OPH
probing	VBG	o	OPH
depth	NN	o	OPH
,	,	o	OPH
probing	VBG	o	OPH
attachment	JJ	o	OPH
level	NN	o	OPH
and	CC	o	OPH
microscopic	NN	o	OPH
counts	NNS	o	OPH
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
0	CD	O	O
,	,	O	O
4	CD	O	O
,	,	O	O
6	CD	O	O
and	CC	O	O
8	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
showed	VBD	O	O
marked	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
probing	VBG	o	OPH
depth	NN	o	OPH
and	CC	o	OPH
density	NN	o	OPH
of	IN	o	OPH
micro-organisms	NN	o	OPH
in	IN	O	O
both	CC	O	O
the	DT	O	O
RP	NNP	i	IC
and	CC	O	O
TC	NNP	i	IC
+	NNP	i	IC
RP	NNP	i	IC
groups	NNS	O	O
.	.	O	O

In	IN	O	O
particular	JJ	O	O
,	,	O	O
the	DT	O	O
TC	NNP	i	IC
+	NNP	i	IC
RP	NNP	i	IC
group	NN	O	O
was	VBD	O	O
characterized	VBN	O	O
by	IN	O	O
a	DT	O	O
decreased	JJ	O	O
rate	NN	o	OPH
of	IN	o	OPH
bleeding	VBG	o	OPH
on	IN	o	OPH
pocket	NN	o	OPH
probing	NN	o	OPH
and	CC	O	O
an	DT	O	O
increased	JJ	O	O
probing	NN	o	OPH
attachment	NN	o	OPH
gain	NN	o	OPH
.	.	O	O

The	DT	O	O
above	JJ	O	O
findings	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
root	NN	O	O
planning	NN	O	O
is	VBZ	O	O
effective	JJ	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
furcation	NN	O	O
involvement	NN	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
effects	NNS	O	O
are	VBP	O	O
enhanced	VBN	O	O
by	IN	O	O
the	DT	O	O
local	JJ	O	O
administration	NN	O	O
of	IN	O	O
TC	NNP	i	IC
films	NNS	O	O
.	.	O	O

Intermediate-term	JJ	O	O
mortality	NN	O	O
and	CC	O	O
cardiac	JJ	i	IS
transplantation	NN	i	IS
in	IN	O	O
infants	NNS	p	PA
with	IN	p	O
single-ventricle	JJ	p	PC
lesions	NNS	p	PC
:	:	O	O
risk	NN	O	O
factors	NNS	O	O
and	CC	O	O
their	PRP$	O	O
interaction	NN	O	O
with	IN	O	O
shunt	NN	O	O
type	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
study	NN	O	O
objective	NN	O	O
was	VBD	O	O
to	TO	O	O
identify	VB	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
death	NN	O	O
and	CC	O	O
cardiac	JJ	i	IS
transplantation	NN	i	IS
in	IN	O	O
infants	NNS	p	PA
undergoing	VBG	p	PC
the	DT	p	PC
Norwood	NNP	p	PC
procedure	NN	p	PC
and	CC	O	O
to	TO	O	O
determine	VB	O	O
differences	NNS	O	O
in	IN	O	O
associations	NNS	O	O
that	WDT	O	O
might	MD	O	O
favor	VB	O	O
the	DT	O	O
modified	JJ	O	O
Blalock-Taussig	NNP	O	O
shunt	NN	O	O
or	CC	O	O
a	DT	O	O
right	JJ	O	O
ventricle-to-pulmonary	JJ	O	O
artery	NN	O	O
shunt	NN	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
used	VBD	O	O
competing	VBG	O	O
risks	NNS	O	O
methodology	NN	O	O
to	TO	O	O
analyze	VB	O	O
death	NN	O	O
without	IN	O	O
transplantation	NN	O	O
,	,	O	O
cardiac	JJ	O	O
transplantation	NN	O	O
,	,	O	O
and	CC	O	O
survival	NN	O	O
without	IN	O	O
transplantation	NN	O	O
.	.	O	O

Parametric	NNP	O	O
time-to-event	JJ	O	O
modeling	NN	O	O
and	CC	O	O
bootstrapping	NN	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
identify	VB	O	O
independent	JJ	O	O
predictors	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Data	NNP	O	O
from	IN	O	O
549	CD	p	O
subjects	NNS	p	O
(	(	p	O
follow-up	JJ	p	O
,	,	p	O
2.7	CD	p	O
?	.	p	O
0.9	CD	p	O
years	NNS	p	O
)	)	O	O
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

Mortality	NNP	O	O
risk	NN	o	O
was	VBD	O	O
characterized	VBN	O	O
by	IN	O	O
early	JJ	O	O
and	CC	O	O
constant	JJ	O	O
phases	NNS	O	O
;	:	O	O
transplant	NN	O	O
was	VBD	O	O
characterized	VBN	O	O
by	IN	O	O
only	RB	O	O
a	DT	O	O
constant	JJ	O	O
phase	NN	O	O
.	.	O	O

Early	JJ	O	O
phase	NN	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
death	NN	o	O
included	VBD	O	O
lower	JJR	O	O
socioeconomic	JJ	O	O
status	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.01	NNP	O	O
)	)	O	O
,	,	O	O
obstructed	VBD	O	O
pulmonary	JJ	O	O
venous	JJ	O	O
return	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
,	,	O	O
smaller	JJR	O	O
ascending	VBG	O	O
aorta	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
anatomic	JJ	O	O
subtype	NN	O	O
.	.	O	O

Constant	JJ	O	O
phase	NN	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
death	NN	o	O
included	VBD	O	O
genetic	JJ	O	O
syndrome	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
and	CC	O	O
lower	JJR	O	O
gestational	JJ	O	O
age	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
right	JJ	O	O
ventricle-to-pulmonary	JJ	O	O
artery	NN	O	O
shunt	NN	O	O
demonstrated	VBD	O	O
better	JJR	O	O
survival	NN	o	OMO
in	IN	O	O
the	DT	O	O
51	CD	O	O
%	NN	O	O
of	IN	O	O
subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
full	JJ	O	O
term	NN	O	O
with	IN	O	O
aortic	JJ	O	O
atresia	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
modified	JJ	O	O
Blalock-Taussig	NNP	O	O
shunt	NN	O	O
was	VBD	O	O
better	RBR	O	O
among	IN	O	O
the	DT	O	O
4	CD	O	O
%	NN	O	O
of	IN	O	O
subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
preterm	VBN	O	O
with	IN	O	O
a	DT	O	O
patent	NN	O	O
aortic	JJ	O	O
valve	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.003	NNP	O	O
)	)	O	O
.	.	O	O

Lower	JJR	O	O
pre-Norwood	NN	O	O
right	JJ	O	O
ventricular	JJ	O	O
fractional	JJ	O	O
area	NN	O	O
change	NN	O	O
,	,	O	O
pre-Norwood	NN	O	O
surgery	NN	O	O
,	,	O	O
and	CC	O	O
anatomy	VBZ	O	O
other	JJ	O	O
than	IN	O	O
hypoplastic	JJ	O	O
left	JJ	O	O
heart	NN	O	O
syndrome	NN	O	O
were	VBD	O	O
independently	RB	O	O
associated	VBN	O	O
with	IN	O	O
transplantation	NN	O	O
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
.03	NNP	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
shunt	NN	O	O
type	NN	O	O
was	VBD	O	O
not	RB	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.43	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Independent	NNP	O	O
risk	NN	O	O
factors	NNS	O	O
for	IN	O	O
intermediate-term	JJ	O	O
mortality	NN	O	O
include	VBP	O	O
lower	JJR	O	O
socioeconomic	JJ	O	O
status	NN	O	O
,	,	O	O
anatomy	RB	O	O
,	,	O	O
genetic	JJ	O	O
syndrome	NN	O	O
,	,	O	O
and	CC	O	O
lower	JJR	O	O
gestational	JJ	O	O
age	NN	O	O
.	.	O	O

Term	JJ	O	O
infants	NNS	p	O
with	IN	O	O
aortic	JJ	O	O
atresia	NN	O	O
benefited	VBD	O	O
from	IN	O	O
a	DT	O	O
right	JJ	O	O
ventricle-to-pulmonary	JJ	O	O
artery	NN	O	O
shunt	NN	O	O
,	,	O	O
and	CC	O	O
preterm	JJ	O	O
infants	NNS	p	O
with	IN	O	O
a	DT	O	O
patent	NN	O	O
aortic	JJ	O	O
valve	NN	O	O
benefited	VBD	O	O
from	IN	O	O
a	DT	O	O
modified	VBN	O	O
Blalock-Taussig	NNP	O	O
shunt	NN	O	O
.	.	O	O

Right	NNP	O	O
ventricular	JJ	O	O
function	NN	O	O
and	CC	O	O
anatomy	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
shunt	VB	O	O
type	NN	O	O
,	,	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
transplantation	NN	O	O
.	.	O	O

In	IN	O	O
school-aged	JJ	p	PA
children	NNS	p	PA
a	DT	O	O
combination	NN	O	O
of	IN	O	O
galacto-oligosaccharides	NNS	i	IPM
and	CC	i	O
Lactobacillus	NNP	i	IPM
GG	NNP	i	IPM
increases	VBZ	O	O
bifidobacteria	RB	O	O
more	JJR	O	O
than	IN	O	O
Lactobacillus	NNP	i	IPM
GG	NNP	i	IPM
on	IN	O	O
its	PRP$	O	O
own	JJ	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
Lactobacillus	NNP	i	IPM
GG	NNP	i	IPM
(	(	i	IPM
LGG	NNP	i	IPM
)	)	i	IPM
and	CC	i	IPM
galacto-oligosaccharides	NNS	i	IPM
(	(	i	IPM
GOS	NNP	i	IPM
)	)	i	IPM
with	IN	O	O
LGG	NNP	i	IPM
on	IN	O	O
its	PRP$	O	O
own	JJ	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
intestinal	JJ	O	O
microbiota	NN	O	O
in	IN	O	O
school-aged	JJ	p	O
children	NNS	p	O
.	.	O	O

The	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blinded	JJ	O	O
,	,	O	O
crossover	NN	O	O
study	NN	O	O
comprised	VBD	O	O
30	CD	p	PSS
healthy	JJ	p	PC
children	NNS	p	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
two	CD	O	O
3-week	JJ	O	O
study	NN	O	O
periods	NNS	O	O
with	IN	O	O
a	DT	O	O
4-week	JJ	O	O
wash-out	JJ	O	O
period	NN	O	O
in	IN	O	O
between	IN	O	O
.	.	O	O

The	DT	O	O
children	NNS	O	O
ingested	VBD	O	O
daily	RB	O	O
65	CD	O	O
ml	NN	O	O
of	IN	O	O
milk-based	JJ	O	O
fruit	NN	O	O
juice	NN	O	O
containing	VBG	O	O
either	CC	O	O
LGG	NNP	i	IPM
alone	RB	O	O
(	(	O	O
6.5	CD	O	O
x	RB	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
CFU	NNP	O	O
)	)	O	O
or	CC	O	O
LGG	NNP	i	IPM
plus	CC	O	O
2	CD	O	O
g	NN	O	O
of	IN	O	O
GOS	NNP	i	IPM
.	.	O	O

Symptom	NNP	O	O
diaries	NNS	O	O
were	VBD	O	O
filled	VBN	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
periods	NNS	O	O
.	.	O	O

Fecal	JJ	O	O
samples	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
and	CC	O	O
end	NN	O	O
of	IN	O	O
both	DT	O	O
study	NN	O	O
periods	NNS	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
both	DT	O	O
study	NN	O	O
periods	NNS	O	O
,	,	O	O
the	DT	O	O
amount	NN	o	OPH
of	IN	o	OPH
bifidobacteria	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
after	IN	O	O
the	DT	O	O
ingestion	NN	O	O
of	IN	O	O
LGG	NNP	i	IPM
+	NNP	i	IPM
GOS	NNP	i	IPM
compared	VBN	O	O
with	IN	O	O
LGG	NNP	i	IPM
alone	RB	O	O
(	(	O	O
geometric	JJ	O	O
mean	VBP	O	O
9.33	CD	O	O
x	$	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
vs.	FW	O	O
4.28	CD	O	O
x	$	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
CFU/g	NNP	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
lactobacilli	NN	o	OPH
or	CC	O	O
LGG	NNP	i	IPM
,	,	O	O
nor	CC	O	O
did	VBD	O	O
gastrointestinal	JJ	o	OPH
symptoms	NNS	o	OPH
,	,	o	OPH
defecation	NN	o	OPH
frequency	NN	o	OPH
,	,	o	OPH
consistency	NN	o	OPH
of	IN	o	OPH
stools	NNS	o	OPH
or	CC	o	OPH
ease	NN	o	OPH
of	IN	o	OPH
defecation	NN	o	OPH
differ	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
study	NN	O	O
periods	NNS	O	O
.	.	O	O

Ingestion	NN	O	O
of	IN	O	O
LGG	NNP	i	IPM
combined	VBD	O	O
with	IN	O	O
2	CD	O	O
g	NN	O	O
of	IN	O	O
GOS	NNP	i	IPM
increased	VBD	O	O
the	DT	O	O
bifidobacteria	NN	o	OPH
more	JJR	O	O
than	IN	O	O
LGG	NNP	i	IPM
on	IN	O	O
its	PRP$	O	O
own	JJ	O	O
and	CC	O	O
thus	RB	O	O
GOS	NNP	i	IPM
clearly	RB	O	O
has	VBZ	O	O
a	DT	O	O
prebiotic	JJ	O	O
effect	NN	O	O
in	IN	O	O
children	NNS	p	PA
.	.	O	O

The	DT	O	O
children	NNS	p	O
tolerated	VBN	O	O
well	RB	O	O
a	DT	O	O
daily	JJ	O	O
intake	NN	O	O
of	IN	O	O
2	CD	O	O
g	NN	O	O
of	IN	O	O
GOS	NNP	i	IPM
.	.	O	O

Ascaris	NNP	O	O
and	CC	O	O
growth	NN	O	O
rates	NNS	O	O
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Three	CD	p	O
hundred	VBD	p	O
forty-one	NN	p	O
Tanzanian	JJ	p	O
preschool	NN	p	O
children	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
levamisole	VB	i	IPM
or	CC	O	O
placebo	VB	i	IC
treatment	NN	O	O
given	VBN	O	O
at	IN	O	O
three-month	JJ	O	O
intervals	NNS	O	O
.	.	O	O

Weights	NNS	o	OPH
and	CC	o	OPH
heights	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
at	IN	O	O
the	DT	O	O
tri-monthly	JJ	O	O
treatment	NN	O	O
visits	NNS	O	O
for	IN	O	O
a	DT	O	O
period	NN	O	O
of	IN	O	O
one	CD	O	O
year	NN	O	O
.	.	O	O

Among	IN	O	O
the	DT	O	O
273	CD	O	O
children	NNS	O	O
who	WP	O	O
were	VBD	O	O
seen	VBN	O	O
and	CC	O	O
weighed	VBN	O	O
at	IN	O	O
the	DT	O	O
one-year	JJ	O	O
follow-up	JJ	O	O
visit	NN	O	O
,	,	O	O
the	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
weight	NN	o	OPH
gain	NN	o	OPH
was	VBD	O	O
8	CD	O	O
per	IN	O	O
cent	NN	O	O
greater	JJR	O	O
for	IN	O	O
those	DT	O	O
receiving	VBG	O	O
levamisole	JJR	i	IPM
than	IN	O	O
for	IN	O	O
placebo-treated	JJ	i	IC
controls	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.06	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
78	CD	O	O
children	NNS	p	O
known	VBN	O	O
to	TO	O	O
be	VB	O	O
infected	VBN	O	O
with	IN	O	O
Ascaris	NNP	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
the	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
weight	NN	o	OPH
gain	NN	o	OPH
was	VBD	O	O
21	CD	O	O
per	IN	O	O
cent	NN	O	O
greater	JJR	O	O
in	IN	O	O
children	NNS	O	O
treated	VBN	O	O
with	IN	O	O
levamisole	NN	i	IPM
than	IN	O	O
in	IN	O	O
those	DT	O	O
receiving	VBG	O	O
placebo	NN	i	IC
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.03	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
height	NN	o	OPH
gain	NN	o	OPH
was	VBD	O	O
no	DT	O	O
different	JJ	O	O
for	IN	O	O
treatment	NN	O	O
and	CC	O	O
placebo	NN	i	IC
groups	NNS	O	O
.	.	O	O

Amonafide	NN	i	IPM
:	:	O	O
An	DT	O	O
active	JJ	O	O
agent	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
previously	RB	p	O
untreated	VBN	p	O
advanced	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
--	:	O	O
a	DT	O	O
cancer	NN	O	O
and	CC	O	O
leukemia	NN	O	O
group	NN	O	O
B	NNP	O	O
study	NN	O	O
(	(	O	O
CALGB	NNP	O	O
8642	CD	O	O
)	)	O	O
.	.	O	O

Amonafide	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
new	JJ	O	O
imide	JJ	O	O
derivative	NN	O	O
of	IN	O	O
naphthalic	JJ	O	O
acid	NN	O	O
.	.	O	O

The	DT	O	O
drug	NN	O	O
had	VBD	O	O
demonstrated	VBN	O	O
significant	JJ	O	O
activity	NN	O	O
in	IN	O	O
preclinical	JJ	O	O
studies	NNS	O	O
and	CC	O	O
some	DT	O	O
activity	NN	O	O
in	IN	O	O
Phase	NNP	O	O
I	PRP	O	O
trials	NNS	O	O
.	.	O	O

The	DT	O	O
drug	NN	O	O
is	VBZ	O	O
extensively	RB	O	O
metabolized	VBN	O	O
and	CC	O	O
detected	VBN	O	O
in	IN	O	O
plasma	NN	O	O
and	CC	O	O
urine	NN	O	O
.	.	O	O

Its	PRP$	O	O
toxicity	NN	O	O
has	VBZ	O	O
previously	RB	O	O
been	VBN	O	O
correlated	VBN	O	O
to	TO	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
an	DT	O	O
active	JJ	O	O
metabolite	NN	O	O
,	,	O	O
N-acetyl-amonafide	NNP	O	O
.	.	O	O

Amonafide	NNP	i	IPM
was	VBD	O	O
chosen	VBN	O	O
for	IN	O	O
inclusion	NN	O	O
in	IN	O	O
the	DT	O	O
Cancer	NNP	O	O
and	CC	O	O
Leukemia	NNP	O	O
Group	NNP	O	O
B	NNP	O	O
(	(	O	O
CALGB	NNP	O	O
)	)	O	O
master	NN	O	O
metastatic	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
protocol	NN	O	O
.	.	O	O

CALGB	NNP	O	O
8642	CD	O	O
randomizes	VBZ	O	O
previously	RB	p	O
untreated	VBN	p	O
metastatic	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
patients	NNS	p	O
either	CC	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
several	JJ	O	O
Phase	NNP	O	O
II	NNP	O	O
agents	NNS	O	O
given	VBN	O	O
for	IN	O	O
up	IN	O	O
to	TO	O	O
four	CD	O	O
cycles	NNS	O	O
and	CC	O	O
then	RB	O	O
followed	VBN	O	O
by	IN	O	O
standard	JJ	O	O
cyclophosphamide-doxorubicin-5-fluorouracil	NN	i	IPM
,	,	O	O
or	CC	O	O
to	TO	O	O
immediate	VB	O	O
treatment	NN	O	O
with	IN	O	O
standard	JJ	O	O
cyclophosphamide-doxorubicin-5-fluorouracil	NN	i	IPH
.	.	O	O

The	DT	O	O
end	NN	O	O
point	NN	O	O
of	IN	O	O
CALGB	NNP	O	O
8642	CD	O	O
is	VBZ	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
difference	NN	O	O
in	IN	O	O
survival	NN	o	OMO
,	,	o	O
toxicity	NN	o	OPH
,	,	o	O
and	CC	o	O
overall	JJ	o	OPH
response	NN	o	OPH
when	WRB	O	O
limited	JJ	O	O
exposure	NN	O	O
to	TO	O	O
Phase	NNP	O	O
II	NNP	O	O
agents	NNS	O	O
precedes	VBZ	O	O
standard	JJ	O	O
chemotherapy	NN	O	O
.	.	O	O

This	DT	O	O
report	NN	O	O
deals	VBZ	O	O
only	RB	O	O
with	IN	O	O
amonafide	RB	i	IPM
as	IN	O	O
a	DT	O	O
Phase	NNP	O	O
II	NNP	O	O
agent	NN	O	O
.	.	O	O

Comparisons	NNS	O	O
with	IN	O	O
the	DT	O	O
cyclophosphamide-doxorubicin-5-fluorouracil	JJ	i	IPM
arm	NN	O	O
will	MD	O	O
not	RB	O	O
be	VB	O	O
addressed	VBN	O	O
.	.	O	O

Patients	NNS	p	O
had	VBD	p	O
to	TO	p	O
have	VB	p	O
histologically	RB	p	O
documented	VBN	p	O
measurable	JJ	p	O
breast	NN	p	PC
cancer	NN	p	PC
and	CC	p	O
a	DT	p	O
performance	NN	p	O
status	NN	p	O
of	IN	p	O
0-1	NNP	p	O
.	.	p	O

Patients	NNS	p	O
could	MD	p	O
not	RB	p	O
have	VB	p	O
had	VBN	p	O
prior	JJ	p	O
chemotherapy	NN	p	PC
for	IN	p	O
metastatic	JJ	p	PC
disease	NN	p	PC
.	.	p	O

Prior	NNP	p	O
adjuvant	JJ	p	PC
chemotherapy	NN	p	PC
was	VBD	p	O
permitted	VBN	p	O
.	.	p	O

Patients	NNS	p	O
could	MD	p	O
not	RB	p	O
have	VB	p	O
visceral	JJ	p	PC
crisis	NN	p	PC
.	.	p	O

Amonafide	NNP	i	IPM
was	VBD	O	O
given	VBN	O	O
at	IN	O	O
300	CD	O	O
mg/m2/day	JJ	O	O
i.v	NN	O	O
.	.	O	O

for	IN	O	O
5	CD	O	O
days	NNS	O	O
,	,	O	O
and	CC	O	O
repeated	VBD	O	O
at	IN	O	O
21-day	JJ	O	O
intervals	NNS	O	O
for	IN	O	O
a	DT	O	O
maximum	NN	O	O
of	IN	O	O
four	CD	O	O
cycles	NNS	O	O
.	.	O	O

Escalation	NN	O	O
and	CC	O	O
reduction	NN	O	O
in	IN	O	O
dose	NN	O	O
was	VBD	O	O
mandated	VBN	O	O
dependent	NN	O	O
on	IN	O	O
hematotoxicity	NN	O	O
or	CC	O	O
lack	NN	O	O
thereof	NN	O	O
.	.	O	O

Toxicity	NN	o	OPH
was	VBD	O	O
primarily	RB	O	O
hematological	JJ	O	O
and	CC	O	O
bimodal	NN	O	O
:	:	O	O
32	CD	O	O
%	NN	O	O
had	VBD	O	O
grade	VBN	O	O
3	CD	O	O
or	CC	O	O
4	CD	O	O
leukopenia	NN	o	OPH
and	CC	O	O
24	CD	O	O
%	NN	O	O
had	VBD	O	O
grade	VBN	O	O
3	CD	O	O
or	CC	O	O
4	CD	O	O
thrombocytopenia	NN	o	OPH
;	:	O	O
22	CD	O	O
%	NN	O	O
had	VBD	O	O
no	DT	O	O
leukopenia	NN	o	OPH
and	CC	O	O
44	CD	O	O
%	NN	O	O
had	VBD	O	O
no	DT	O	O
thrombocytopenia	NN	o	OPH
.	.	O	O

The	DT	O	O
response	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
18	CD	O	O
%	NN	O	O
,	,	O	O
including	VBG	O	O
one	CD	O	O
complete	JJ	O	O
response	NN	O	O
.	.	O	O

When	WRB	O	O
response	NN	O	O
was	VBD	O	O
analyzed	VBN	O	O
by	IN	O	O
hematological	JJ	o	OPH
toxicity	NN	o	OPH
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
35.7	CD	O	O
%	NN	O	O
response	NN	O	O
if	IN	O	O
patients	NNS	O	O
had	VBD	O	O
leukopenia	VBN	o	OPH
grade	NN	O	O
3/4	CD	O	O
(	(	O	O
versus	IN	O	O
8.3	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.08	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
50	CD	O	O
%	NN	O	O
response	NN	O	O
if	IN	O	O
patients	NNS	O	O
had	VBD	O	O
thrombocytopenia	VBN	o	OPH
grade	NN	O	O
3/4	CD	O	O
(	(	O	O
versus	IN	O	O
7.1	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
amonafide	NN	i	IPM
is	VBZ	O	O
somewhat	RB	O	O
active	JJ	O	O
in	IN	O	O
previously	RB	p	O
untreated	VBN	p	O
breast	NN	p	PC
cancer	NN	p	PC
patients	NNS	p	O
.	.	O	O

There	EX	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
steep	JJ	O	O
dose-response	NN	O	O
curve	NN	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
significant	JJ	O	O
correlation	NN	O	O
between	IN	O	O
myelosuppression	NN	O	O
and	CC	O	O
response	NN	O	O
.	.	O	O

Rates	NNS	o	OOt
of	IN	o	OOt
responses	NNS	o	OOt
in	IN	O	O
patients	NNS	O	O
adequately	RB	O	O
dosed	VBN	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
with	IN	O	O
significant	JJ	O	O
hematotoxicity	NN	O	O
)	)	O	O
with	IN	O	O
amonafide	NN	O	O
ranged	VBD	O	O
from	IN	O	O
35	CD	O	O
to	TO	O	O
50	CD	O	O
%	NN	O	O
.	.	O	O

Further	JJ	O	O
studies	NNS	O	O
will	MD	O	O
incorporate	VB	O	O
individualized	JJ	O	O
dosing	NN	O	O
based	VBN	O	O
on	IN	O	O
pretreatment	NN	O	O
acetylator	NN	O	O
phenotyping	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
simvastatin	NN	i	IPM
on	IN	O	O
hemostasis	NN	O	O
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
isolated	JJ	p	PC
hypertriglyceridemia	NN	p	PC
.	.	O	O

BACKGROUNDS/AIMS	NNP	O	O
Elevated	NNP	O	O
triglyceride	NN	O	O
levels	NNS	O	O
seem	VBP	O	O
to	TO	O	O
predispose	VB	O	O
to	TO	O	O
the	DT	O	O
earlier	JJR	O	O
development	NN	O	O
and	CC	O	O
accelerated	JJ	O	O
progression	NN	O	O
of	IN	O	O
coronary	JJ	O	O
artery	NN	O	O
disease	NN	O	O
.	.	O	O

In	IN	O	O
our	PRP$	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
assessed	VBD	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
whether	IN	O	O
simvastatin	JJ	i	IPM
treatment	NN	O	O
affects	NNS	O	O
coagulation	NN	o	OPH
and	CC	o	OPH
fibrinolysis	NN	o	OPH
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
isolated	JJ	p	PC
hypertriglyceridemia	NN	p	PC
.	.	O	O

METHODS	NNP	O	O
The	DT	O	O
study	NN	O	O
included	VBD	O	O
39	CD	p	O
patients	NNS	p	O
with	IN	p	O
elevated	JJ	p	O
triglyceride	NN	p	O
levels	NNS	p	O
and	CC	p	O
peripheral	JJ	p	O
artery	NN	p	O
sclerosis	NN	p	O
,	,	O	O
treated	VBD	O	O
for	IN	O	O
90	CD	O	O
days	NNS	O	O
with	IN	O	O
either	DT	O	O
simvastatin	NN	i	IPM
(	(	O	O
40	CD	O	O
mg	NNS	O	O
daily	RB	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
.	.	O	O

Plasma	NNP	o	OPH
lipids	NNS	o	OPH
,	,	o	OPH
glucose	JJ	o	OPH
homeostasis	NN	o	OPH
markers	NNS	o	OPH
and	CC	O	O
hemostasic	JJ	o	OPH
variables	NNS	o	OPH
were	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Simvastatin	NNP	i	IPM
,	,	O	O
but	CC	O	O
not	RB	O	O
placebo	VB	i	IC
,	,	O	O
administered	VBN	O	O
to	TO	O	O
these	DT	O	O
patients	NNS	O	O
reduced	VBD	O	O
plasma	JJ	o	OPH
levels/activity	NN	o	OPH
of	IN	o	OPH
fibrinogen	NN	o	OPH
(	(	O	O
from	IN	O	O
3.5	CD	O	O
?	.	O	O
0.4	CD	O	O
to	TO	O	O
2.8	CD	O	O
?	.	O	O
0.3	CD	O	O
g/l	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
factor	NN	o	O
VII	NNP	o	O
(	(	O	O
from	IN	O	O
144.2	CD	O	O
?	.	O	O
16.9	CD	O	O
to	TO	O	O
112.5	CD	O	O
?	.	O	O
14.0	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
plasminogen	JJ	o	O
activator	NN	o	O
inhibitor-1	NN	o	O
(	(	O	O
from	IN	O	O
76.9	CD	O	O
?	.	O	O
13.5	CD	O	O
to	TO	O	O
50.2	CD	O	O
?	.	O	O
9.2	CD	O	O
ng/ml	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
without	IN	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
von	NN	o	O
Willebrand	NNP	o	O
factor	NN	o	O
levels	NNS	o	O
,	,	O	O
and	CC	O	O
tended	VBD	O	O
to	TO	O	O
prolong	VB	O	O
the	DT	O	O
prothrombin	NN	o	O
and	CC	o	O
partial	JJ	o	O
thromboplastin	NN	o	O
times	NNS	o	O
.	.	O	O

CONCLUSION	NNP	O	O
Our	PRP$	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
statin	NN	i	O
treatment	NN	O	O
produces	VBZ	O	O
a	DT	O	O
multidirectional	JJ	O	O
effect	NN	O	O
on	IN	O	O
coagulation	NN	o	O
and	CC	o	O
fibrinolysis	NN	o	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
isolated	JJ	p	O
hypertriglyceridemia	NN	p	O
and	CC	O	O
that	IN	O	O
this	DT	O	O
treatment	NN	O	O
may	MD	O	O
bring	VB	O	O
some	DT	O	O
benefits	NNS	O	O
to	TO	O	O
patients	NNS	p	O
with	IN	p	O
elevated	JJ	p	O
triglyceride	NN	p	O
levels	NNS	p	O
.	.	O	O

Combined	VBN	O	O
descriptive	JJ	O	O
and	CC	O	O
explanatory	JJ	O	O
information	NN	O	O
improves	VBZ	O	O
peers	NNS	o	OME
'	POS	o	OME
perceptions	NNS	o	OME
of	IN	O	O
autism	NN	O	O
.	.	O	O

Authors	NNS	O	O
examined	VBD	O	O
the	DT	O	O
combined	JJ	O	O
effects	NNS	O	O
of	IN	O	O
descriptive	JJ	O	O
and	CC	O	O
explanatory	JJ	O	O
information	NN	O	O
on	IN	O	O
peers	NNS	o	OME
'	POS	o	OME
perceptions	NNS	o	OME
and	CC	o	OME
behavioral	JJ	o	OME
intentions	NNS	o	OME
toward	IN	O	O
an	DT	O	O
unfamiliar	JJ	O	O
child	NN	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

Children	NNP	p	PA
(	(	p	O
N	NNP	p	O
=	NNP	p	O
576	CD	p	O
;	:	p	O
M	NNP	p	O
age	NN	p	O
=	VBD	p	O
10.06	CD	p	O
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
view	VB	O	O
two	CD	O	O
videotapes	NNS	O	O
of	IN	O	O
a	DT	O	O
boy	NN	O	O
engaging	VBG	O	O
in	IN	O	O
typical	JJ	O	O
and	CC	O	O
autistic	JJ	O	O
behaviors	NNS	O	O
receiving	VBG	O	O
either	RB	O	O
descriptive	JJ	i	IE
(	(	i	IE
AUT-D	NNP	i	IE
)	)	i	IE
or	CC	O	O
descriptive	JJ	i	IE
and	CC	i	IE
explanatory	JJ	i	IE
information	NN	i	IE
(	(	i	IE
AUT-D	NNP	i	IE
+	NNP	i	IE
E	NNP	i	IE
)	)	i	IE
.	.	O	O

Children	NNP	O	O
responded	VBD	O	O
to	TO	O	O
measures	NNS	O	O
of	IN	O	O
attitudes	NNS	O	O
(	(	o	O
Adjective	NNP	o	OME
Checklist	NNP	o	OME
)	)	o	O
and	CC	O	O
behavioral	JJ	O	O
intentions	NNS	O	O
(	(	o	O
Shared	NNP	o	OME
Activities	NNP	o	OME
Questionnaire	NNP	o	OME
)	)	o	O
.	.	O	O

Children	NNP	O	O
rated	VBD	O	O
the	DT	O	O
typical	JJ	O	O
boy	NN	O	O
more	RBR	O	O
favorably	RB	O	O
than	IN	O	O
the	DT	O	O
boy	NN	O	O
showing	VBG	O	O
autistic	JJ	O	O
symptoms	NNS	O	O
.	.	O	O

When	WRB	O	O
compared	VBN	O	O
to	TO	O	O
descriptive	VB	O	O
information	NN	O	O
alone	RB	O	O
,	,	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
descriptive	JJ	O	O
and	CC	O	O
explanatory	JJ	O	O
information	NN	O	O
resulted	VBD	O	O
in	IN	O	O
improved	JJ	O	O
third-	JJ	O	O
and	CC	O	O
fourth-graders	NNS	O	O
'	''	O	O
but	CC	O	O
not	RB	O	O
fifth-graders	NNS	O	O
'	POS	O	O
attitudes	NNS	O	O
toward	IN	O	O
the	DT	O	O
child	NN	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

Combined	VBN	O	O
information	NN	O	O
improved	VBN	O	O
behavioral	JJ	O	O
intentions	NNS	O	O
across	IN	O	O
grades	NNS	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
girls	NNS	O	O
(	(	O	O
vs.	FW	O	O
boys	NNS	O	O
)	)	O	O
were	VBD	O	O
more	RBR	O	O
responsive	JJ	O	O
to	TO	O	O
information	NN	O	O
as	IN	O	O
evidenced	VBN	O	O
by	IN	O	O
differences	NNS	O	O
in	IN	O	O
academic	JJ	O	O
intentions	NNS	O	O
.	.	O	O

The	DT	O	O
combination	NN	O	O
of	IN	O	O
descriptive	JJ	i	IE
and	CC	i	IE
explanatory	JJ	i	IE
information	NN	i	IE
about	IN	O	O
autism	NN	O	O
appears	VBZ	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
positive	JJ	O	O
effect	NN	O	O
on	IN	O	O
children	NNS	o	OME
's	POS	o	OME
attitudes	NNS	o	OME
and	CC	o	OME
behavioral	JJ	o	OME
intentions	NNS	o	OME
.	.	O	O

Implications	NNS	O	O
of	IN	O	O
the	DT	O	O
findings	NNS	O	O
are	VBP	O	O
briefly	RB	O	O
discussed	VBN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
study	NN	O	O
limitations	NNS	O	O
and	CC	O	O
recommendations	NNS	O	O
for	IN	O	O
future	JJ	O	O
research	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
mild	JJ	i	IPH
physical	JJ	i	IPH
exercise	NN	i	IPH
on	IN	O	O
serum	NN	o	OPH
lipoproteins	NNS	o	OPH
and	CC	O	O
metabolites	NNS	o	OPH
of	IN	o	OPH
arachidonic	JJ	o	OPH
acid	NN	o	OPH
:	:	O	O
a	DT	O	O
controlled	VBN	O	O
randomised	JJ	O	O
trial	NN	O	O
in	IN	O	O
middle	JJ	p	PA
aged	VBN	p	PA
men	NNS	p	PSE
.	.	O	O

To	TO	O	O
study	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
physical	JJ	i	IPH
exercise	NN	i	IPH
on	IN	O	O
biochemical	JJ	o	OPH
risk	NN	o	OPH
factors	NNS	o	OPH
for	IN	o	OPH
ischaemic	JJ	o	OPH
heart	NN	o	OPH
disease	NN	o	OPH
31	CD	p	PSS
healthy	JJ	p	PC
middle	NNS	p	O
aged	VBN	p	O
men	NNS	p	O
undertook	IN	O	O
regular	JJ	i	IPH
physical	JJ	i	IPH
exercise	NN	i	IPH
for	IN	O	O
two	CD	O	O
months	NNS	O	O
and	CC	O	O
29	CD	O	O
served	VBD	O	O
as	IN	O	O
controls	NNS	O	O
in	IN	O	O
a	DT	O	O
randomised	JJ	O	O
trial	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
men	NNS	O	O
taking	VBG	O	O
regular	JJ	O	O
exercise	NN	O	O
serum	NN	o	OPH
cholesterol	NN	o	OPH
concentrations	NNS	o	OPH
increased	VBD	O	O
26	CD	O	O
%	NN	O	O
more	JJR	O	O
in	IN	O	O
the	DT	O	O
high	JJ	o	OPH
density	NN	o	OPH
lipoprotein	VBP	o	OPH
subfraction	NN	o	OPH
two	CD	o	OPH
(	(	o	OPH
HDL2	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
decreased	VBD	O	O
31	CD	O	O
%	NN	O	O
more	JJR	O	O
in	IN	O	O
the	DT	O	O
subfraction	NN	o	OPH
three	CD	o	OPH
(	(	o	OPH
HDL3	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
9	CD	O	O
%	NN	O	O
more	JJR	O	O
in	IN	O	O
the	DT	O	O
low	JJ	o	OPH
density	NN	o	OPH
lipoprotein	NN	o	OPH
fraction	NN	o	OPH
than	IN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

A	DT	O	O
tendency	NN	O	O
towards	NNS	O	O
increased	VBD	O	O
plasma	JJ	o	OPH
6-keto-prostaglandin	JJ	o	OPH
F1	NNP	o	OPH
alpha	NN	o	OPH
concentration	NN	o	OPH
and	CC	O	O
decreased	VBD	O	O
serum	NN	o	OPH
thromboxane	NN	o	OPH
B2	NNP	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
found	VBN	O	O
during	IN	O	O
the	DT	O	O
period	NN	O	O
of	IN	O	O
regular	JJ	O	O
exercise	NN	i	IPH
,	,	O	O
but	CC	O	O
prostaglandin	VBP	o	OPH
E2	NNP	o	OPH
concentrations	NNS	o	OPH
remained	VBD	O	O
unchanged	JJ	O	O
.	.	O	O

The	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	JJ	o	OPH
6-keto-prostaglandin	JJ	o	OPH
F1	NNP	o	OPH
alpha	NN	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
serum	JJ	o	OPH
HDL2	NNP	o	OPH
cholesterol	NN	o	OPH
concentration	NN	o	OPH
in	IN	O	O
the	DT	O	O
group	NN	O	O
taking	VBG	O	O
regular	JJ	O	O
exercise	NN	i	IPH
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
mild	JJ	i	IPH
regular	JJ	i	IPH
physical	JJ	i	IPH
exercise	NN	i	IPH
favourably	RB	O	O
influences	VBZ	O	O
cholesterol	NN	O	O
distribution	NN	O	O
in	IN	O	O
serum	NN	o	OPH
lipoproteins	NNS	o	OPH
in	IN	O	O
healthy	JJ	p	O
middle	NN	p	O
aged	VBN	p	O
men	NNS	p	O
and	CC	O	O
may	MD	O	O
have	VB	O	O
beneficial	JJ	O	O
effects	NNS	O	O
on	IN	O	O
circulating	VBG	o	OPH
metabolites	NNS	o	OPH
of	IN	o	OPH
arachidonic	JJ	o	OPH
acid	NN	o	OPH
.	.	O	O

Use	NNP	O	O
of	IN	O	O
hormonal	JJ	i	IPM
contraceptives	NNS	i	IPM
and	CC	O	O
risk	NN	O	O
of	IN	O	O
HIV-1	NNP	O	O
transmission	NN	O	O
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
cohort	NN	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Hormonal	NNP	i	IPM
contraceptives	NNS	i	IPM
are	VBP	O	O
used	VBN	O	O
widely	RB	O	O
but	CC	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
HIV-1	NNP	O	O
risk	NN	O	O
are	VBP	O	O
unclear	JJ	O	O
.	.	O	O

We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
hormonal	JJ	i	IPM
contraceptive	NN	i	IPM
use	NN	O	O
and	CC	O	O
risk	NN	O	O
of	IN	O	O
HIV-1	NNP	O	O
acquisition	NN	O	O
by	IN	O	O
women	NNS	O	O
and	CC	O	O
HIV-1	JJ	O	O
transmission	NN	O	O
from	IN	O	O
HIV-1-infected	JJ	O	O
women	NNS	O	O
to	TO	O	O
their	PRP$	O	O
male	JJ	O	O
partners	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
followed	VBD	O	O
up	RP	O	O
3790	CD	p	O
heterosexual	JJ	p	O
HIV-1-serodiscordant	JJ	p	O
couples	NNS	p	O
participating	VBG	p	O
in	IN	p	O
two	CD	p	O
longitudinal	JJ	p	O
studies	NNS	p	O
of	IN	p	O
HIV-1	NNP	p	O
incidence	NN	p	O
in	IN	p	O
seven	CD	p	O
African	JJ	p	O
countries	NNS	p	O
.	.	O	O

Among	IN	O	O
injectable	JJ	O	O
and	CC	O	O
oral	JJ	O	O
hormonal	JJ	i	IPM
contraceptive	NN	i	IPM
users	NNS	O	O
and	CC	O	O
non-users	NNS	O	O
,	,	O	O
we	PRP	O	O
compared	VBN	O	O
rates	NNS	O	O
of	IN	O	O
HIV-1	NNP	O	O
acquisition	NN	O	O
by	IN	O	O
women	NNS	O	O
and	CC	O	O
HIV-1	JJ	O	O
transmission	NN	O	O
from	IN	O	O
women	NNS	O	O
to	TO	O	O
men	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
was	VBD	O	O
HIV-1	JJ	O	O
seroconversion	NN	O	O
.	.	O	O

We	PRP	O	O
used	VBD	O	O
Cox	NNP	O	O
proportional	JJ	O	O
hazards	NNS	O	O
regression	NN	O	O
and	CC	O	O
marginal	JJ	O	O
structural	JJ	O	O
modelling	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
contraceptive	NN	O	O
use	NN	O	O
on	IN	O	O
HIV-1	NNP	O	O
risk	NN	O	O
.	.	O	O

FINDINGS	NNP	O	O
Among	IN	O	O
1314	CD	p	O
couples	NNS	p	O
in	IN	p	O
which	WDT	p	O
the	DT	p	O
HIV-1-seronegative	JJ	p	O
partner	NN	p	O
was	VBD	p	O
female	JJ	p	O
(	(	O	O
median	JJ	O	O
follow-up	NN	O	O
18?0	CD	O	O
[	JJ	O	O
IQR	NNP	O	O
12?6-24?2	JJ	O	O
]	NNP	O	O
months	NNS	O	O
)	)	O	O
,	,	O	O
rates	NNS	O	O
of	IN	O	O
HIV-1	NNP	o	O
acquisition	NN	o	O
were	VBD	O	O
6?61	CD	O	O
per	IN	O	O
100	CD	O	O
person-years	NNS	O	O
in	IN	O	O
women	NNS	O	O
who	WP	O	O
used	VBD	O	O
hormonal	JJ	i	O
contraception	NN	i	O
and	CC	O	O
3?78	CD	O	O
per	IN	O	O
100	CD	O	O
person-years	NNS	O	O
in	IN	O	O
those	DT	O	O
who	WP	O	O
did	VBD	O	O
not	RB	O	O
(	(	O	O
adjusted	VBN	O	O
hazard	RB	O	O
ratio	JJ	O	O
1?98	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1?06-3?68	CD	O	O
,	,	O	O
p=0?03	NN	O	O
)	)	O	O
.	.	O	O

Among	IN	O	O
2476	CD	O	O
couples	NNS	p	O
in	IN	p	O
which	WDT	p	O
the	DT	p	O
HIV-1-seronegative	JJ	p	O
partner	NN	p	O
was	VBD	p	O
male	JJ	p	O
(	(	O	O
median	JJ	O	O
follow-up	NN	O	O
18?7	CD	O	O
[	JJ	O	O
IQR	NNP	O	O
12?8-24?2	JJ	O	O
]	NNP	O	O
months	NNS	O	O
)	)	O	O
,	,	O	O
rates	NNS	O	O
of	IN	O	O
HIV-1	NNP	o	O
transmission	NN	o	O
from	IN	O	O
women	NNS	O	O
to	TO	O	O
men	NNS	O	O
were	VBD	O	O
2?61	CD	O	O
per	IN	O	O
100	CD	O	O
person-years	NNS	O	O
in	IN	O	O
couples	NNS	O	O
in	IN	O	O
which	WDT	O	O
women	NNS	O	O
used	VBD	O	O
hormonal	JJ	i	O
contraception	NN	i	O
and	CC	O	O
1?51	CD	O	O
per	IN	O	O
100	CD	O	O
person-years	NNS	O	O
in	IN	O	O
couples	NNS	O	O
in	IN	O	O
which	WDT	O	O
women	NNS	O	O
did	VBD	O	O
not	RB	O	O
use	VB	O	O
hormonal	JJ	i	O
contraception	NN	i	O
(	(	O	O
adjusted	VBN	O	O
hazard	RB	O	O
ratio	JJ	O	O
1?97	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1?12-3?45	CD	O	O
,	,	O	O
p=0?02	NN	O	O
)	)	O	O
.	.	O	O

Marginal	JJ	O	O
structural	JJ	O	O
model	NN	O	O
analyses	NNS	O	O
generated	VBD	O	O
much	RB	O	O
the	DT	O	O
same	JJ	O	O
results	NNS	O	O
to	TO	O	O
the	DT	O	O
Cox	NNP	O	O
proportional	JJ	O	O
hazards	NNS	O	O
regression	NN	O	O
.	.	O	O

INTERPRETATION	NNP	O	O
Women	NNP	O	O
should	MD	O	O
be	VB	O	O
counselled	VBN	O	O
about	IN	O	O
potentially	RB	O	O
increased	VBN	O	O
risk	NN	o	O
of	IN	o	O
HIV-1	NNP	o	O
acquisition	NN	o	O
and	CC	o	O
transmission	NN	o	O
with	IN	O	O
hormonal	JJ	i	O
contraception	NN	i	O
,	,	O	O
especially	RB	O	O
injectable	JJ	O	O
methods	NNS	O	O
,	,	O	O
and	CC	O	O
about	IN	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
dual	JJ	O	O
protection	NN	O	O
with	IN	O	O
condoms	NNS	O	O
to	TO	O	O
decrease	VB	O	O
HIV-1	NNP	O	O
risk	NN	O	O
.	.	O	O

Non-hormonal	JJ	O	O
or	CC	O	O
low-dose	JJ	O	O
hormonal	JJ	i	O
contraceptive	NN	i	O
methods	NNS	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
for	IN	O	O
women	NNS	O	O
with	IN	O	O
or	CC	O	O
at-risk	JJ	O	O
for	IN	O	O
HIV-1	NNP	O	O
.	.	O	O

FUNDING	NNP	O	O
US	NNP	O	O
National	NNP	O	O
Institutes	NNP	O	O
of	IN	O	O
Health	NNP	O	O
and	CC	O	O
the	DT	O	O
Bill	NNP	O	O
&	CC	O	O
Melinda	NNP	O	O
Gates	NNP	O	O
Foundation	NNP	O	O
.	.	O	O

Long-term	JJ	O	O
survival	NN	O	O
in	IN	O	O
a	DT	O	O
phase	NN	O	O
III	NNP	O	O
,	,	O	O
randomised	VBD	O	O
study	NN	O	O
of	IN	O	O
topotecan	JJ	i	IPM
versus	NN	O	O
paclitaxel	NN	i	IPM
in	IN	O	O
advanced	JJ	p	O
epithelial	JJ	p	O
ovarian	JJ	p	O
carcinoma	NN	p	O
.	.	O	O

BACKGROUND	IN	O	O
We	PRP	O	O
have	VBP	O	O
continued	VBN	O	O
to	TO	O	O
monitor	VB	O	O
the	DT	O	O
survival	NN	O	O
of	IN	O	O
patients	NNS	O	O
randomised	VBN	O	O
in	IN	O	O
a	DT	O	O
previously	RB	O	O
reported	VBN	O	O
multicentre	JJ	O	O
phase	NN	O	O
III	NNP	O	O
study	NN	O	O
of	IN	O	O
topotecan	JJ	i	IPM
versus	NN	O	O
paclitaxel	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
epithelial	JJ	p	O
ovarian	JJ	p	O
cancer	NN	p	O
who	WP	p	O
had	VBD	p	O
failed	VBN	p	O
one	CD	p	O
prior	JJ	p	O
platinum-based	JJ	p	O
regimen	NNS	p	O
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Patients	NNPS	p	O
with	IN	p	O
bidimensionally	RB	p	O
measurable	JJ	p	O
disease	NN	p	O
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
topotecan	VB	i	IPM
(	(	O	O
1.5	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/day	NN	O	O
for	IN	O	O
5	CD	O	O
days	NNS	O	O
)	)	O	O
or	CC	O	O
paclitaxel	NN	i	IPM
(	(	O	O
175	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/day	NN	O	O
as	IN	O	O
a	DT	O	O
3-h	JJ	O	O
infusion	NN	O	O
)	)	O	O
every	DT	O	O
21	CD	O	O
days	NNS	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
eligible	JJ	O	O
for	IN	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
alternate	NN	O	O
therapy	NN	O	O
at	IN	O	O
third	JJ	O	O
line	NN	O	O
.	.	O	O

The	DT	O	O
European	JJ	o	OOt
Organisation	NNP	o	OOt
for	IN	o	OOt
Research	NNP	o	OOt
and	CC	o	OOt
Treatment	NNP	o	OOt
of	IN	o	OOt
Cancer	NNP	o	OOt
Quality	NNP	o	OOt
of	IN	o	OOt
Life	NNP	o	OOt
(	(	o	OOt
EORTC	NNP	o	OOt
QOL	NNP	o	OOt
)	)	o	OOt
-C30	VBP	o	OOt
questionnaire	NN	o	OOt
was	VBD	O	O
also	RB	O	O
used	VBN	O	O
to	TO	O	O
measure	VB	O	O
eight	CD	O	O
symptoms	NNS	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
during	IN	O	O
each	DT	O	O
course	NN	O	O
(	(	O	O
pain	NN	o	OPA
,	,	o	O
anorexia	NN	o	OPH
,	,	o	O
diarrhoea	NN	o	OPH
,	,	o	O
fatigue	NN	o	OPH
,	,	o	O
nausea	NN	o	OPH
and	CC	o	O
vomiting	NN	o	OPH
,	,	o	O
dyspnea	NN	o	OPH
,	,	o	O
constipation	NN	o	OPH
and	CC	o	O
insomnia	NN	o	OPH
)	)	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
226	CD	p	O
patients	NNS	p	O
were	VBD	O	O
evaluable	JJ	O	O
for	IN	O	O
response	NN	O	O
.	.	O	O

Demographic	JJ	O	O
characteristics	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
,	,	O	O
as	IN	O	O
were	VBD	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
EORTC	NNP	O	O
QOL-30	NNP	O	O
questionnaire	NN	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
topotecan	JJ	i	IPM
group	NN	O	O
,	,	O	O
median	JJ	O	O
time	NN	O	O
to	TO	O	O
progression	NN	o	OPH
was	VBD	O	O
18.9	CD	O	O
weeks	NNS	O	O
(	(	O	O
range	NN	O	O
<	RB	O	O
1	CD	O	O
to	TO	O	O
92.6+	CD	O	O
weeks	NNS	O	O
;	:	O	O
25	CD	O	O
%	NN	O	O
censored	VBN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
,	,	O	O
for	IN	O	O
paclitaxel	NN	i	IPM
,	,	O	O
14.7	CD	O	O
weeks	NNS	O	O
(	(	O	O
range	NN	O	O
<	RB	O	O
1	CD	O	O
to	TO	O	O
137.3+	CD	O	O
weeks	NNS	O	O
;	:	O	O
12.3	CD	O	O
%	NN	O	O
censored	VBN	O	O
)	)	O	O
;	:	O	O
P	NNP	O	O
=	VBD	O	O
0.076	CD	O	O
.	.	O	O

At	IN	O	O
4	CD	O	O
years	NNS	O	O
post-randomisation	NN	O	O
,	,	O	O
median	JJ	o	OMO
survival	NN	o	OMO
in	IN	O	O
the	DT	O	O
topotecan	JJ	i	IPM
group	NN	O	O
was	VBD	O	O
63.0	CD	O	O
weeks	NNS	O	O
(	(	O	O
range	NN	O	O
<	RB	O	O
1	CD	O	O
to	TO	O	O
238.4+	CD	O	O
weeks	NNS	O	O
;	:	O	O
20.5	CD	O	O
%	NN	O	O
censored	VBN	O	O
)	)	O	O
and	CC	O	O
,	,	O	O
for	IN	O	O
paclitaxel	NN	i	IPM
,	,	O	O
53.0	CD	O	O
weeks	NNS	O	O
(	(	O	O
range	NN	O	O
<	RB	O	O
1	CD	O	O
to	TO	O	O
226.3+	CD	O	O
weeks	NNS	O	O
;	:	O	O
12.3	CD	O	O
%	NN	O	O
censored	VBN	O	O
)	)	O	O
;	:	O	O
P	NNP	O	O
=	VBD	O	O
0.44	CD	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Topotecan	NNP	i	IPM
continues	VBZ	O	O
to	TO	O	O
demonstrate	VB	O	O
comparable	JJ	O	O
efficacy	NN	o	OOt
and	CC	O	O
survival	NN	o	OMO
to	TO	O	O
paclitaxel	VB	i	IPM
with	IN	O	O
manageable	JJ	O	O
and	CC	O	O
non-cumulative	JJ	O	O
haematological	JJ	o	OPH
toxicity	NN	o	OPH
.	.	O	O

Non-haematological	JJ	o	OPH
toxicity	NN	o	OPH
was	VBD	O	O
generally	RB	O	O
mild	VBN	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
long-term	JJ	O	O
survival	NN	O	O
rate	NN	O	O
indicates	VBZ	O	O
substantial	JJ	O	O
therapeutic	JJ	O	O
benefit	NN	O	O
for	IN	O	O
this	DT	O	O
group	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
topotecan	JJ	i	IPM
at	IN	O	O
relapse	NN	p	O
of	IN	p	O
ovarian	JJ	p	O
cancer	NN	p	O
.	.	O	O

Influence	NN	O	O
of	IN	O	O
diets	NNS	O	O
rich	JJ	O	O
in	IN	O	O
Maillard	NNP	i	IPM
reaction	NN	i	IPM
products	NNS	i	IPM
on	IN	O	O
calcium	NN	o	OPH
bioavailability	NN	o	OPH
.	.	O	O

Assays	NNS	O	O
in	IN	O	O
male	JJ	p	PSE
adolescents	NNS	p	PA
and	CC	O	O
in	IN	O	O
Caco-2	NNP	O	O
cells	NNS	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
high	JJ	O	O
intake	NN	O	O
of	IN	O	O
Maillard	NNP	i	IPH
reaction	NN	i	IPH
products	NNS	i	IPH
(	(	i	O
MRP	NNP	i	O
)	)	i	O
on	IN	O	O
calcium	NN	o	OPH
availability	NN	o	OPH
in	IN	O	O
adolescents	NNS	p	O
and	CC	O	O
across	IN	O	O
Caco-2	NNP	O	O
cell	NN	O	O
monolayers	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
2	CD	O	O
week	NN	O	O
randomized	VBN	O	O
two-period	JJ	O	O
crossover	NN	O	O
trial	NN	O	O
,	,	O	O
18	CD	p	PSS
male	NN	p	PSE
adolescents	NNS	p	PA
consumed	VBD	O	O
two	CD	O	O
diets	NNS	O	O
,	,	O	O
named	VBN	O	O
white	JJ	i	IPM
diet	NN	i	IPM
(	(	i	IPM
WD	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
brown	JJ	i	IPM
diet	NN	i	IPM
(	(	i	IPM
BD	NNP	i	IPM
)	)	i	IPM
,	,	O	O
which	WDT	O	O
were	VBD	O	O
poor	JJ	O	O
and	CC	O	O
rich	JJ	O	O
in	IN	O	O
MRP	NNP	i	IPM
,	,	O	O
respectively	RB	O	O
.	.	O	O

A	DT	O	O
3	CD	O	O
day	NN	O	O
balance	NN	O	O
was	VBD	O	O
performed	VBN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
each	DT	O	O
period	NN	O	O
,	,	O	O
and	CC	O	O
fasting	VBG	o	OPH
blood	NN	o	OPH
samples	NNS	o	OPH
were	VBD	O	O
collected	VBN	O	O
.	.	O	O

Calcium	NNP	o	OPH
solubility	NN	o	OPH
and	CC	o	O
absorption	NN	o	OPH
across	IN	o	OPH
Caco-2	NNP	o	OPH
cells	NNS	o	OPH
were	VBD	O	O
studied	VBN	O	O
after	IN	O	O
the	DT	O	O
in	IN	O	O
vitro	JJ	O	O
digestion	NN	O	O
of	IN	O	O
the	DT	O	O
diets	NNS	O	O
.	.	O	O

The	DT	O	O
in	IN	O	O
vitro	NN	O	O
assay	NN	O	O
showed	VBD	O	O
similar	JJ	O	O
solubility	NN	o	OPH
after	IN	O	O
the	DT	O	O
in	IN	O	O
vitro	JJ	O	O
digestion	NN	O	O
and	CC	O	O
similar	JJ	O	O
transport	NN	O	O
across	IN	O	O
Caco-2	NNP	O	O
cells	NNS	O	O
.	.	O	O

In	IN	O	O
accordance	NN	O	O
,	,	O	O
calcium	NN	o	OPH
bioavailability	NN	o	OPH
in	IN	O	O
adolescents	NNS	O	O
did	VBD	O	O
not	RB	O	O
vary	JJ	O	O
between	IN	O	O
the	DT	O	O
diets	NNS	O	O
(	(	O	O
%	NN	O	O
WD	NNP	O	O
=	VBZ	O	O
40.4	CD	O	O
+/-	JJ	O	O
5.1	CD	O	O
,	,	O	O
%	NN	O	O
BD	NNP	O	O
=	VBZ	O	O
38.2	CD	O	O
+/-	JJ	O	O
3.6	CD	O	O
)	)	O	O
.	.	O	O

Serum	NNP	o	OPH
and	CC	o	OPH
urine	JJ	o	OPH
biochemical	JJ	o	OPH
parameters	NNS	o	OPH
related	VBN	o	OPH
to	TO	o	OPH
calcium	NN	o	OPH
status	NN	o	OPH
and	CC	o	OPH
bone	NN	o	OPH
metabolism	NN	o	OPH
remained	VBD	O	O
unaltered	JJ	O	O
.	.	O	O

Only	RB	O	O
deoxypyridinoline	JJ	o	OPH
values	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
after	IN	O	O
consumption	NN	O	O
of	IN	O	O
the	DT	O	O
BD	NNP	O	O
(	(	O	O
13.0	CD	O	O
+/-	JJ	O	O
1.1	CD	O	O
compared	VBN	O	O
to	TO	O	O
18.3	CD	O	O
+/-	JJ	O	O
2.1	CD	O	O
nM/Mm	JJ	O	O
Cr	NNP	O	O
in	IN	O	O
the	DT	O	O
WD	NNP	O	O
)	)	O	O
,	,	O	O
possibly	RB	O	O
indicative	JJ	O	O
of	IN	O	O
less	RBR	O	O
efficient	JJ	O	O
bone	NN	o	OOt
turnover	NN	o	OOt
during	IN	O	O
this	DT	O	O
period	NN	O	O
.	.	O	O

As	IN	O	O
calcium	NN	O	O
acquired	VBD	O	O
during	IN	O	O
adolescence	NN	O	O
is	VBZ	O	O
essential	JJ	O	O
to	TO	O	O
maximize	VB	O	O
peak	JJ	O	O
bone	NN	O	O
mass	NN	O	O
and	CC	O	O
to	TO	O	O
prevent	VB	O	O
osteoporosis	NN	O	O
,	,	O	O
possible	JJ	O	O
long-term	JJ	O	O
effects	NNS	O	O
of	IN	O	O
excessive	JJ	O	O
MRP	NNP	i	IPM
intake	NN	O	O
during	IN	O	O
this	DT	O	O
period	NN	O	O
warrant	JJ	O	O
attention	NN	O	O
.	.	O	O

Double-blind	NNP	O	O
comparison	NN	O	O
of	IN	O	O
doxepin	NN	i	IPM
versus	NN	O	O
bupropion	NN	i	IPM
in	IN	O	O
outpatients	NNS	p	O
with	IN	p	O
a	DT	p	O
major	JJ	p	O
depressive	JJ	p	PC
disorder	NN	p	PC
.	.	O	O

A	DT	O	O
double-blind	NN	O	O
controlled	VBN	O	O
study	NN	O	O
comparing	VBG	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
bupropion	NN	i	IPM
to	TO	O	O
doxepin	VB	i	IPM
in	IN	O	O
outpatients	NNS	p	O
with	IN	p	O
primary	JJ	p	PC
depression	NN	p	PC
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
drugs	NNS	O	O
.	.	O	O

Following	VBG	O	O
a	DT	O	O
7-day	JJ	O	O
placebo	NN	i	IC
washout	NN	O	O
period	NN	O	O
,	,	O	O
patients	NNS	O	O
could	MD	O	O
be	VB	O	O
treated	VBN	O	O
for	IN	O	O
up	RB	O	O
to	TO	O	O
13	CD	O	O
weeks	NNS	O	O
on	IN	O	O
either	DT	O	O
treatment	NN	O	O
.	.	O	O

Antidepressant	JJ	o	OME
response	NN	o	OME
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
the	DT	O	O
Hamilton	NNP	o	OME
Depression	NNP	o	OME
and	CC	o	OME
Anxiety	NNP	o	OME
Scales	NNP	o	OME
,	,	o	O
Clinical	NNP	o	OME
Global	NNP	o	OME
Severity	NNP	o	OME
and	CC	o	O
Improvement	NNP	o	OME
Ratings	NNP	o	OME
,	,	O	O
and	CC	O	O
the	DT	O	O
Zung	NNP	o	OME
Self-Rating	NNP	o	OME
Depression	NNP	o	OME
Scale	NNP	o	OME
.	.	O	O

Comparable	JJ	O	O
efficacy	NN	o	OOt
between	IN	O	O
the	DT	O	O
compounds	NNS	O	O
was	VBD	O	O
found	VBN	O	O
across	IN	O	O
the	DT	O	O
13-week	JJ	O	O
study	NN	O	O
.	.	O	O

Doxepin	NNP	i	IPM
differed	VBD	O	O
from	IN	O	O
bupropion	NN	i	IPM
mainly	RB	O	O
on	IN	O	O
the	DT	O	O
sleep	JJ	o	OME
factor	NN	O	O
of	IN	O	O
the	DT	O	O
Hamilton	NNP	o	OME
Depression	NNP	o	OME
Scale	NNP	o	OME
,	,	O	O
with	IN	O	O
doxepin	NN	i	IPM
improving	VBG	O	O
sleep	NN	o	O
to	TO	O	O
a	DT	O	O
greater	JJR	O	O
extent	NN	O	O
than	IN	O	O
bupropion	NN	i	IPM
.	.	O	O

Doxepin	NNP	i	IPM
produced	VBD	O	O
a	DT	O	O
greater	JJR	O	O
incidence	NN	O	O
of	IN	O	O
anticholinergic	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
,	,	O	O
including	VBG	O	O
dry	JJ	o	OA
mouth	NN	o	OA
,	,	o	O
constipation	NN	o	OA
,	,	o	O
sleepiness	NN	o	OA
,	,	o	O
and	CC	o	O
tiredness	NN	o	OA
,	,	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
bupropion	NN	i	IPM
.	.	O	O

Also	RB	O	O
,	,	O	O
increased	VBD	O	O
appetite	NN	o	OA
and	CC	o	OA
weight	JJ	o	OA
gain	NN	o	OA
were	VBD	O	O
consistent	JJ	O	O
side	NN	O	O
effects	NNS	O	O
of	IN	O	O
doxepin	NN	i	IPM
relative	NN	O	O
to	TO	O	O
bupropion	NN	i	IPM
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
propofol	NN	i	IPM
,	,	O	O
droperidol	NN	i	IPM
,	,	O	O
and	CC	O	O
metoclopramide	NN	i	IPM
for	IN	O	O
prophylaxis	NN	O	O
of	IN	O	O
postoperative	JJ	o	OPH
nausea	NN	o	OPH
and	CC	o	OPH
vomiting	NN	o	OPH
after	IN	O	O
breast	NN	p	O
cancer	NN	p	O
surgery	NN	p	O
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
in	IN	O	O
Japanese	JJ	p	O
patients	NNS	p	O
.	.	O	O

BACKGROUND	NNP	O	O
Breast	NNP	O	O
cancer	NN	O	O
surgery	NN	O	O
performed	VBN	O	O
with	IN	O	O
the	DT	O	O
patient	NN	p	O
under	IN	p	O
general	JJ	p	O
anesthesia	NN	p	O
has	VBZ	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
relatively	RB	O	O
high	JJ	O	O
incidence	NN	O	O
of	IN	O	O
postoperative	JJ	o	OPH
nausea	NN	o	OPH
and	CC	o	OPH
vomiting	NN	o	OPH
(	(	o	OPH
PONV	NNP	o	OPH
)	)	o	OPH
.	.	O	O

Between	$	O	O
60	CD	O	O
%	NN	O	O
and	CC	O	O
80	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
who	WP	O	O
undergo	VBP	O	O
mastectomy	NNS	O	O
(	(	O	O
with	IN	O	O
axillary	JJ	O	O
dissection	NN	O	O
)	)	O	O
experience	NN	O	O
PONV	NNP	o	OPH
.	.	O	O

We	PRP	O	O
previously	RB	O	O
reported	VBD	O	O
that	IN	O	O
propofol	NN	i	IPM
at	IN	O	O
a	DT	O	O
subhypnotic	JJ	O	O
dose	NN	O	O
of	IN	O	O
0.5	CD	O	O
mg/kg	NN	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
placebo	NN	i	IC
in	IN	O	O
preventing	VBG	O	O
PONV	NNP	o	O
in	IN	O	O
women	NNS	O	O
who	WP	O	O
undergo	VBP	O	O
mastectomy	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
a	DT	O	O
subhypnotic	JJ	O	O
dose	NN	O	O
of	IN	O	O
propofol	NN	i	IPM
with	IN	O	O
the	DT	O	O
conventional	JJ	O	O
antiemetics	NNS	O	O
droperidol	NN	i	IPM
and	CC	O	O
metoclopramide	NN	i	IPM
for	IN	O	O
the	DT	O	O
prophylaxis	NN	O	O
of	IN	O	O
PONV	NNP	o	O
after	IN	O	O
breast	NN	p	PC
cancer	NN	p	PC
surgery	NN	p	PC
in	IN	p	O
Japanese	JJ	p	PC
patients	NNS	p	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
,	,	O	O
Japanese	JJ	p	O
women	NNS	p	PSE
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
1	CD	O	O
of	IN	O	O
4	CD	O	O
groups	NNS	O	O
to	TO	O	O
receive	VB	O	O
IV	NNP	O	O
administration	NN	O	O
of	IN	O	O
propofol	JJ	i	IPM
0.5	CD	O	O
mg/kg	NN	O	O
,	,	O	O
droperidol	VBZ	i	IPM
20	CD	O	O
microg/kg	NN	O	O
,	,	O	O
metoclopramide	RB	i	IPM
0.2	CD	O	O
mg/kg	NN	O	O
,	,	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	i	IC
isotonic	JJ	i	IC
saline	NN	i	IC
)	)	i	IC
immediately	RB	O	O
after	IN	O	O
skin	JJ	O	O
suture	NN	O	O
.	.	O	O

A	DT	O	O
standard	JJ	O	O
general	JJ	O	O
anesthetic	JJ	O	O
technique	NN	O	O
,	,	O	O
including	VBG	O	O
sevoflurane	NN	O	O
and	CC	O	O
air	NN	O	O
in	IN	O	O
oxygen	NN	O	O
,	,	O	O
was	VBD	O	O
used	VBN	O	O
.	.	O	O

All	DT	O	O
episodes	NNS	O	O
of	IN	O	O
PONV	NNP	o	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
anesthesia	JJ	O	O
administration	NN	O	O
were	VBD	O	O
recorded	VBN	O	O
by	IN	O	O
an	DT	O	O
investigator	NN	O	O
who	WP	O	O
was	VBD	O	O
blinded	VBN	O	O
to	TO	O	O
treatment	NN	O	O
assignment	NN	O	O
.	.	O	O

The	DT	O	O
investigator	NN	O	O
questioned	VBD	O	O
the	DT	O	O
patients	NNS	O	O
as	IN	O	O
to	TO	O	O
whether	IN	O	O
they	PRP	O	O
experienced	VBD	O	O
extrapyramidal	NN	o	OPH
symptoms	NNS	o	OPH
.	.	O	O

To	TO	O	O
maintain	VB	O	O
the	DT	O	O
integrity	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
results	NNS	O	O
,	,	O	O
none	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
received	VBD	O	O
preanesthetic	JJ	O	O
medication	NN	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
100	CD	p	PSS
women	NNS	p	O
(	(	p	O
mean	JJ	p	PA
[	NNP	p	PA
SD	NNP	p	PA
]	NNP	p	PA
age	NN	p	PA
,	,	p	PA
52	CD	p	PA
[	NN	p	PA
7	CD	p	PA
]	CD	p	PA
years	NNS	p	PA
;	:	p	O
height	VBD	p	O
,	,	p	O
154	CD	p	O
[	NN	p	O
6	CD	p	O
]	NNP	p	O
cm	NN	p	O
;	:	p	O
weight	NN	p	O
,	,	p	O
54	CD	p	O
[	NN	p	O
7	CD	p	O
]	NNP	p	O
kg	NN	p	O
)	)	p	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Each	DT	O	O
study	NN	O	O
group	NN	O	O
comprised	VBD	O	O
25	CD	O	O
patients	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
treatment	NN	O	O
groups	NNS	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
patient	VB	O	O
demographics	NNS	O	O
,	,	O	O
surgery	NN	O	O
type	NN	O	O
,	,	O	O
or	CC	O	O
awakening	VBG	O	O
time	NN	O	O
.	.	O	O

The	DT	O	O
prevalences	NNS	O	O
of	IN	O	O
PONV	NNP	o	O
0	CD	O	O
to	TO	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
anesthesia	NN	O	O
were	VBD	O	O
28	CD	O	O
%	NN	O	O
with	IN	O	O
propofol	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.005	CD	O	O
)	)	O	O
,	,	O	O
32	CD	O	O
%	NN	O	O
with	IN	O	O
droperidol	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.011	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
60	CD	O	O
%	NN	O	O
with	IN	O	O
metoclopramide	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
NS	NNP	O	O
)	)	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	O
(	(	O	O
68	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
PONV	NNP	o	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
propofol	NN	i	IPM
and	CC	O	O
those	DT	O	O
receiving	VBG	O	O
droperidol	NN	i	IPM
,	,	O	O
and	CC	O	O
propofol	NN	i	IPM
and	CC	O	O
droperidol	NN	i	IPM
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
significantly	RB	O	O
lower	JJR	O	O
prevalences	NNS	O	O
of	IN	O	O
PONV	NNP	o	O
compared	VBN	O	O
with	IN	O	O
metoclopramide	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.022	CD	O	O
and	CC	O	O
P	NNP	O	O
=	NNP	O	O
0.043	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Extrapyramidal	NNP	o	O
symptoms	NNS	o	O
were	VBD	O	O
not	RB	O	O
reported	VBN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
prevalences	NNS	O	O
of	IN	O	O
PONV	NNP	o	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
propofol	NN	i	IPM
0.5	CD	O	O
mg/kg	NN	O	O
and	CC	O	O
droperidol	NN	i	IPM
20	CD	O	O
microg/kg	NN	O	O
0	CD	O	O
to	TO	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
anesthesia	NN	O	O
in	IN	O	O
this	DT	O	O
small	JJ	O	O
,	,	O	O
select	JJ	O	O
group	NN	O	O
of	IN	O	O
Japanese	JJ	O	O
women	NNS	O	O
who	WP	O	O
underwent	VBP	O	O
breast	NN	O	O
cancer	NN	O	O
surgery	NN	O	O
.	.	O	O

The	DT	O	O
prevalences	NNS	O	O
of	IN	O	O
PONV	NNP	o	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
with	IN	O	O
propofol	NN	i	IPM
and	CC	O	O
droperidol	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
metoclopramide	JJ	i	IPM
0.2	CD	O	O
mg/kg	NN	O	O
and	CC	O	O
placebo	NN	i	IPM
.	.	O	O

Effect	NN	O	O
of	IN	O	O
different	JJ	O	O
rates	NNS	O	O
of	IN	O	O
infusion	NN	O	O
of	IN	O	O
propofol	NN	i	IPM
for	IN	O	O
induction	NN	O	O
of	IN	O	O
anaesthesia	NN	O	O
in	IN	O	O
elderly	JJ	p	PA
patients	NNS	p	PA
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
changing	VBG	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
infusion	NN	O	O
of	IN	O	O
propofol	NN	i	IPM
for	IN	O	O
induction	NN	O	O
of	IN	O	O
anaesthesia	NN	O	O
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
60	CD	p	PA
elderly	JJ	p	PA
patients	NNS	p	PA
.	.	O	O

Propofol	NNP	i	IPM
was	VBD	O	O
administered	VBN	O	O
at	IN	O	O
300	CD	O	O
,	,	O	O
600	CD	O	O
or	CC	O	O
1200	CD	O	O
ml	JJ	O	O
h-1	JJ	O	O
until	IN	O	O
loss	NN	o	OPH
of	IN	o	OPH
consciousness	NN	o	OPH
(	(	O	O
as	IN	O	O
judged	VBN	O	O
by	IN	O	O
loss	NN	o	OPH
of	IN	o	OPH
verbal	JJ	o	OPH
contact	NN	o	OPH
with	IN	o	OPH
the	DT	o	OPH
patient	NN	o	OPH
)	)	o	O
had	VBD	O	O
been	VBN	O	O
achieved	VBN	O	O
.	.	O	O

The	DT	O	O
duration	NN	o	OOt
of	IN	o	OOt
induction	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
longer	JJR	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
with	IN	O	O
the	DT	O	O
slower	JJR	O	O
infusion	NN	O	O
rates	NNS	O	O
(	(	O	O
104	CD	O	O
,	,	O	O
68	CD	O	O
and	CC	O	O
51	CD	O	O
s	NN	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
total	JJ	o	OOt
dose	NN	o	OOt
used	VBN	O	O
was	VBD	O	O
significantly	RB	O	O
less	JJR	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
(	(	O	O
1.2	CD	O	O
,	,	O	O
1.6	CD	O	O
and	CC	O	O
2.5	CD	O	O
mg	NN	O	O
kg-1	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
decrease	NN	O	O
in	IN	O	O
systolic	JJ	o	OPH
and	CC	o	OPH
diastolic	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
300-ml	JJ	O	O
h-1	JJ	O	O
group	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
induction	NN	O	O
and	CC	O	O
immediately	RB	O	O
after	IN	O	O
induction	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
apnoea	NN	o	OPH
was	VBD	O	O
also	RB	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
slower	JJR	O	O
infusion	NN	O	O
group	NN	O	O
.	.	O	O

Goal	NNP	o	OME
attainment	NN	o	OME
scaling	NN	o	OME
as	IN	O	O
an	DT	O	O
outcome	NN	O	O
measure	NN	O	O
in	IN	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trials	NNS	O	O
of	IN	O	O
psychosocial	JJ	i	IPS
interventions	NNS	i	IPS
in	IN	O	O
autism	NN	p	PC
.	.	O	O

Goal	NNP	o	OME
attainment	JJ	o	OME
scaling	NN	o	OME
(	(	o	OME
GAS	NNP	o	OME
)	)	o	OME
holds	VBZ	O	O
promise	NN	O	O
as	IN	O	O
an	DT	O	O
idiographic	JJ	O	O
approach	NN	O	O
for	IN	O	O
measuring	VBG	O	O
outcomes	NNS	O	O
of	IN	O	O
psychosocial	JJ	i	IE
interventions	NNS	i	IE
in	IN	O	O
community	NN	O	O
settings	NNS	O	O
.	.	O	O

GAS	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
criticized	VBN	O	O
for	IN	O	O
untested	JJ	O	O
assumptions	NNS	O	O
of	IN	O	O
scaling	VBG	O	O
level	NN	O	O
(	(	O	O
i.e.	JJ	O	O
,	,	O	O
interval	JJ	O	O
or	CC	O	O
ordinal	JJ	O	O
)	)	O	O
,	,	O	O
inter-individual	JJ	O	O
equivalence	NN	O	O
and	CC	O	O
comparability	NN	O	O
,	,	O	O
and	CC	O	O
reliability	NN	O	O
of	IN	O	O
coding	VBG	O	O
across	IN	O	O
different	JJ	O	O
behavioral	JJ	O	O
observation	NN	O	O
methods	NNS	O	O
.	.	O	O

We	PRP	O	O
tested	VBD	O	O
assumptions	NNS	O	O
of	IN	O	O
equality	NN	O	O
between	IN	O	O
GAS	NNP	O	O
descriptions	NNS	O	O
for	IN	O	O
outcome	JJ	O	O
measurement	NN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
measurability	NN	O	O
,	,	O	O
equidistance	NN	O	O
,	,	O	O
level	NN	O	O
of	IN	O	O
difficulty	NN	O	O
,	,	O	O
comparability	NN	O	O
of	IN	O	O
behavior	NN	O	O
samples	NNS	O	O
collected	VBN	O	O
from	IN	O	O
teachers	NNS	O	O
vs.	FW	O	O
researchers	NNS	O	O
and	CC	O	O
live	JJ	O	O
vs.	FW	O	O
videotape	NN	O	O
)	)	O	O
.	.	O	O

Results	NNP	O	O
suggest	VBP	O	O
GAS	NNP	O	O
descriptions	NNS	O	O
can	MD	O	O
be	VB	O	O
evaluated	VBN	O	O
for	IN	O	O
equivalency	NN	O	O
,	,	O	O
that	IN	O	O
teacher	RB	O	O
collected	VBN	O	O
behavior	NN	O	O
samples	NNS	O	O
are	VBP	O	O
representative	JJ	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
varied	JJ	O	O
sources	NNS	O	O
of	IN	O	O
behavior	NN	O	O
samples	NNS	O	O
can	MD	O	O
be	VB	O	O
reliably	RB	O	O
coded	VBN	O	O
.	.	O	O

GAS	NNP	O	O
is	VBZ	O	O
a	DT	O	O
promising	JJ	O	O
measurement	NN	O	O
approach	NN	O	O
.	.	O	O

Recommendations	NNS	O	O
are	VBP	O	O
provided	VBN	O	O
to	TO	O	O
ensure	VB	O	O
methodological	JJ	O	O
quality	NN	O	O
.	.	O	O

Spotty	JJ	O	O
calcification	NN	O	O
as	IN	O	O
a	DT	O	O
marker	NN	O	O
of	IN	O	O
accelerated	JJ	O	O
progression	NN	o	OPH
of	IN	o	OPH
coronary	JJ	o	OPH
atherosclerosis	NN	o	OPH
:	:	O	O
insights	NNS	O	O
from	IN	O	O
serial	JJ	O	O
intravascular	JJ	O	O
ultrasound	NN	O	O
.	.	O	O

OBJECTIVES	CC	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
atheroma	JJ	o	OPH
progression	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
spotty	JJ	p	O
calcification	NN	p	O
.	.	O	O

BACKGROUND	NNP	O	O
Although	IN	O	O
extensively	RB	O	O
calcified	VBN	O	O
atherosclerotic	JJ	O	O
lesions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
proposed	VBN	O	O
to	TO	O	O
be	VB	O	O
clinically	RB	O	O
quiescent	JJ	O	O
,	,	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
spotty	JJ	O	O
calcification	NN	O	O
within	IN	O	O
plaque	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increased	JJ	O	O
incidence	NN	O	O
of	IN	O	O
ischemic	JJ	O	O
cardiovascular	JJ	O	O
events	NNS	O	O
.	.	O	O

The	DT	O	O
relationship	NN	O	O
between	IN	O	O
spotty	JJ	O	O
calcification	NN	O	O
and	CC	O	O
disease	NN	o	OPH
progression	NN	o	OPH
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
total	NN	p	O
of	IN	p	O
1,347	CD	p	PSS
stable	JJ	p	O
patients	NNS	p	O
with	IN	p	O
angiographic	JJ	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
underwent	JJ	O	O
serial	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
atheroma	JJ	o	OPH
burden	NN	o	OPH
with	IN	O	O
intravascular	JJ	O	O
ultrasound	NN	O	O
imaging	NN	O	O
.	.	O	O

Patients	NNS	p	O
with	IN	p	O
spotty	JJ	p	O
calcification	NN	p	O
were	VBD	p	O
identified	VBN	p	O
based	VBN	p	O
on	IN	p	O
the	DT	p	O
presence	NN	p	O
of	IN	p	O
lesions	NNS	p	O
(	(	p	O
1	CD	p	O
to	TO	p	O
4	CD	p	O
mm	NNS	p	O
in	IN	p	O
length	NN	p	O
)	)	p	O
containing	VBG	p	O
an	DT	p	O
arc	NN	p	O
of	IN	p	O
calcification	NN	p	O
of	IN	p	O
<	$	p	O
90?	CD	p	O
.	.	O	O

Clinical	JJ	O	O
characteristics	NNS	o	O
and	CC	o	O
disease	NN	o	O
progression	NN	o	O
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
patients	NNS	O	O
with	IN	O	O
spotty	JJ	O	O
calcification	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
922	CD	O	O
)	)	O	O
and	CC	O	O
those	DT	O	O
with	IN	O	O
no	DT	O	O
calcification	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
425	CD	O	O
)	)	O	O
.	.	O	O

RESULTS	JJ	O	O
Patients	NNS	p	O
with	IN	p	O
spotty	JJ	p	O
calcification	NN	p	O
were	VBD	p	O
older	JJR	p	O
(	(	p	O
age	NN	p	O
56	CD	p	O
years	NNS	p	O
vs.	IN	p	O
54	CD	O	O
years	NNS	p	O
;	:	p	O
p	VBZ	p	O
=	$	p	O
0.001	CD	p	O
)	)	p	O
,	,	p	O
more	RBR	p	O
likely	JJ	p	O
to	TO	p	O
be	VB	p	O
male	JJ	p	O
(	(	p	O
68	CD	p	O
%	NN	p	O
vs.	FW	p	O
54	CD	O	O
%	NN	p	O
;	:	p	O
p	CC	O	O
=	VB	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
have	VBP	O	O
a	DT	O	O
history	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
mellitus	NNS	O	O
(	(	O	O
30	CD	O	O
%	NN	O	O
vs.	FW	O	O
24	CD	O	O
%	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
myocardial	JJ	O	O
infarction	NN	O	O
(	(	O	O
28	CD	O	O
%	NN	O	O
vs.	FW	O	O
20	CD	O	O
%	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.004	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
have	VBP	O	O
lower	JJR	O	O
on-treatment	JJ	O	O
high-density	NN	o	O
lipoprotein	NN	o	O
cholesterol	NN	o	O
levels	NNS	o	O
(	(	O	O
48	CD	O	O
?	.	O	O
16	CD	O	O
mg/dl	NN	O	O
vs.	FW	O	O
51	CD	O	O
?	.	O	O
17	CD	O	O
mg/dl	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
spotty	JJ	O	O
calcification	NN	O	O
demonstrated	VBD	O	O
a	DT	O	O
greater	JJR	O	O
percent	JJ	o	O
atheroma	NN	o	O
volume	NN	o	O
(	(	o	O
PAV	NNP	o	O
)	)	o	O
(	(	O	O
36.0	CD	O	O
?	.	O	O
7.6	CD	O	O
%	NN	O	O
vs.	FW	O	O
29.0	CD	O	O
?	.	O	O
8.5	CD	O	O
%	NN	O	O
;	:	O	O
p	CC	O	O
<	VB	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
total	JJ	o	O
atheroma	NN	o	O
volume	NN	o	O
(	(	O	O
174.6	CD	O	O
?	.	O	O
71.9	CD	O	O
mm	NN	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
vs.	FW	O	O
133.9	CD	O	O
?	.	O	O
64.9	CD	O	O
mm	NN	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
;	:	O	O
p	CC	O	O
<	VB	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

On	IN	O	O
serial	JJ	O	O
evaluation	NN	O	O
,	,	O	O
spotty	JJ	O	O
calcification	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
greater	JJR	O	O
progression	NN	o	O
of	IN	o	O
PAV	NNP	o	O
(	(	O	O
+0.43	NNP	O	O
?	.	O	O
0.07	CD	O	O
%	NN	O	O
vs.	FW	O	O
+0.02	NNP	O	O
?	.	O	O
0.11	CD	O	O
%	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.002	CD	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
intensive	JJ	O	O
low-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
and	CC	O	O
blood	NN	O	O
pressure	NN	O	O
lowering	VBG	O	O
therapy	NN	O	O
slowed	VBD	O	O
disease	JJ	O	O
progression	NN	O	O
,	,	O	O
these	DT	O	O
efficacies	NNS	O	O
were	VBD	O	O
attenuated	VBN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
spotty	JJ	p	O
calcification	NN	p	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
presence	NN	O	O
of	IN	O	O
spotty	JJ	O	O
calcification	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
more	RBR	O	O
extensive	JJ	O	O
and	CC	O	O
diffuse	NN	O	O
coronary	JJ	o	O
atherosclerosis	NN	o	O
and	CC	O	O
accelerated	JJ	O	O
disease	NN	O	O
progression	NN	O	O
despite	IN	O	O
use	NN	O	O
of	IN	O	O
medical	JJ	O	O
therapies	NNS	O	O
.	.	O	O

Review	NN	O	O
of	IN	O	O
the	DT	O	O
Multicenter	NNP	O	O
Trial	NNP	O	O
Committee	NNP	O	O
report	NN	O	O
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
study	NN	O	O
on	IN	O	O
the	DT	O	O
prophylaxis	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
deep	JJ	O	O
venous	JJ	O	O
thrombosis	NN	O	O
.	.	O	O

The	DT	O	O
etiology	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
deep	JJ	O	O
venous	JJ	O	O
thrombosis	NN	O	O
(	(	O	O
DVT	NNP	O	O
)	)	O	O
is	VBZ	O	O
thought	VBN	O	O
to	TO	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
factors	NNS	O	O
including	VBG	O	O
stasis	NN	O	O
,	,	O	O
a	DT	O	O
hypercoagulable	JJ	O	O
state	NN	O	O
and	CC	O	O
venous	JJ	O	O
endothelial	JJ	O	O
damage	NN	O	O
.	.	O	O

Methods	NNS	O	O
of	IN	O	O
prophylaxis	NN	O	O
are	VBP	O	O
directed	VBN	O	O
toward	IN	O	O
correcting	VBG	O	O
one	CD	O	O
or	CC	O	O
more	JJR	O	O
of	IN	O	O
these	DT	O	O
pathologic	JJ	O	O
events	NNS	O	O
.	.	O	O

Methods	NNS	O	O
counteracting	VBG	O	O
more	JJR	O	O
than	IN	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
factors	NNS	O	O
can	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
be	VB	O	O
even	RB	O	O
more	RBR	O	O
effective	JJ	O	O
.	.	O	O

The	DT	O	O
combination	NN	O	O
of	IN	O	O
dihydroergotamine	NN	i	IPM
(	(	i	IPM
DHE	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
heparin	NN	i	IPM
was	VBD	O	O
anticipated	VBN	O	O
to	TO	O	O
minimize	VB	O	O
stasis	NN	O	O
and	CC	O	O
the	DT	O	O
hypercoagulable	JJ	O	O
state	NN	O	O
respectively	RB	O	O
.	.	O	O

Based	VBN	O	O
upon	IN	O	O
current	JJ	O	O
experimental	JJ	O	O
evidence	NN	O	O
and	CC	O	O
current	JJ	O	O
theory	NN	O	O
,	,	O	O
an	DT	O	O
additional	JJ	O	O
benefit	NN	O	O
might	MD	O	O
include	VB	O	O
minimizing	VBG	O	O
venous	JJ	O	O
endothelial	JJ	O	O
injury	NN	O	O
by	IN	O	O
controlling	VBG	O	O
venomotor	NN	O	O
tone	NN	O	O
.	.	O	O

A	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
multicenter	JJ	O	O
trial	NN	O	O
was	VBD	O	O
designed	VBN	O	O
and	CC	O	O
performed	VBN	O	O
in	IN	O	O
the	DT	O	O
United	NNP	p	O
States	NNPS	p	O
evaluating	VBG	O	O
the	DT	O	O
prophylactic	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
DHE	NNP	i	IPM
0.5	CD	O	O
mg	NN	O	O
plus	CC	O	O
heparin	JJ	i	IPM
5000	CD	O	O
U	NNP	O	O
,	,	O	O
DHE	NNP	i	IPM
0.5	CD	O	O
mg	NN	O	O
plus	CC	O	O
heparin	JJ	i	IPM
2500	CD	O	O
U	NNP	O	O
,	,	O	O
heparin	NN	i	IPM
5000	CD	O	O
U	NNP	O	O
,	,	O	O
and	CC	O	O
DHE	NNP	i	IPM
0.5	CD	O	O
mg	NN	O	O
versus	NN	O	O
placebo	NN	i	IC
.	.	O	O

General	NNP	p	O
surgical	JJ	p	O
patients	NNS	p	O
including	VBG	p	O
those	DT	p	O
undergoing	JJ	p	O
noncardiac	JJ	p	O
thoracic	NN	p	O
and	CC	p	O
pelvic	JJ	p	O
operations	NNS	p	O
who	WP	p	O
were	VBD	p	O
identified	VBN	p	O
at	IN	p	O
moderate	JJ	p	O
to	TO	p	O
high	JJ	p	O
risk	NN	p	O
for	IN	p	O
postop	JJ	p	O
DVT	NNP	p	O
were	VBD	p	O
included	VBN	p	O
.	.	O	O

Study	NNP	O	O
medications	NNS	O	O
were	VBD	O	O
injected	VBN	O	O
subcutaneously	RB	O	O
two	CD	O	O
hours	NNS	O	O
preoperatively	RB	O	O
and	CC	O	O
every	DT	O	O
12	CD	O	O
hours	NNS	O	O
postoperatively	RB	O	O
for	IN	O	O
5-7	JJ	O	O
days	NNS	O	O
or	CC	O	O
until	IN	O	O
the	DT	O	O
125I-fibrinogen-uptake	JJ	O	O
test	NN	O	O
(	(	O	O
RFUT	NNP	O	O
)	)	O	O
became	VBD	O	O
positive	JJ	O	O
.	.	O	O

Eight	NNP	p	O
hundred	VBD	p	O
and	CC	p	O
eighty	JJ	p	O
eight	CD	p	O
patients	NNS	p	O
were	VBD	p	O
entered	VBN	p	O
into	IN	p	O
this	DT	p	O
trial	NN	p	O
and	CC	p	O
744	CD	p	O
(	(	p	O
85	CD	p	O
%	NN	p	O
)	)	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Results	NNP	O	O
showed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
benefit	NN	O	O
from	IN	O	O
DHE/Hep	NNP	i	IPM
5000	CD	O	O
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
compared	VBN	O	O
to	TO	O	O
other	JJ	O	O
active	JJ	O	O
agents	NNS	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

None	NN	O	O
of	IN	O	O
the	DT	O	O
other	JJ	O	O
active	JJ	O	O
agents	NNS	O	O
showed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
prophylactic	JJ	O	O
benefit	NN	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Time-varying	JJ	O	O
smoking	NN	O	O
abstinence	NN	O	O
predicts	VBZ	O	O
lower	JJR	O	O
depressive	JJ	o	OME
symptoms	NNS	o	OME
following	VBG	O	O
smoking	VBG	O	O
cessation	NN	O	O
treatment	NN	O	O
.	.	O	O

INTRODUCTION	NNP	O	O
The	DT	O	O
question	NN	O	O
of	IN	O	O
whether	IN	O	O
abstinence	NN	O	O
during	IN	O	O
the	DT	O	O
months	NNS	O	O
following	VBG	O	O
a	DT	O	O
planned	VBN	O	O
quit	NN	O	O
attempt	NN	O	O
exacerbates	VBZ	O	O
or	CC	O	O
improves	VBZ	O	O
depressive	JJ	o	OME
symptoms	NNS	o	OME
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
clinical	JJ	O	O
issue	NN	O	O
.	.	O	O

Extant	NNP	O	O
research	NN	O	O
has	VBZ	O	O
primarily	RB	O	O
modeled	VBN	O	O
between-person	JJ	O	O
covariation	NN	O	O
between	IN	O	O
postquit	NN	O	O
abstinence	NN	O	O
and	CC	O	O
depressive	JJ	O	O
symptom	NN	O	O
trajectories	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
this	DT	O	O
approach	NN	O	O
can	MD	O	O
not	RB	O	O
account	VB	O	O
for	IN	O	O
potential	JJ	O	O
third	JJ	O	O
variables	NNS	O	O
between	IN	O	O
participants	NNS	O	O
that	WDT	O	O
may	MD	O	O
affect	VB	O	O
both	DT	O	O
smoking	NN	O	O
and	CC	O	O
depression	NN	O	O
.	.	O	O

Accordingly	RB	O	O
,	,	O	O
the	DT	O	O
current	JJ	O	O
study	NN	O	O
examined	VBD	O	O
within-person	JJ	O	O
covariation	NN	O	O
between	IN	O	O
time-varying	JJ	O	O
abstinence	NN	O	O
and	CC	O	O
depressive	JJ	o	OME
symptom	NN	o	OME
in	IN	O	O
a	DT	O	O
multilevel	NN	O	O
model	NN	O	O
(	(	O	O
MLM	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
allowed	VBD	O	O
for	IN	O	O
transitions	NNS	O	O
between	IN	O	O
smoking	VBG	O	O
statuses	NNS	O	O
within	IN	O	O
a	DT	O	O
participant	NN	O	O
.	.	O	O

METHODS	JJ	O	O
Participants	NNS	p	O
were	VBD	p	O
236	CD	p	O
heavy	JJ	p	PC
drinking	NN	p	PC
smokers	NNS	p	PC
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
testing	VBG	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
incorporating	VBG	O	O
brief	JJ	O	O
alcohol	NN	i	IE
intervention	NN	i	IE
into	IN	O	O
smoking	VBG	O	O
cessation	NN	O	O
treatment	NN	O	O
.	.	O	O

Depressive	NNP	o	OME
symptoms	NNS	o	OME
and	CC	O	O
biochemically	RB	o	OPH
verified	JJ	o	OPH
abstinence	NN	o	OPH
were	VBD	O	O
assessed	VBN	O	O
1	CD	O	O
week	NN	O	O
prior	RB	O	O
to	TO	O	O
and	CC	O	O
2	CD	O	O
,	,	O	O
8	CD	O	O
,	,	O	O
16	CD	O	O
,	,	O	O
and	CC	O	O
26	CD	O	O
weeks	NNS	O	O
after	IN	O	O
quit	NN	O	O
date	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
MLMs	NNP	O	O
indicated	VBD	O	O
a	DT	O	O
slight	JJ	O	O
increase	NN	O	O
in	IN	O	O
depressive	JJ	o	OME
symptoms	NNS	o	OME
over	IN	O	O
time	NN	O	O
in	IN	O	O
the	DT	O	O
sample	NN	O	O
as	IN	O	O
a	DT	O	O
whole	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
an	DT	O	O
inverse	JJ	O	O
relation	NN	O	O
between	IN	O	O
time-varying	JJ	O	O
abstinence	NN	O	O
(	(	O	O
vs.	IN	O	O
smoking	NN	O	O
)	)	O	O
and	CC	O	O
concurrent	JJ	O	O
level	NN	o	OME
of	IN	o	OME
depressive	JJ	o	OME
symptoms	NNS	o	OME
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
transitions	NNS	O	O
from	IN	O	O
smoking	VBG	O	O
to	TO	O	O
abstinence	VB	O	O
within	IN	O	O
individuals	NNS	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
reductions	NNS	O	O
in	IN	O	O
depressive	JJ	o	OME
symptoms	NNS	o	OME
.	.	O	O

CONCLUSIONS	NNP	O	O
During	IN	O	O
the	DT	O	O
first	JJ	O	O
6	CD	O	O
months	NNS	O	O
following	VBG	O	O
a	DT	O	O
planned	VBN	O	O
quit	NN	O	O
attempt	NN	O	O
,	,	O	O
being	VBG	O	O
abstinent	NN	O	O
in	IN	O	O
a	DT	O	O
particular	JJ	O	O
week	NN	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
lower	JJR	O	O
levels	NNS	O	O
of	IN	O	O
concurrent	NN	O	O
depressive	NN	o	OME
symptoms	NNS	o	OME
.	.	O	O

These	DT	O	O
results	NNS	O	O
are	VBP	O	O
not	RB	O	O
concordant	JJ	O	O
with	IN	O	O
the	DT	O	O
view	NN	O	O
that	IN	O	O
intentional	JJ	O	O
smoking	NN	O	O
abstinence	NN	O	O
exacerbates	VBZ	O	O
depressive	JJ	o	OME
symptoms	NNS	o	OME
.	.	O	O

Efforts	NNS	O	O
to	TO	O	O
promote	VB	O	O
smoking	VBG	O	O
cessation	NN	O	O
should	MD	O	O
highlight	VB	O	O
that	IN	O	O
individuals	NNS	O	O
are	VBP	O	O
likely	JJ	O	O
to	TO	O	O
feel	VB	O	O
more	RBR	O	O
rather	RB	O	O
than	IN	O	O
less	JJR	O	O
psychologically	RB	O	O
healthy	JJ	O	O
when	WRB	O	O
they	PRP	O	O
successfully	RB	O	O
quit	VBP	O	O
smoking	NN	O	O
.	.	O	O

Analysis	NN	O	O
of	IN	O	O
prevention	NN	O	O
program	NN	O	O
effectiveness	NN	O	O
with	IN	O	O
clustered	VBN	O	O
data	NNS	O	O
using	VBG	O	O
generalized	JJ	O	O
estimating	NN	O	O
equations	NNS	O	O
.	.	O	O

Experimental	JJ	O	O
studies	NNS	O	O
of	IN	O	O
prevention	NN	O	O
programs	NNS	O	O
often	RB	O	O
randomize	VBP	O	O
clusters	NNS	O	O
of	IN	O	O
individuals	NNS	O	O
rather	RB	O	O
than	IN	O	O
individuals	NNS	O	O
to	TO	O	O
treatment	NN	O	O
conditions	NNS	O	O
.	.	O	O

When	WRB	O	O
the	DT	O	O
correlation	NN	O	O
among	IN	O	O
individuals	NNS	O	O
within	IN	O	O
clusters	NNS	O	O
is	VBZ	O	O
not	RB	O	O
accounted	VBN	O	O
for	IN	O	O
in	IN	O	O
statistical	JJ	O	O
analysis	NN	O	O
,	,	O	O
the	DT	O	O
standard	JJ	O	O
errors	NNS	O	O
are	VBP	O	O
biased	VBN	O	O
,	,	O	O
potentially	RB	O	O
resulting	VBG	O	O
in	IN	O	O
misleading	VBG	O	O
conclusions	NNS	O	O
about	IN	O	O
the	DT	O	O
significance	NN	O	O
of	IN	O	O
treatment	NN	O	O
effects	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
demonstrates	VBZ	O	O
the	DT	O	O
generalized	JJ	i	IOt
estimating	NN	i	IOt
equations	NNS	i	IOt
(	(	i	IOt
GEE	NNP	i	IOt
)	)	i	IOt
method	NN	O	O
,	,	O	O
focusing	VBG	O	O
specifically	RB	O	O
on	IN	O	O
the	DT	O	O
GEE-independent	NNP	i	IPH
method	NN	O	O
,	,	O	O
to	TO	O	O
control	VB	O	O
for	IN	O	O
within-cluster	JJ	O	O
correlation	NN	O	O
in	IN	O	O
regression	NN	O	O
models	NNS	O	O
with	IN	O	O
either	DT	O	O
continuous	JJ	O	O
or	CC	O	O
binary	JJ	O	O
outcomes	NNS	O	O
.	.	O	O

The	DT	O	O
GEE-independent	JJ	i	IPH
method	NN	O	O
yields	NNS	O	O
consistent	JJ	O	O
and	CC	O	O
robust	JJ	O	O
variance	NN	O	O
estimates	NNS	O	O
.	.	O	O

Data	NNS	O	O
from	IN	O	O
project	NN	O	O
DARE	NNP	O	O
,	,	O	O
a	DT	O	O
youth	NN	p	O
substance	NN	O	O
abuse	NN	O	O
prevention	NN	O	O
program	NN	O	O
,	,	O	O
are	VBP	O	O
used	VBN	O	O
for	IN	O	O
illustration	NN	O	O
.	.	O	O

The	DT	O	O
safety	NN	O	O
of	IN	O	O
whey	JJ	i	IPM
protein	NN	i	IPM
concentrate	NN	i	IPM
derived	VBN	O	O
from	IN	O	O
the	DT	O	O
milk	NN	O	O
of	IN	O	O
cows	NNS	O	O
immunized	VBN	O	O
against	IN	O	O
Clostridium	NNP	O	O
difficile	NN	O	O
.	.	O	O

A	DT	O	O
whey	JJ	i	IPM
protein	NN	i	IPM
concentrate	NN	i	IPM
prepared	VBN	O	O
from	IN	O	O
the	DT	O	O
milk	NN	O	O
of	IN	O	O
cows	NNS	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
immunized	VBN	i	IPM
against	IN	i	IPM
Clostridium	NNP	i	IPM
difficile	NN	i	IPM
(	(	i	O
C.	NNP	i	O
difficile	NN	i	IPM
)	)	i	IPM
and	CC	i	IPM
its	PRP$	i	IPM
toxins	NNS	i	IPM
,	,	i	IPM
toxin	NN	i	IPM
A	NNP	i	IPM
and	CC	i	IPM
toxin	NN	i	IPM
B	NNP	i	IPM
,	,	O	O
is	VBZ	O	O
produced	VBN	O	O
for	IN	O	O
use	NN	O	O
as	IN	O	O
a	DT	O	O
medical	JJ	O	O
food	NN	O	O
for	IN	O	O
the	DT	O	O
dietary	JJ	O	O
management	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
C.	NNP	p	O
difficile-associated	JJ	p	O
diarrhea	NN	p	O
(	(	p	O
CDAD	NNP	p	O
)	)	p	O
to	TO	O	O
prevent	VB	O	O
a	DT	O	O
relapse	NN	O	O
of	IN	O	O
the	DT	O	O
infection	NN	O	O
.	.	O	O

The	DT	O	O
safety	NN	O	O
of	IN	O	O
anti-C.	JJ	i	O
difficile	NN	i	IPM
whey	NN	i	IPM
protein	VBP	i	IPM
concentrate	NN	i	IPM
(	(	i	IPM
anti-CD	JJ	i	IPM
WPC	NNP	i	IPM
)	)	i	IPM
is	VBZ	O	O
supported	VBN	O	O
by	IN	O	O
analytical	JJ	O	O
data	NNS	O	O
comparing	VBG	O	O
the	DT	O	O
composition	NN	O	O
of	IN	O	O
raw	JJ	O	O
milk	NN	O	O
from	IN	O	O
immunized	JJ	O	O
cows	NNS	O	O
versus	VBP	O	O
that	IN	O	O
from	IN	O	O
non-immunized	JJ	O	O
cows	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
composition	NN	O	O
of	IN	O	O
anti-CD	JJ	i	IPM
WPC	NNP	i	IPM
versus	NN	O	O
that	IN	O	O
of	IN	O	O
regular	JJ	i	IPM
whey	NN	i	IPM
protein	NN	i	IPM
concentrate	NN	i	IPM
.	.	O	O

Additionally	RB	O	O
,	,	O	O
a	DT	O	O
prospective	JJ	O	O
clinical	JJ	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
77	CD	p	O
patients	NNS	p	O
with	IN	p	O
CDAD	NNP	p	O
to	TO	O	O
demonstrate	VB	O	O
the	DT	O	O
safety	NN	O	O
of	IN	O	O
consuming	VBG	O	O
anti-CD	JJ	i	IPM
WPC	NNP	i	IPM
to	TO	O	O
prevent	VB	O	O
relapse	NN	O	O
of	IN	O	O
the	DT	O	O
infection	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
,	,	O	O
which	WDT	O	O
included	VBD	O	O
adverse	JJ	O	O
event	NN	O	O
monitoring	NN	O	O
,	,	O	O
physical	JJ	O	O
examinations	NNS	O	O
,	,	O	O
and	CC	O	O
extensive	JJ	O	O
hematological	NN	O	O
and	CC	O	O
biochemical	JJ	O	O
assessments	NNS	O	O
,	,	O	O
showed	VBD	O	O
that	IN	O	O
anti-CD	JJ	i	IPM
WPC	NNP	i	IPM
is	VBZ	O	O
safe	JJ	o	OOt
to	TO	O	O
consume	VB	O	O
by	IN	O	O
patients	NNS	p	O
with	IN	p	O
CDAD	NNP	p	O
.	.	O	O

The	DT	O	O
available	JJ	O	O
analytical	JJ	O	O
and	CC	O	O
clinical	JJ	O	O
evidence	NN	O	O
demonstrate	NN	O	O
that	IN	O	O
anti-CD	JJ	i	IPM
WPC	NNP	i	IPM
is	VBZ	O	O
safe	JJ	o	OOt
for	IN	O	O
use	NN	O	O
by	IN	O	O
individuals	NNS	p	O
with	IN	p	O
CDAD	NNP	p	O
,	,	O	O
under	IN	O	O
the	DT	O	O
described	JJ	O	O
conditions	NNS	O	O
of	IN	O	O
use	NN	O	O
.	.	O	O

EORTC	NNP	O	O
protocols	NNS	O	O
in	IN	O	O
prostatic	JJ	p	O
cancer	NN	p	O
.	.	O	O

An	DT	O	O
interim	JJ	O	O
report	NN	O	O
.	.	O	O

Two	CD	O	O
parallel	JJ	O	O
prospective	JJ	O	O
randomized	VBN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
undertaken	VBN	O	O
by	IN	O	O
the	DT	O	O
EORTC	NNP	O	O
Urological	NNP	O	O
Group	NNP	O	O
in	IN	O	O
previously	RB	p	PC
untreated	JJ	p	PC
patients	NNS	p	PSS
with	IN	p	PSS
prostatic	JJ	p	PSS
cancer	NN	p	PSS
in	IN	O	O
order	NN	O	O
to	TO	O	O
compare	VB	O	O
low	JJ	O	O
dose	JJ	O	O
Stilboestrol	NNP	i	IPM
versus	NN	O	O
Cyproterone	NNP	i	IPM
acetate	NN	i	IPM
versus	NN	O	O
Medroxyprogesterone	NNP	i	IPM
acetate	NN	i	IPM
in	IN	O	O
the	DT	O	O
first	JJ	O	O
trial	NN	O	O
,	,	O	O
and	CC	O	O
Stilboestrol	NNP	i	IPM
versus	VBP	O	O
Estracyt	NNP	i	IPM
in	IN	O	O
the	DT	O	O
second	JJ	O	O
trial	NN	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
follow	JJ	O	O
up	NN	O	O
is	VBZ	O	O
still	RB	O	O
short	JJ	O	O
,	,	O	O
no	DT	O	O
superiority	NN	O	O
of	IN	O	O
the	DT	O	O
other	JJ	O	O
drugs	NNS	O	O
over	IN	O	O
Stilboestrol	NNP	i	IPM
had	VBD	O	O
appeared	VBN	O	O
so	RB	O	O
far	RB	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
either	DT	O	O
objective	JJ	O	O
response	NN	O	O
or	CC	O	O
significant	JJ	O	O
side	NN	o	OA
effects	NNS	o	OA
apart	RB	O	O
from	IN	O	O
gynaecomastia	NN	o	OPH
.	.	O	O

In	IN	O	O
the	DT	O	O
third	JJ	O	O
trial	NN	O	O
,	,	O	O
patients	NNS	p	PSS
with	IN	p	PSS
advanced	JJ	p	PC
disease	NN	p	PC
no	RB	p	PC
longer	RBR	p	PC
responsive	VB	p	PC
to	TO	p	PC
hormonal	JJ	p	PC
treatment	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
either	DT	O	O
Adriamycin	NNP	i	IPM
or	CC	O	O
Procarbazine	NNP	i	IPM
.	.	O	O

Toxicity	NN	o	OA
and	CC	o	O
early	JJ	o	OMO
death	NN	o	OMO
were	VBD	O	O
particularly	RB	O	O
frequent	JJ	O	O
in	IN	O	O
Procarbazine	NNP	i	IPM
treated	VBD	O	O
patients	NNS	O	O
,	,	O	O
whereas	NNS	O	O
most	JJS	O	O
patients	NNS	O	O
progressed	VBN	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

Clinical	JJ	o	OOt
performance	NN	o	OOt
of	IN	O	O
the	DT	O	O
Reichert	NNP	i	IPM
AT550	NNP	i	IPM
:	:	O	O
a	DT	O	O
new	JJ	O	O
non-contact	JJ	O	O
tonometer	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
level	NN	o	OOt
of	IN	o	OOt
accuracy	NN	o	OOt
for	IN	O	O
measurements	NNS	o	OOt
of	IN	O	O
intra-ocular	JJ	O	O
pressure	NN	O	O
(	(	O	O
IOP	NNP	O	O
)	)	O	O
obtained	VBD	O	O
with	IN	O	O
a	DT	O	O
new	JJ	O	O
non-contact	JJ	O	O
tonometer	NN	O	O
(	(	O	O
NCT	NNP	O	O
)	)	O	O
the	DT	O	O
Reichert	NNP	i	IPM
AT550	NNP	i	IPM
.	.	O	O

Measurements	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
against	IN	O	O
those	DT	O	O
obtained	VBN	O	O
with	IN	O	O
the	DT	O	O
Reichert	NNP	i	IPH
Xpert	NNP	i	IPH
Plus	NNP	i	IPH
,	,	O	O
Goldmann	NNP	i	IOt
applanation	NN	i	IOt
tonometer	NN	i	IOt
and	CC	O	O
Perkins	NNP	i	IOt
tonometer	NN	i	IOt
.	.	O	O

Thirty-five	JJ	p	O
university	NN	p	O
students	NNS	p	O
were	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
the	DT	O	O
four	CD	O	O
tonometers	NNS	O	O
in	IN	O	O
a	DT	O	O
randomised	JJ	O	O
order	NN	O	O
,	,	O	O
with	IN	O	O
non-contact	JJ	O	O
tonometry	NN	O	O
performed	VBD	O	O
first	RB	O	O
.	.	O	O

Each	DT	O	O
of	IN	O	O
the	DT	O	O
four	CD	O	O
measurement	NN	O	O
devices	NNS	O	O
had	VBD	O	O
its	PRP$	O	O
own	JJ	O	O
trained	JJ	O	O
clinical	JJ	O	O
observer	NN	O	O
.	.	O	O

Plots	NNP	O	O
of	IN	O	O
differences	NNS	O	O
of	IN	O	O
IOP	NNP	O	O
as	IN	O	O
a	DT	O	O
function	NN	O	O
of	IN	O	O
the	DT	O	O
mean	NN	O	O
for	IN	O	O
each	DT	O	O
pair	NN	O	O
of	IN	O	O
instruments	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
.	.	O	O

No	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
when	WRB	O	O
comparing	VBG	O	O
the	DT	O	O
AT550	NNP	i	IPH
NCT	NNP	i	IPH
with	IN	O	O
contact	JJ	O	O
applanation	NN	O	O
tonometry	NN	O	O
(	(	O	O
AT	NNP	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
displaying	VBG	O	O
the	DT	O	O
closest	JJS	O	O
level	NN	O	O
of	IN	O	O
agreement	NN	O	O
(	(	O	O
as	IN	O	O
represented	VBN	O	O
by	IN	O	O
the	DT	O	O
lowest	JJS	O	O
mean	JJ	O	O
difference	NN	O	O
and	CC	O	O
the	DT	O	O
narrowest	JJS	O	O
confidence	NN	O	O
interval	NN	O	O
)	)	O	O
with	IN	O	O
the	DT	O	O
Goldmann	NNP	i	IPM
tonometer	NN	i	IPM
(	(	O	O
limits	NNS	O	O
of	IN	O	O
agreement	NN	O	O
,	,	O	O
0.12+/-2.17	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
readings	NNS	O	O
of	IN	O	O
IOP	NNP	o	OOt
with	IN	O	O
the	DT	O	O
AT550	NNP	i	IPH
NCT	NNP	i	IPH
are	VBP	O	O
clinically	RB	O	O
comparable	JJ	O	O
with	IN	O	O
those	DT	O	O
obtained	VBN	O	O
with	IN	O	O
Goldmann	NNP	i	IPM
tonometry	NN	i	IPM
in	IN	O	O
a	DT	O	O
population	NN	O	O
with	IN	O	O
IOP	NNP	O	O
within	IN	O	O
the	DT	O	O
normal	JJ	O	O
range	NN	O	O
.	.	O	O

[	VB	O	O
The	DT	O	O
sympatho-adrenergic	JJ	O	O
stress	NN	O	O
reaction	NN	O	O
in	IN	O	O
ear	JJ	p	PC
surgery	NN	p	PC
using	VBG	O	O
various	JJ	O	O
anesthesia	JJ	O	O
technics	NNS	O	O
]	VBP	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
various	JJ	O	O
anaesthetic	JJ	O	O
procedures	NNS	O	O
on	IN	O	O
the	DT	O	O
endocrine	NN	O	O
stress	NN	O	O
responses	NNS	O	O
during	IN	O	O
ear	JJ	p	O
microsurgical	JJ	p	O
operations	NNS	p	O
.	.	O	O

Simple	JJ	p	O
mastoidectomies	NNS	p	O
,	,	p	O
radical	JJ	p	O
mastoidectomies	NNS	p	O
and	CC	p	O
tympano	NN	p	O
plastics	NNS	p	O
were	VBD	p	O
carried	VBN	p	O
out	IN	p	O
in	IN	p	O
49	CD	p	O
patients	NNS	p	O
under	IN	O	O
the	DT	O	O
following	VBG	O	O
randomised	VBD	O	O
anaesthetic	JJ	O	O
procedures	NNS	O	O
:	:	O	O
Group	NNP	O	O
1	CD	O	O
halothane	NN	i	IPM
anaesthesia	NN	O	O
and	CC	O	O
retroauricular	JJ	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
with	IN	O	O
lidocaine	NN	i	IPM
and	CC	O	O
ornipressin	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
,	,	O	O
Group	NNP	O	O
2	CD	O	O
fentanyl	NN	i	IPM
anaesthesia	NN	O	O
and	CC	O	O
retroauricular	JJ	O	O
anaesthesia	NN	O	O
with	IN	O	O
lidocaine	NN	i	IPM
and	CC	O	O
ornipressin	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
,	,	O	O
Group	NNP	O	O
3	CD	O	O
fentanyl	NN	i	IPM
anaesthesia	NN	O	O
and	CC	O	O
retroauricular	JJ	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
with	IN	O	O
lidocaine	NN	i	IPM
and	CC	O	O
epinephrine	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
Group	NNP	O	O
4	CD	O	O
retroauricular	JJ	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
with	IN	O	O
prilocaine	NN	i	IPM
and	CC	O	O
epinephrine	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
plasma	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
epinephrine	NN	o	OPH
,	,	o	OPH
norepinephrine	NN	o	OPH
,	,	o	OPH
glucose	NN	o	OPH
,	,	o	OPH
lactate	NN	o	OPH
and	CC	O	O
free	JJ	O	O
glycerol	NN	O	O
were	VBD	O	O
measured	VBN	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
mean	VB	O	O
arterial	JJ	O	O
pressure	NN	O	O
(	(	O	O
MAP	NNP	O	O
)	)	O	O
and	CC	O	O
heart	NN	O	O
rate	NN	O	O
(	(	O	O
HR	NNP	O	O
)	)	O	O
immediately	RB	O	O
before	IN	O	O
anaesthesia	NN	O	O
,	,	O	O
10	CD	O	O
minutes	NNS	O	O
after	IN	O	O
skin	JJ	O	O
incision	NN	O	O
,	,	O	O
10	CD	O	O
minutes	NNS	O	O
after	IN	O	O
having	VBG	O	O
started	VBD	O	O
bone	CD	O	O
drilling	NN	O	O
,	,	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
operation	NN	O	O
and	CC	O	O
3	CD	O	O
hours	NNS	O	O
after	IN	O	O
operation	NN	O	O
.	.	O	O

All	DT	O	O
data	NNS	O	O
were	VBD	O	O
subjected	VBN	O	O
to	TO	O	O
covariance	VB	O	O
analysis	NN	O	O
including	VBG	O	O
the	DT	O	O
age	NN	O	O
factor	NN	O	O
.	.	O	O

Plasma	NNP	o	OPH
catecholamine	JJ	o	OPH
concentrations	NNS	o	OPH
remained	VBD	O	O
within	IN	O	O
the	DT	O	O
normal	JJ	O	O
range	NN	O	O
during	IN	O	O
the	DT	O	O
investigation	NN	O	O
in	IN	O	O
patients	NNS	O	O
subjected	VBN	O	O
to	TO	O	O
general	JJ	O	O
anaesthesia	NN	O	O
(	(	O	O
Groups	NNP	O	O
1-3	CD	O	O
)	)	O	O
.	.	O	O

Plasma	NNP	o	OPH
catecholamines	NNS	o	OPH
(	(	o	OPH
epinephrine	NN	o	OPH
and	CC	o	OPH
norepinephrine	NN	o	OPH
)	)	o	OPH
increased	VBD	O	O
significantly	RB	O	O
in	IN	O	O
Group	NNP	O	O
4	CD	O	O
(	(	O	O
retroauricular	JJ	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
group	NN	O	O
variabilities	VBZ	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
MAP	NNP	o	OPH
and	CC	O	O
HR	NNP	o	OPH
.	.	O	O

The	DT	O	O
plasma	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
epinephrine	NN	o	OPH
and	CC	o	OPH
norepinephrine	JJ	o	OPH
demonstrate	NN	O	O
a	DT	O	O
direct	JJ	O	O
response	NN	O	O
to	TO	O	O
stress	NN	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
secondary	JJ	O	O
change	NN	O	O
in	IN	O	O
glucose	NN	o	OPH
,	,	o	OPH
lactate	NN	o	OPH
and	CC	o	OPH
free	JJ	o	OPH
glycerol	NN	o	OPH
.	.	O	O

The	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
of	IN	O	O
general	JJ	O	O
anaesthesia	NN	O	O
is	VBZ	O	O
documented	VBN	O	O
by	IN	O	O
normal	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
epinephrine	NN	O	O
and	CC	O	O
norepinephrine	NN	O	O
throughout	IN	O	O
the	DT	O	O
operation	NN	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Inhaled	VBN	O	O
fluticasone	NN	i	IPM
reduces	NNS	O	O
sputum	VBP	o	OPH
inflammatory	JJ	o	OPH
indices	NNS	o	OPH
in	IN	O	O
severe	JJ	p	PC
bronchiectasis	NN	p	PC
.	.	O	O

Although	IN	O	O
corticosteroid	JJ	O	O
therapy	NN	O	O
might	MD	O	O
be	VB	O	O
clinically	RB	O	O
beneficial	JJ	O	O
for	IN	O	O
bronchiectasis	NN	O	O
,	,	O	O
very	RB	O	O
little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
of	IN	O	O
its	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
inflammatory	NN	o	OPH
and	CC	o	OPH
infective	JJ	o	OPH
markers	NNS	o	OPH
in	IN	O	O
bronchiectasis	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
therefore	RB	O	O
performed	VBN	O	O
a	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
4-wk	JJ	O	O
administration	NN	O	O
of	IN	O	O
inhaled	JJ	O	O
fluticasone	NN	i	IPM
in	IN	O	O
bronchiectasis	NN	O	O
.	.	O	O

Twenty-four	CD	p	PSS
patients	NNS	p	PSS
(	(	p	O
12	CD	p	PSE
female	NN	p	PSE
;	:	p	O
mean	JJ	p	PA
age	NN	p	PA
51	CD	p	PA
yr	NN	p	PA
)	)	p	O
were	VBD	O	O
randomized	VBN	O	O
into	IN	O	O
receiving	VBG	O	O
either	CC	O	O
inhaled	JJ	O	O
fluticasone	NN	i	IPM
(	(	O	O
500	CD	O	O
microgram	NN	O	O
twice	RB	O	O
daily	RB	O	O
)	)	O	O
via	IN	O	O
the	DT	O	O
Accuhaler	NNP	O	O
device	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
12	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
.	.	O	O

At	IN	O	O
each	DT	O	O
visit	NN	O	O
,	,	O	O
spirometry	NN	o	O
,	,	o	O
24-h	JJ	o	O
sputum	NN	o	O
volume	NN	o	O
,	,	o	O
sputum	NN	o	O
leukocyte	NN	o	O
density	NN	o	O
,	,	o	O
bacterial	JJ	o	O
densities	NNS	o	O
,	,	O	O
and	CC	O	O
concentrations	NNS	o	OPH
of	IN	o	OPH
interleukin	NN	o	OPH
(	(	o	OPH
IL	NNP	o	OPH
)	)	o	OPH
-1beta	NN	o	OPH
,	,	o	O
IL-8	NNP	o	OPH
,	,	o	OPH
tumor	NN	o	OPH
necrosis	NN	o	OPH
factor-alpha	JJ	o	OPH
(	(	o	OPH
TNF-alpha	NNP	o	OPH
)	)	o	OPH
,	,	O	O
and	CC	O	O
leukotriene	JJ	o	OPH
B4	NNP	o	OPH
(	(	o	OPH
LTB4	NNP	o	OPH
)	)	o	OPH
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
decrease	NN	O	O
in	IN	O	O
sputum	NN	o	OPH
leukocyte	NN	o	OPH
density	NN	o	OPH
and	CC	O	O
IL-1beta	NNP	o	OPH
,	,	o	O
IL-8	NNP	o	OPH
,	,	O	O
and	CC	O	O
LTB4	NNP	o	OPH
after	IN	O	O
fluticasone	NN	i	IPM
treatment	NN	O	O
.	.	O	O

The	DT	O	O
fluticasone	NN	i	IPM
group	NN	O	O
had	VBD	O	O
one	CD	O	O
and	CC	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
three	CD	O	O
episodes	NNS	O	O
of	IN	O	O
exacerbation	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
spirometry	NN	o	OPH
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
or	CC	O	O
any	DT	O	O
reported	JJ	O	O
adverse	JJ	o	OA
reactions	NNS	o	OA
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
show	VB	O	O
that	IN	O	O
high-dose	JJ	O	O
fluticasone	NN	O	O
is	VBZ	O	O
effective	JJ	O	O
in	IN	O	O
reducing	VBG	O	O
the	DT	O	O
sputum	NN	o	OPH
inflammatory	NN	o	OPH
indices	NNS	o	OPH
in	IN	O	O
bronchiectasis	NN	O	O
.	.	O	O

Large-scale	JJ	O	O
and	CC	O	O
long-term	JJ	O	O
studies	NNS	O	O
are	VBP	O	O
indicated	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
inhaled	JJ	O	O
steroid	JJ	O	O
therapy	NN	O	O
on	IN	O	O
the	DT	O	O
inflammatory	JJ	O	O
components	NNS	O	O
in	IN	O	O
bronchiectasis	NN	p	PC
.	.	O	O

[	RB	O	O
Clinical	NNP	O	O
study	NN	O	O
on	IN	O	O
treatment	NN	O	O
of	IN	O	O
endometriosis-related	JJ	p	O
infertility	NN	p	O
patients	NNS	p	O
by	IN	O	O
laparoscopic	NN	i	IPH
surgery	NN	i	IPH
in	IN	O	O
combination	NN	O	O
of	IN	O	O
quyu	JJ	i	IPM
jiedu	NN	i	IPM
recipe	NN	i	IPM
]	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
study	VB	O	O
the	DT	O	O
clinical	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
the	DT	O	O
laparoscopic	NN	i	IPH
surgery	NN	i	IPH
in	IN	O	O
combination	NN	O	O
of	IN	O	O
Quyu	NNP	i	IPM
Jiedu	NNP	i	IPM
Recipe	NNP	i	IPM
(	(	i	IPM
QYJDR	NNP	i	IPM
)	)	i	IPM
on	IN	O	O
endometriosis	NN	p	O
(	(	p	O
EMs	NNP	p	O
)	)	p	O
-related	VBD	p	O
infertility	NN	p	O
patients	NNS	p	O
.	.	O	O

METHODS	NNP	O	O
130	CD	p	O
EMs-related	JJ	p	O
infertility	NN	p	O
patients	NNS	p	O
of	IN	p	O
blood	NN	p	O
stasis	NN	p	O
and	CC	p	O
toxin	NN	p	O
accumulation	NN	p	O
syndrome	NN	p	O
diagnosed	VBD	p	O
and	CC	p	O
treated	VBN	p	O
by	IN	p	O
laparoscopic	NN	p	O
surgery	NN	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
i.e.	FW	O	O
,	,	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
(	(	O	O
75	CD	O	O
cases	NNS	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
55	CD	O	O
cases	NNS	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
routine	JJ	O	O
progesterone	NN	i	IPM
treatment	NN	O	O
after	IN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
.	.	O	O

QYJDR	NNP	i	IPM
was	VBD	O	O
given	VBN	O	O
to	TO	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
after	IN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
,	,	O	O
lasting	VBG	O	O
for	IN	O	O
twelve	JJ	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
pregnancy	NN	o	OPH
rate	NN	o	OPH
within	IN	O	O
one	CD	O	O
year	NN	O	O
after	IN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
Chinese	JJ	o	OPH
medicine	NN	o	OPH
syndrome	NN	o	OPH
integrals	NNS	o	OPH
,	,	o	OPH
serum	JJ	o	OPH
endometrium	NN	o	OPH
antibody	NN	o	OPH
(	(	o	OPH
EMAb	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
cancer	NN	o	OPH
antigen	NN	o	OPH
125	CD	o	OPH
(	(	o	OPH
CA125	NNP	o	OPH
)	)	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
before	RB	O	O
drug	NN	O	O
therapy	NN	O	O
and	CC	O	O
three	CD	O	O
months	NNS	O	O
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
pregnancy	NN	o	OPH
rate	NN	o	OPH
within	IN	O	O
one	CD	O	O
year	NN	O	O
after	IN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
was	VBD	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
[	VBD	O	O
61.33	CD	O	O
%	NN	O	O
(	(	O	O
46/75	CD	O	O
)	)	O	O
vs	FW	O	O
45.45	CD	O	O
%	NN	O	O
(	(	O	O
25/55	CD	O	O
)	)	O	O
]	NN	O	O
,	,	O	O
showing	VBG	O	O
significant	JJ	O	O
difference	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
Chinese	JJ	o	OPH
medicine	NN	o	OPH
syndrome	JJ	o	OPH
integral	NN	o	OPH
was	VBD	O	O
(	(	O	O
16.07	CD	O	O
+/-	JJ	O	O
6.77	CD	O	O
)	)	O	O
score	NN	O	O
and	CC	O	O
(	(	O	O
7.25	CD	O	O
+/-	JJ	O	O
3.27	CD	O	O
)	)	O	O
score	NN	O	O
before	IN	O	O
and	CC	O	O
3	CD	O	O
months	NNS	O	O
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
in	IN	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
,	,	O	O
while	IN	O	O
it	PRP	O	O
was	VBD	O	O
(	(	O	O
15.92	CD	O	O
+/-	JJ	O	O
7.51	CD	O	O
)	)	O	O
score	NN	O	O
and	CC	O	O
(	(	O	O
12.73	CD	O	O
+/-	JJ	O	O
6.12	CD	O	O
)	)	O	O
score	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
Chinese	JJ	o	OPH
medicine	NN	o	OPH
syndrome	JJ	o	OPH
integral	JJ	o	OPH
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
was	VBD	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
before	IN	O	O
drug	NN	O	O
therapy	NN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
group	NN	O	O
.	.	O	O

Besides	IN	O	O
,	,	O	O
the	DT	O	O
integral	JJ	O	O
difference	NN	O	O
between	IN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
was	VBD	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
[	NNP	O	O
(	(	O	O
9.12	CD	O	O
+/-	JJ	O	O
6.16	CD	O	O
)	)	O	O
score	NN	O	O
vs	NN	O	O
(	(	O	O
3.48	CD	O	O
+/-	JJ	O	O
2.06	CD	O	O
)	)	O	O
score	NN	O	O
)	)	O	O
]	NN	O	O
,	,	O	O
showing	VBG	O	O
statistical	JJ	O	O
difference	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
three-month	JJ	O	O
drug	NN	O	O
therapy	NN	O	O
,	,	O	O
the	DT	O	O
serum	NN	o	OPH
EMAb	NNP	o	OPH
negative	JJ	O	O
conversion	NN	O	O
rate	NN	O	O
was	VBD	O	O
obviously	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
44.44	CD	O	O
%	NN	O	O
vs	JJ	O	O
15.62	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
showing	VBG	O	O
statistical	JJ	O	O
difference	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
serum	NN	o	OPH
CA125	NNP	o	OPH
level	NN	o	OPH
was	VBD	O	O
(	(	O	O
31.88	CD	O	O
+/-	JJ	O	O
15.78	CD	O	O
)	)	O	O
U/mL	NNP	O	O
before	IN	O	O
drug	NN	O	O
therapy	NN	O	O
and	CC	O	O
(	(	O	O
18.82	CD	O	O
+/-	JJ	O	O
10.08	CD	O	O
)	)	O	O
U/mL	NNP	O	O
three	CD	O	O
months	NNS	O	O
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
in	IN	O	O
the	DT	O	O
test	NN	O	O
group	NN	O	O
,	,	O	O
while	IN	O	O
it	PRP	O	O
was	VBD	O	O
(	(	O	O
30.63	CD	O	O
+/-	JJ	O	O
19.28	CD	O	O
)	)	O	O
U/mL	NN	O	O
and	CC	O	O
(	(	O	O
18.05	CD	O	O
+/-	JJ	O	O
11.20	CD	O	O
)	)	O	O
U/mL	NNP	O	O
respectively	RB	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
lowered	VBN	O	O
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
with	IN	O	O
statistical	JJ	O	O
difference	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
statistical	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
after	IN	O	O
drug	NN	O	O
therapy	NN	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
laparoscopic	NN	i	IS
surgery	NN	i	IS
in	IN	O	O
combination	NN	O	O
of	IN	O	O
QYJDR	NNP	i	IS
could	MD	O	O
effectively	RB	O	O
improve	VB	O	O
clinical	JJ	O	O
symptoms	NNS	O	O
of	IN	O	O
EMs	NNP	O	O
patients	NNS	O	O
of	IN	O	O
blood	NN	o	OPH
stasis	NN	o	OPH
and	CC	O	O
toxin	NN	o	OPH
accumulation	NN	o	OPH
syndrome	NN	o	OPH
,	,	O	O
promote	VBP	O	O
negative	JJ	o	OPH
conversion	NN	o	OPH
of	IN	o	OPH
EMAb	NNP	o	OPH
,	,	O	O
lower	JJR	O	O
serum	NN	o	OPH
CA125	NNP	o	OPH
levels	NNS	o	OPH
,	,	O	O
and	CC	O	O
elevate	VB	O	O
the	DT	O	O
clinical	JJ	o	OPH
pregnancy	NN	o	OPH
rate	NN	o	OPH
.	.	O	O

QYJDR	NNP	i	IS
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
formula	NN	O	O
in	IN	O	O
treatment	NN	O	O
of	IN	O	O
EMs-related	JJ	O	O
infertility	NN	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
continuous	JJ	i	IPH
femoral	JJ	i	IPH
nerve	NN	i	IPH
block	NN	i	IPH
(	(	i	IPH
CFNB	NNP	i	IPH
)	)	i	IPH
and	CC	O	O
continuous	JJ	i	IPH
epidural	JJ	i	IPH
infusion	NN	i	IPH
(	(	i	IPH
CEI	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
postoperative	JJ	O	O
analgesia	NN	O	O
and	CC	O	O
knee	NN	O	O
rehabilitation	NN	O	O
after	IN	O	O
total	JJ	p	O
knee	NN	p	O
arthroplasty	NN	p	O
(	(	p	O
TKA	NNP	p	O
)	)	p	O
.	.	O	O

BACKGROUND	NNP	O	O
Postoperative	NNP	O	O
epidural	JJ	O	O
analgesia	NN	O	O
(	(	O	O
EA	NNP	O	O
)	)	O	O
and	CC	O	O
femoral	JJ	i	IPH
nerve	NN	i	IPH
block	NN	i	IPH
(	(	i	IPH
FNB	NNP	i	IPH
)	)	i	IPH
provided	VBD	O	O
effective	JJ	O	O
pain	NN	O	O
relief	NN	O	O
However	RB	O	O
,	,	O	O
EA	NNP	O	O
has	VBZ	O	O
common	JJ	O	O
side	NN	O	O
effects	NNS	O	O
such	JJ	O	O
as	IN	O	O
nausea	NN	O	O
,	,	O	O
vomiting	VBG	O	O
,	,	O	O
pruritus	NN	O	O
,	,	O	O
dizziness	NN	O	O
,	,	O	O
and	CC	O	O
hypotension	NN	O	O
.	.	O	O

Some	DT	O	O
investigations	NNS	O	O
found	VBD	O	O
that	IN	O	O
those	DT	O	O
side	JJ	O	O
effects	NNS	O	O
were	VBD	O	O
less	RBR	O	O
in	IN	O	O
FNB	NNP	O	O
than	IN	O	O
in	IN	O	O
EA	NNP	O	O
.	.	O	O

However	RB	O	O
the	DT	O	O
analgesic	JJ	O	O
equivalent	NN	O	O
of	IN	O	O
both	DT	O	O
techniques	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
confirmed	VBN	O	O
.	.	O	O

OBJECTIVE	IN	O	O
The	DT	O	O
authors	NNS	O	O
compared	VBN	O	O
continuous	JJ	i	IPH
epidural	JJ	i	IPH
infusion	NN	i	IPH
(	(	i	IPH
CEI	NNP	i	IPH
)	)	i	IPH
with	IN	O	O
continuous	JJ	i	IPH
femoral	JJ	i	IPH
nerve	NN	i	IPH
block	NN	i	IPH
(	(	i	IPH
CFNB	NNP	i	IPH
)	)	i	IPH
regarding	VBG	O	O
the	DT	O	O
postoperative	JJ	o	OOt
analgesic	JJ	o	OOt
efficacy	NN	o	OOt
,	,	o	O
side	NN	o	OA
effects	NNS	o	OA
,	,	o	O
postoperative	JJ	o	OPH
knee	NN	o	OPH
rehabilitation	NN	o	OPH
,	,	o	O
and	CC	o	O
hospital	JJ	o	OOt
length	NN	o	OOt
of	IN	o	OOt
stay	NN	o	OOt
(	(	o	OOt
LOS	NNP	o	OOt
)	)	o	OOt
.	.	O	O

MATERIAL	NNP	O	O
AND	NNP	O	O
METHOD	NNP	O	O
In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
controlled	VBD	O	O
study	NN	O	O
,	,	O	O
61	CD	p	PSS
ASA	NNP	p	PC
physical	JJ	p	PC
status	NN	p	PC
I-III	NNP	p	PC
patients	NNS	p	PC
scheduled	VBN	p	O
for	IN	p	O
elective	JJ	p	O
unilateral	JJ	p	O
total	NN	p	O
knee	NN	p	O
arthroplasty	NN	p	O
(	(	p	O
TKA	NNP	p	O
)	)	p	O
under	IN	p	O
spinal	JJ	p	O
anesthesia	NN	p	O
(	(	p	O
SA	NNP	p	O
)	)	p	O
participated	VBD	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
allocated	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
ward	NN	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
Group	NNP	O	O
I	PRP	O	O
(	(	O	O
CEI	NNP	i	IPH
)	)	O	O
were	VBD	O	O
maintained	VBN	O	O
by	IN	O	O
continuous	JJ	O	O
infusion	NN	O	O
of	IN	O	O
0.125	CD	O	O
%	NN	O	O
levobupivacaine	NN	i	IPM
with	IN	O	O
morphine	JJ	i	IPM
0.0125	CD	O	O
mg/ml	NN	O	O
(	(	O	O
4	CD	O	O
ml/hr	NN	O	O
)	)	O	O
,	,	O	O
Group	NNP	O	O
II	NNP	O	O
(	(	O	O
CFNB	NNP	i	IPH
)	)	O	O
were	VBD	O	O
maintained	VBN	O	O
by	IN	O	O
0.125	CD	O	O
%	NN	O	O
levobupivacaine	NN	i	IPM
(	(	O	O
8	CD	O	O
ml/hr	NN	O	O
)	)	O	O
.	.	O	O

RESULTS	JJ	O	O
Patients	NNPS	O	O
in	IN	O	O
the	DT	O	O
CFNB	NNP	i	IPH
group	NN	O	O
,	,	O	O
the	DT	O	O
VAS	NNP	o	OOt
scores	NNS	o	OOt
at	IN	O	O
PO6-12	NNP	O	O
hr	NN	O	O
and	CC	O	O
tramadol	NN	o	OOt
IV	NNP	o	OOt
requirement	NN	o	OOt
were	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
than	IN	O	O
the	DT	O	O
CEI	NNP	i	IPH
group	NN	O	O
(	(	O	O
VAS	NNP	O	O
:	:	O	O
PO6	NNP	O	O
hr	VBD	O	O
p-value	JJ	O	O
=	NN	O	O
0.001	CD	O	O
,	,	O	O
PO12	NNP	O	O
hr	VBD	O	O
p-value	JJ	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
CEI	NNP	i	IPH
group	NN	O	O
experienced	VBD	O	O
dizziness	NN	o	OA
,	,	o	O
pruritus	NN	o	OA
,	,	o	O
and	CC	o	O
PONV	NNP	o	OA
more	JJR	O	O
than	IN	O	O
the	DT	O	O
CFNB	NNP	i	IPH
group	NN	O	O
significantly	RB	O	O
.	.	O	O

Patient	JJ	o	OOt
satisfaction	NN	o	OOt
was	VBD	O	O
greater	JJR	O	O
with	IN	O	O
the	DT	O	O
CFNB	NNP	i	IPH
group	NN	O	O
although	IN	O	O
postoperative	JJ	o	OPH
knee	NN	o	OPH
rehabilitation	NN	o	OPH
and	CC	O	O
the	DT	O	O
hospital	NN	o	OOt
LOS	NNP	o	OOt
were	VBD	O	O
not	RB	O	O
different	JJ	O	O
.	.	O	O

CONCLUSION	NNP	O	O
CFNB	NNP	i	IPH
represents	VBZ	O	O
the	DT	O	O
optimal	JJ	O	O
analgesia	NN	O	O
with	IN	O	O
fewer	JJR	O	O
side	NN	o	OA
effects	NNS	o	OA
and	CC	O	O
greater	JJR	O	O
patient	NN	o	OOt
,	,	o	OOt
satisfaction	NN	o	OOt
.	.	O	O

The	DT	O	O
rehabilitation	NN	o	OOt
indices	NNS	o	OOt
and	CC	O	O
duration	NN	o	OOt
of	IN	o	OOt
hospital	NN	o	OOt
stay	NN	o	OOt
are	VBP	O	O
comparable	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

Epidemiology	NN	O	O
of	IN	O	O
stroke	NN	O	O
.	.	O	O

Importance	NN	O	O
of	IN	O	O
preventive	JJ	O	O
pharmacological	JJ	O	O
strategies	NNS	O	O
in	IN	O	O
elderly	JJ	p	O
patients	NNS	p	O
and	CC	O	O
associated	JJ	O	O
costs	NNS	O	O
.	.	O	O

Stroke	NNP	O	O
is	VBZ	O	O
a	DT	O	O
major	JJ	O	O
cause	NN	O	O
of	IN	O	O
death	NN	O	O
and	CC	O	O
disability	NN	O	O
in	IN	O	O
developed	JJ	O	O
countries	NNS	O	O
.	.	O	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
stroke	NN	O	O
increases	NNS	O	O
exponentially	RB	O	O
with	IN	O	O
age	NN	O	O
,	,	O	O
yet	RB	O	O
,	,	O	O
traditionally	RB	O	O
,	,	O	O
many	JJ	O	O
medical	JJ	O	O
practitioners	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reluctant	JJ	O	O
to	TO	O	O
treat	VB	O	O
hypertension	NN	O	O
in	IN	p	O
older	JJR	p	O
patients	NNS	p	O
.	.	O	O

Since	IN	O	O
1991	CD	O	O
,	,	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
3	CD	O	O
major	JJ	O	O
trials	NNS	O	O
--	:	O	O
the	DT	O	O
British	JJ	O	O
Medical	NNP	O	O
Research	NNP	O	O
Council	NNP	O	O
(	(	O	O
MRC	NNP	O	O
)	)	O	O
trial	NN	O	O
of	IN	O	O
treatment	NN	O	O
in	IN	O	O
older	JJR	p	O
adults	NNS	p	O
,	,	O	O
the	DT	O	O
Swedish	JJ	O	O
Trial	NNP	O	O
in	IN	O	O
Old	NNP	p	O
Patients	NNPS	p	O
with	IN	p	O
Hypertension	NNP	p	O
(	(	O	O
STOP-Hypertension	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
Systolic	NNP	O	O
Hypertension	NNP	O	O
in	IN	O	O
the	DT	O	O
Elderly	JJ	O	O
Program	NNP	O	O
(	(	O	O
SHEP	NNP	O	O
)	)	O	O
--	:	O	O
have	VBP	O	O
conclusively	RB	O	O
established	VBN	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
treating	VBG	O	O
older	JJR	p	O
patients	NNS	p	O
(	(	p	O
>	JJ	p	O
60	CD	p	O
years	NNS	p	O
)	)	p	O
with	IN	p	O
both	DT	p	O
diastolic	JJ	p	O
and	CC	p	O
isolated	JJ	p	O
systolic	JJ	p	O
hypertension	NN	p	O
.	.	O	O

International	NNP	O	O
guidelines	NNS	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
hypertension	NN	O	O
--	:	O	O
including	VBG	O	O
the	DT	O	O
Fifth	NNP	O	O
Report	NNP	O	O
of	IN	O	O
the	DT	O	O
Joint	NNP	O	O
National	NNP	O	O
Committee	NNP	O	O
,	,	O	O
the	DT	O	O
1993	CD	O	O
report	NN	O	O
of	IN	O	O
the	DT	O	O
World	NNP	O	O
Health	NNP	O	O
Organization	NNP	O	O
and	CC	O	O
the	DT	O	O
International	NNP	O	O
Society	NNP	O	O
of	IN	O	O
Hypertension	NNP	O	O
and	CC	O	O
the	DT	O	O
second	JJ	O	O
report	NN	O	O
of	IN	O	O
the	DT	O	O
British	JJ	O	O
Hypertension	NNP	O	O
Society	NNP	O	O
Working	NNP	O	O
Party	NNP	O	O
--	:	O	O
have	VBP	O	O
all	DT	O	O
been	VBN	O	O
modified	VBN	O	O
to	TO	O	O
reflect	VB	O	O
the	DT	O	O
emerging	VBG	O	O
evidence	NN	O	O
concerning	VBG	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
treating	VBG	O	O
older	JJR	O	O
patients	NNS	O	O
.	.	O	O

Cost-effectiveness	JJ	o	OOt
data	NNS	o	OOt
are	VBP	O	O
similarly	RB	O	O
in	IN	O	O
accord	NN	O	O
with	IN	O	O
giving	VBG	O	O
high	JJ	O	O
priority	NN	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
older	JJR	p	O
individuals	NNS	p	O
with	IN	p	O
hypertension	NN	p	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
tunnelling	VBG	i	IPH
on	IN	O	O
epidural	JJ	O	O
catheter	NN	O	O
migration	NN	O	O
.	.	O	O

A	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomised	VBD	O	O
study	NN	O	O
of	IN	O	O
82	CD	p	PSS
patients	NNS	p	O
having	VBG	p	O
postoperative	JJ	p	PC
epidural	JJ	p	PC
analgesia	NN	p	PC
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
tunnelling	NN	i	IPH
of	IN	O	O
an	DT	O	O
epidural	JJ	O	O
catheter	NN	O	O
influences	VBZ	O	O
its	PRP$	O	O
migration	NN	o	OPH
.	.	O	O

Tunnelling	NN	i	IPH
of	IN	O	O
the	DT	O	O
catheter	NN	O	O
subcutaneously	RB	O	O
for	IN	O	O
a	DT	O	O
distance	NN	O	O
of	IN	O	O
5	CD	O	O
cm	NN	O	O
reduced	VBD	O	O
the	DT	O	O
incidence	NN	o	OOt
of	IN	o	OOt
inward	JJ	o	OOt
migration	NN	o	OOt
of	IN	O	O
1	CD	O	O
cm	NN	O	O
or	CC	O	O
more	JJR	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
standard	JJ	O	O
method	NN	O	O
of	IN	O	O
fixation	NN	O	O
with	IN	O	O
a	DT	O	O
transparent	JJ	O	O
adhesive	JJ	O	O
dressing	NN	O	O
.	.	O	O

This	DT	O	O
effect	NN	O	O
was	VBD	O	O
more	RBR	O	O
marked	JJ	O	O
if	IN	O	O
the	DT	O	O
epidural	JJ	O	O
catheter	NN	O	O
was	VBD	O	O
sited	VBN	O	O
in	IN	O	O
the	DT	O	O
thoracic	NN	O	O
rather	RB	O	O
than	IN	O	O
the	DT	O	O
lumbar	JJ	O	O
area	NN	O	O
.	.	O	O

Sixty	CD	O	O
two	CD	O	O
percent	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
26	CD	O	O
)	)	O	O
of	IN	O	O
tunnelled	JJ	i	IPH
catheters	NNS	i	IPH
remained	VBD	O	O
within	IN	O	O
0.5	CD	O	O
cm	NNS	O	O
of	IN	O	O
their	PRP$	O	O
original	JJ	O	O
position	NN	o	OOt
compared	VBN	O	O
to	TO	O	O
38	CD	O	O
%	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
16	CD	O	O
)	)	O	O
of	IN	O	O
non-tunnelled	JJ	i	IPH
catheters	NNS	i	IPH
,	,	O	O
although	IN	O	O
this	DT	O	O
difference	NN	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

Outward	NNP	O	O
catheter	NN	o	OPH
migration	NN	o	OPH
was	VBD	O	O
not	RB	O	O
reduced	VBN	O	O
by	IN	O	O
subcutaneous	JJ	O	O
tunnelling	NN	i	IPH
.	.	O	O

Effect	NN	O	O
of	IN	O	O
the	DT	O	O
essential	JJ	i	IPM
oils	NNS	i	IPM
of	IN	i	IPM
garlic	NN	i	IPM
and	CC	i	IPM
onion	NN	i	IPM
on	IN	O	O
alimentary	JJ	O	O
hyperlipemia	NN	O	O
.	.	O	O

SUMMARY	VB	O	O
The	DT	O	O
effect	NN	O	O
of	IN	O	O
garlic	NN	i	IPM
and	CC	i	IPM
onion	NN	i	IPM
on	IN	O	O
alimentary	JJ	O	O
hyperlipemia	NN	O	O
,	,	O	O
induced	VBN	O	O
by	IN	O	O
feeding	VBG	O	O
100	CD	O	O
g	JJ	O	O
butter	NN	O	O
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
studied	VBN	O	O
in	IN	O	O
10	CD	p	O
healthy	JJ	p	O
subjects	NNS	p	O
.	.	O	O

The	DT	O	O
freshly	RB	O	O
extracted	JJ	O	O
juice	NN	O	O
of	IN	O	O
50	CD	O	O
g	NN	O	O
of	IN	O	O
garlic	NN	i	IPM
or	CC	i	IPM
onion	NN	i	IPM
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
an	DT	O	O
equivalent	JJ	O	O
amount	NN	O	O
of	IN	O	O
their	PRP$	O	O
ether-extracted	JJ	O	O
essential	JJ	i	IPM
oils	NNS	i	IPM
,	,	O	O
was	VBD	O	O
administered	VBN	O	O
randomly	RB	O	O
on	IN	O	O
four	CD	O	O
different	JJ	O	O
days	NNS	O	O
during	IN	O	O
a	DT	O	O
one-week	JJ	O	O
period	NN	O	O
.	.	O	O

Garlic	NNP	i	IPM
and	CC	i	IPM
onion	NN	i	IPM
have	VBP	O	O
a	DT	O	O
significant	JJ	O	O
protective	JJ	O	O
action	NN	O	O
against	IN	O	O
fat-induced	JJ	O	O
increases	NNS	O	O
in	IN	O	O
serum	NN	o	OPH
cholesterol	NN	o	OPH
and	CC	o	OPH
plasma	NN	o	OPH
fibrinogen	NN	o	OPH
and	CC	O	O
decreases	NNS	O	O
in	IN	O	O
coagulation	NN	o	OPH
time	NN	o	OPH
and	CC	O	O
fibrinolytic	JJ	o	OPH
activity	NN	o	OPH
.	.	O	O

The	DT	O	O
essential	JJ	O	O
oil	NN	O	O
fraction	NN	O	O
,	,	O	O
which	WDT	O	O
contains	VBZ	O	O
all	PDT	O	O
the	DT	O	O
taste	NN	O	O
and	CC	O	O
odour	NN	O	O
,	,	O	O
exactly	RB	O	O
duplicated	VBD	O	O
the	DT	O	O
beneficial	JJ	O	O
effects	NNS	o	OPH
of	IN	O	O
whole	JJ	O	O
garlic	NN	i	IPM
and	CC	O	O
onion	NN	i	IPM
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
concluded	VBD	O	O
that	IN	O	O
the	DT	O	O
active	JJ	O	O
principle	NN	O	O
of	IN	O	O
garlic	JJ	i	IPM
and	CC	i	IPM
onion	NN	i	IPM
is	VBZ	O	O
the	DT	O	O
essential	JJ	O	O
oil	NN	O	O
,	,	O	O
which	WDT	O	O
chemically	RB	O	O
is	VBZ	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
sulphur-containing	JJ	O	O
compounds	NNS	O	O
,	,	O	O
mainly	RB	O	O
allyl	VBZ	O	O
propyl	JJ	O	O
disulphide	NN	O	O
and	CC	O	O
diallyl	JJ	O	O
disulphide	NN	O	O
.	.	O	O

The	DT	O	O
course	NN	O	O
of	IN	O	O
depression	NN	O	O
in	IN	O	O
recent	JJ	p	O
onset	NN	p	O
rheumatoid	NN	p	PC
arthritis	NN	p	PC
:	:	O	O
the	DT	O	O
predictive	JJ	O	O
role	NN	O	O
of	IN	O	O
disability	NN	o	OPH
,	,	o	OPH
illness	JJ	o	OPH
perceptions	NNS	o	OPH
,	,	o	OPH
pain	NN	o	OPH
and	CC	o	OPH
coping	NN	o	OPH
.	.	O	O

BACKGROUND	NNP	O	O
This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
depression	NN	O	O
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
recently	RB	p	O
diagnosed	VBN	p	O
rheumatoid	NN	p	PC
arthritis	NN	p	PC
(	(	p	PC
RA	NNP	p	PC
)	)	p	PC
and	CC	O	O
to	TO	O	O
investigate	VB	O	O
predictors	NNS	O	O
of	IN	O	O
depression	NN	o	O
.	.	O	O

METHODS	NNP	O	O
Twenty-two	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
a	DT	p	O
history	NN	p	O
of	IN	p	O
recently	RB	p	O
diagnosed	VBN	p	O
RA	NNP	p	PC
of	IN	p	O
less	JJR	p	O
than	IN	p	O
2	CD	p	O
years	NNS	p	O
were	VBD	O	O
assessed	VBN	O	O
on	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
clinical	JJ	o	OPH
outcome	NN	o	OPH
and	CC	o	OPH
process	NN	o	OPH
measures	NNS	o	OPH
on	IN	O	O
six	CD	O	O
assessment	JJ	O	O
occasions	NNS	O	O
over	IN	O	O
a	DT	O	O
21-month	JJ	O	O
period	NN	O	O
.	.	O	O

These	DT	O	O
22	CD	p	PSS
patients	NNS	p	O
constituted	VBD	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
of	IN	O	O
a	DT	O	O
controlled	VBN	O	O
trial	NN	O	O
and	CC	O	O
received	VBN	O	O
standard	JJ	i	IC
outpatient	NN	i	IC
clinic	JJ	i	IC
treatment	NN	i	IC
during	IN	O	O
follow-up	JJ	O	O
.	.	O	O

RESULTS	JJ	O	O
Patients	NNPS	O	O
became	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
depressed	JJ	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

A	DT	O	O
set	NN	O	O
of	IN	O	O
five	CD	O	O
factors	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
consistently	RB	O	O
predict	VB	o	OPH
depression	NN	o	OPH
at	IN	O	O
the	DT	O	O
following	JJ	O	O
assessment	NN	O	O
.	.	O	O

These	DT	O	O
were	VBD	O	O
initial	JJ	O	O
level	NN	O	O
of	IN	O	O
depression	NN	o	OME
,	,	o	O
disability	NN	o	OPH
,	,	o	O
pain	NN	o	OPA
,	,	o	O
beliefs	VB	o	OME
about	IN	o	OME
the	DT	o	OME
consequences	NNS	o	OME
of	IN	o	OME
arthritis	NN	o	OME
and	CC	o	OME
coping	VBG	o	OME
strategies	NNS	o	OME
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
confirm	VBP	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
psychological	JJ	O	O
factors	NNS	O	O
in	IN	O	O
early	JJ	O	O
RA	NNP	O	O
and	CC	O	O
their	PRP$	O	O
relative	JJ	O	O
independence	NN	O	O
from	IN	O	O
physical	JJ	O	O
findings	NNS	O	O
.	.	O	O

This	DT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
study	NN	O	O
to	TO	O	O
document	VB	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
illness	JJ	O	O
perceptions	NNS	O	O
in	IN	O	O
recent	JJ	O	O
onset	NN	O	O
RA	NNP	O	O
.	.	O	O

[	JJ	O	O
Effect	NNP	O	O
of	IN	O	O
transcranial	JJ	i	IPH
electrostimulation	NN	i	IPH
on	IN	O	O
clinical	JJ	O	O
and	CC	O	O
laboratory	JJ	O	O
characteristics	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
gastric	JJ	p	PC
ulcer	JJ	p	PC
]	NN	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
included	VBD	O	O
100	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
gastric	JJ	p	PC
ulcer	NNS	p	PC
aged	VBN	p	O
from	IN	p	O
16	CD	p	PA
to	TO	p	PA
60	CD	p	PA
years	NNS	p	PA
.	.	O	O

In	IN	O	O
58	CD	O	O
patients	NNS	O	O
,	,	O	O
traditional	JJ	i	IPM
treatment	NN	i	IPM
was	VBD	O	O
supplemented	VBN	O	O
by	IN	O	O
transcranial	JJ	i	IPH
electrotherapy	NN	i	IPH
using	VBG	O	O
a	DT	O	O
TRANSAIR-02	JJ	O	O
apparatus	NN	O	O
.	.	O	O

Laboratory	NNP	O	O
studies	NNS	O	O
included	VBD	O	O
measurements	NNS	O	O
of	IN	O	O
lactoferrin	NN	o	OOt
(	(	o	OPH
LF	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
tumour	JJ	o	OOt
necrosis	NN	o	OOt
factor-alpha	NN	o	OOt
(	(	o	OOt
TNF-alpha	NNP	o	OOt
)	)	o	OOt
,	,	O	O
besides	VBZ	O	O
standard	JJ	O	O
analyses	NNS	O	O
.	.	O	O

Combined	VBN	O	O
treatment	NN	O	O
(	(	i	IPM
traditional	JJ	i	IPM
therapy	NN	i	IPM
plus	CC	i	IPM
electrostimulation	NN	i	IPH
)	)	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
duration	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
main	JJ	o	OPH
symptoms	NNS	o	OPH
of	IN	O	O
the	DT	O	O
gastric	JJ	p	PC
ulcer	NN	p	PC
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
severity	NN	O	O
of	IN	O	O
ulceration	NN	O	O
process	NN	O	O
,	,	O	O
patients	NNS	O	O
'	POS	O	O
age	NN	O	O
and	CC	O	O
sex	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
it	PRP	O	O
facilitated	VBD	O	O
ulcer	JJ	o	OPH
scarring	NN	o	OPH
and	CC	O	O
had	VBD	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
dynamics	NNS	O	O
of	IN	O	O
serum	NN	o	OPH
LF	NNP	o	OPH
and	CC	o	OPH
TNF-alpha	NNP	o	OPH
levels	NNS	o	OPH
.	.	O	O

[	JJ	O	O
Postural	NNP	O	O
biofeedback	NN	O	O
and	CC	O	O
locomotion	NN	O	O
reeducation	NN	O	O
in	IN	O	O
stroke	NN	p	PC
patients	NNS	p	PC
]	VBP	O	O
.	.	O	O

AIMS	NNP	O	O
To	TO	O	O
compare	VB	O	O
,	,	O	O
in	IN	O	O
post-acute	JJ	p	O
hemiparetic	JJ	p	O
patients	NNS	p	O
,	,	O	O
gait	NN	o	OOt
improvement	NN	o	OOt
after	IN	O	O
conventional	JJ	i	IPH
physical	JJ	i	IPH
therapy	NN	i	IPH
alone	RB	i	IPH
or	CC	O	O
with	IN	i	O
a	DT	i	O
specialised	JJ	i	IE
balance	NN	i	IE
retraining	VBG	i	IE
program	NN	i	IE
.	.	O	O

PATIENTS	VB	O	O
Twenty-six	JJ	p	O
patients	NNS	p	O
within	IN	p	O
3	CD	p	O
months	NNS	p	O
of	IN	p	O
onset	NN	p	O
of	IN	p	O
stroke	NN	p	O
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
receive	VB	O	O
physical	JJ	i	IPH
therapy	NN	i	IPH
(	(	O	O
control	VB	O	O
group	NN	O	O
)	)	O	O
or	CC	O	O
therapy	NN	i	IPH
and	CC	i	IPH
retraining	NN	i	IPH
(	(	O	O
experimental	JJ	O	O
group	NN	O	O
)	)	O	O
,	,	O	O
most	JJS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
with	IN	O	O
left	JJ	O	O
hemiplegia	NN	O	O
.	.	O	O

The	DT	O	O
experimental	JJ	O	O
group	NN	O	O
was	VBD	O	O
significantly	RB	O	O
older	JJR	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

METHOD	NNP	O	O
Thirteen	NNP	O	O
patients	NNS	O	O
received	VBD	O	O
early	JJ	O	O
conventional	JJ	i	IC
therapy	NN	i	IC
,	,	O	O
and	CC	O	O
13	CD	O	O
received	VBD	O	O
therapy	NN	i	IPH
combined	VBN	i	IPH
with	IN	i	IPH
standing	VBG	i	IPH
balance	NN	i	IPH
training	NN	i	IPH
by	IN	i	IPH
biofeedback	NN	i	IPH
(	(	i	IPH
BPM	NNP	i	IPH
Monitor	NNP	i	IPH
)	)	i	IPH
.	.	O	O

Clinical	JJ	O	O
measures	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
at	IN	O	O
entry	NN	O	O
(	(	O	O
J0	NNP	O	O
)	)	O	O
,	,	O	O
once	RB	O	O
when	WRB	O	O
subjects	NNS	O	O
began	VBD	O	O
to	TO	O	O
walk	VB	O	O
(	(	O	O
JM	NNP	O	O
)	)	O	O
and	CC	O	O
30	CD	O	O
days	NNS	O	O
later	RB	O	O
(	(	O	O
JM	NNP	O	O
+	NNP	O	O
30	CD	O	O
)	)	O	O
.	.	O	O

Gait	NNP	o	OOt
spatiotemporal	JJ	o	OOt
parameters	NNS	o	OOt
were	VBD	O	O
collected	VBN	O	O
by	IN	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
Vicon	NNP	O	O
system	NN	O	O
at	IN	O	O
JM	NNP	O	O
and	CC	O	O
JM	NNP	O	O
+	NNP	O	O
30	CD	O	O
.	.	O	O

RESULTS	VB	O	O
Whatever	IN	O	O
the	DT	O	O
method	NN	O	O
of	IN	O	O
rehabilitation	NN	O	O
,	,	O	O
the	DT	O	O
clinical	JJ	o	OOt
scores	NNS	o	OOt
improved	VBN	O	O
significantly	RB	O	O
between	IN	O	O
J0	NNP	O	O
and	CC	O	O
JM	NNP	O	O
+	NNP	O	O
30	CD	O	O
,	,	O	O
except	IN	O	O
for	IN	O	O
spasticity	NN	O	O
.	.	O	O

The	DT	O	O
time	NN	o	OOt
between	IN	o	OOt
stroke	NN	o	OOt
and	CC	o	OOt
the	DT	o	OOt
beginning	NN	o	OOt
of	IN	o	OOt
walking	NN	o	OOt
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

Gait	NNP	o	OPH
velocity	NN	o	OPH
increased	VBD	O	O
significantly	RB	O	O
between	IN	O	O
JM	NNP	O	O
and	CC	O	O
JM	NNP	O	O
+	NNP	O	O
30	CD	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
with	IN	O	O
no	DT	O	O
difference	NN	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
walking	NN	o	OPH
pattern	NN	o	OPH
was	VBD	O	O
improved	VBN	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
of	IN	O	O
the	DT	O	O
duration	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
paretic	JJ	o	OOt
limb	NN	o	OOt
single	JJ	o	OOt
stance	NN	o	OOt
.	.	O	O

The	DT	O	O
experimental	JJ	O	O
group	NN	O	O
significantly	RB	O	O
improved	VBD	O	O
the	DT	O	O
duration	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
reception	NN	o	OOt
double	JJ	o	OOt
stance	NN	o	OOt
on	IN	o	OOt
the	DT	o	OOt
paretic	JJ	o	OOt
limb	NN	o	OOt
between	IN	O	O
JM	NNP	O	O
and	CC	O	O
JM	NNP	O	O
+	NNP	O	O
30	CD	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Both	NNP	O	O
groups	NNS	O	O
demonstrated	VBD	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
rehabilitation	NN	O	O
unit	NN	O	O
.	.	O	O

The	DT	O	O
benefits	NNS	O	O
of	IN	O	O
visual	JJ	O	O
biofeedback	NN	O	O
by	IN	O	O
forceplate	NN	O	O
system	NN	O	O
training	VBG	O	O
suggest	JJ	O	O
particular	JJ	O	O
improvement	NN	O	O
of	IN	O	O
anticipation	NN	O	O
equilibrium	NN	O	O
with	IN	O	O
conventional	JJ	i	IPH
therapy	NN	i	IPH
.	.	O	O

Social	NNP	O	O
skills	NNS	O	O
improvement	NN	O	O
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
high-functioning	JJ	p	PC
autism	NN	p	PC
:	:	O	O
a	DT	O	O
pilot	NN	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

High-functioning	JJ	O	O
autism	NN	O	O
(	(	O	O
HFA	NNP	O	O
)	)	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
persistent	JJ	O	O
impairment	NN	O	O
in	IN	O	O
social	JJ	O	O
interaction	NN	O	O
despite	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
mental	JJ	O	O
retardation	NN	O	O
.	.	O	O

Although	IN	O	O
an	DT	O	O
increasing	VBG	O	O
number	NN	O	O
of	IN	O	O
group-based	JJ	O	O
programs	NNS	O	O
for	IN	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
social	JJ	O	O
skills	NNS	O	O
have	VBP	O	O
been	VBN	O	O
described	VBN	O	O
,	,	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trials	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
their	PRP$	O	O
efficacy	NN	O	O
.	.	O	O

To	TO	O	O
compare	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
Social	NNP	i	IE
Skills	NNP	i	IE
Training	NNP	i	IE
Group-based	JJ	i	IE
Program	NNP	i	IE
(	(	i	IE
SST-GP	NNP	i	IE
)	)	i	IE
and	CC	O	O
a	DT	O	O
Leisure	NN	i	IE
Activities	VBZ	i	IE
Group-based	JJ	i	IE
Program	NNP	i	IE
(	(	i	IE
LA-GP	NNP	i	IE
)	)	i	IE
on	IN	O	O
the	DT	O	O
perception	NN	O	O
of	IN	O	O
facial	JJ	O	O
emotions	NNS	O	O
and	CC	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
(	(	O	O
QoL	NNP	O	O
)	)	O	O
in	IN	O	O
young	JJ	O	O
people	NNS	O	O
with	IN	O	O
HFA	NNP	O	O
.	.	O	O

Eligible	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
children	NNS	p	PA
and	CC	p	PA
adolescents	NNS	p	PA
with	IN	p	O
HFA	NNP	p	PC
.	.	O	O

Participants	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
SST	NNP	i	IE
or	CC	O	O
LA	NNP	i	IE
group	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
an	DT	O	O
improvement	NN	O	O
of	IN	O	O
2	CD	O	O
points	NNS	O	O
in	IN	O	O
error	NN	o	OME
rates	NNS	o	OME
for	IN	o	OME
facial	JJ	o	OME
emotion	NN	o	OME
labeling	NN	o	OME
(	(	o	OME
DANVA2	NNP	o	OME
)	)	o	OME
from	IN	O	O
baseline	NN	O	O
.	.	O	O

After	IN	O	O
the	DT	O	O
6-month	JJ	O	O
training	NN	O	O
period	NN	O	O
,	,	O	O
the	DT	O	O
SST	NNP	i	IE
Group	NNP	O	O
made	VBD	O	O
fewer	JJR	O	O
errors	NNS	O	O
in	IN	O	O
labeling	VBG	O	O
anger	NN	O	O
on	IN	O	O
adult	NN	O	O
faces	VBZ	O	O
,	,	O	O
whereas	JJ	O	O
error	NN	O	O
rates	NNS	O	O
in	IN	O	O
the	DT	O	O
LA	NNP	i	IE
Group	NNP	O	O
remained	VBD	O	O
stable	JJ	O	O
.	.	O	O

Progress	NN	O	O
in	IN	O	O
the	DT	O	O
ability	NN	o	OME
to	TO	o	OME
recognize	VB	o	OME
anger	NN	o	OME
in	IN	O	O
the	DT	O	O
SST	NNP	i	IE
Group	NNP	O	O
was	VBD	O	O
due	JJ	O	O
to	TO	O	O
better	JJR	O	O
recognition	NN	O	O
of	IN	O	O
low	JJ	O	O
intensity	NN	O	O
stimuli	NN	O	O
on	IN	O	O
adult	NN	O	O
faces	VBZ	O	O
.	.	O	O

QoL	NNP	o	OPH
increased	VBD	O	O
in	IN	O	O
the	DT	O	O
SST	NNP	i	IE
Group	NNP	O	O
in	IN	O	O
the	DT	O	O
dimension	NN	O	O
of	IN	O	O
school	NN	O	O
environment	NN	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
marker	NN	O	O
of	IN	O	O
the	DT	O	O
transfer	NN	O	O
of	IN	O	O
skills	NNS	O	O
acquired	VBN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
setting	VBG	O	O
to	TO	O	O
their	PRP$	O	O
use	NN	O	O
in	IN	O	O
the	DT	O	O
community	NN	O	O
.	.	O	O

The	DT	O	O
SST-GP	NNP	i	IE
had	VBD	O	O
higher	JJR	O	O
efficacy	NN	o	OOt
than	IN	O	O
the	DT	O	O
LA-GP	NNP	i	IE
.	.	O	O

Data	NNP	O	O
justify	NN	O	O
replication	NN	O	O
using	VBG	O	O
larger	JJR	O	O
samples	NNS	O	O
.	.	O	O

[	RB	O	O
Intravenous	JJ	O	O
treatment	NN	O	O
of	IN	O	O
postpartum	NN	p	O
anemia	NN	O	O
with	IN	O	O
trivalent	JJ	i	IPM
ferrum	NN	i	IPM
preparation	NN	i	IPM
]	NNP	O	O
.	.	O	O

AIM	NNP	O	O
OF	IN	O	O
THE	NNP	O	O
STUDY	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
effectivity	NN	o	OOt
and	CC	O	O
safeness	NN	o	OOt
of	IN	O	O
intravenous	JJ	O	O
treatment	NN	O	O
of	IN	O	O
pospartal	JJ	O	O
anemia	NN	O	O
with	IN	O	O
trivalent	JJ	i	IPM
ferrum	NN	i	IPM
preparation	NN	i	IPM
.	.	O	O

TYPE	NNP	O	O
OF	IN	O	O
THE	NNP	O	O
STUDY	NNP	O	O
Prospective	NNP	O	O
randomized	VBD	O	O
study	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Department	NNP	O	O
of	IN	O	O
Obstetric	NNP	O	O
and	CC	O	O
Gynecology	NNP	O	O
2nd	CD	O	O
Medical	NNP	O	O
Faculty	NNP	O	O
Charles	NNP	O	O
University	NNP	O	O
and	CC	O	O
Teaching	NNP	O	O
Hospital	NNP	O	O
Motol	NNP	O	O
,	,	O	O
Prague	NNP	p	O
,	,	O	O
and	CC	O	O
Department	NNP	O	O
of	IN	O	O
Obstetric	NNP	O	O
and	CC	O	O
Gynecology	NNP	O	O
1st	CD	O	O
Medical	NNP	O	O
Faculty	NNP	O	O
and	CC	O	O
Teaching	NNP	O	O
Hospital	NNP	O	O
Bulovka	NNP	O	O
,	,	O	O
Prague	NNP	p	O
.	.	O	O

METHODS	NNP	O	O
500	CD	O	O
mg	NN	O	O
of	IN	O	O
sacharose	JJ	i	IPM
ferric	JJ	i	IPM
oxide	NN	i	IPM
(	(	i	IPM
Venofer	NNP	i	IPM
)	)	i	IPM
was	VBD	O	O
intravenously	RB	O	O
administered	VBN	O	O
in	IN	O	O
two	CD	O	O
days	NNS	O	O
regimen	NNS	O	O
to	TO	O	O
50	CD	p	PSS
women	NNS	p	PSS
with	IN	p	O
clinical	JJ	p	O
and	CC	p	O
lab	JJ	p	O
signs	NNS	p	O
of	IN	p	O
postpartal	JJ	p	PC
anemia	NN	p	PC
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
administered	JJ	O	O
drug	NN	O	O
was	VBD	O	O
determined	VBN	O	O
by	IN	O	O
comparsion	NN	O	O
of	IN	O	O
values	NNS	o	OPH
of	IN	o	OPH
red	JJ	o	OPH
blood	NN	o	OPH
count	NN	o	OPH
recovered	VBD	O	O
before	IN	O	O
the	DT	O	O
treatment	NN	O	O
,	,	O	O
2nd	CD	O	O
or	CC	O	O
3rd	CD	O	O
day	NN	O	O
post	NN	O	O
administration	NN	O	O
and	CC	O	O
two	CD	O	O
weeks	NNS	O	O
later	RB	O	O
.	.	O	O

The	DT	O	O
serum	NN	o	OPH
values	NNS	o	OPH
of	IN	o	OPH
soluble	JJ	o	OPH
transferrin	NN	o	OPH
receptors	NNS	o	OPH
and	CC	o	OPH
ferritin	NNS	o	OPH
were	VBD	O	O
observed	VBN	O	O
as	IN	O	O
markers	NNS	O	O
of	IN	O	O
iron	NN	o	OPH
cell	NN	o	OPH
saturation	NN	o	OPH
and	CC	O	O
body	NN	o	OPH
iron	NN	o	OPH
reserves	NNS	o	OPH
,	,	O	O
too	RB	O	O
.	.	O	O

Integral	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
the	DT	O	O
monitoring	NN	O	O
of	IN	O	O
adverse	JJ	o	OA
events	NNS	o	OA
during	IN	O	O
the	DT	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Venofer	NNP	i	IPM
came	VBD	O	O
in	IN	O	O
sight	NN	O	O
as	IN	O	O
effective	JJ	o	OOt
drug	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pospartal	JJ	O	O
anemia	NN	O	O
and	CC	O	O
could	MD	O	O
become	VB	O	O
as	IN	O	O
the	DT	O	O
alternative	NN	O	O
to	TO	O	O
blood	VB	O	O
transfusion	NN	O	O
in	IN	O	O
mid-severe	JJ	O	O
cases	NNS	O	O
.	.	O	O

It	PRP	O	O
should	MD	O	O
be	VB	O	O
emphasized	VBN	O	O
that	IN	O	O
we	PRP	O	O
have	VBP	O	O
not	RB	O	O
encountered	VBN	O	O
any	DT	O	O
serious	JJ	o	OA
adverse	JJ	o	OA
event	NN	o	OA
with	IN	O	O
intravenous	JJ	O	O
trivalent	NN	i	IPM
saccharose	VBD	i	IPM
ferric	JJ	i	IPM
oxide	JJ	i	IPM
treatment	NN	O	O
.	.	O	O

Intrathecal	JJ	O	O
morphine	NN	i	IPM
suppresses	NNS	O	O
NK	NNP	o	OPH
cell	NN	o	OPH
activity	NN	o	OPH
following	VBG	O	O
abdominal	JJ	O	O
surgery	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
effects	NNS	O	O
of	IN	O	O
morphine	NN	i	IPM
on	IN	O	O
natural	JJ	o	OPH
killer	NN	o	OPH
(	(	o	OPH
NK	NNP	o	OPH
)	)	o	OPH
cell	NN	o	OPH
activity	NN	o	OPH
were	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
patients	NNS	p	O
who	WP	p	O
underwent	JJ	p	PC
hysterectomy	NN	p	PC
.	.	O	O

METHODS	NNP	O	O
Forty	NNP	p	O
patients	NNS	p	O
were	VBD	p	O
divided	VBN	p	O
into	IN	p	O
four	CD	p	O
groups	NNS	p	O
of	IN	p	O
ten	NN	p	O
.	.	O	O

The	DT	O	O
groups	NNS	O	O
received	VBD	O	O
intrathecal	JJ	O	O
0.5	CD	O	O
mg	NN	O	O
morphine	NN	i	IPM
(	(	O	O
Group	NNP	O	O
IT0.5	NNP	O	O
)	)	O	O
,	,	O	O
intrathecal	JJ	O	O
0.1	CD	O	O
mg	NN	O	O
morphine	NN	i	IPM
(	(	O	O
Group	NNP	O	O
IT0.1	NNP	O	O
)	)	O	O
or	CC	O	O
10	CD	O	O
mg	NNS	O	O
morphine	JJ	i	IPM
i.v	NN	O	O
.	.	O	O

(	(	O	O
Group	NNP	O	O
IV	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
remaining	VBG	O	O
ten	JJ	O	O
patients	NNS	O	O
served	VBD	O	O
as	IN	O	O
controls	NNS	O	O
and	CC	O	O
received	VBN	O	O
inhalation	NN	O	O
anesthesia	NN	O	O
alone	RB	O	O
(	(	O	O
Group	NNP	O	O
C	NNP	O	O
)	)	O	O
.	.	O	O

Blood	NN	O	O
samples	NNS	O	O
were	VBD	O	O
withdrawn	VBN	O	O
before	RB	O	O
and	CC	O	O
two	CD	O	O
hours	NNS	O	O
after	IN	O	O
surgery	NN	O	O
and	CC	O	O
on	IN	O	O
postoperative	JJ	O	O
days	NNS	O	O
one	CD	O	O
and	CC	O	O
two	CD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
blood	NN	O	O
NK	NNP	O	O
cell	NN	O	O
activity	NN	O	O
using	VBG	O	O
a	DT	O	O
chromium	NN	O	O
release	NN	O	O
assay	VBP	O	O
with	IN	O	O
K562	NNP	O	O
cells	NNS	O	O
as	IN	O	O
targets	NNS	O	O
,	,	O	O
plasma	JJ	O	O
catecholamines	NNS	O	O
and	CC	O	O
cortisol	NN	O	O
levels	NNS	O	O
.	.	O	O

The	DT	O	O
postoperative	JJ	o	OPA
pain	NN	o	OPA
score	NN	o	OPA
and	CC	o	O
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
studied	VBN	O	O
in	IN	O	O
the	DT	O	O
four	CD	O	O
groups	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
Group	NNP	O	O
IT0.5	NNP	O	O
,	,	O	O
the	DT	O	O
NK	NNP	o	OPH
cell	NN	o	OPH
activity	NN	o	OPH
was	VBD	O	O
lower	JJR	O	O
on	IN	O	O
postoperative	JJ	O	O
day	NN	O	O
1	CD	O	O
(	(	O	O
23.9	CD	O	O
+/-	JJ	O	O
8.4	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
the	DT	O	O
baseline	NN	O	O
level	NN	O	O
(	(	O	O
45.7	CD	O	O
+/-	JJ	O	O
13	CD	O	O
%	NN	O	O
)	)	O	O
before	IN	O	O
surgery	NN	O	O
,	,	O	O
and	CC	O	O
recovered	VBD	O	O
on	IN	O	O
postoperative	JJ	O	O
day	NN	O	O
2	CD	O	O
.	.	O	O

In	IN	O	O
Groups	NNP	O	O
IT0.1	NNP	O	O
,	,	O	O
C	NNP	O	O
and	CC	O	O
IV	NNP	O	O
,	,	O	O
the	DT	O	O
NK	NNP	o	OPH
cell	NN	o	OPH
activities	NNS	o	OPH
showed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
changes	NNS	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
four	CD	O	O
groups	NNS	O	O
,	,	O	O
neither	CC	O	O
plasma	JJ	o	OPH
adrenaline	NN	o	OPH
nor	CC	O	O
noradrenaline	JJ	o	OPH
concentrations	NNS	o	OPH
changed	VBD	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
four	CD	O	O
groups	NNS	O	O
,	,	O	O
the	DT	O	O
plasma	NN	o	OPH
cortisol	NN	o	OPH
levels	NNS	o	OPH
increased	VBN	O	O
after	IN	O	O
surgery	NN	O	O
,	,	O	O
on	IN	O	O
postoperative	JJ	O	O
days	NNS	O	O
1	CD	O	O
and	CC	O	O
2	CD	O	O
.	.	O	O

The	DT	O	O
pain	NN	o	OPA
score	NN	o	OPA
was	VBD	O	O
lower	JJR	O	O
two	CD	O	O
hours	NNS	O	O
after	IN	O	O
surgery	NN	O	O
and	CC	O	O
on	IN	O	O
postoperative	JJ	O	O
day	NN	O	O
1	CD	O	O
in	IN	O	O
Group	NNP	O	O
IT0.5	NNP	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
other	JJ	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
long-lasting	JJ	O	O
analgesic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
intrathecal	JJ	O	O
0.5	CD	O	O
mg	JJ	O	O
morphine	NN	i	IPM
suppress	NN	O	O
the	DT	O	O
immune	JJ	O	O
response	NN	O	O
following	VBG	O	O
abdominal	JJ	O	O
surgery	NN	O	O
.	.	O	O

[	NN	O	O
Limbal	NNP	i	IS
epithelial	NN	i	IS
autograft	NN	i	IS
transplantation	NN	i	IS
in	IN	O	O
treatment	NN	O	O
of	IN	O	O
pterygium	NN	p	PC
]	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
observe	VB	O	O
the	DT	O	O
therapeutic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
limbal	JJ	i	IS
epithelial	JJ	i	IS
autograft	NN	i	IS
transplantation	NN	i	IS
and	CC	O	O
pterygium	NN	i	IS
excision	NN	i	IS
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pterygium	NN	p	PC
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
prospective	JJ	O	O
randomized	VBN	O	O
paired-eye	JJ	O	O
trial	NN	O	O
was	VBD	O	O
studied	VBN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
208	CD	p	PSS
patients	NNS	p	PSS
(	(	p	O
229	CD	p	O
eyes	NNS	p	O
)	)	p	O
with	IN	p	O
initial	JJ	p	O
pterygium	NN	p	PC
,	,	O	O
and	CC	O	O
they	PRP	O	O
were	VBD	O	O
allocated	VBN	O	O
to	TO	O	O
two	CD	O	O
groups	NNS	O	O
:	:	O	O
excision	NN	i	IS
of	IN	i	IS
pterygium	NN	i	IS
with	IN	O	O
limbal	JJ	i	IS
epithelial	JJ	i	IS
autograft	NN	i	IS
transplantation	NN	i	IS
surgery	NN	i	IS
(	(	O	O
A	NNP	O	O
group	NN	O	O
,	,	O	O
106	CD	O	O
cases	NNS	O	O
and	CC	O	O
124	CD	O	O
eyes	NNS	O	O
)	)	O	O
and	CC	O	O
simple	JJ	i	IS
pterygium	NN	i	IS
excision	NN	i	IS
(	(	O	O
B	NNP	O	O
group	NN	O	O
,	,	O	O
102	CD	O	O
cases	NNS	O	O
and	CC	O	O
105	CD	O	O
eyes	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
criteria	NN	O	O
for	IN	O	O
recovery	NN	O	O
were	VBD	O	O
corneal	JJ	O	O
transparency	NN	O	O
with	IN	O	O
stable	JJ	O	O
epithelial	JJ	o	OPH
healing	NN	o	OPH
and	CC	O	O
no	DT	O	O
abnormal	JJ	o	OPH
proliferation	NN	o	OPH
of	IN	o	OPH
pterygium-like	JJ	o	OPH
tissue	NN	o	OPH
.	.	O	O

The	DT	O	O
post-operative	JJ	O	O
follow-up	JJ	O	O
periods	NNS	O	O
ranged	VBD	O	O
from	IN	O	O
18	CD	O	O
approximately	RB	O	O
28	CD	O	O
(	(	O	O
22.4	CD	O	O
+/-	JJ	O	O
4.9	CD	O	O
)	)	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Some	DT	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
lost	VBD	O	O
follow-up	JJ	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
eyes	NNS	O	O
followed	VBD	O	O
up	RB	O	O
,	,	O	O
5	CD	O	O
of	IN	O	O
11	CD	O	O
2	CD	O	O
eyes	NNS	O	O
(	(	O	O
4.5	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
A	NNP	O	O
group	NN	O	O
and	CC	O	O
41	CD	O	O
of	IN	O	O
96	CD	O	O
eyes	NNS	O	O
(	(	O	O
42.7	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
B	NNP	O	O
group	NN	O	O
were	VBD	O	O
recurred	VBN	O	O
,	,	O	O
the	DT	O	O
difference	NN	O	O
being	VBG	O	O
very	RB	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
To	TO	O	O
provide	VB	O	O
a	DT	O	O
new	JJ	O	O
stem	NN	O	O
cell	NN	O	O
source	NN	O	O
,	,	O	O
limbal	JJ	i	IS
epithelial	JJ	i	IS
autograft	NN	i	IS
transplantation	NN	i	IS
,	,	O	O
for	IN	O	O
an	DT	O	O
injured	JJ	O	O
limb	NN	O	O
us	PRP	O	O
is	VBZ	O	O
a	DT	O	O
reasonable	JJ	O	O
therapeutic	JJ	O	O
method	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pterygium	NN	O	O
.	.	O	O

Reduced	VBN	O	O
platelet	NN	o	OPH
thromboxane	NN	o	OPH
formation	NN	o	OPH
after	IN	O	O
long-term	JJ	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
dihydropyridine	JJ	i	IPM
calcium	NN	i	IPM
channel	NN	i	IPM
blocker	NN	i	IPM
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
with	IN	O	O
nitrendipine	NN	i	IPM
in	IN	O	O
borderline	JJ	p	O
hypertensive	JJ	p	O
patients	NNS	p	O
with	IN	p	O
IDDM-type	NNP	p	O
diabetes	NNS	p	O
mellitus	NN	p	O
.	.	O	O

Twenty-nine	JJ	p	O
IDDM	NNP	p	O
patients	NNS	p	O
with	IN	p	O
borderline	JJ	p	O
hypertension	NN	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
or	CC	O	O
nitrendipine	VB	i	IPM
treatment	NN	O	O
.	.	O	O

Nitrendipine	NNP	i	IPM
was	VBD	O	O
given	VBN	O	O
orally	RB	O	O
at	IN	O	O
a	DT	O	O
dosage	NN	O	O
of	IN	O	O
20	CD	O	O
mg	NNS	O	O
once	RB	O	O
daily	RB	O	O
over	IN	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

Stimulated	VBN	o	OPH
platelet	NN	o	OPH
thromboxane	NN	o	OPH
formation	NN	o	OPH
at	IN	O	O
rest	NN	O	O
and	CC	O	O
after	IN	O	O
standardized	VBN	O	O
,	,	O	O
non	JJ	O	O
exhausting	VBG	O	O
exercise	NN	O	O
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
standard	JJ	O	O
methods	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
plasma	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
platelet	NN	o	OPH
factor	NN	o	OPH
4	CD	o	OPH
and	CC	o	OPH
aggregation	NN	o	OPH
responses	NNS	o	OPH
to	TO	o	OPH
collagen	VB	o	OPH
and	CC	o	OPH
ADP	NNP	o	OPH
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
thromboxane	NN	o	OPH
formation	NN	o	OPH
after	IN	O	O
stimulation	NN	O	O
with	IN	O	O
collagen	NN	O	O
(	(	O	O
0.3	CD	O	O
and	CC	O	O
1.0	CD	O	O
micrograms/ml	NN	O	O
)	)	O	O
and	CC	O	O
1	CD	O	O
mM	NN	O	O
arachidonic	JJ	O	O
acid	NN	O	O
(	(	O	O
AA	NNP	O	O
)	)	O	O
was	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
the	DT	O	O
resting	NN	O	O
state	NN	O	O
.	.	O	O

Exercise	NN	o	OPH
induced	JJ	o	OPH
change	NN	o	OPH
of	IN	o	OPH
thromboxane	NN	o	OPH
synthesis	NN	o	OPH
in	IN	O	O
response	NN	O	O
to	TO	O	O
1.0	CD	O	O
micrograms/ml	NNS	O	O
collagen	NN	O	O
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
parallel	JJ	O	O
,	,	O	O
PF4	NNP	o	OPH
plasma	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
lowered	VBN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Whole	JJ	o	OPH
blood	NN	o	OPH
aggregation	NN	o	OPH
after	IN	o	OPH
collagen	NN	o	OPH
stimulation	NN	o	OPH
(	(	O	O
1.0	CD	O	O
micrograms/ml	NN	O	O
)	)	O	O
was	VBD	O	O
reduced	VBN	O	O
after	IN	O	O
4	CD	O	O
weeks	NNS	O	O
of	IN	O	O
nitrendipine	JJ	i	IPM
treatment	NN	O	O
,	,	O	O
but	CC	O	O
ADP	NNP	O	O
(	(	O	O
5	CD	O	O
microM	NN	O	O
)	)	O	O
induced	VBD	O	O
aggregation	NN	o	OPH
was	VBD	O	O
not	RB	O	O
.	.	O	O

These	DT	O	O
effects	NNS	O	O
of	IN	O	O
nitrendipine	NN	i	IPM
were	VBD	O	O
not	RB	O	O
seen	VBN	O	O
in	IN	O	O
platelet	NN	O	O
rich	JJ	O	O
plasma	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
long-term	JJ	O	O
nitrendipine	JJ	i	IPM
treatment	NN	O	O
may	MD	O	O
inhibit	VB	O	O
collagen	NN	o	OPH
dependent	JJ	o	OPH
platelet	NN	o	OPH
activation	NN	o	OPH
in	IN	O	O
the	DT	O	O
blood	NN	O	O
of	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
with	IN	p	O
borderline	JJ	p	O
hypertension	NN	p	O
.	.	O	O

Fluoroscopic	NNP	O	O
functional	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
bileaflet	NN	i	IS
prostheses	NNS	i	IS
:	:	O	O
effect	NN	O	O
of	IN	O	O
different	JJ	O	O
intraoperative	JJ	O	O
valve	NN	O	O
orientation	NN	O	O
.	.	O	O

Fluoroscopy	NNP	O	O
is	VBZ	O	O
a	DT	O	O
reliable	JJ	O	O
,	,	O	O
easy	JJ	O	O
,	,	O	O
and	CC	O	O
readily	RB	O	O
available	JJ	O	O
technique	NN	O	O
to	TO	O	O
follow-up	JJ	O	O
prosthesis	NN	O	O
functioning	NN	O	O
after	IN	O	O
heart	NN	O	O
valve	NN	O	O
surgery	NN	O	O
.	.	O	O

The	DT	O	O
different	JJ	O	O
orientation	NN	O	O
given	VBN	O	O
to	TO	O	O
the	DT	O	O
prosthesis	NN	O	O
may	MD	O	O
represent	VB	O	O
a	DT	O	O
limitation	NN	O	O
of	IN	O	O
the	DT	O	O
technique	NN	O	O
accounting	NN	O	O
for	IN	O	O
unsatisfactory	JJ	O	O
results	NNS	O	O
in	IN	O	O
10	CD	O	O
%	NN	O	O
to	TO	O	O
40	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
whether	IN	O	O
and	CC	O	O
to	TO	O	O
what	WP	O	O
extent	VB	O	O
different	JJ	O	O
intraoperative	JJ	O	O
valve	NN	O	O
orientation	NN	O	O
influence	NN	O	O
feasibility	NN	o	OOt
and	CC	O	O
accuracy	NN	o	OOt
of	IN	O	O
postoperative	JJ	O	O
fluoroscopic	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
bileaflet	NN	i	IS
prostheses	NNS	i	IS
.	.	O	O

We	PRP	O	O
prospectively	RB	O	O
evaluated	VBD	O	O
90	CD	p	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
aortic	JJ	p	O
,	,	p	O
mitral	JJ	p	O
,	,	p	O
and/or	JJ	p	O
tricuspid	JJ	p	O
valve	FW	p	O
replacement	NN	p	O
with	IN	p	O
Sorin	NNP	i	IPH
Bicarbon	NNP	i	IPH
or	CC	i	O
CarboMedics	NNPS	i	IPH
bileaflet	NN	i	IPH
prostheses	NNS	i	IPH
.	.	O	O

Fifty	NNP	O	O
percent	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
prostheses	NNS	i	O
oriented	VBN	O	O
in	IN	O	O
a	DT	O	O
perpendicular	NN	O	O
or	CC	O	O
a	DT	O	O
parallel	JJ	O	O
position	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
the	DT	O	O
ventricular	JJ	O	O
septum	NN	O	O
.	.	O	O

Fluoroscopic	NNP	O	O
evaluation	NN	O	O
was	VBD	O	O
considered	VBN	O	O
appropriate	JJ	O	O
when	WRB	O	O
the	DT	O	O
prosthesis	NN	O	O
'	POS	O	O
tilting	VBG	O	O
disk	NN	O	O
projection	NN	O	O
was	VBD	O	O
obtained	VBN	O	O
.	.	O	O

The	DT	O	O
valve	NN	O	O
's	POS	O	O
hemodynamic	JJ	o	OPH
performance	NN	o	OPH
was	VBD	O	O
investigated	VBN	O	O
through	IN	O	O
Doppler	NNP	O	O
study	NN	O	O
.	.	O	O

A	DT	O	O
proper	JJ	O	O
fluoroscopic	NN	o	OOt
evaluation	NN	o	OOt
was	VBD	O	O
rapidly	RB	O	O
(	(	O	O
15	CD	O	O
+/-	JJ	O	O
5	CD	O	O
seconds	NNS	O	O
)	)	O	O
achieved	VBN	O	O
in	IN	O	O
all	DT	O	O
patients	NNS	O	O
with	IN	O	O
the	DT	O	O
former	JJ	O	O
orientation	NN	O	O
,	,	O	O
whereas	IN	O	O
it	PRP	O	O
was	VBD	O	O
impossible	JJ	O	O
to	TO	O	O
obtain	VB	O	O
it	PRP	O	O
in	IN	O	O
8	CD	O	O
of	IN	O	O
20	CD	O	O
(	(	O	O
40	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
19	CD	O	O
of	IN	O	O
20	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
4	CD	O	O
of	IN	O	O
5	CD	O	O
(	(	O	O
80	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
the	DT	O	O
latter	JJ	O	O
orientation	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
remaining	VBG	O	O
patients	NNS	O	O
extremely	RB	O	O
angulated	VBN	O	O
,	,	O	O
uneasy	JJ	O	O
projection	NN	O	O
was	VBD	O	O
often	RB	O	O
required	VBN	O	O
to	TO	O	O
get	VB	O	O
a	DT	O	O
correct	JJ	O	O
fluoroscopic	NN	O	O
image	NN	O	O
.	.	O	O

The	DT	O	O
Doppler	NNP	O	O
study	NN	O	O
showed	VBD	O	O
a	DT	O	O
similarly	RB	O	O
favorable	JJ	O	O
hemodynamic	JJ	o	OPH
performance	NN	o	OPH
regardless	NN	O	O
of	IN	O	O
valve	JJ	O	O
orientation	NN	O	O
.	.	O	O

Prosthesis	NNP	i	IS
orientation	NN	O	O
crucially	RB	O	O
affects	VBZ	O	O
the	DT	O	O
rate	NN	o	OOt
of	IN	o	OOt
success	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
fluoroscopic	JJ	o	OOt
evaluation	NN	o	OOt
.	.	O	O

The	DT	O	O
orientation	NN	O	O
perpendicular	NN	O	O
to	TO	O	O
the	DT	O	O
ventricular	JJ	O	O
septum	NN	O	O
greatly	RB	O	O
facilitates	VBZ	O	O
the	DT	O	O
postoperative	JJ	O	O
feasibility	NN	o	OOt
and	CC	o	OOt
accuracy	NN	o	OOt
of	IN	o	OOt
fluoroscopy	NN	o	OOt
,	,	O	O
and	CC	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
detrimental	JJ	O	O
to	TO	O	O
the	DT	O	O
valve	NN	o	OPH
's	POS	o	OPH
hemodynamic	JJ	o	OPH
performance	NN	o	OPH
.	.	O	O

This	DT	O	O
valve	JJ	O	O
orientation	NN	O	O
may	MD	O	O
provide	VB	O	O
a	DT	O	O
better	JJR	O	O
fluoroscopic	NN	o	OPH
window	NN	O	O
whenever	WRB	O	O
a	DT	O	O
valve	NN	O	O
dysfunction	NN	O	O
is	VBZ	O	O
suspected	VBN	O	O
.	.	O	O

Trial	JJ	O	O
design	NN	O	O
challenges	NNS	O	O
when	WRB	O	O
combining	VBG	O	O
medication	NN	i	IPM
and	CC	O	O
parent	NN	i	IE
training	NN	i	IE
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
pervasive	JJ	p	PC
developmental	NN	p	PC
disorders	NNS	p	PC
.	.	O	O

This	DT	O	O
paper	NN	O	O
presents	VBZ	O	O
the	DT	O	O
rationale	NN	O	O
for	IN	O	O
a	DT	O	O
24-week	JJ	O	O
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
designed	VBN	O	O
to	TO	O	O
test	VB	O	O
whether	IN	O	O
risperidone	NN	i	IPM
plus	CC	O	O
structured	JJ	i	IE
parent	NN	i	IE
training	NN	i	IE
would	MD	O	O
be	VB	O	O
superior	JJ	O	O
to	TO	O	O
risperidone	VB	i	IPM
only	RB	O	O
on	IN	O	O
measures	NNS	O	O
of	IN	O	O
noncompliance	NN	o	OME
,	,	o	O
irritability	NN	o	OME
and	CC	o	O
adaptive	JJ	o	OME
functioning	NN	o	OME
.	.	O	O

In	IN	O	O
this	DT	O	O
model	NN	O	O
,	,	O	O
medication	NN	O	O
reduces	NNS	O	O
tantrums	NNS	o	OME
,	,	o	OME
aggression	NN	o	OME
and	CC	o	OME
self-injury	NN	o	OME
;	:	O	O
parent	NN	O	O
training	NN	O	O
promotes	NNS	O	O
improvement	NN	O	O
in	IN	O	O
noncompliance	NN	o	OME
and	CC	o	O
adaptive	JJ	o	OME
functioning	NN	o	OME
.	.	O	O

Thus	RB	O	O
,	,	O	O
medication	NN	O	O
and	CC	O	O
parent	NN	O	O
training	NN	O	O
target	NN	O	O
related	VBN	O	O
,	,	O	O
but	CC	O	O
separate	JJ	O	O
,	,	O	O
outcomes	RB	O	O
.	.	O	O

At	IN	O	O
week	NN	O	O
24	CD	O	O
,	,	O	O
the	DT	O	O
medication	NN	O	O
was	VBD	O	O
gradually	RB	O	O
withdrawn	VBN	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
combined	JJ	O	O
treatment	NN	O	O
group	NN	O	O
could	MD	O	O
be	VB	O	O
managed	VBN	O	O
on	IN	O	O
a	DT	O	O
lower	JJR	O	O
dose	NN	O	O
or	CC	O	O
off	IN	O	O
medication	NN	O	O
without	IN	O	O
relapse	NN	O	O
.	.	O	O

Both	DT	O	O
symptom	JJ	o	OOt
reduction	NN	O	O
and	CC	O	O
functional	JJ	o	OOt
improvement	NN	O	O
are	VBP	O	O
important	JJ	O	O
clinical	JJ	O	O
treatment	NN	O	O
targets	NNS	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
experimental	JJ	O	O
evidence	NN	O	O
on	IN	O	O
the	DT	O	O
beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
combining	VBG	O	O
pharmacotherapy	NN	O	O
and	CC	O	O
exportable	JJ	O	O
behavioral	JJ	O	O
interventions	NNS	O	O
is	VBZ	O	O
needed	VBN	O	O
to	TO	O	O
guide	VB	O	O
clinical	JJ	O	O
practice	NN	O	O
.	.	O	O

The	DT	O	O
efficacy	NN	O	O
of	IN	O	O
prophylactic	JJ	O	O
ondansetron	NN	i	IPM
,	,	O	O
droperidol	NN	i	IPM
,	,	O	O
perphenazine	NN	i	IPM
,	,	O	O
and	CC	O	O
metoclopramide	RB	i	IPM
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
after	IN	O	O
major	JJ	O	O
gynecologic	NN	O	O
surgery	NN	O	O
.	.	O	O

The	DT	O	O
prophylactic	JJ	O	O
antiemetic	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
(	(	O	O
i.v	JJ	O	O
.	.	O	O

)	)	O	O
ondansetron	NN	i	IPM
,	,	O	O
droperidol	NN	i	IPM
,	,	O	O
perphenazine	NN	i	IPM
,	,	O	O
and	CC	O	O
metoclopramide	NN	i	IPM
was	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
of	IN	O	O
360	CD	p	PSS
ASA	NNP	p	PC
physical	JJ	p	PC
status	NN	p	PC
I-III	NNP	p	PC
patients	NNS	p	O
undergoing	VBG	p	O
total	JJ	p	O
abdominal	JJ	p	O
hysterectomy	NN	p	O
(	(	p	O
TAH	NNP	p	O
)	)	p	O
.	.	O	O

Subjects	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
i.v.	NN	O	O
,	,	O	O
one	CD	O	O
of	IN	O	O
ondansetron	NN	i	IPM
4	CD	O	O
mg	NN	O	O
,	,	O	O
droperidol	VBZ	i	IPM
1.25	CD	O	O
mg	NN	O	O
,	,	O	O
perphenazine	VBP	i	IPM
5	CD	O	O
mg	NN	O	O
,	,	O	O
metoclopramide	RB	i	IPM
10	CD	O	O
mg	NN	O	O
,	,	O	O
or	CC	O	O
placebo	RB	i	IC
prior	JJ	O	O
to	TO	O	O
induction	NN	O	O
of	IN	O	O
anesthesia	NN	O	O
.	.	O	O

Hypotension	NNP	o	OPH
immediately	RB	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
metoclopramide	NN	i	IPM
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
two	CD	O	O
patients	NNS	O	O
and	CC	O	O
four	CD	O	O
patients	NNS	O	O
given	VBN	O	O
ondansetron	RP	O	O
developed	JJ	O	O
profound	NN	O	O
systolic	JJ	O	O
hypotension	NN	O	O
at	IN	O	O
induction	NN	O	O
of	IN	O	O
anesthesia	NN	O	O
.	.	O	O

Twenty-two	JJ	O	O
percent	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
droperidol	NN	O	O
became	VBD	O	O
sedated	JJ	O	O
.	.	O	O

Postoperatively	RB	O	O
,	,	O	O
patients	NNS	O	O
developing	VBG	O	O
severe	JJ	o	OPH
nausea	NN	o	OPH
,	,	o	OPH
retching	NN	o	OPH
,	,	o	OPH
or	CC	o	OPH
vomiting	NN	o	OPH
,	,	O	O
defined	VBD	O	O
as	IN	O	O
severe	JJ	o	OPH
emetic	JJ	o	OPH
sequelae	NN	o	OPH
(	(	o	OPH
SES	NNP	o	OPH
)	)	o	OPH
,	,	O	O
were	VBD	O	O
deemed	VBN	O	O
to	TO	O	O
have	VB	O	O
failed	VBN	O	O
antiemetic	JJ	O	O
prophylaxis	NN	O	O
and	CC	O	O
received	VBN	O	O
antiemetic	JJ	O	O
rescue	NN	O	O
.	.	O	O

A	DT	O	O
significantly	RB	O	O
larger	JJR	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
i.v	NN	O	O
.	.	O	O

ondansetron	NN	O	O
(	(	O	O
63	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
droperidol	NN	O	O
(	(	O	O
76	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
perphenazine	NN	O	O
(	(	O	O
70	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
free	JJ	O	O
of	IN	O	O
SES	NNP	o	OPH
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
placebo	VB	O	O
(	(	O	O
43	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
P	NNP	O	O
<	VBD	O	O
0.05	CD	O	O
.	.	O	O

Metoclopramide	NNP	O	O
was	VBD	O	O
ineffective	JJ	O	O
.	.	O	O

Although	IN	O	O
ondansetron	NN	O	O
,	,	O	O
droperidol	NN	O	O
,	,	O	O
and	CC	O	O
perphenazine	NN	O	O
were	VBD	O	O
effective	JJ	o	OOt
in	IN	O	O
providing	VBG	O	O
antiemetic	JJ	O	O
prophylaxis	NN	O	O
,	,	O	O
only	RB	O	O
i.v	NN	O	O
.	.	O	O

perphenazine	NN	O	O
was	VBD	O	O
free	JJ	O	O
of	IN	O	O
side	JJ	o	OA
effects	NNS	o	OA
.	.	O	O

Hence	NNP	O	O
,	,	O	O
we	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
perphenazine	NN	O	O
is	VBZ	O	O
the	DT	O	O
best	JJS	O	O
choice	NN	O	O
for	IN	O	O
antiemetic	JJ	O	O
prophylaxis	NN	O	O
after	IN	O	O
TAH	NNP	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
rosuvastatin	NN	i	O
monotherapy	NN	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
fenofibrate	NN	i	O
or	CC	O	O
?-3	JJ	i	O
fatty	JJ	i	O
acids	NNS	i	O
on	IN	O	O
lipoprotein	JJ	o	O
subfraction	NN	o	O
profile	NN	o	O
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
mixed	JJ	p	PC
dyslipidaemia	NN	p	PC
and	CC	p	PC
metabolic	JJ	p	PC
syndrome	NN	p	PC
.	.	O	O

BACKGROUND	NNP	O	O
Raised	VBD	O	O
triglycerides	NNS	O	O
(	(	O	O
TG	NNP	O	O
)	)	O	O
,	,	O	O
decreased	VBD	O	O
high-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
(	(	O	O
HDL-C	NNP	O	O
)	)	O	O
levels	NNS	O	O
and	CC	O	O
a	DT	O	O
predominance	NN	O	O
of	IN	O	O
small	JJ	O	O
dense	NN	O	O
low	JJ	O	O
density	NN	O	O
lipoproteins	NNS	O	O
(	(	O	O
sdLDL	NN	O	O
)	)	O	O
are	VBP	O	O
characteristics	NNS	O	O
of	IN	O	O
the	DT	O	O
metabolic	JJ	p	O
syndrome	NN	p	O
(	(	p	O
MetS	NNP	p	O
)	)	p	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
high-dose	JJ	O	O
rosuvastatin	NN	i	O
monotherapy	NN	O	O
with	IN	O	O
moderate	JJ	O	O
dosing	NN	O	O
combined	VBN	O	O
with	IN	O	O
fenofibrate	NN	i	O
or	CC	O	O
?-3	JJ	i	O
fatty	JJ	i	O
acids	NNS	i	O
on	IN	O	O
the	DT	O	O
lipoprotein	JJ	o	O
subfraction	NN	o	O
profile	NN	o	O
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
mixed	JJ	p	PC
dyslipidaemia	NN	p	PC
and	CC	p	PC
MetS	NNP	p	PC
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
previously	RB	O	O
randomised	VBD	O	O
patients	NNS	O	O
with	IN	O	O
low-density	JJ	O	O
lipoprotein	NNS	O	O
cholesterol	NN	O	O
(	(	O	O
LDL-C	NNP	O	O
)	)	O	O
>	VBZ	O	O
160	CD	O	O
and	CC	O	O
TG	NNP	O	O
>	NNP	O	O
200	CD	O	O
mg/dl	NN	O	O
to	TO	O	O
rosuvastatin	VB	i	O
monotherapy	NN	O	O
40	CD	O	O
mg/day	NN	O	O
(	(	O	O
R	NNP	O	O
group	NN	O	O
,	,	O	O
n	RB	O	O
=	VBZ	O	O
30	CD	O	O
)	)	O	O
or	CC	O	O
rosuvastatin	$	i	O
10	CD	O	O
mg/day	NN	O	O
combined	VBN	O	O
with	IN	O	O
fenofibrate	JJ	i	O
200	CD	O	O
mg/day	NN	O	O
(	(	O	O
RF	NNP	O	O
group	NN	O	O
,	,	O	O
n	RB	O	O
=	VBZ	O	O
30	CD	O	O
)	)	O	O
or	CC	O	O
?-3	JJ	i	O
fatty	JJ	i	O
acids	NNS	i	O
2	CD	O	O
g/day	NN	O	O
(	(	O	O
R?	NNP	O	O
group	NN	O	O
,	,	O	O
n	RB	O	O
=	VBZ	O	O
30	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
only	RB	O	O
patients	NNS	p	PC
with	IN	p	PC
MetS	NNP	p	PC
were	VBD	p	O
included	VBN	p	O
(	(	O	O
24	CD	O	O
,	,	O	O
23	CD	O	O
and	CC	O	O
24	CD	O	O
in	IN	O	O
the	DT	O	O
R	NNP	O	O
,	,	O	O
RF	NNP	O	O
and	CC	O	O
R?	NNP	O	O
groups	NNS	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
12	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
lipoprotein	JJ	o	O
subfraction	NN	o	O
profile	NN	o	O
was	VBD	O	O
determined	VBN	O	O
by	IN	O	O
polyacrylamide	JJ	O	O
3	CD	O	O
%	NN	O	O
gel	JJ	O	O
electrophoresis	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
mean	JJ	o	O
LDL	NNP	o	O
size	NN	o	O
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
in	IN	O	O
all	DT	O	O
groups	NNS	O	O
.	.	O	O

This	DT	O	O
change	NN	O	O
was	VBD	O	O
more	RBR	O	O
prominent	JJ	O	O
with	IN	O	O
RF	NNP	i	O
than	IN	O	O
with	IN	O	O
other	JJ	O	O
treatments	NNS	O	O
in	IN	O	O
parallel	JJ	O	O
with	IN	O	O
its	PRP$	O	O
greater	JJR	O	O
hypotriglyceridemic	JJ	o	O
capacity	NN	o	O
(	(	O	O
p	JJ	O	O
<	$	O	O
0.05	CD	O	O
compared	VBN	O	O
with	IN	O	O
R	NNP	O	O
and	CC	O	O
R?	NNP	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
decrease	NN	O	O
in	IN	O	O
insulin	NN	o	O
resistance	NN	o	O
by	IN	O	O
RF	NNP	O	O
was	VBD	O	O
also	RB	O	O
noted	VBN	O	O
.	.	O	O

Only	RB	O	O
RF	NNP	i	O
significantly	RB	O	O
raised	VBD	O	O
HDL-C	NNP	o	O
levels	NNS	o	O
(	(	O	O
by	IN	O	O
7.7	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
by	IN	O	O
increasing	VBG	O	O
the	DT	O	O
cholesterol	NN	O	O
of	IN	O	O
small	JJ	O	O
HDL	NNP	O	O
particles	NNS	O	O
.	.	O	O

The	DT	O	O
cholesterol	NN	O	O
of	IN	o	O
larger	JJR	o	O
HDL	NNP	o	O
subclasses	NNS	o	O
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
by	IN	O	O
R	NNP	i	O
and	CC	O	O
R?	NNP	i	O
.	.	O	O

CONCLUSIONS	NNP	O	O
All	NNP	O	O
regimens	VBZ	O	O
increased	VBN	O	O
mean	JJ	O	O
LDL	NNP	o	O
size	NN	o	O
;	:	O	O
RF	NNP	O	O
was	VBD	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
.	.	O	O

A	DT	O	O
differential	JJ	O	O
effect	NN	O	O
of	IN	O	O
treatments	NNS	O	O
was	VBD	O	O
noted	VBN	O	O
on	IN	O	O
the	DT	O	O
HDL	NNP	O	O
subfraction	NN	O	O
profile	NN	O	O
.	.	O	O

Prediction	NN	O	O
of	IN	O	O
creatinine	JJ	o	OPH
clearance	NN	o	OPH
from	IN	o	OPH
serum	JJ	o	OPH
creatinine	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
rheumatoid	JJ	p	O
arthritis	NN	p	O
:	:	O	O
comparison	NN	O	O
of	IN	O	O
six	CD	O	O
formulae	NNS	O	O
and	CC	O	O
one	CD	O	O
nomogram	NN	O	O
.	.	O	O

The	DT	O	O
estimation	NN	O	O
of	IN	O	O
glomerular	JJ	o	OPH
filtration	NN	o	OPH
rate	NN	o	OPH
is	VBZ	O	O
important	JJ	O	O
for	IN	O	O
the	DT	O	O
medical	JJ	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
rheumatoid	JJ	p	O
arthritis	NN	p	O
(	(	p	O
RA	NNP	p	O
)	)	p	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
determination	NN	O	O
of	IN	O	O
endogenous	JJ	O	O
creatinine	JJ	O	O
clearance	NN	O	O
(	(	O	O
Clcr	NNP	O	O
)	)	O	O
from	IN	O	O
a	DT	O	O
24-h	JJ	O	O
urine	JJ	O	O
collection	NN	O	O
is	VBZ	O	O
an	DT	O	O
unreliable	JJ	O	O
and	CC	O	O
time-consuming	JJ	O	O
procedure	NN	O	O
.	.	O	O

We	PRP	O	O
therefore	RB	O	O
tested	VBD	O	O
the	DT	O	O
accuracy	NN	O	O
of	IN	O	O
six	CD	O	O
equations	NNS	O	O
and	CC	O	O
one	CD	O	O
nomogram	NN	O	O
for	IN	O	O
the	DT	O	O
prediction	NN	o	O
of	IN	o	O
Clcr	NNP	o	OPH
from	IN	o	OPH
serum	JJ	o	OPH
creatinine	NN	o	OPH
(	(	o	OPH
Scr	NNP	o	OPH
)	)	o	O
in	IN	O	O
38	CD	p	O
patients	NNS	p	O
with	IN	p	O
RA	NNP	p	O
and	CC	p	O
20	CD	p	O
controls	NNS	p	O
.	.	O	O

A	DT	O	O
positive	JJ	O	O
correlation	NN	o	OPH
was	VBD	O	O
found	VBN	O	O
for	IN	O	O
all	DT	O	O
methods	NNS	O	O
in	IN	O	O
the	DT	O	O
controls	NNS	O	O
(	(	O	O
r	VB	O	O
=	NNP	O	O
0.83-0.94	NN	O	O
)	)	O	O
and	CC	O	O
RA	NNP	O	O
patients	NNS	O	O
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.51-0.69	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
methods	NNS	O	O
did	VBD	O	O
not	RB	O	O
overestimate	VB	O	O
Clcr	NNP	O	O
in	IN	O	O
RA	NNP	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
RA	NNP	O	O
group	NN	O	O
the	DT	O	O
simple	JJ	O	O
formula	NN	O	O
published	VBN	O	O
by	IN	O	O
Cockcroft	NNP	O	O
[	NNP	O	O
Clcr	NNP	O	O
=	NNP	O	O
(	(	O	O
(	(	O	O
140	CD	O	O
-	:	O	O
age	NN	O	O
)	)	O	O
x	VBZ	O	O
body	NN	O	O
weight	NN	O	O
)	)	O	O
/	NN	O	O
(	(	O	O
72	CD	O	O
x	NNP	O	O
Scr	NNP	O	O
)	)	O	O
,	,	O	O
x	$	O	O
0.85	CD	O	O
for	IN	O	O
females	NNS	O	O
]	VBP	O	O
showed	VBD	O	O
the	DT	O	O
best	JJS	O	O
correlation	NN	O	O
with	IN	O	O
the	DT	O	O
measured	VBN	O	O
Clcr	NNP	O	O
.	.	O	O

In	IN	O	O
RA	NNP	O	O
the	DT	O	O
Cockroft	NNP	O	O
formula	NN	O	O
can	MD	O	O
reliably	RB	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
predict	VB	o	O
Clcr	NNP	o	O
from	IN	o	O
Scr	NNP	o	O
.	.	O	O

Cophenylcaine	NNP	i	IPM
spray	NN	O	O
vs.	FW	O	O
placebo	NN	i	IC
in	IN	O	O
flexible	JJ	p	O
nasendoscopy	NN	p	O
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
double-blind	NN	O	O
randomised	VBD	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

Practices	NNS	O	O
vary	VBP	O	O
across	IN	O	O
the	DT	O	O
UK	NNP	O	O
on	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
topical	JJ	O	O
preparation	NN	O	O
prior	RB	O	O
to	TO	O	O
flexible	JJ	O	O
fibreoptic	JJ	O	O
nasendoscopy	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
double-blind	NN	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
randomised	VBD	O	O
98	CD	p	PSS
patients	NNS	p	O
to	TO	O	O
receive	VB	O	O
cophenylcaine	NN	i	IPM
or	CC	O	O
placebo	NN	i	IC
nasal	JJ	O	O
spray	NN	O	O
before	IN	O	O
flexible	JJ	p	O
nasendoscopy	NN	p	O
.	.	O	O

A	DT	O	O
visual	JJ	O	O
analogue	NN	O	O
scale	NN	O	O
(	(	O	O
1-100	JJ	O	O
)	)	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
record	VB	O	O
pain	NN	o	OPA
,	,	o	OPA
unpleasantness	NN	o	OPA
of	IN	o	OPA
taste	NN	o	OPA
and	CC	o	OPA
overall	JJ	o	OPA
discomfort	NN	o	OPA
experienced	VBD	o	OPA
.	.	O	O

Overall	JJ	O	O
,	,	O	O
the	DT	O	O
procedure	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
minimal	JJ	O	O
pain	NN	o	OPA
and	CC	o	OPA
discomfort	NN	o	OPA
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
pain	NN	o	OPA
or	CC	o	OPA
overall	JJ	o	OPA
discomfort	NN	o	OPA
experienced	VBD	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
the	DT	O	O
sensation	NN	o	OPH
of	IN	o	OPH
bad	JJ	o	OPH
taste	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
worse	JJR	O	O
in	IN	O	O
the	DT	O	O
cophenylcaine	NN	i	IPM
group	NN	O	O
.	.	O	O

In	IN	O	O
linear	JJ	O	O
regression	NN	O	O
,	,	O	O
factors	NNS	O	O
that	WDT	O	O
predicted	VBD	O	O
the	DT	O	O
overall	JJ	O	O
unpleasantness	NN	o	OOt
of	IN	O	O
the	DT	O	O
experience	NN	O	O
were	VBD	O	O
primarily	RB	O	O
pain	VBN	o	OPA
experienced	JJ	O	O
and	CC	O	O
secondarily	JJ	O	O
unpleasantness	NN	o	OME
of	IN	o	OME
taste	NN	o	OME
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
routine	JJ	O	O
use	NN	O	O
of	IN	O	O
cophenylcaine	NN	i	IPM
for	IN	O	O
nasal	JJ	O	O
preparation	NN	O	O
is	VBZ	O	O
not	RB	O	O
justified	VBN	O	O
before	IN	O	O
flexible	JJ	p	O
nasendoscopy	NN	p	O
.	.	O	O

Group	NNP	i	IE
cognitive	JJ	i	IE
behavior	NN	i	IE
therapy	NN	i	IE
for	IN	O	O
children	NNS	p	PC
with	IN	p	PC
high-functioning	JJ	p	PC
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
and	CC	p	PC
anxiety	NN	p	PC
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Children	NNP	p	O
with	IN	O	O
high-functioning	JJ	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
(	(	O	O
ASD	NNP	O	O
)	)	O	O
are	VBP	O	O
at	IN	O	O
high	JJ	O	O
risk	NN	O	O
for	IN	O	O
developing	VBG	O	O
significant	JJ	O	O
anxiety	NN	O	O
.	.	O	O

Anxiety	NN	O	O
can	MD	O	O
adversely	RB	O	O
impact	VB	O	O
functioning	VBG	O	O
across	IN	O	O
school	NN	O	O
,	,	O	O
home	NN	O	O
and	CC	O	O
community	NN	O	O
environments	NNS	O	O
.	.	O	O

Cognitive	JJ	i	IE
behavioral	JJ	i	IE
therapies	NNS	i	IE
(	(	i	IE
CBT	NNP	i	IE
)	)	i	IE
are	VBP	O	O
frequently	RB	O	O
used	VBN	O	O
with	IN	O	O
success	NN	O	O
for	IN	O	O
children	NNS	O	O
with	IN	O	O
anxiety	NN	o	OME
symptoms	NNS	o	OME
.	.	O	O

Modified	NNP	O	O
CBT	NNP	i	IE
interventions	NNS	O	O
for	IN	O	O
anxiety	NN	p	O
in	IN	p	O
children	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
have	VBP	O	O
also	RB	O	O
yielded	VBN	O	O
promising	JJ	O	O
results	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
Fifty	NNP	p	O
children	NNS	p	O
with	IN	p	O
high-functioning	JJ	p	O
ASD	NNP	p	O
and	CC	p	O
anxiety	NN	p	O
were	VBD	O	O
randomizedto	JJ	O	O
group	NN	O	O
CBT	NNP	i	IE
or	CC	O	O
treatment-as-usual	JJ	i	IE
(	(	i	IE
TAU	NNP	i	IE
)	)	i	IE
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
.	.	O	O

Independent	NNP	O	O
clinical	JJ	O	O
evaluators	NNS	O	O
,	,	O	O
blind	NN	O	O
to	TO	O	O
condition	NN	O	O
,	,	O	O
completed	VBN	O	O
structured	JJ	O	O
interviews	NNS	O	O
(	(	o	O
Anxiety	NNP	o	O
Disorders	NNP	o	O
Interview	NNP	o	O
Schedule	NNP	o	O
?	.	o	O
Parent	NNP	o	O
Version	NNP	o	O
;	:	o	O
ADIS-P	NNP	o	O
)	)	o	O
pre-	NN	O	O
and	CC	O	O
post-intervention	NN	O	O
condition	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Forty-seven	JJ	p	O
children	NNS	p	O
completed	VBN	O	O
either	CC	O	O
the	DT	O	O
CBT	NNP	i	IE
or	CC	O	O
TAU	NNP	i	IE
condition	NN	O	O
.	.	O	O

Results	NNS	O	O
indicated	VBD	O	O
markedly	RB	O	O
better	RBR	O	O
outcomes	NNS	O	O
for	IN	O	O
the	DT	O	O
CBT	NNP	i	IE
group	NN	O	O
.	.	O	O

Significant	JJ	O	O
differences	NNS	O	O
by	IN	O	O
group	NN	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
Clinician	JJ	o	O
Severity	NNP	o	O
Ratings	NNP	o	O
,	,	o	O
diagnostic	JJ	o	OME
status	NN	o	OME
,	,	o	O
and	CC	o	O
clinician	JJ	o	O
ratings	NNS	o	O
of	IN	o	O
global	JJ	o	O
improvement	NN	o	O
.	.	O	O

In	IN	O	O
the	DT	O	O
intent-to-treat	JJ	O	O
sample	NN	O	O
,	,	O	O
10	CD	O	O
of	IN	O	O
20	CD	O	O
children	NNS	O	O
(	(	O	O
50	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
CBT	NNP	i	O
group	NN	O	O
had	VBD	O	O
a	DT	O	O
clinically	RB	O	O
meaningful	JJ	O	O
positive	JJ	O	O
treatment	NN	O	O
response	NN	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
2	CD	O	O
of	IN	O	O
23	CD	O	O
children	NNS	O	O
(	(	O	O
8.7	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
TAU	NNP	i	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Initial	JJ	O	O
results	NNS	O	O
from	IN	O	O
this	DT	O	O
randomized	VBN	O	O
,	,	O	O
designed	VBN	O	O
treatment	NN	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
agroup	NN	O	O
CBT	NNP	i	O
intervention	NN	O	O
specifically	RB	O	O
developed	VBD	O	O
for	IN	O	O
children	NNS	O	O
with	IN	O	O
ASD	NNP	O	O
may	MD	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
decreasing	VBG	O	O
anxiety	NN	O	O
.	.	O	O

Limitations	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
include	VBP	O	O
small	JJ	O	O
sample	JJ	O	O
size	NN	O	O
,	,	O	O
lack	NN	O	O
of	IN	O	O
an	DT	O	O
attention	NN	O	O
control	NN	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
use	NN	O	O
of	IN	O	O
outcome	NN	O	O
measures	NNS	O	O
normed	VBN	O	O
with	IN	O	O
typically	RB	O	O
developing	VBG	O	O
children	NNS	O	O
Lowering	VBG	O	O
the	DT	O	O
triglyceride/high-density	NN	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
ratio	NN	o	OPH
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
beneficial	JJ	O	O
impact	NN	O	O
of	IN	O	O
pioglitazone	NN	i	IPM
on	IN	O	O
progression	NN	O	O
of	IN	O	O
coronary	JJ	o	OPH
atherosclerosis	NN	o	OPH
in	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
:	:	O	O
insights	NNS	O	O
from	IN	O	O
the	DT	O	O
PERISCOPE	NNP	O	O
(	(	O	O
Pioglitazone	NNP	O	O
Effect	NNP	O	O
on	IN	O	O
Regression	NNP	O	O
of	IN	O	O
Intravascular	NNP	O	O
Sonographic	NNP	O	O
Coronary	NNP	O	O
Obstruction	NNP	O	O
Prospective	NNP	O	O
Evaluation	NNP	O	O
)	)	O	O
study	NN	O	O
.	.	O	O

OBJECTIVES	CC	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
favorable	JJ	O	O
effect	NN	O	O
of	IN	O	O
pioglitazone	NN	i	IPM
on	IN	O	O
atheroma	JJ	O	O
progression	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Diabetes	NNP	O	O
mellitus	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
accelerated	JJ	O	O
coronary	JJ	O	O
atheroma	NN	O	O
progression	NN	O	O
.	.	O	O

Pioglitazone	NN	i	IPM
slowed	VBD	O	O
progression	NN	O	O
compared	VBN	O	O
with	IN	O	O
glimepiride	NN	O	O
in	IN	O	O
this	DT	O	O
population	NN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
all	DT	O	O
,	,	O	O
360	CD	p	O
diabetic	JJ	p	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
pioglitazone	NN	i	IPM
or	CC	O	O
glimepiride	NN	i	IPM
for	IN	O	O
18	CD	O	O
months	NNS	O	O
in	IN	O	O
the	DT	O	O
PERISCOPE	NNP	O	O
(	(	O	O
Pioglitazone	NNP	O	O
Effect	NNP	O	O
on	IN	O	O
Regression	NNP	O	O
of	IN	O	O
Intravascular	NNP	O	O
Sonographic	NNP	O	O
Coronary	NNP	O	O
Obstruction	NNP	O	O
Prospective	NNP	O	O
Evaluation	NNP	O	O
)	)	O	O
study	NN	O	O
.	.	O	O

Coronary	NNP	o	OPH
atheroma	NN	o	OPH
progression	NN	o	OPH
was	VBD	O	O
evaluated	VBN	O	O
by	IN	O	O
serial	JJ	O	O
intravascular	JJ	O	O
ultrasound	NN	O	O
.	.	O	O

The	DT	O	O
relationship	NN	O	O
between	IN	O	O
changes	NNS	o	OPH
in	IN	o	OPH
biochemical	JJ	o	OPH
parameters	NNS	o	OPH
,	,	o	O
percent	JJ	o	OPH
atheroma	NN	o	OPH
volume	NN	o	OPH
,	,	o	O
and	CC	o	O
total	JJ	o	OPH
atheroma	NN	o	OPH
volume	NN	o	OPH
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

RESULTS	JJ	O	O
Pioglitazone-treated	JJ	i	IPM
patients	NNS	O	O
demonstrated	VBD	O	O
greater	JJR	O	O
increases	NNS	O	O
in	IN	O	O
high-density	NN	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
(	(	o	OPH
HDL-C	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
reductions	NNS	O	O
in	IN	O	O
glycated	JJ	o	OPH
hemoglobin	NN	o	OPH
,	,	o	OPH
triglycerides	NNS	o	OPH
,	,	o	OPH
and	CC	o	OPH
C-reactive	JJ	o	OPH
protein	NN	o	OPH
.	.	O	O

Significant	JJ	O	O
correlations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
between	IN	O	O
changes	NNS	O	O
in	IN	O	O
percent	NN	o	OPH
atheroma	NN	o	OPH
volume	NN	o	OPH
and	CC	o	OPH
triglycerides	NNS	o	OPH
(	(	O	O
r	VB	O	O
=	RB	O	O
0.15	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
,	,	O	O
triglyceride/HDL-C	JJ	o	OPH
ratio	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NN	O	O
0.16	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
glycated	VBD	o	OPH
hemoglobin	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NN	O	O
0.16	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
with	IN	O	O
pioglitazone	NN	i	IPM
,	,	O	O
and	CC	O	O
changes	NNS	O	O
in	IN	O	O
low-density	NN	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NNP	O	O
-0.15	NNP	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
apolipoprotein	RB	o	OPH
B	NNP	o	OPH
(	(	O	O
r	NN	O	O
=	NNP	O	O
-0.16	NNP	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
apolipoprotein	RB	o	OPH
A-I	NNP	o	OPH
(	(	O	O
r	NN	O	O
=	NNP	O	O
-0.20	NNP	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
with	IN	O	O
glimepiride	NN	i	IPM
.	.	O	O

Substantial	JJ	O	O
atheroma	JJ	O	O
regression	NN	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
progression	NN	O	O
,	,	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
greater	JJR	O	O
relative	JJ	O	O
increases	NNS	O	O
in	IN	O	O
HDL-C	NNP	o	OPH
(	(	O	O
14.2	CD	O	O
%	NN	O	O
vs.	FW	O	O
7.8	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
,	,	O	O
relative	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
triglycerides	NNS	o	OPH
(	(	O	O
-13.3	CD	O	O
%	NN	O	O
vs.	FW	O	O
-1.9	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.045	CD	O	O
)	)	O	O
,	,	O	O
triglyceride/HDL-C	JJ	o	OPH
ratio	NN	o	OPH
(	(	O	O
-22.5	NNP	O	O
vs.	FW	O	O
-9.9	NNP	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
decrease	NN	O	O
in	IN	O	O
glycated	JJ	o	OPH
hemoglobin	NN	o	OPH
(	(	O	O
-0.6	CD	O	O
%	NN	O	O
vs.	FW	O	O
-0.3	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Multivariable	JJ	O	O
analysis	NN	O	O
revealed	VBD	O	O
that	IN	O	O
pioglitazone-induced	JJ	i	IOt
effects	NNS	O	O
on	IN	O	O
triglyceride/HDL-C	NN	o	OPH
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
changes	NNS	O	O
in	IN	O	O
percent	NN	o	OPH
atheroma	NN	o	OPH
volume	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
and	CC	O	O
total	JJ	o	OPH
atheroma	NN	o	OPH
volume	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Favorable	JJ	O	O
effects	NNS	O	O
of	IN	O	O
pioglitazone	NN	i	IPM
on	IN	O	O
the	DT	O	O
triglyceride/HDL-C	JJ	o	OPH
ratio	NN	o	OPH
correlated	VBN	O	O
with	IN	O	O
delayed	JJ	O	O
atheroma	NN	o	OPH
progression	NN	o	OPH
in	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
.	.	O	O

This	DT	O	O
finding	NN	O	O
highlights	VBZ	O	O
the	DT	O	O
potential	JJ	O	O
importance	NN	O	O
of	IN	O	O
targeting	VBG	O	O
atherogenic	JJ	O	O
dyslipidemia	NN	O	O
in	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
.	.	O	O

Bacteremia	NNP	O	O
due	JJ	O	O
to	TO	O	O
Bacteroides	NNP	O	O
fragilis	NN	O	O
after	IN	O	O
elective	JJ	p	PC
appendectomy	NN	p	PC
in	IN	p	O
renal	JJ	p	PC
transplant	NN	p	PC
recipients	NNS	p	O
.	.	O	O

Bacteremia	NNP	O	O
caused	VBN	O	O
by	IN	O	O
Bacteroides	NNP	O	O
fragilis	NN	O	O
occurred	VBD	O	O
in	IN	O	O
four	CD	O	O
of	IN	O	O
75	CD	p	PSS
children	NNS	p	PA
after	IN	p	O
renal	JJ	p	O
transplantation	NN	p	O
,	,	O	O
and	CC	O	O
B.	NNP	O	O
fragilis	NN	O	O
was	VBD	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
cause	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
bacteremia	NN	O	O
.	.	O	O

Bacteroides	NNP	O	O
bacteremia	NN	O	O
was	VBD	O	O
significantly	RB	O	O
associated	VBN	O	O
with	IN	O	O
performance	NN	O	O
of	IN	O	O
elective	JJ	O	O
appendectomy	NN	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
transplantation	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
with	IN	O	O
profound	JJ	O	O
lymphocytopenia	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
patient	NN	O	O
received	VBD	O	O
antibiotics	NNS	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
surgery	NN	O	O
or	CC	O	O
prior	RB	O	O
to	TO	O	O
the	DT	O	O
first	JJ	O	O
positive	JJ	O	O
blood	NN	O	O
culture	NN	O	O
,	,	O	O
yet	RB	O	O
B.	NNP	O	O
fragilis	NN	O	O
was	VBD	O	O
the	DT	O	O
single	JJ	O	O
organism	NN	O	O
isolated	VBN	O	O
from	IN	O	O
blood	NN	O	O
and	CC	O	O
abscesses	NNS	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

A	DT	O	O
role	NN	O	O
for	IN	O	O
lymphocytes	NNS	O	O
in	IN	O	O
containment	NN	O	O
of	IN	O	O
B.	NNP	O	O
fragilis	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
suggested	VBN	O	O
previously	RB	O	O
,	,	O	O
although	IN	O	O
unexplained	JJ	O	O
occurrence	NN	o	OPH
of	IN	o	OPH
bacteroides	NNS	o	OPH
bacteremia	VBP	o	OPH
in	IN	O	O
immunocompromised	JJ	O	O
patients	NNS	O	O
has	VBZ	O	O
occasionally	RB	O	O
been	VBN	O	O
reported	VBN	O	O
.	.	O	O

Lymphocytes	VBZ	O	O
themselves	PRP	O	O
may	MD	O	O
be	VB	O	O
important	JJ	O	O
in	IN	O	O
this	DT	O	O
host-bacterium	JJ	O	O
interaction	NN	O	O
,	,	O	O
or	CC	O	O
lymphocytopenia	NN	o	OPH
may	MD	O	O
be	VB	O	O
the	DT	O	O
marker	NN	O	O
for	IN	O	O
a	DT	O	O
more	RBR	O	O
generalized	JJ	O	O
deficiency	NN	O	O
in	IN	O	O
host	NN	O	O
defenses	NNS	O	O
.	.	O	O

A	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
,	,	O	O
multicenter	NN	O	O
safety	NN	O	O
and	CC	O	O
immunogenicity	NN	O	O
study	NN	O	O
of	IN	O	O
a	DT	O	O
refrigerator-stable	JJ	O	O
formulation	NN	O	O
of	IN	O	O
Zostavax	NNP	i	IPM
.	.	O	O

The	DT	O	O
vaccine	NN	O	O
Zostavax	NNP	i	IPM
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
prevent	VB	O	O
herpes	NNS	O	O
zoster	NNP	O	O
(	(	O	O
HZ	NNP	O	O
)	)	O	O
and	CC	O	O
postherpetic	JJ	O	O
neuralgia	NN	O	O
and	CC	O	O
is	VBZ	O	O
recommended	VBN	O	O
for	IN	O	O
individuals	NNS	O	O
>	CD	O	O
or	CC	O	O
=60	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
compared	VBN	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	O	O
the	DT	O	O
immunogenicity	NN	o	OOt
of	IN	O	O
a	DT	O	O
refrigerator-stable	JJ	O	O
formulation	NN	O	O
(	(	O	O
Zostavax	NNP	i	IPM
refrigerated	VBD	O	O
)	)	O	O
with	IN	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
current	JJ	O	O
formulation	NN	O	O
(	(	O	O
Zostavax	NNP	i	IPM
frozen	RB	O	O
)	)	O	O
in	IN	O	O
subjects	NNS	p	O
>	VBP	p	O
or	CC	p	O
=50	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
.	.	O	O

Subjects	VBZ	p	O
with	IN	p	O
a	DT	p	O
negative	JJ	p	O
history	NN	p	O
for	IN	p	O
HZ	NNP	p	O
were	VBD	O	O
randomized	VBN	O	O
1:1	CD	O	O
to	TO	O	O
receive	VB	O	O
one	CD	O	O
dose	NN	O	O
of	IN	O	O
either	DT	O	O
formulation	NN	O	O
.	.	O	O

Enrollment	NN	p	O
was	VBD	p	O
stratified	VBN	p	O
1:2	CD	p	O
by	IN	p	O
age	NN	p	O
(	(	p	O
50	CD	p	O
to	TO	p	O
59	CD	p	O
years	NNS	p	O
and	CC	p	O
>	NN	p	O
or	CC	p	O
=60	CD	p	O
years	NNS	p	O
)	)	O	O
.	.	O	O

Safety	NN	o	OOt
was	VBD	O	O
evaluated	VBN	O	O
for	IN	O	O
28	CD	O	O
days	NNS	O	O
postvaccination	NN	O	O
.	.	O	O

Varicella-zoster	JJ	o	OPH
virus	NN	o	OPH
(	(	o	OPH
VZV	NNP	o	OPH
)	)	o	OPH
antibody	NN	o	OPH
responses	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
by	IN	O	O
a	DT	O	O
glycoprotein	JJ	O	O
enzyme-linked	JJ	O	O
immunosorbent	NN	O	O
assay	NN	O	O
(	(	O	O
gpELISA	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
endpoints	NNS	O	O
were	VBD	O	O
the	DT	O	O
VZV	NNP	o	OPH
antibody	NN	o	OPH
geometric	JJ	o	OPH
mean	NN	o	OPH
titer	NN	o	OPH
(	(	o	OPH
GMT	NNP	o	OPH
;	:	O	O
day	NN	O	O
28	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
VZV	NNP	o	OPH
antibody	NN	o	OPH
geometric	JJ	o	OPH
mean	NN	o	OPH
rise	NN	o	OPH
(	(	o	OPH
GMR	NNP	o	OPH
;	:	O	O
days	NNS	O	O
1	CD	O	O
to	TO	O	O
28	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
vaccine-related	JJ	o	OA
serious	JJ	o	OA
adverse	JJ	o	OA
experiences	NNS	o	OA
(	(	o	OA
AEs	NNP	o	OA
)	)	o	OA
over	IN	O	O
28	CD	O	O
days	NNS	O	O
.	.	O	O

The	DT	O	O
refrigerated	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
182	CD	O	O
)	)	O	O
and	CC	O	O
frozen	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
185	CD	O	O
)	)	O	O
formulations	NNS	O	O
induced	VBD	O	O
similar	JJ	O	O
GMTs	NNP	o	OPH
(	(	O	O
727.4	CD	O	O
and	CC	O	O
834.4	CD	O	O
gpELISA	NN	O	O
units/ml	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
;	:	O	O
the	DT	O	O
estimated	VBN	O	O
GMT	NNP	o	OPH
ratio	NN	O	O
(	(	O	O
refrigerated	VBN	O	O
formulation/frozen	RB	O	O
formulation	NN	O	O
)	)	O	O
was	VBD	O	O
0.87	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.71	CD	O	O
to	TO	O	O
1.07	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
GMRs	NNPS	o	OPH
were	VBD	O	O
2.6-	JJ	O	O
and	CC	O	O
2.9-fold	JJ	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

No	DT	O	O
vaccine-related	JJ	o	OA
serious	JJ	o	OA
AEs	NNP	o	OA
were	VBD	O	O
reported	VBN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
safety	NN	o	OOt
profiles	NNS	O	O
of	IN	O	O
the	DT	O	O
formulations	NNS	O	O
were	VBD	O	O
generally	RB	O	O
similar	JJ	O	O
.	.	O	O

The	DT	O	O
frequencies	NNS	O	O
of	IN	O	O
injection-site	JJ	o	OA
AEs	NNP	o	OA
during	IN	O	O
follow-up	JJ	O	O
were	VBD	O	O
35.6	CD	O	O
%	NN	O	O
and	CC	O	O
46.4	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
refrigerated	JJ	O	O
and	CC	O	O
the	DT	O	O
frozen	JJ	O	O
formulation	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
were	VBD	O	O
generally	RB	O	O
mild	VBN	O	O
.	.	O	O

The	DT	O	O
frequencies	NNS	O	O
of	IN	O	O
systemic	JJ	o	OA
AEs	NNP	o	OA
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
and	CC	O	O
those	DT	O	O
of	IN	O	O
vaccine-related	JJ	o	OA
AEs	NNP	o	OA
were	VBD	O	O
approximately	RB	O	O
6	CD	O	O
%	NN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
refrigerator-stable	JJ	O	O
formulation	NN	O	O
of	IN	O	O
Zostavax	NNP	i	IPM
has	VBZ	O	O
an	DT	O	O
acceptable	JJ	O	O
safety	NN	o	OOt
profile	NN	O	O
and	CC	O	O
is	VBZ	O	O
as	RB	O	O
immunogenic	JJ	o	OOt
as	IN	O	O
the	DT	O	O
frozen	JJ	O	O
formulation	NN	O	O
;	:	O	O
thus	RB	O	O
,	,	O	O
the	DT	O	O
vaccine	NN	O	O
may	MD	O	O
be	VB	O	O
used	VBN	O	O
in	IN	O	O
clinical	JJ	O	O
settings	NNS	O	O
where	WRB	O	O
freezer	NN	O	O
availability	NN	O	O
is	VBZ	O	O
limited	VBN	O	O
.	.	O	O

Interventions	NNS	O	O
in	IN	O	O
the	DT	O	O
initial	JJ	p	O
prodromal	JJ	p	PC
states	NNS	p	PC
of	IN	p	PC
psychosis	NN	p	PC
in	IN	O	O
Germany	NNP	p	O
:	:	O	O
concept	NN	O	O
and	CC	O	O
recruitment	NN	O	O
.	.	O	O

BACKGROUND	VB	O	O
The	DT	O	O
Early	JJ	O	O
Detection	NN	O	O
and	CC	O	O
Intervention	NNP	O	O
Programme	NNP	O	O
of	IN	O	O
the	DT	O	O
German	JJ	O	O
Research	NNP	O	O
Network	NNP	O	O
on	IN	O	O
Schizophrenia	NNP	O	O
(	(	O	O
GRNS	NNP	O	O
)	)	O	O
investigates	VBZ	O	O
the	DT	O	O
initial	JJ	p	O
prodromal	JJ	p	PC
phase	NN	p	PC
of	IN	p	PC
psychosis	NN	p	PC
in	IN	O	O
a	DT	O	O
multidimensional	JJ	O	O
approach	NN	O	O
.	.	O	O

Two	CD	O	O
intervention	NN	O	O
strategies	NNS	O	O
are	VBP	O	O
being	VBG	O	O
studied	VBN	O	O
by	IN	O	O
two	CD	O	O
large-scale	JJ	O	O
multicentre	JJ	O	O
projects	NNS	O	O
.	.	O	O

AIMS	NNP	O	O
To	TO	O	O
present	VB	O	O
the	DT	O	O
concept	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
studies	NNS	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
provide	VB	O	O
an	DT	O	O
interim	JJ	O	O
report	NN	O	O
of	IN	O	O
the	DT	O	O
recruitment	JJ	O	O
procedure	NN	O	O
.	.	O	O

METHOD	NNP	O	O
Comprehensive	NNP	i	IPS
cognitive-behavioural	JJ	i	IPS
therapy	NN	i	IPS
has	VBZ	O	O
been	VBN	O	O
developed	VBN	O	O
for	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
early	JJ	p	O
initial	JJ	p	O
prodromal	JJ	p	O
state	NN	p	O
.	.	O	O

For	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
late	JJ	p	O
initial	JJ	p	O
prodromal	JJ	p	O
state	NN	p	O
the	DT	O	O
atypical	JJ	i	IPM
neuroleptic	JJ	i	IPM
amisulpride	NN	i	IPM
is	VBZ	O	O
explored	VBN	O	O
.	.	O	O

Both	DT	O	O
interventions	NNS	O	O
are	VBP	O	O
evaluated	VBN	O	O
in	IN	O	O
randomised	JJ	O	O
controlled	VBN	O	O
trials	NNS	O	O
using	VBG	O	O
clinical	JJ	O	O
management	NN	O	O
as	IN	O	O
the	DT	O	O
control	NN	O	O
condition	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Between	NNP	O	O
January	NNP	O	O
2001	CD	O	O
and	CC	O	O
March	NNP	O	O
2003	CD	O	O
,	,	O	O
1212	CD	p	PSS
individuals	NNS	p	O
seeking	VBG	p	O
help	NN	p	O
for	IN	p	O
mental	JJ	p	O
health	NN	p	O
problems	NNS	p	O
were	VBD	O	O
screened	VBN	O	O
for	IN	O	O
putative	JJ	O	O
prodromal	NN	O	O
symptoms	NNS	O	O
at	IN	O	O
four	CD	O	O
university	NN	O	O
centres	NNS	O	O
.	.	O	O

More	JJR	p	O
than	IN	p	O
388	CD	p	PSS
individuals	NNS	p	O
fulfilled	VBD	p	O
criteria	NNS	p	O
for	IN	p	O
both	DT	p	O
interventions	NNS	p	O
and	CC	p	O
188	CD	p	PSS
(	(	p	O
48.5	CD	p	O
%	NN	p	O
)	)	p	O
gave	VBD	p	O
informed	VBN	p	O
consent	NN	p	O
to	TO	p	O
participate	VB	p	O
in	IN	p	O
the	DT	p	O
trials	NNS	p	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
screening	NN	O	O
procedure	NN	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
feasible	JJ	O	O
and	CC	O	O
trial	NN	O	O
participation	NN	O	O
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
acceptable	JJ	O	O
to	TO	O	O
a	DT	O	O
relevant	JJ	O	O
proportion	NN	O	O
of	IN	O	O
people	NNS	O	O
at	IN	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
developing	VBG	O	O
psychosis	NN	O	O
.	.	O	O

Anti-emetic	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
prophylactic	JJ	O	O
granisetron	NNS	i	IPM
compared	VBN	O	O
with	IN	O	O
perphenazine	NN	i	IPM
for	IN	O	O
the	DT	O	O
prevention	NN	o	OPH
of	IN	O	O
post-operative	JJ	O	O
vomiting	NN	O	O
in	IN	O	O
children	NNS	p	PA
.	.	O	O

We	PRP	O	O
have	VBP	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
granisetron	NN	i	IPM
with	IN	O	O
perphenazine	NN	i	IPM
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
vomiting	VBG	O	O
after	IN	O	O
tonsillectomy	NN	p	O
with	IN	p	O
or	CC	p	O
without	IN	p	O
adenoidectomy	NN	p	O
in	IN	p	O
children	NNS	p	O
.	.	O	O

In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
,	,	O	O
90	CD	p	PSS
paediatric	JJ	p	O
patients	NNS	p	O
,	,	p	O
ASA	NNP	p	O
I	PRP	p	O
,	,	p	O
aged	VBN	p	O
4-10	CD	p	PA
years	NNS	p	PA
,	,	O	O
received	VBD	O	O
granisetron	NN	i	IPM
40	CD	O	O
mg	JJ	O	O
kg-1	NN	O	O
or	CC	O	O
perphenazine	VB	i	IPM
70	CD	O	O
mg	JJ	O	O
kg-1	NN	O	O
(	(	O	O
n	JJ	O	O
=	RB	O	O
45	CD	O	O
each	DT	O	O
)	)	O	O
intravenously	RB	O	O
immediately	RB	O	O
after	IN	O	O
an	DT	O	O
inhalation	NN	O	O
induction	NN	O	O
of	IN	O	O
anaesthesia	NN	O	O
.	.	O	O

A	DT	O	O
standard	JJ	O	O
general	JJ	O	O
anaesthetic	JJ	O	O
technique	NN	O	O
was	VBD	O	O
employed	VBN	O	O
throughout	IN	O	O
.	.	O	O

A	DT	O	O
complete	JJ	o	OPH
response	NN	o	OPH
,	,	o	OPH
defined	VBD	o	OPH
as	IN	o	OPH
no	DT	o	OPH
emesis	NN	o	OPH
with	IN	o	OPH
no	DT	o	OPH
need	NN	o	OPH
for	IN	o	OPH
another	DT	o	OPH
rescue	NN	o	OPH
antiemetic	JJ	o	OPH
,	,	O	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
3	CD	O	O
h	NN	O	O
(	(	O	O
0-3	JJ	O	O
h	NN	O	O
)	)	O	O
after	IN	O	O
anesthesia	NN	O	O
was	VBD	O	O
87	CD	O	O
%	NN	O	O
with	IN	O	O
granisetron	NN	i	IPM
and	CC	O	O
78	CD	O	O
%	NN	O	O
with	IN	O	O
perphenazine	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.204	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
corresponding	JJ	o	OPH
incidence	NN	o	OPH
during	IN	O	O
the	DT	O	O
next	JJ	O	O
21	CD	O	O
h	NN	O	O
(	(	O	O
3-24	JJ	O	O
h	NN	O	O
)	)	O	O
after	IN	O	O
anaesthesia	NN	O	O
was	VBD	O	O
87	CD	O	O
%	NN	O	O
and	CC	O	O
62	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.007	CD	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
clinically	RB	O	O
serious	JJ	O	O
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
granisetron	NN	i	IPM
is	VBZ	O	O
a	DT	O	O
better	JJR	O	O
anti-emetic	JJ	O	O
than	IN	O	O
perphenazine	NN	i	IPM
for	IN	O	O
the	DT	O	O
long-term	JJ	o	O
prevention	NN	o	O
of	IN	O	O
post-operative	JJ	o	OPH
vomiting	NN	o	OPH
in	IN	O	O
children	NNS	p	O
undergoing	VBG	p	O
general	JJ	p	O
anaesthesia	NN	p	O
for	IN	p	O
tonsillectomy	NN	p	PC
.	.	p	O

Comparison	NNP	O	O
of	IN	O	O
budesonide	JJ	i	IPM
Turbuhaler	NNP	i	IPM
with	IN	O	O
budesonide	JJ	i	IPM
aqua	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
seasonal	JJ	p	O
allergic	JJ	p	O
rhinitis	NN	p	O
.	.	O	O

Rhinocort	NNP	O	O
Study	NNP	O	O
Group	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
budesonide	NN	i	IPM
Turbuhaler	NNP	i	IPM
400	CD	O	O
microg/day	NN	O	O
with	IN	O	O
budesonide	JJ	i	IPM
aqua	NN	i	IPM
256	CD	O	O
microg/day	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
seasonal	JJ	O	O
allergic	JJ	O	O
rhinitis	NN	O	O
(	(	O	O
SAR	NNP	O	O
)	)	O	O
.	.	O	O

Secondarily	RB	O	O
to	TO	O	O
ascertain	VB	O	O
patients	NNS	o	OME
'	POS	o	OME
preferences	NNS	o	OME
for	IN	O	O
the	DT	O	O
two	CD	O	O
nasal	JJ	O	O
devices	NNS	O	O
and	CC	O	O
to	TO	O	O
assess	VB	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
multicentre	NN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
double-	JJ	O	O
dummy	NN	O	O
,	,	O	O
parallel	JJ	O	O
groups	NNS	O	O
study	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Private	NNP	O	O
practices	NNS	O	O
and	CC	O	O
hospital	NN	O	O
clinics	NNS	O	O
in	IN	O	O
Ontario	NNP	p	O
,	,	p	O
Quebec	NNP	p	O
and	CC	p	O
Manitoba	NNP	p	O
.	.	O	O

POPULATION	NNP	O	O
Two	CD	p	O
hundred	VBD	p	O
and	CC	p	O
eighty-four	JJ	p	O
out-patients	NNS	p	O
with	IN	p	O
SAR	NNP	p	O
,	,	p	O
who	WP	p	O
were	VBD	p	O
symptomatic	JJ	p	O
during	IN	p	O
the	DT	p	O
ragweed	NN	p	O
season	NN	p	O
,	,	p	O
volunteered	VBD	p	O
for	IN	p	O
enrolment	NN	p	O
(	(	p	O
243	CD	p	O
randomized	VBN	p	O
)	)	p	O
.	.	O	O

RESULTS	JJ	O	O
Mean	JJ	o	OPH
daily	JJ	o	OPH
nasal	NN	o	OPH
symptom	NN	o	OPH
scores	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
with	IN	O	O
treatment	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
from	IN	O	O
baseline	NN	O	O
for	IN	O	O
eye	NN	o	OPH
symptoms	NNS	o	OPH
.	.	O	O

Most	JJS	O	O
patients	NNS	O	O
(	(	O	O
more	JJR	O	O
than	IN	O	O
80	CD	O	O
%	NN	O	O
)	)	O	O
achieved	VBN	O	O
substantial	JJ	O	O
control	NN	O	O
of	IN	O	O
their	PRP$	O	O
symptoms	NNS	O	O
with	IN	O	O
budesonide	NN	i	IPM
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
nasal	NN	o	OA
and	CC	o	OA
non-nasal	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
were	VBD	O	O
epistaxis	JJ	o	OA
and	CC	O	O
headache	NN	o	OA
.	.	O	O

Turbuhaler	NNP	i	IPM
was	VBD	O	O
easier	JJR	O	O
to	TO	O	O
use	VB	O	O
and	CC	O	O
more	RBR	O	O
convenient	JJ	O	O
to	TO	O	O
carry	VB	O	O
,	,	O	O
had	VBD	O	O
less	JJR	O	O
of	IN	O	O
an	DT	O	O
unpleasant	JJ	O	O
taste	NN	O	O
,	,	O	O
and	CC	O	O
caused	VBD	O	O
less	JJR	O	O
nasal	JJ	o	OA
irritation	NN	o	OA
than	IN	O	O
the	DT	O	O
aqua	JJ	O	O
spray	NN	O	O
.	.	O	O

More	JJR	O	O
than	IN	O	O
twice	RB	O	O
as	IN	O	O
many	JJ	O	O
patients	NNS	O	O
preferred	JJ	O	O
Turbuhaler	NNP	i	IPM
to	TO	O	O
the	DT	O	O
aqua	NN	i	IPM
spray	NN	i	IPM
(	(	O	O
69	CD	O	O
%	NN	O	O
versus	IN	O	O
31	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Improvement	NN	O	O
in	IN	O	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
clinic	VB	O	O
visits	NNS	O	O
was	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Once	RB	O	O
daily	JJ	O	O
use	NN	O	O
of	IN	O	O
256	CD	O	O
mg	NN	O	O
of	IN	O	O
budesonide	NN	i	IPM
aqua	NN	i	IPM
and	CC	O	O
400	CD	O	O
mg	NN	O	O
of	IN	O	O
budesonide	NN	i	IPM
Turbuhaler	NNP	i	IPM
are	VBP	O	O
equally	RB	O	O
safe	JJ	o	OOt
and	CC	O	O
efficacious	JJ	o	OOt
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
SAR	NNP	p	O
.	.	O	O

Patients	NNS	O	O
preferred	VBD	O	O
the	DT	O	O
budesonide	NN	i	IPM
powder	NN	i	IPM
formulation	NN	O	O
delivered	VBD	O	O
via	IN	O	O
Turbuhaler	NNP	i	IPM
two	CD	O	O
to	TO	O	O
one	CD	O	O
over	IN	O	O
the	DT	O	O
aqua	JJ	i	IPM
formulation	NN	O	O
.	.	O	O

Phase	NNP	O	O
III	NNP	O	O
study	NN	O	O
of	IN	O	O
concurrent	JJ	i	IPM
chemoradiotherapy	NN	i	IPM
versus	NN	O	O
radiotherapy	NN	i	IPM
alone	RB	O	O
for	IN	O	O
advanced	JJ	p	PC
nasopharyngeal	JJ	p	PC
carcinoma	NN	p	PC
:	:	O	O
positive	JJ	O	O
effect	NN	O	O
on	IN	O	O
overall	JJ	o	OMO
and	CC	o	OMO
progression-free	JJ	o	OMO
survival	NN	o	OMO
.	.	O	O

PURPOSE	NNP	O	O
Nasopharyngeal	NNP	p	PC
carcinoma	NN	p	PC
(	(	p	PC
NPC	NNP	p	PC
)	)	p	PC
is	VBZ	O	O
a	DT	O	O
radiosensitive	JJ	O	O
and	CC	O	O
chemosensitive	JJ	O	O
tumor	NN	O	O
.	.	O	O

This	DT	O	O
randomized	JJ	O	O
phase	NN	O	O
III	NNP	O	O
trial	NN	O	O
compared	VBN	O	O
concurrent	JJ	i	IPM
chemoradiotherapy	NN	i	IPM
(	(	i	IPM
CCRT	NNP	i	IPM
)	)	i	IPM
versus	NN	O	O
radiotherapy	NN	i	IPM
(	(	i	IPM
RT	NNP	i	IPM
)	)	i	IPM
alone	RB	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	PC
NPC	NNP	p	PC
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
From	NNP	p	O
December	NNP	p	O
1993	CD	p	O
to	TO	p	O
April	NNP	p	O
1999	CD	p	O
,	,	p	O
284	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
1992	CD	p	O
American	NNP	p	O
Joint	NNP	p	O
Committee	NNP	p	O
on	IN	p	O
Cancer	NNP	p	PC
stage	NN	p	PC
III	NNP	p	PC
to	TO	p	PC
IV	NNP	p	PC
(	(	p	PC
M0	NNP	p	PC
)	)	p	PC
NPC	NNP	p	PC
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
into	IN	O	O
two	CD	O	O
arms	NNS	O	O
.	.	O	O

Similar	JJ	O	O
dosage	NN	O	O
and	CC	O	O
fractionation	NN	O	O
of	IN	O	O
RT	NNP	O	O
was	VBD	O	O
administered	VBN	O	O
in	IN	O	O
both	DT	O	O
arms	NNS	O	O
.	.	O	O

The	DT	O	O
investigational	JJ	O	O
arm	NN	O	O
received	VBD	O	O
two	CD	O	O
cycles	NNS	O	O
of	IN	O	O
concurrent	JJ	O	O
chemotherapy	NN	i	IPM
with	IN	O	O
cisplatin	NN	i	IPM
20	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/d	NN	O	O
plus	CC	O	O
fluorouracil	JJ	i	IPM
400	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/d	NN	O	O
by	IN	O	O
96-hour	CD	O	O
continuous	JJ	O	O
infusion	NN	O	O
during	IN	O	O
the	DT	O	O
weeks	NNS	O	O
1	CD	O	O
and	CC	O	O
5	CD	O	O
of	IN	O	O
RT	NNP	O	O
.	.	O	O

Survival	NNP	o	OMO
analysis	NN	o	OMO
was	VBD	O	O
estimated	VBN	O	O
by	IN	O	O
the	DT	O	O
Kaplan-Meier	NNP	O	O
method	NN	O	O
and	CC	O	O
compared	VBN	O	O
by	IN	O	O
the	DT	O	O
log-rank	JJ	O	O
test	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Baseline	NNP	O	O
patient	JJ	O	O
characteristics	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
in	IN	O	O
both	DT	O	O
arms	NNS	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
median	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
65	CD	O	O
months	NNS	O	O
,	,	O	O
26.2	CD	O	O
%	NN	O	O
(	(	O	O
37	CD	O	O
of	IN	O	O
141	CD	O	O
)	)	O	O
and	CC	O	O
46.2	CD	O	O
%	NN	O	O
(	(	O	O
66	CD	O	O
of	IN	O	O
143	CD	O	O
)	)	O	O
of	IN	O	O
patients	NNS	O	O
developed	JJ	O	O
tumor	NN	o	OPH
relapse	NN	o	OPH
in	IN	O	O
the	DT	O	O
CCRT	NNP	i	IPM
and	CC	O	O
RT-alone	NNP	i	IPM
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
5-year	JJ	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
72.3	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
CCRT	NNP	i	IPM
arm	NN	O	O
and	CC	O	O
54.2	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
RT-only	JJ	i	IPM
arm	NN	O	O
(	(	O	O
P	NNP	O	O
=.0022	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
5-year	JJ	o	OMO
progression-free	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
71.6	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
CCRT	NNP	i	IPM
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
53.0	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
RT-only	JJ	i	IPM
group	NN	O	O
(	(	O	O
P	NNP	O	O
=.0012	NNP	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
significantly	RB	O	O
more	JJR	O	O
toxicity	NN	o	OPH
was	VBD	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
CCRT	NNP	i	IPM
arm	NN	O	O
,	,	O	O
including	VBG	O	O
leukopenia	NN	o	OPH
and	CC	O	O
emesis	NN	o	OPH
,	,	O	O
compliance	NN	O	O
with	IN	O	O
the	DT	O	O
combined	JJ	O	O
treatment	NN	O	O
was	VBD	O	O
good	JJ	O	O
.	.	O	O

The	DT	O	O
second	JJ	O	O
cycle	NN	O	O
of	IN	O	O
concurrent	JJ	O	O
chemotherapy	NN	O	O
was	VBD	O	O
refused	VBN	O	O
by	IN	O	O
nine	CD	O	O
patients	NNS	O	O
and	CC	O	O
was	VBD	O	O
delayed	VBN	O	O
for	IN	O	O
>	NN	O	O
or	CC	O	O
=	$	O	O
1	CD	O	O
week	NN	O	O
for	IN	O	O
another	DT	O	O
nine	CD	O	O
patients	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
treatment-related	JJ	o	OMO
deaths	NNS	o	OMO
in	IN	O	O
either	DT	O	O
arm	NN	O	O
.	.	O	O

CONCLUSION	NN	O	O
We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
CCRT	NNP	i	IPM
is	VBZ	O	O
superior	JJ	O	O
to	TO	O	O
RT	VB	i	IPM
alone	RB	O	O
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	PC
NPC	NNP	p	PC
in	IN	O	O
endemic	JJ	O	O
areas	NNS	O	O
.	.	O	O

Preschoolers	NNS	p	PA
acquire	VB	O	O
general	JJ	O	O
knowledge	NN	O	O
by	IN	O	O
sharing	VBG	O	O
in	IN	O	O
pretense	NN	i	IE
.	.	O	O

Children	NNP	O	O
acquire	VB	O	O
general	JJ	O	O
knowledge	NN	O	O
about	IN	O	O
many	JJ	O	O
kinds	NNS	O	O
of	IN	O	O
things	NNS	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
are	VBP	O	O
few	JJ	O	O
known	VBN	O	O
means	NNS	O	O
by	IN	O	O
which	WDT	O	O
this	DT	O	O
knowledge	NN	O	O
is	VBZ	O	O
acquired	VBN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
article	NN	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
proposed	VBN	O	O
that	IN	O	O
children	NNS	O	O
acquire	VB	O	O
generic	JJ	O	O
knowledge	NN	O	O
by	IN	O	O
sharing	VBG	O	O
in	IN	O	O
pretend	JJ	i	IE
play	NN	i	IE
.	.	O	O

In	IN	O	O
Experiment	JJ	O	O
1	CD	O	O
,	,	O	O
twenty-two	JJ	p	PSS
3-	JJ	p	PA
to	TO	p	PA
4-year-olds	NNS	p	PA
watched	VBN	O	O
pretense	NN	i	IE
in	IN	O	O
which	WDT	O	O
a	DT	O	O
puppet	NN	O	O
represented	VBD	O	O
a	DT	O	O
nerp	NN	O	O
(	(	O	O
an	DT	O	O
unfamiliar	JJ	O	O
kind	NN	O	O
of	IN	O	O
animal	NN	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
instance	NN	O	O
,	,	O	O
in	IN	O	O
one	CD	O	O
scenario	NN	O	O
,	,	O	O
the	DT	O	O
nerp	JJ	O	O
ate	NN	O	O
and	CC	O	O
disliked	VBD	O	O
a	DT	O	O
carrot	NN	O	O
.	.	O	O

When	WRB	O	O
subsequently	RB	O	O
asked	VBD	O	O
generic	JJ	O	O
questions	NNS	O	O
about	IN	O	O
real	JJ	O	O
nerps	NNS	O	O
,	,	O	O
children	NNS	p	PA
's	POS	O	O
responses	NNS	o	OME
suggested	VBD	O	O
that	IN	O	O
they	PRP	O	O
had	VBD	O	O
learned	VBN	O	O
general	JJ	O	O
facts	NNS	O	O
(	(	O	O
e.g.	NN	O	O
,	,	O	O
nerps	RB	O	O
dislike	JJ	O	O
carrots	NNS	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
Experiment	JJ	O	O
2	CD	O	O
,	,	O	O
thirty-two	JJ	p	PSS
4-	JJ	p	PA
to	TO	p	PA
5-year-olds	NNS	p	PA
learned	VBN	O	O
from	IN	O	O
scenarios	NNS	i	IE
lacking	VBG	i	IE
pretend	JJ	i	IE
speech	NN	i	IE
or	CC	i	IE
sound	JJ	i	IE
effects	NNS	i	IE
.	.	O	O

The	DT	O	O
findings	NNS	O	O
reveal	VBP	O	O
a	DT	O	O
long	JJ	O	O
overlooked	JJ	O	O
means	NNS	O	O
by	IN	O	O
which	WDT	O	O
children	NNS	p	PA
can	MD	O	O
acquire	VB	O	O
generic	JJ	O	O
knowledge	NN	O	O
.	.	O	O

[	JJ	O	O
Efficacy	NNP	O	O
of	IN	O	O
paliperidone	NN	i	IPM
extended-release	JJ	O	O
tablets	NNS	O	O
in	IN	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
social	JJ	o	OME
functions	NNS	o	OME
in	IN	O	O
schizophrenics	NNS	p	PC
:	:	O	O
a	DT	O	O
randomized	NN	O	O
and	CC	O	O
controlled	VBD	O	O
study	NN	O	O
]	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
explore	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
paliperidone	NN	i	IPM
extended-release	JJ	O	O
tablets	NNS	O	O
in	IN	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
social	JJ	o	OME
functions	NNS	o	OME
in	IN	O	O
schizophrenics	NNS	p	PC
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
81	CD	p	PC
schizophrenics	NNS	p	PC
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
study	NN	O	O
group	NN	O	O
with	IN	O	O
paliperidone	NN	i	IPM
extended-release	JJ	O	O
tablets	NNS	O	O
and	CC	O	O
control	NN	O	O
group	NN	O	O
with	IN	O	O
risperidone	NN	i	IPM
for	IN	O	O
a	DT	O	O
12-week	JJ	O	O
treatment	NN	O	O
.	.	O	O

They	PRP	O	O
were	VBD	O	O
assessed	VBN	O	O
and	CC	O	O
analyzed	VBN	O	O
by	IN	O	O
positive	JJ	o	OME
and	CC	o	OME
negative	JJ	o	OME
symptoms	NNS	o	OME
scales	NNS	o	OME
(	(	o	OME
PANSS	NNP	o	OME
)	)	o	OME
,	,	o	OME
social	JJ	o	OME
disability	NN	o	OME
screening	VBG	o	OME
schedule	NN	o	OME
(	(	o	OME
SDSS	NNP	o	OME
)	)	o	OME
and	CC	O	O
treatment	NN	o	OME
emergent	NN	o	OME
symptom	NN	o	OME
scale	NN	o	OME
(	(	o	OME
TESS	NNP	o	OME
)	)	o	OME
at	IN	O	O
baseline	NN	O	O
,	,	O	O
6	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
and	CC	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
study	NN	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
factors	NNS	o	OME
and	CC	o	OME
total	JJ	o	OME
scores	NNS	o	OME
of	IN	o	OME
PANSS	NNP	o	OME
in	IN	O	O
the	DT	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
[	NNP	O	O
(	(	O	O
12.0	CD	O	O
?	.	O	O
2.8	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
12.1	CD	O	O
?	.	O	O
3.6	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
26.2	CD	O	O
?	.	O	O
5.0	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
50.2	CD	O	O
?	.	O	O
8.7	CD	O	O
)	)	O	O
]	NN	O	O
were	VBD	O	O
all	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
at	IN	O	O
baseline	JJ	O	O
[	NNP	O	O
(	(	O	O
24.7	CD	O	O
?	.	O	O
5.3	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
23.8	CD	O	O
?	.	O	O
3.6	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
45.0	CD	O	O
?	.	O	O
2.9	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
93.5	CD	O	O
?	.	O	O
6.8	CD	O	O
)	)	O	O
]	NN	O	O
(	(	O	O
t	JJ	O	O
=	NNP	O	O
9.60-16.78	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
study	NN	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
positive	JJ	o	OPH
factor	NN	o	OPH
,	,	o	OPH
negative	JJ	o	OPH
factor	NN	o	OPH
and	CC	o	OPH
total	JJ	o	OPH
scores	NNS	o	OPH
of	IN	o	OPH
PANSS	NNP	o	OPH
in	IN	O	O
the	DT	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
[	NNP	O	O
(	(	O	O
12.0	CD	O	O
?	.	O	O
2.8	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
12.1	CD	O	O
?	.	O	O
3.6	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
50.2	CD	O	O
?	.	O	O
8.7	CD	O	O
)	)	O	O
]	NN	O	O
were	VBD	O	O
all	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
6	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
[	NNP	O	O
(	(	O	O
14.2	CD	O	O
?	.	O	O
1.8	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
14.6	CD	O	O
?	.	O	O
2.4	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
56.5	CD	O	O
?	.	O	O
6.4	CD	O	O
)	)	O	O
]	NN	O	O
(	(	O	O
t	JJ	O	O
=	NNP	O	O
2.58-4.26	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
factors	NNS	o	OPH
and	CC	o	OPH
total	JJ	o	OPH
scores	NNS	o	OPH
of	IN	o	OPH
PANSS	NNP	o	OPH
in	IN	O	O
study	NN	O	O
group	NN	O	O
[	NNP	O	O
(	(	O	O
12.0	CD	O	O
?	.	O	O
2.8	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
12.1	CD	O	O
?	.	O	O
3.6	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
26.2	CD	O	O
?	.	O	O
5.0	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
50.2	CD	O	O
?	.	O	O
8.7	CD	O	O
)	)	O	O
]	NN	O	O
were	VBD	O	O
all	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
control	NN	O	O
group	NN	O	O
[	NNP	O	O
(	(	O	O
16.9	CD	O	O
?	.	O	O
4.9	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
18.7	CD	O	O
?	.	O	O
5.3	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
32.5	CD	O	O
?	.	O	O
5.1	CD	O	O
)	)	O	O
,	,	O	O
(	(	O	O
68.1	CD	O	O
?	.	O	O
13.0	CD	O	O
)	)	O	O
]	NN	O	O
(	(	O	O
t	JJ	O	O
=	NNP	O	O
-4.28	NNP	O	O
--	:	O	O
5.67	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
study	NN	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
total	JJ	O	O
scores	NNS	o	O
of	IN	o	O
SDSS	NNP	o	O
in	IN	O	O
the	DT	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
5.93	CD	O	O
?	.	O	O
2.78	CD	O	O
)	)	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
at	IN	O	O
baseline	NN	O	O
(	(	O	O
13.9	CD	O	O
?	.	O	O
3.4	CD	O	O
)	)	O	O
(	(	O	O
t	JJ	O	O
=	NN	O	O
10.83	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
study	NN	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
total	JJ	O	O
scores	NNS	o	O
of	IN	o	O
SDSS	NNP	o	O
in	IN	O	O
the	DT	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
5.9	CD	O	O
?	.	O	O
2.8	CD	O	O
)	)	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
6	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
7.6	CD	O	O
?	.	O	O
2.9	CD	O	O
)	)	O	O
(	(	O	O
t	JJ	O	O
=	NN	O	O
5.21	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

But	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
t	JJ	O	O
=	NN	O	O
1.88	CD	O	O
,	,	O	O
P	NNP	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
12	CD	O	O
(	(	O	O
th	NN	O	O
)	)	O	O
weekend	NN	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
total	JJ	O	O
scores	NNS	o	O
of	IN	o	O
SDSS	NNP	o	O
in	IN	O	O
study	NN	O	O
group	NN	O	O
(	(	O	O
5.9	CD	O	O
?	.	O	O
2.8	CD	O	O
)	)	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
8.8	CD	O	O
?	.	O	O
2.9	CD	O	O
)	)	O	O
(	(	O	O
t	JJ	O	O
=	NNP	O	O
-4.49	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
severe	JJ	o	O
adverse	JJ	o	O
effect	NN	o	O
was	VBD	O	O
reported	VBN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Paliperidone	NNP	i	O
extended-release	JJ	O	O
tablets	NNS	O	O
are	VBP	O	O
effective	JJ	O	O
to	TO	O	O
improve	VB	O	O
social	JJ	o	O
functions	NNS	o	O
and	CC	O	O
psychiatric	JJ	o	O
symptoms	NNS	o	O
of	IN	O	O
schizophrenics	NNS	p	O
.	.	O	O

A	DT	O	O
controlled	VBN	O	O
study	NN	O	O
of	IN	O	O
psychiatric	JJ	i	IE
hospital	NN	i	IE
versus	NN	O	O
community	NN	i	IE
treatment	NN	i	IE
-	:	O	O
the	DT	O	O
effect	NN	o	OME
on	IN	o	OME
relatives	NNS	o	OME
.	.	O	O

One	CD	p	PSS
hundred	CD	p	PSS
and	CC	p	PSS
twenty	JJ	p	PSS
patients	NNS	p	O
presenting	VBG	p	O
at	IN	p	O
Macquarie	NNP	p	O
Hospital	NNP	p	O
for	IN	p	O
admission	NN	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
group	NN	O	O
patients	NNS	O	O
received	VBD	O	O
standard	JJ	i	IE
hospital	NN	i	IE
care	NN	i	IE
and	CC	i	IE
follow-up	NN	i	IE
.	.	O	O

The	DT	O	O
project	NN	O	O
group	NN	O	O
patients	NNS	O	O
were	VBD	O	O
not	RB	O	O
admitted	VBN	O	O
if	IN	O	O
this	DT	O	O
could	MD	O	O
be	VB	O	O
avoided	VBN	O	O
;	:	O	O
instead	RB	O	O
they	PRP	O	O
were	VBD	O	O
taken	VBN	O	O
back	RB	i	IE
to	TO	i	IE
the	DT	i	IE
community	NN	i	IE
by	IN	O	O
the	DT	O	O
project	NN	O	O
team	NN	O	O
who	WP	O	O
provided	VBD	O	O
them	PRP	O	O
and	CC	O	O
their	PRP$	O	O
relatives	NNS	O	O
with	IN	O	O
comprehensive	JJ	O	O
,	,	O	O
assertive	JJ	O	O
and	CC	O	O
prolonged	JJ	O	O
follow-up	JJ	i	IE
treatment	NN	i	IE
backed	VBN	O	O
by	IN	O	O
a	DT	O	O
24-hour	JJ	O	O
crisis	NN	O	O
service	NN	O	O
.	.	O	O

The	DT	O	O
majority	NN	O	O
(	(	O	O
63	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
project	NN	O	O
group	NN	O	O
had	VBD	O	O
no	DT	O	O
admission	NN	O	O
during	IN	O	O
the	DT	O	O
10	CD	O	O
month	NN	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

Initially	RB	O	O
,	,	O	O
the	DT	O	O
burden	NN	o	OME
on	IN	o	OME
the	DT	o	OME
relatives	NNS	o	OME
of	IN	O	O
the	DT	O	O
project	NN	O	O
group	NN	O	O
was	VBD	O	O
higher	JJR	O	O
,	,	O	O
but	CC	O	O
by	IN	O	O
one	CD	O	O
month	NN	O	O
it	PRP	O	O
was	VBD	O	O
somewhat	RB	O	O
lower	JJR	O	O
and	CC	O	O
by	IN	O	O
four	CD	O	O
months	NNS	O	O
it	PRP	O	O
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
the	DT	O	O
burden	NN	O	O
on	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
relatives	VBZ	O	O
.	.	O	O

Relatives	NNS	O	O
of	IN	O	O
the	DT	O	O
project	NN	O	O
group	NN	O	O
patients	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
satisfied	JJ	o	OME
with	IN	O	O
the	DT	O	O
treatment	NN	O	O
than	IN	O	O
control	NN	O	O
group	NN	O	O
relatives	VBZ	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
clearly	RB	O	O
feasible	JJ	O	O
to	TO	O	O
treat	VB	O	O
most	JJS	O	O
psychiatric	JJ	p	PC
patients	NNS	p	O
in	IN	O	O
the	DT	O	O
community	NN	O	O
without	IN	O	O
increasing	VBG	O	O
the	DT	O	O
burden	NN	o	OME
on	IN	o	OME
their	PRP$	o	OME
relatives	NNS	o	OME
.	.	O	O

Prospective	JJ	O	O
study	NN	O	O
of	IN	O	O
short	JJ	O	O
and	CC	O	O
ultrashort	JJ	O	O
regimens	NNS	O	O
of	IN	O	O
gonadotropin-releasing	JJ	i	IPM
hormone	NN	i	IPM
agonist	NN	i	IPM
in	IN	O	O
an	DT	O	O
in	IN	O	O
vitro	JJ	O	O
fertilization	NN	O	O
program	NN	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
usefulness	NN	o	OOt
of	IN	O	O
the	DT	O	O
ultrashort	JJ	O	O
regimen	NNS	O	O
of	IN	O	O
gonadotropin-releasing	JJ	i	IPM
hormone	NN	i	IPM
agonist	NN	i	IPM
(	(	i	IPM
GnRH-a	NNP	i	IPM
)	)	i	O
in	IN	O	O
ovulation	NN	O	O
induction	NN	O	O
in	IN	O	O
an	DT	O	O
in	IN	p	O
vitro	JJ	p	O
fertilization	NN	p	O
(	(	p	O
IVF	NNP	p	O
)	)	p	O
program	NN	O	O
.	.	O	O

DESIGN	VB	O	O
A	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
comparing	VBG	O	O
short	JJ	O	O
and	CC	O	O
ultrashort	JJ	O	O
regimens	NNS	O	O
of	IN	O	O
GnRH-a	NNP	i	IPM
.	.	O	O

SETTING	NN	O	O
Aberdeen	NNP	O	O
Assisted	NNP	O	O
Reproduction	NNP	O	O
Unit	NNP	O	O
.	.	O	O

PATIENTS	NNP	O	O
Forty-eight	JJ	p	O
patients	NNS	p	O
having	VBG	p	O
IVF	NNP	p	O
for	IN	p	O
the	DT	p	O
first	JJ	p	O
time	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
protocols	NNS	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Response	NNP	o	OPH
to	TO	o	OPH
ovarian	JJ	o	OPH
stimulation	NN	o	OPH
and	CC	o	OPH
occurrence	NN	o	OPH
of	IN	o	OPH
spontaneous	JJ	o	OPH
luteinizing	VBG	o	OPH
hormone	NN	o	OPH
(	(	o	OPH
LH	NNP	o	OPH
)	)	o	OPH
surges	VBZ	o	OPH
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
ovulation	NN	o	OPH
induction	NN	o	OPH
,	,	o	OPH
fertilization	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
pregnancy	NN	o	OPH
rates	NNS	o	OPH
the	DT	O	O
ultrashort	JJ	O	O
regimen	NNS	O	O
produces	VBZ	O	O
results	NNS	O	O
that	WDT	O	O
were	VBD	O	O
no	DT	O	O
different	JJ	O	O
to	TO	O	O
the	DT	O	O
short	JJ	O	O
regimen	NNS	O	O
but	CC	O	O
it	PRP	O	O
did	VBD	O	O
not	RB	O	O
always	RB	O	O
prevent	VB	O	O
an	DT	O	O
LH	NNP	o	OPH
surge	NN	o	OPH
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
ultrashort	JJ	O	O
regimen	NNS	O	O
can	MD	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
alternative	NN	O	O
for	IN	O	O
ovarian	JJ	O	O
stimulation	NN	O	O
of	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
IVF	NNP	p	O
.	.	O	O

[	JJ	O	O
Neoton	NNP	i	IPM
and	CC	O	O
thrombolytic	JJ	i	IPM
therapy	NN	i	IPM
of	IN	O	O
myocardial	JJ	p	PC
infarction	NN	p	PC
]	NNP	O	O
.	.	O	O

AIM	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
neoton	JJ	i	IPM
therapy	NN	O	O
effects	NNS	O	O
in	IN	O	O
acute	JJ	p	PC
myocardial	JJ	p	PC
infarction	NN	p	PC
(	(	p	PC
MI	NNP	p	PC
)	)	p	PC
on	IN	O	O
systolic	JJ	o	OPH
function	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
left	JJ	o	OPH
ventricle	NN	o	OPH
,	,	o	O
arrhythmia	NN	o	OPH
and	CC	o	O
clinical	JJ	o	OPH
symptoms	NNS	o	OPH
in	IN	O	O
patients	NNS	p	O
on	IN	p	O
thrombolytic	JJ	i	IPM
therapy	NN	i	IPM
(	(	p	O
TLT	NNP	i	IPM
)	)	p	O
.	.	O	O

MATERIAL	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
106	CD	p	PSS
males	NNS	p	PSE
with	IN	p	O
Q-MI	NNP	p	PC
entered	VBD	p	O
the	DT	p	O
study	NN	p	O
.	.	O	O

47	CD	O	O
received	VBD	O	O
treatment	NN	O	O
without	IN	O	O
TLT	NNP	i	IC
and	CC	O	O
neoton	NN	i	IC
,	,	O	O
30	CD	O	O
patients	NNS	O	O
received	VBD	O	O
TLT	NNP	i	IPM
with	IN	O	O
streptokinase	JJ	i	IPM
preparations	NNS	O	O
,	,	O	O
29	CD	O	O
patients	NNS	O	O
were	VBD	O	O
given	VBN	O	O
streptokinase	JJ	i	IPM
preparations	NNS	i	IPM
and	CC	O	O
neoton	NN	i	IPM
.	.	O	O

Left	NNP	o	OPH
ventricular	JJ	o	OPH
systolic	JJ	o	OPH
function	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
echocardiography	NN	O	O
on	IN	O	O
day	NN	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
7	CD	O	O
,	,	O	O
14	CD	O	O
,	,	O	O
21	CD	O	O
and	CC	O	O
28	CD	O	O
;	:	O	O
arrhythmia	NN	o	OPH
was	VBD	O	O
analysed	VBN	O	O
at	IN	O	O
Holter	NNP	O	O
monitoring	VBG	O	O
in	IN	O	O
day	NN	O	O
1	CD	O	O
and	CC	O	O
2	CD	O	O
of	IN	O	O
MI	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
TLT	NNP	O	O
failed	VBD	O	O
to	TO	O	O
arrest	VB	O	O
progression	NN	O	O
of	IN	O	O
left	JJ	O	O
ventricular	JJ	O	O
dilation	NN	O	O
by	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
hospital	NN	O	O
stay	NN	O	O
.	.	O	O

Patients	NNS	O	O
given	VBN	O	O
neoton	NNS	i	IPM
in	IN	O	O
acute	JJ	O	O
period	NN	O	O
of	IN	O	O
MI	NNP	O	O
had	VBD	O	O
no	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
end	NN	O	O
systolic	NN	o	OPH
and	CC	o	OPH
diastolic	JJ	o	OPH
volumes	NNS	o	OPH
of	IN	O	O
the	DT	O	O
left	JJ	O	O
ventricle	NN	O	O
in	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
months	NNS	O	O
after	IN	O	O
MI	NNP	O	O
onset	NN	O	O
.	.	O	O

Antiarrhythmic	NNP	O	O
action	NN	O	O
of	IN	O	O
neoton	NN	i	IPM
manifested	VBN	O	O
on	IN	O	O
MI	NNP	O	O
day	NN	O	O
2	CD	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Neoton	NNP	i	IPM
given	VBN	O	O
to	TO	O	O
MI	NNP	O	O
patients	NNS	O	O
receiving	VBG	O	O
TLT	NNP	O	O
prevents	NNS	O	O
progression	NN	O	O
of	IN	O	O
left	JJ	o	OPH
ventricular	JJ	o	OPH
systolic	JJ	o	OPH
dysfunction	NN	o	OPH
and	CC	O	O
establishment	NN	O	O
of	IN	O	O
predictors	NNS	O	O
of	IN	O	O
unfavourable	JJ	O	O
outcome	NN	O	O
.	.	O	O

Measurement	NN	O	O
of	IN	O	O
transfer	NN	O	O
factor	NN	O	O
during	IN	O	O
constant	JJ	O	O
exhalation	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Transfer	NNP	o	OPH
factor	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
lung	NN	o	OPH
for	IN	o	OPH
carbon	NN	o	OPH
monoxide	NN	o	OPH
(	(	o	OPH
TLCO	NNP	o	OPH
)	)	o	OPH
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
a	DT	O	O
new	JJ	O	O
method	NN	O	O
based	VBN	O	O
on	IN	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
ratio	NN	O	O
of	IN	O	O
the	DT	O	O
concentrations	NNS	O	O
of	IN	O	O
carbon	NN	O	O
monoxide	NN	O	O
to	TO	O	O
an	DT	O	O
inert	NN	O	O
gas	NN	O	O
(	(	O	O
methane	NN	O	O
)	)	O	O
relative	NN	O	O
to	TO	O	O
lung	NN	O	O
volume	NN	O	O
during	IN	O	O
a	DT	O	O
constant	JJ	O	O
exhalation	NN	O	O
.	.	O	O

Since	IN	O	O
this	DT	O	O
new	JJ	O	O
technique	NN	O	O
is	VBZ	O	O
based	VBN	O	O
solely	RB	O	O
upon	JJ	O	O
exhalation	NN	O	O
,	,	O	O
anomalies	NNS	O	O
associated	VBN	O	O
with	IN	O	O
inspiration	NN	O	O
and	CC	O	O
breath	NN	O	O
holding	VBG	O	O
do	VBP	O	O
not	RB	O	O
affect	VB	O	O
results	NNS	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
because	IN	O	O
prolonged	JJ	O	O
breath	NN	O	O
holding	NN	O	O
is	VBZ	O	O
not	RB	O	O
required	VBN	O	O
,	,	O	O
measurements	NNS	O	O
can	MD	O	O
readily	RB	O	O
be	VB	O	O
made	VBN	O	O
in	IN	O	O
dyspnoeic	JJ	p	PC
patients	NNS	p	O
.	.	O	O

METHODS	NNP	O	O
Exhalation	NNP	o	OPH
TLCO	NNP	o	OPH
(	(	o	OPH
TLCO	NNP	o	OPH
,	,	o	OPH
ex	NN	o	OPH
)	)	o	OPH
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
standard	NN	o	OPH
(	(	o	OPH
Jones	NNP	o	OPH
and	CC	o	OPH
Meade	NNP	o	OPH
)	)	o	OPH
10	CD	o	OPH
second	JJ	o	OPH
breath	NN	o	OPH
holding	VBG	o	OPH
TLCO	NNP	o	OPH
(	(	o	OPH
TLCO	NNP	o	OPH
,	,	o	OPH
bh	NN	o	OPH
)	)	o	OPH
in	IN	O	O
100	CD	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
.	.	O	O

Patients	NNS	O	O
did	VBD	O	O
not	RB	O	O
practise	VB	O	O
the	DT	O	O
exhalation	NN	O	O
manoeuvre	NN	O	O
prior	RB	O	O
to	TO	O	O
testing	VBG	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
comparative	JJ	O	O
results	NNS	O	O
were	VBD	O	O
very	RB	O	O
close	RB	O	O
;	:	O	O
mean	JJ	O	O
difference	NN	O	O
(	(	O	O
bias	JJ	O	O
)	)	O	O
+/-	JJ	O	O
standard	JJ	O	O
deviation	NN	O	O
(	(	O	O
precision	NN	O	O
)	)	O	O
was	VBD	O	O
0.05	CD	O	O
(	(	O	O
0.84	CD	O	O
)	)	O	O
mmol/min/kPa	NN	O	O
.	.	O	O

The	DT	O	O
relation	NN	o	OPH
was	VBD	O	O
equally	RB	O	O
strong	JJ	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
severe	JJ	p	PC
pulmonary	JJ	p	PC
disease	NN	p	PC
;	:	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
FEV1	NNP	O	O
<	$	O	O
1.51	CD	O	O
the	DT	O	O
mean	NN	O	O
difference	NN	O	O
was	VBD	O	O
0.21	CD	O	O
(	(	O	O
0.80	CD	O	O
)	)	O	O
mmol/min/kPa	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Since	IN	O	O
the	DT	O	O
results	NNS	O	O
were	VBD	O	O
essentially	RB	O	O
identical	JJ	O	O
between	IN	O	O
the	DT	O	O
techniques	NNS	O	O
,	,	O	O
it	PRP	O	O
seems	VBZ	O	O
that	IN	O	O
comparable	JJ	O	O
pathophysiological	JJ	O	O
factors	NNS	O	O
affect	VBP	O	O
TLCO	NNP	O	O
during	IN	O	O
breath	NN	O	O
holding	NN	O	O
and	CC	O	O
constant	JJ	O	O
exhalation	NN	O	O
.	.	O	O

Constant	JJ	O	O
exhalation	NN	O	O
may	MD	O	O
therefore	RB	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
alternative	NN	O	O
to	TO	O	O
the	DT	O	O
breath	NN	O	O
holding	NN	O	O
technique	NN	O	O
for	IN	O	O
clinical	JJ	O	O
measurement	NN	O	O
of	IN	O	O
TLCO	NNP	O	O
.	.	O	O

Identifying	VBG	O	O
patients	NNS	O	O
at	IN	O	O
high	JJ	O	O
risk	NN	O	O
for	IN	O	O
neutropenic	JJ	o	OPH
complications	NNS	o	OPH
during	IN	O	O
chemotherapy	NN	O	O
for	IN	O	O
metastatic	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
with	IN	O	O
doxorubicin	NN	i	IPM
or	CC	O	O
pegylated	VBN	i	IPM
liposomal	JJ	i	IPM
doxorubicin	NN	i	IPM
:	:	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
a	DT	O	O
prediction	NN	O	O
model	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
develop	VB	O	O
a	DT	O	O
cycle-based	JJ	O	O
risk	NN	O	O
prediction	NN	O	O
model	NN	O	O
for	IN	O	O
neutropenic	JJ	o	OPH
complications	NNS	o	OPH
(	(	o	OPH
NC	NNP	o	OPH
)	)	o	OPH
during	IN	O	O
chemotherapy	NN	O	O
with	IN	O	O
doxorubicin	NN	i	IPM
(	(	i	O
DOX	NNP	i	O
)	)	i	O
or	CC	O	O
a	DT	O	O
pegylated	JJ	i	IPM
liposomal	JJ	i	IPM
formulation	NN	i	IPM
(	(	i	IPM
PLD	NNP	i	IPM
)	)	i	IPM
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
metastatic	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
(	(	p	O
MBC	NNP	p	O
)	)	p	O
.	.	O	O

METHODS	NNP	O	O
Data	NNP	O	O
analyzed	VBD	O	O
was	VBD	O	O
from	IN	O	O
a	DT	O	O
phase	NN	O	O
III	NNP	O	O
,	,	O	O
randomized	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
DOX	NNP	i	IPM
(	(	O	O
60	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
every	DT	O	O
3	CD	O	O
weeks	NNS	O	O
)	)	O	O
or	CC	O	O
PLD	NNP	i	IPM
(	(	O	O
50	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
every	DT	O	O
4	CD	O	O
weeks	NNS	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
line	NN	O	O
therapy	NN	O	O
for	IN	O	O
MBC	NNP	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
509	CD	O	O
)	)	O	O
(	(	O	O
O'Brien	NNP	O	O
et	RB	O	O
al	RB	O	O
,	,	O	O
Ann	NNP	O	O
Oncol	NNP	O	O
.	.	O	O

2004	CD	O	O
;	:	O	O
15:440-449	JJ	O	O
)	)	O	O
.	.	O	O

NC	NNP	o	OPH
were	VBD	O	O
defined	VBN	O	O
as	IN	O	O
an	DT	O	O
absolute	NN	o	OPH
neutrophil	NN	o	OPH
count	NN	o	OPH
<	NNP	o	O
or	CC	o	O
=1.5	NNP	o	O
x	VBP	o	O
10	CD	o	O
(	(	o	O
9	CD	o	O
)	)	o	O
cells/L	NN	o	O
(	(	O	O
ie	JJ	O	O
,	,	O	O
>	JJ	O	O
or	CC	O	O
=grade	JJ	O	O
II	NNP	O	O
)	)	O	O
before	IN	O	O
the	DT	O	O
next	JJ	O	O
cycle	NN	O	O
,	,	O	O
febrile	JJ	o	OPH
neutropenia	NN	o	OPH
or	CC	o	O
neutropenia	NN	o	OPH
with	IN	o	O
a	DT	o	O
documented	JJ	o	OPH
infection	NN	o	OPH
.	.	O	O

Patient	NNP	O	O
and	CC	O	O
hematologic	JJ	O	O
factors	NNS	O	O
potentially	RB	O	O
associated	VBN	O	O
with	IN	O	O
NC	NNP	O	O
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

Factors	NNS	O	O
with	IN	O	O
a	DT	O	O
P	NNP	O	O
value	NN	O	O
of	IN	O	O
<	NNP	O	O
or	CC	O	O
=0.25	NNP	O	O
within	IN	O	O
a	DT	O	O
cycle	NN	O	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
a	DT	O	O
generalized	JJ	O	O
estimating	NN	O	O
equations	NNS	O	O
regression	NN	O	O
model	NN	O	O
.	.	O	O

Using	VBG	O	O
backward	JJ	O	O
elimination	NN	O	O
,	,	O	O
we	PRP	O	O
derived	VBD	O	O
a	DT	O	O
risk	NN	O	O
scoring	VBG	O	O
algorithm	NN	O	O
(	(	O	O
range	VB	O	O
0-63	NN	O	O
)	)	O	O
from	IN	O	O
the	DT	O	O
final	JJ	O	O
reduced	VBN	O	O
model	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Risk	NNP	O	O
factors	NNS	O	O
retained	VBD	O	O
in	IN	O	O
the	DT	O	O
model	NN	O	O
included	VBD	O	O
poor	JJ	o	OPH
performance	NN	o	OPH
status	NN	o	OPH
,	,	o	O
absolute	VB	o	OPH
neutrophil	JJ	o	OPH
count	NN	o	OPH
<	NN	o	O
or	CC	o	O
=2.0	VB	o	O
x	JJ	o	O
10	CD	o	O
(	(	o	O
9	CD	o	O
)	)	o	O
cells/L	NN	o	O
in	IN	O	O
the	DT	O	O
previous	JJ	O	O
cycle	NN	O	O
,	,	O	O
the	DT	O	O
first	JJ	O	O
cycle	NN	O	O
of	IN	O	O
chemotherapy	NN	O	O
,	,	O	O
DOX	NNP	i	IPM
versus	NN	O	O
PLD	NNP	i	IPM
and	CC	O	O
advanced	JJ	O	O
age	NN	o	O
.	.	O	O

A	DT	O	O
precycle	NN	o	OPH
risk	NN	o	OPH
score	NN	o	OPH
from	IN	O	O
>	NN	O	O
or	CC	O	O
=25	NN	O	O
to	TO	O	O
<	VB	O	O
40	CD	O	O
for	IN	O	O
a	DT	O	O
given	VBN	O	O
patient	NN	O	O
was	VBD	O	O
identified	VBN	O	O
as	IN	O	O
being	VBG	O	O
the	DT	O	O
optimal	JJ	O	O
threshold	NN	O	O
for	IN	O	O
sensitivity	NN	O	O
(	(	O	O
58.0	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
specificity	NN	O	O
(	(	O	O
78.7	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
a	DT	O	O
score	NN	O	O
at	IN	O	O
or	CC	O	O
beyond	IN	O	O
this	DT	O	O
threshold	NN	O	O
would	MD	O	O
be	VB	O	O
considered	VBN	O	O
at	IN	O	O
high	JJ	O	O
risk	NN	o	OOt
for	IN	O	O
developing	VBG	O	O
NC	NNP	O	O
in	IN	O	O
later	JJ	O	O
cycles	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
The	DT	O	O
use	NN	O	O
of	IN	O	O
this	DT	O	O
model	NN	O	O
may	MD	O	O
enhance	VB	O	O
patient	NN	O	O
care	NN	O	O
by	IN	O	O
targeting	VBG	O	O
preventative	JJ	O	O
therapies	NNS	O	O
(	(	O	O
eg	NN	O	O
,	,	O	O
granulocyte	NN	O	O
colony	NN	O	O
stimulating	VBG	O	O
factor	NN	O	O
or	CC	O	O
PLD	NNP	O	O
)	)	O	O
to	TO	O	O
those	DT	O	O
MBC	NNP	O	O
patients	NNS	p	O
most	RBS	O	O
likely	JJ	O	O
to	TO	O	O
experience	VB	O	O
NC	NNP	o	OPH
during	IN	O	O
anthracycline-based	JJ	O	O
chemotherapy	NN	O	O
.	.	O	O

A	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
of	IN	O	O
fluvoxamine	NN	i	IPM
in	IN	O	O
adults	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	O
.	.	O	O

BACKGROUND	NNP	O	O
Autistic	NNP	O	O
disorder	NN	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
a	DT	O	O
fundamental	JJ	O	O
disturbance	NN	O	O
in	IN	O	O
social	JJ	O	O
interaction	NN	O	O
,	,	O	O
impairments	NNS	O	O
in	IN	O	O
communication	NN	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
markedly	RB	O	O
restricted	JJ	O	O
repertoire	NN	O	O
of	IN	O	O
activities	NNS	O	O
and	CC	O	O
interests	NNS	O	O
.	.	O	O

Abnormalities	NNS	O	O
in	IN	O	O
the	DT	O	O
serotonin	NN	O	O
neurotransmitter	NN	O	O
system	NN	O	O
have	VBP	O	O
been	VBN	O	O
identified	VBN	O	O
in	IN	O	O
some	DT	O	O
persons	NNS	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

No	DT	O	O
consistently	RB	O	O
effective	JJ	O	O
and	CC	O	O
safe	JJ	O	O
drugs	NNS	O	O
have	VBP	O	O
been	VBN	O	O
developed	VBN	O	O
for	IN	O	O
treating	VBG	O	O
the	DT	O	O
symptoms	NNS	O	O
of	IN	O	O
autism	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Thirty	NNP	p	PSS
adults	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
completed	VBD	O	O
a	DT	O	O
12-week	JJ	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
the	DT	O	O
potent	NN	O	O
and	CC	O	O
selective	JJ	O	O
serotonin	NN	O	O
uptake	JJ	O	O
inhibitor	NN	O	O
fluvoxamine	NN	i	IPM
maleate	NN	i	IPM
.	.	O	O

Behavioral	JJ	o	OME
ratings	NNS	o	OME
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
4	CD	O	O
,	,	O	O
8	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Eight	NNP	O	O
(	(	O	O
53	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
15	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
fluvoxamine-treated	JJ	i	IPM
group	NN	O	O
were	VBD	O	O
categorized	VBN	O	O
as	IN	O	O
responders	NNS	O	O
compared	VBN	O	O
with	IN	O	O
none	NN	O	O
of	IN	O	O
15	CD	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

Fluvoxamine	NNP	i	IPM
was	VBD	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	i	IC
in	IN	O	O
reducing	VBG	O	O
repetitive	JJ	o	OME
thoughts	NNS	o	OME
and	CC	o	OME
behavior	NN	o	OME
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
,	,	O	O
maladaptive	JJ	o	OME
behavior	NN	o	OME
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
aggression	NN	o	OME
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.03	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
improving	VBG	O	O
some	DT	O	O
aspects	NNS	O	O
of	IN	O	O
social	JJ	o	OME
relatedness	NN	o	OME
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.04	NNP	O	O
)	)	O	O
,	,	O	O
especially	RB	O	O
language	NN	o	OME
usage	NN	o	OME
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.008	NNP	O	O
)	)	O	O
.	.	O	O

Treatment	JJ	O	O
response	NN	O	O
was	VBD	O	O
not	RB	O	O
correlated	VBN	O	O
with	IN	O	O
age	NN	O	O
level	NN	O	O
of	IN	O	O
autistic	JJ	O	O
behavior	NN	O	O
,	,	O	O
or	CC	O	O
full-scale	JJ	O	O
IQ	NNP	O	O
.	.	O	O

Other	JJ	O	O
than	IN	O	O
mild	JJ	o	OA
sedation	NN	o	OA
and	CC	o	OA
nausea	NN	o	OA
in	IN	O	O
a	DT	O	O
few	JJ	O	O
patients	NNS	O	O
,	,	O	O
fluvoxamine	NN	i	IPM
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
.	.	O	O

No	DT	O	O
dyskinesias	NN	o	OA
,	,	o	O
adverse	JJ	o	OA
cardiovascular	JJ	o	OA
events	NNS	o	OA
,	,	o	O
or	CC	o	O
seizures	NNS	o	OA
occurred	VBD	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Fluvoxamine	NNP	i	IPM
is	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
placebo	NN	i	IC
in	IN	O	O
the	DT	O	O
short-term	JJ	O	O
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
symptoms	NNS	O	O
of	IN	O	O
autistic	JJ	O	O
disorder	NN	O	O
in	IN	O	O
adults	NNS	O	O
.	.	O	O

Controlled	JJ	O	O
studies	NNS	O	O
of	IN	O	O
fluvoxamine	NN	i	IPM
and	CC	O	O
other	JJ	O	O
potent	NN	O	O
and	CC	O	O
selective	JJ	O	O
serotonin	NN	O	O
uptake	JJ	O	O
inhibitors	NNS	O	O
seem	VBP	O	O
warranted	VBN	O	O
in	IN	O	O
children	NNS	O	O
and	CC	O	O
adolescents	NNS	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

Insulin	NNP	i	IPM
pump	NN	i	IPM
therapy	NN	O	O
started	VBD	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
diagnosis	NN	O	O
:	:	O	O
effects	NNS	O	O
on	IN	O	O
glycemic	JJ	o	OPH
control	NN	o	OPH
and	CC	O	O
pancreatic	JJ	o	O
?-cell	NN	o	O
function	NN	o	O
in	IN	O	O
type	NN	p	O
1	CD	p	O
diabetes	NNS	p	O
.	.	O	O

BACKGROUND	NNP	O	O
In	IN	O	O
the	DT	O	O
interest	NN	O	O
of	IN	O	O
preserving	VBG	O	O
residual	JJ	O	O
insulin	NN	O	O
secretory	NN	O	O
capacity	NN	O	O
present	NN	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
diagnosis	NN	O	O
with	IN	O	O
type	JJ	p	O
1	CD	p	O
diabetes	NNS	p	O
(	(	p	O
T1D	NNP	p	O
)	)	p	O
,	,	O	O
we	PRP	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	O
of	IN	O	O
starting	VBG	O	O
insulin	JJ	i	O
pump	NN	i	O
therapy	NN	O	O
at	IN	O	O
diagnosis	NN	O	O
with	IN	O	O
standard	JJ	O	O
multiple	JJ	O	O
daily	JJ	O	O
insulin	NN	i	O
injections	NNS	O	O
(	(	O	O
MDIs	NNP	O	O
)	)	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
pilot	JJ	O	O
trial	NN	O	O
comparing	VBG	O	O
MDI	NNP	i	O
therapy	NN	O	O
with	IN	O	O
continuous	JJ	O	O
subcutaneous	JJ	O	O
insulin	NN	i	O
therapy	NN	i	O
(	(	O	O
pump	JJ	i	O
therapy	NN	i	O
)	)	O	O
in	IN	O	O
24	CD	p	O
patients	NNS	p	O
,	,	p	O
8-18	CD	p	O
years	NNS	p	O
old	JJ	p	O
,	,	p	O
with	IN	p	O
newly	RB	p	O
diagnosed	VBN	p	O
T1D	NNP	p	O
.	.	O	O

Subjects	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
at	IN	O	O
enrollment	NN	O	O
and	CC	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
9	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
after	IN	O	O
initial	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
T1D	NNP	O	O
.	.	O	O

Preservation	NN	O	O
of	IN	o	O
insulin	NN	o	O
secretion	NN	o	O
,	,	o	O
measured	VBN	O	O
by	IN	O	O
mixed-meal-stimulated	JJ	o	O
C-peptide	JJ	o	O
secretion	NN	o	O
,	,	O	O
was	VBD	O	O
compared	VBN	O	O
after	IN	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Between-group	JJ	O	O
differences	NNS	O	O
in	IN	O	O
glycosylated	JJ	o	O
hemoglobin	NN	o	O
(	(	o	O
HbA1c	NNP	o	O
)	)	o	O
,	,	o	O
continuous	JJ	o	O
glucose	NN	o	O
sensor	NN	o	O
data	NNS	o	O
,	,	o	O
insulin	NN	o	O
utilization	NN	o	O
,	,	o	O
anthropometric	JJ	o	O
measures	NNS	o	O
,	,	o	O
and	CC	o	O
patient	JJ	o	O
satisfaction	NN	o	O
with	IN	O	O
therapy	NN	O	O
were	VBD	O	O
also	RB	O	O
compared	VBN	O	O
at	IN	O	O
multiple	JJ	O	O
time	NN	O	O
points	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Initiation	NNP	O	O
of	IN	O	O
pump	NN	i	O
therapy	NN	i	O
within	IN	O	O
1	CD	O	O
month	NN	O	O
of	IN	O	O
diagnosis	NN	O	O
resulted	VBD	O	O
in	IN	O	O
consistently	RB	O	O
higher	JJR	O	O
mixed-meal	JJ	o	O
tolerance	NN	o	O
test-stimulated	JJ	o	O
C-peptide	JJ	o	O
values	NNS	o	O
at	IN	O	O
all	DT	O	O
time	NN	O	O
points	NNS	O	O
,	,	O	O
although	IN	O	O
these	DT	O	O
differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

Nonetheless	NNP	O	O
,	,	O	O
improved	JJ	O	O
glycemic	JJ	o	O
control	NN	o	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
insulin	JJ	i	O
pump-treated	JJ	O	O
subjects	NNS	O	O
(	(	O	O
more	JJR	O	O
time	NN	O	O
spent	VBN	O	O
with	IN	O	O
normoglycemia	NN	O	O
,	,	O	O
better	JJR	O	O
mean	JJ	O	O
HbA1c	NNP	o	O
)	)	O	O
,	,	O	O
and	CC	O	O
pump-treated	JJ	O	O
subjects	NNS	O	O
reported	VBN	O	O
comparatively	RB	O	O
greater	JJR	O	O
satisfaction	NN	o	O
with	IN	O	O
route	NN	O	O
of	IN	O	O
treatment	NN	O	O
administration	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Initiation	NNP	O	O
of	IN	O	O
insulin	NN	i	O
pump	NN	i	O
therapy	NN	i	O
at	IN	O	O
diagnosis	NN	O	O
improved	JJ	O	O
glycemic	JJ	o	O
control	NN	o	O
,	,	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
,	,	O	O
and	CC	O	O
contributed	VBD	O	O
to	TO	O	O
improved	VBN	O	O
patient	JJ	o	O
satisfaction	NN	o	O
with	IN	O	O
treatment	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
also	RB	O	O
suggests	VBZ	O	O
that	IN	O	O
earlier	JJR	O	O
use	NN	O	O
of	IN	O	O
pump	NN	O	O
therapy	NN	O	O
might	MD	O	O
help	VB	O	O
to	TO	O	O
preserve	VB	O	O
residual	JJ	o	O
?-cell	NNP	o	O
function	NN	o	O
,	,	O	O
although	IN	O	O
a	DT	O	O
larger	JJR	O	O
clinical	JJ	O	O
trial	NN	O	O
would	MD	O	O
be	VB	O	O
required	VBN	O	O
to	TO	O	O
confirm	VB	O	O
this	DT	O	O
.	.	O	O

Economic	JJ	o	OOt
evaluation	NN	o	OOt
of	IN	O	O
aquatic	JJ	i	IPH
exercise	NN	i	IPH
for	IN	O	O
persons	NNS	p	O
with	IN	p	O
osteoarthritis	NN	p	PC
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
estimate	VB	O	O
cost	NN	o	OOt
and	CC	O	O
outcomes	NNS	o	O
of	IN	O	O
the	DT	O	O
Arthritis	NNP	O	O
Foundation	NNP	O	O
aquatic	JJ	i	IPH
exercise	NN	i	IPH
classes	NNS	i	IPH
from	IN	O	O
the	DT	O	O
societal	JJ	O	O
perspective	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
trial	NN	O	O
of	IN	O	O
20-week	JJ	O	O
aquatic	JJ	i	IPH
classes	NNS	i	IPH
.	.	O	O

Cost	NN	o	OOt
per	IN	o	OOt
quality-adjusted	JJ	o	OOt
life	NN	o	OOt
year	NN	o	OOt
(	(	o	OOt
QALY	NNP	o	OOt
)	)	o	OOt
gained	VBD	O	O
was	VBD	O	O
estimated	VBN	O	O
using	VBG	O	O
trial	NN	O	O
data	NNS	O	O
.	.	O	O

Sample	NNP	O	O
size	NN	O	O
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
80	CD	O	O
%	NN	O	O
power	NN	O	O
to	TO	O	O
reject	VB	O	O
the	DT	O	O
null	JJ	O	O
hypothesis	NN	O	O
that	IN	O	O
the	DT	O	O
cost/QALY	NN	o	OOt
gained	VBD	O	O
would	MD	O	O
not	RB	O	O
exceed	VB	O	O
$	$	O	O
50,000	CD	O	O
.	.	O	O

SUBJECTS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
Recruited	VBD	O	O
249	CD	p	PSS
adults	NNS	p	PA
from	IN	p	O
Washington	NNP	p	O
State	NNP	p	O
aged	VBD	p	PA
55	CD	p	PA
to	TO	p	PA
75	CD	p	PA
with	IN	p	O
a	DT	p	O
doctor-confirmed	JJ	p	O
diagnosis	NN	p	O
of	IN	p	O
osteoarthritis	NN	p	PC
to	TO	O	O
participate	VB	O	O
in	IN	O	O
aquatic	JJ	i	IPH
classes	NNS	i	IPH
.	.	O	O

The	DT	O	O
Quality	NN	o	OOt
of	IN	o	OOt
Well-Being	NNP	o	OOt
Scale	NNP	o	OOt
(	(	o	OOt
QWB	NNP	o	OOt
)	)	o	OOt
and	CC	O	O
Current	NNP	o	OOt
Health	NNP	o	OOt
Desirability	NNP	o	OOt
Rating	NNP	o	OOt
(	(	o	OOt
CHDR	NNP	o	OOt
)	)	o	OOt
were	VBD	O	O
used	VBN	O	O
for	IN	O	O
economic	JJ	O	O
evaluation	NN	O	O
,	,	O	O
supplemented	VBN	O	O
by	IN	O	O
the	DT	O	O
arthritis-specific	JJ	o	OPH
Health	NNP	o	OPH
Assessment	NNP	o	OPH
Questionnaire	NNP	o	OPH
(	(	o	OPH
HAQ	NNP	o	OPH
)	)	o	OPH
,	,	O	O
Center	NNP	o	OPH
for	IN	o	OPH
Epidemiologic	NNP	o	OPH
Studies-Depression	NNP	o	OPH
Scale	NNP	o	OPH
(	(	o	OPH
CES-D	NNP	o	OPH
)	)	o	O
,	,	O	O
and	CC	O	O
Perceived	NNP	o	OOt
Quality	NNP	o	OOt
of	IN	o	OOt
Life	NNP	o	OOt
Scale	NNP	o	OOt
(	(	o	OOt
PQOL	NNP	o	OOt
)	)	o	OOt
collected	VBD	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
postclass	NN	O	O
.	.	O	O

Outcome	NNP	O	O
results	NNS	O	O
applied	VBD	O	O
to	TO	O	O
life	NN	O	O
expectancy	NN	O	O
tables	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
estimate	VB	O	O
QALYs	NNP	o	OOt
.	.	O	O

Use	NNP	o	OOt
of	IN	o	OOt
health	NN	o	OOt
care	NN	o	OOt
facilities	NNS	o	OOt
was	VBD	O	O
assessed	VBN	O	O
from	IN	O	O
diaries/questionnaires	NNS	O	O
and	CC	O	O
Medicare	NNP	o	OOt
reimbursement	NN	o	OOt
rates	NNS	o	OOt
used	VBD	O	O
to	TO	O	O
estimate	VB	O	O
costs	NNS	O	O
.	.	O	O

Nonparametric	NNP	O	O
bootstrap	NN	O	O
sampling	NN	O	O
of	IN	O	O
costs/QALY	NN	o	OOt
ratios	NNS	o	OOt
established	VBD	O	O
the	DT	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
around	IN	O	O
the	DT	O	O
estimates	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Aquatic	JJ	i	IPH
exercisers	NNS	i	IPH
reported	VBD	O	O
equal	JJ	O	O
(	(	O	O
QWB	NNP	o	OPH
)	)	O	O
or	CC	O	O
better	JJR	O	O
(	(	O	O
CHDR	NNP	o	OPH
,	,	o	OPH
HAQ	NNP	o	OPH
,	,	o	OPH
PQOL	NNP	o	OPH
)	)	O	O
health-related	JJ	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
compared	VBN	O	O
with	IN	O	O
controls	NNS	O	O
.	.	O	O

Outcomes	NNS	O	O
improved	VBN	O	O
with	IN	O	O
regular	JJ	O	O
class	NN	O	O
attendance	NN	O	O
.	.	O	O

Costs/QALY	NNP	o	OOt
gained	VBD	O	O
discounted	VBN	O	O
at	IN	O	O
3	CD	O	O
%	NN	O	O
were	VBD	O	O
$	$	O	O
205,186	CD	O	O
using	VBG	O	O
the	DT	O	O
QWB	NNP	o	OPH
and	CC	O	O
$	$	O	O
32,643	CD	O	O
using	VBG	O	O
the	DT	O	O
CHRD	NNP	o	OPH
.	.	O	O

CONCLUSION	NNP	O	O
Aquatic	NNP	i	IPH
exercise	NN	i	IPH
exceeded	VBD	O	O
$	$	O	O
50,000	CD	O	O
per	IN	O	O
QALY	NN	o	OOt
gained	VBN	O	O
using	VBG	O	O
the	DT	O	O
community-weighted	JJ	O	O
outcome	NN	O	O
but	CC	O	O
fell	VBD	O	O
below	IN	O	O
this	DT	O	O
arbitrary	JJ	O	O
budget	NN	O	O
constraint	NN	O	O
when	WRB	O	O
using	VBG	O	O
the	DT	O	O
participant-weighted	JJ	O	O
measure	NN	O	O
.	.	O	O

Confidence	NN	O	O
intervals	NNS	O	O
around	IN	O	O
these	DT	O	O
ratios	NNS	O	O
suggested	VBD	O	O
wide	JJ	O	O
variability	NN	O	O
of	IN	O	O
cost	NN	O	O
effectiveness	NN	O	O
of	IN	O	O
aquatic	JJ	i	IPH
exercise	NN	i	IPH
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
individualized	JJ	i	IPS
breast	NN	i	IPS
cancer	NN	i	IPS
risk	NN	i	IPS
counseling	NN	i	IPS
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Studies	NNPS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
a	DT	O	O
majority	NN	O	O
of	IN	O	O
women	NNS	p	PSE
with	IN	p	O
a	DT	p	O
family	NN	p	O
history	NN	p	O
of	IN	p	O
breast	NN	p	PC
cancer	NN	p	PC
have	VBP	O	O
exaggerated	VBN	O	O
perceptions	NNS	O	O
of	IN	O	O
their	PRP$	O	O
own	JJ	O	O
risk	NN	O	O
of	IN	O	O
this	DT	O	O
disease	NN	O	O
and	CC	O	O
experience	NN	O	O
excessive	JJ	O	O
anxiety	NN	O	O
.	.	O	O

In	IN	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
need	NN	O	O
to	TO	O	O
communicate	VB	O	O
more	JJR	O	O
accurate	JJ	O	O
risk	NN	O	O
information	NN	O	O
to	TO	O	O
these	DT	O	O
women	NNS	O	O
,	,	O	O
specialized	JJ	O	O
programs	NNS	O	O
for	IN	O	O
breast	NN	O	O
cancer	NN	O	O
risk	NN	O	O
counseling	VBG	O	O
have	VBP	O	O
been	VBN	O	O
initiated	VBN	O	O
in	IN	O	O
medical	JJ	O	O
centers	NNS	O	O
across	IN	O	O
the	DT	O	O
United	NNP	O	O
States	NNPS	O	O
.	.	O	O

PURPOSE	VB	O	O
Our	PRP$	O	O
purpose	NN	O	O
was	VBD	O	O
1	CD	O	O
)	)	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
a	DT	O	O
standardized	JJ	O	O
protocol	NN	O	O
for	IN	O	O
individualized	JJ	i	IPS
breast	NN	i	IPS
cancer	NN	i	IPS
risk	NN	i	IPS
counseling	VBG	i	IPS
on	IN	O	O
comprehension	NN	O	O
of	IN	O	O
personal	JJ	O	O
risk	NN	O	O
among	IN	O	O
first-degree	JJ	p	O
relatives	NNS	p	O
of	IN	p	O
index	NN	p	O
breast	NN	p	O
cancer	NN	p	O
patients	NNS	p	O
and	CC	O	O
2	CD	O	O
)	)	O	O
to	TO	O	O
identify	VB	O	O
women	NNS	O	O
most	RBS	O	O
and	CC	O	O
least	JJS	O	O
likely	JJ	O	O
to	TO	O	O
benefit	VB	O	O
from	IN	O	O
such	JJ	O	O
counseling	NN	O	O
.	.	O	O

METHODS	NNP	O	O
This	DT	O	O
study	NN	O	O
is	VBZ	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
comparing	VBG	O	O
individualized	VBN	i	IPS
breast	NN	i	IPS
cancer	NN	i	IPS
risk	NN	i	IPS
counseling	VBG	i	IPS
to	TO	O	O
general	JJ	i	IC
health	NN	i	IC
counseling	NN	i	IC
(	(	i	IC
control	NN	i	IC
)	)	i	IC
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
200	CD	p	PSS
women	NNS	p	O
aged	VBN	p	O
35	CD	p	PA
years	NNS	p	PA
and	CC	p	O
older	JJR	p	O
who	WP	p	O
had	VBD	p	O
a	DT	p	O
family	NN	p	O
history	NN	p	O
of	IN	p	O
breast	NN	p	O
cancer	NN	p	O
in	IN	p	O
a	DT	p	O
first-degree	JJ	p	O
relative	NN	p	O
.	.	O	O

Women	NNS	p	O
with	IN	p	O
a	DT	p	O
personal	JJ	p	O
history	NN	p	O
of	IN	p	O
cancer	NN	p	O
were	VBD	p	O
excluded	VBN	p	O
.	.	O	O

Risk	NNP	o	OME
comprehension	NN	o	OME
was	VBD	O	O
assessed	VBN	O	O
as	IN	O	O
the	DT	O	O
concordance	NN	O	O
between	IN	O	O
perceived	VBN	O	O
subjective	JJ	O	O
lifetime	NN	O	O
breast	NN	O	O
cancer	NN	O	O
risk	NN	O	O
and	CC	O	O
estimated	VBN	O	O
objective	JJ	O	O
lifetime	NN	O	O
risk	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
logistic	JJ	O	O
regression	NN	O	O
analysis	NN	O	O
showed	VBD	O	O
that	IN	O	O
women	NNS	O	O
who	WP	O	O
received	VBD	O	O
risk	NN	i	IE
counseling	NN	i	IE
were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
improve	VB	O	O
their	PRP$	O	O
risk	NN	o	OME
comprehension	NN	o	OME
,	,	O	O
compared	VBN	O	O
with	IN	O	O
women	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
condition	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
[	CD	O	O
OR	NNP	O	O
]	NNP	O	O
=	VBZ	O	O
3.5	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
=	NNP	O	O
1.3-9.5	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
about	RB	O	O
two	CD	O	O
thirds	NNS	O	O
of	IN	O	O
women	NNS	O	O
continued	VBN	O	O
to	TO	O	O
overestimate	VB	O	O
their	PRP$	O	O
lifetime	NN	o	OME
risks	NNS	o	OME
substantially	RB	O	O
following	VBG	O	O
counseling	VBG	O	O
.	.	O	O

Examination	NN	O	O
of	IN	O	O
subjects	NNS	O	O
by	IN	O	O
treatment	NN	O	O
interaction	NN	O	O
effects	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
risk	NN	i	IPS
counseling	VBG	i	IPS
did	VBD	O	O
not	RB	O	O
produce	VB	O	O
improved	JJ	O	O
comprehension	NN	o	OME
among	IN	O	O
the	DT	O	O
large	JJ	O	O
proportion	NN	O	O
of	IN	O	O
women	NNS	O	O
who	WP	O	O
had	VBD	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
anxious	JJ	O	O
preoccupation	NN	O	O
with	IN	O	O
breast	NN	O	O
cancer	NN	O	O
at	IN	O	O
base	NN	O	O
line	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
white	JJ	O	O
women	NNS	O	O
were	VBD	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
benefit	VB	O	O
than	IN	O	O
African-American	JJ	O	O
women	NNS	O	O
(	(	O	O
OR	NNP	O	O
=	VBZ	O	O
0.34	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
=	NNP	O	O
0.11-0.99	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Efforts	NNPS	O	O
to	TO	O	O
counsel	NN	O	O
women	NNS	O	O
about	IN	O	O
their	PRP$	O	O
breast	NN	O	O
cancer	NN	O	O
risks	NNS	O	O
are	VBP	O	O
not	RB	O	O
likely	JJ	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
unless	IN	O	O
their	PRP$	O	O
breast	NN	O	O
cancer	NN	O	O
anxieties	NNS	O	O
are	VBP	O	O
also	RB	O	O
addressed	VBN	O	O
.	.	O	O

IMPLICATIONS	NNP	O	O
Attention	NNP	O	O
to	TO	O	O
the	DT	O	O
psychological	JJ	O	O
aspects	NNS	O	O
of	IN	O	O
breast	NN	O	O
cancer	NN	O	O
risk	NN	O	O
will	MD	O	O
be	VB	O	O
critical	JJ	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
risk-counseling	JJ	i	IE
programs	NNS	i	IE
that	WDT	O	O
incorporate	VBP	O	O
testing	VBG	O	O
for	IN	O	O
the	DT	O	O
recently	RB	O	O
cloned	VBN	O	O
breast	NN	O	O
cancer	NN	O	O
susceptibility	NN	O	O
gene	NN	O	O
,	,	O	O
BRCA1	NNP	O	O
(	(	O	O
and	CC	O	O
BRCA2	NNP	O	O
when	WRB	O	O
that	DT	O	O
gene	NN	O	O
has	VBZ	O	O
also	RB	O	O
been	VBN	O	O
cloned	VBN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
of	IN	O	O
asthma	NN	p	PC
in	IN	p	O
adults	NNS	p	PA
using	VBG	O	O
sodium	NN	i	IPM
cromoglycate	NN	i	IPM
pressurized	VBN	O	O
aerosol	NN	O	O
:	:	O	O
a	DT	O	O
double-blind	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

Sodium	NN	i	IPM
cromoglycate	NN	i	IPM
formulated	VBN	O	O
as	IN	O	O
a	DT	O	O
pressurized	JJ	O	O
aerosol	NN	O	O
(	(	O	O
2	CD	O	O
mg	RB	O	O
4-times	JJ	O	O
daily	JJ	O	O
)	)	O	O
and	CC	O	O
placebo	NN	i	IC
were	VBD	O	O
compared	VBN	O	O
in	IN	O	O
31	CD	p	PSS
adult	NN	p	PA
asthmatic	JJ	p	PC
patients	NNS	p	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
crossover	NN	O	O
trial	NN	O	O
lasting	VBG	O	O
12	CD	O	O
weeks	NNS	O	O
.	.	O	O

Sodium	NNP	i	IPM
cromoglycate	NN	i	IPM
was	VBD	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	i	IC
in	IN	O	O
improving	VBG	O	O
breathlessness	NN	o	OPH
at	IN	o	OPH
rest	NN	o	OPH
(	(	O	O
p	IN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
breathlessness	NN	o	OPH
on	IN	o	OPH
exertion	NN	o	OPH
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
quality	NN	o	OPH
of	IN	o	OPH
sleep	NN	o	OPH
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
also	RB	O	O
in	IN	O	O
improving	VBG	O	O
the	DT	O	O
morning	NN	o	OPH
peak	NN	o	OPH
expiratory	NN	o	OPH
flow	NN	o	OPH
rate	NN	o	OPH
value	NN	o	OPH
(	(	O	O
p	IN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Both	CC	O	O
the	DT	O	O
patients	NNS	O	O
'	POS	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
clinicians	NNS	O	O
'	POS	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
treatment	NN	O	O
opinions	NNS	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
treatment	NN	o	OME
preferences	NNS	o	OME
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
favoured	VBD	O	O
sodium	NN	i	IPM
cromoglycate	NN	i	IPM
.	.	O	O

Moreover	RB	O	O
,	,	O	O
usage	NN	O	O
of	IN	O	O
bronchodilators	NNS	O	O
(	(	O	O
theophylline	NN	O	O
and	CC	O	O
aerosol	JJ	O	O
beta-stimulants	NNS	O	O
combined	VBN	O	O
)	)	O	O
declined	VBD	O	O
significantly	RB	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
during	IN	O	O
sodium	NN	i	IPM
cromoglycate	NN	i	IPM
treatment	NN	O	O
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
.	.	O	O

No	DT	O	O
side-effects	NNS	o	OA
were	VBD	O	O
reported	VBN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
show	NN	O	O
that	IN	O	O
sodium	NN	i	IPM
cromoglycate	NN	i	IPM
delivered	VBN	O	O
by	IN	O	O
pressurized	JJ	O	O
aerosol	NN	O	O
was	VBD	O	O
significantly	RB	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	i	IC
,	,	O	O
not	RB	O	O
only	RB	O	O
in	IN	O	O
improving	VBG	O	O
asthmatic	JJ	o	OPH
symptoms	NNS	o	OPH
,	,	O	O
but	CC	O	O
also	RB	O	O
in	IN	O	O
reducing	VBG	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
concomitant	JJ	O	O
bronchodilator	NN	o	OOt
therapy	NN	o	OOt
required	VBN	o	OOt
.	.	O	O

Language	NNP	o	OME
outcome	NN	o	OME
in	IN	O	O
autism	NN	p	O
:	:	O	O
randomized	JJ	O	O
comparison	NN	O	O
of	IN	O	O
joint	JJ	i	IPH
attention	NN	i	IPH
and	CC	O	O
play	NN	i	IPH
interventions	NNS	i	IPH
.	.	O	O

This	DT	O	O
study	NN	O	O
reports	VBZ	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
aimed	VBN	O	O
at	IN	O	O
joint	JJ	i	IPH
attention	NN	i	IPH
(	(	i	IPH
JA	NNP	i	IPH
)	)	i	IPH
and	CC	O	O
symbolic	JJ	i	IPH
play	NN	i	IPH
(	(	i	IPH
SP	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
preschool	NN	p	PA
children	NNS	p	PA
with	IN	p	PA
autism	NN	p	PA
,	,	O	O
with	IN	O	O
prediction	NN	O	O
to	TO	O	O
language	NN	o	OME
outcome	RB	o	OME
12	CD	O	O
months	NNS	O	O
later	RB	O	O
.	.	O	O

Participants	NNS	p	O
were	VBD	p	O
58	CD	p	O
children	NNS	p	O
(	(	p	O
46	CD	p	O
boys	NNS	p	O
)	)	p	O
with	IN	p	O
autism	NN	p	O
between	IN	p	O
3	CD	p	O
and	CC	p	O
4	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
.	.	p	O

Children	NNP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
a	DT	O	O
JA	NNP	i	IE
intervention	NN	O	O
,	,	O	O
an	DT	O	O
SP	NNP	i	IE
intervention	NN	O	O
,	,	O	O
or	CC	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Interventions	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
30	CD	O	O
min	JJ	O	O
daily	JJ	O	O
for	IN	O	O
5-6	JJ	O	O
weeks	NNS	O	O
.	.	O	O

Assessments	NNS	O	O
of	IN	O	O
JA	NNP	o	OME
skills	NNS	o	OME
,	,	o	O
SP	NNP	o	OME
skills	NNS	o	OME
,	,	o	O
mother-child	JJ	o	OME
interactions	NNS	o	OME
,	,	o	O
and	CC	o	O
language	NN	o	OME
development	NN	o	OME
were	VBD	O	O
collected	VBN	O	O
at	IN	O	O
4	CD	O	O
time	NN	O	O
points	NNS	O	O
:	:	O	O
pre-	NN	O	O
and	CC	O	O
postintervention	NN	O	O
and	CC	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
postintervention	NN	O	O
by	IN	O	O
independent	JJ	O	O
testers	NNS	O	O
.	.	O	O

Results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
expressive	JJ	o	OME
language	NN	o	OME
gains	NNS	o	OME
were	VBD	O	O
greater	JJR	O	O
for	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
results	NNS	O	O
could	MD	O	O
not	RB	O	O
be	VB	O	O
explained	VBN	O	O
by	IN	O	O
differences	NNS	O	O
in	IN	O	O
other	JJ	O	O
interventions	NNS	O	O
in	IN	O	O
which	WDT	O	O
children	NNS	O	O
participated	VBD	O	O
.	.	O	O

For	IN	O	O
children	NNS	O	O
beginning	VBG	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
lowest	JJS	O	O
language	NN	O	O
levels	NNS	O	O
,	,	O	O
the	DT	O	O
JA	NNP	i	IE
intervention	NN	O	O
improved	VBD	O	O
language	NN	o	OME
outcome	NN	o	OME
significantly	RB	O	O
more	RBR	O	O
than	IN	O	O
did	VBD	O	O
the	DT	O	O
SP	NNP	i	IPH
or	CC	O	O
control	VB	O	O
interventions	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
clinically	RB	O	O
significant	JJ	O	O
benefits	NNS	O	O
of	IN	O	O
actively	RB	O	O
treating	VBG	O	O
JA	NNP	i	IE
and	CC	O	O
SP	NNP	i	IPH
skills	NNS	O	O
in	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
guided	JJ	O	O
imagery	NN	O	O
with	IN	O	O
relaxation	NN	i	IPS
training	NN	i	IPS
on	IN	O	O
anxiety	NN	o	OME
and	CC	O	O
quality	NN	o	OME
of	IN	o	OME
life	NN	o	OME
among	IN	O	O
patients	NNS	p	O
with	IN	p	O
inflammatory	JJ	p	PC
bowel	NN	p	PC
disease	NN	p	PC
.	.	O	O

BACKGROUND	NNP	O	O
Inflammatory	NNP	O	O
Bowel	NNP	O	O
Disease	NNP	O	O
(	(	O	O
IBD	NNP	O	O
)	)	O	O
impacts	VBZ	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
(	(	o	O
QoL	NNP	o	O
)	)	o	O
.	.	O	O

Psychological	JJ	O	O
factors	NNS	O	O
influence	VBP	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
and	CC	O	O
should	MD	O	O
be	VB	O	O
targeted	VBN	O	O
for	IN	O	O
intervention	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Our	PRP$	O	O
study	NN	O	O
was	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomised	VBD	O	O
control	NN	O	O
trial	NN	O	O
.	.	O	O

Fifty-six	JJ	p	PSS
outpatients	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
chosen	VBN	O	O
and	CC	O	O
allocated	VBN	O	O
to	TO	O	O
a	DT	O	O
treatment	NN	O	O
group	NN	O	O
or	CC	O	O
a	DT	O	O
waiting-list	JJ	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Treatment	NNP	O	O
group	NN	O	O
patients	NNS	O	O
attended	VBD	O	O
three	CD	O	O
relaxation-training	JJ	i	IE
sessions	NNS	i	IE
and	CC	O	O
received	VBD	O	O
an	DT	O	O
audio	JJ	O	O
disc	NN	O	O
for	IN	O	O
home	NN	O	O
practice	NN	O	O
.	.	O	O

Evaluations	NNS	O	O
performed	VBD	O	O
pre	JJ	O	O
and	CC	O	O
post-treatment	JJ	O	O
:	:	O	O
state	NN	o	OME
anxiety	NN	o	OME
was	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
the	DT	O	O
State-Trait	NNP	o	OME
Anxiety	NNP	o	OME
Inventory	NNP	o	OME
,	,	o	OME
QoL	NNP	o	OME
with	IN	o	OME
the	DT	o	OME
IBD	NNP	o	OME
Questionnaire	NNP	o	OME
.	.	O	O

The	DT	O	O
Visual	NNP	o	OOt
Analogue	NNP	o	OOt
Scale	NNP	o	OOt
assessed	VBD	O	O
pain	NN	o	OPA
,	,	o	O
depression	NN	o	OME
,	,	o	O
stress	NN	o	OME
and	CC	O	O
mood	NN	o	OME
.	.	O	O

Patients	NNS	O	O
completed	VBD	O	O
a	DT	O	O
symptom	JJ	O	O
monitoring	NN	O	O
diary	NN	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
group	NN	O	O
's	POS	O	O
symptoms	NNS	O	O
were	VBD	O	O
monitored	VBN	O	O
without	IN	O	O
study-related	JJ	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Thirty-nine	JJ	p	PSS
subjects	NNS	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
and	CC	O	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
data	NN	O	O
analysis	NN	O	O
.	.	O	O

Following	VBG	O	O
the	DT	O	O
relaxation-training	JJ	i	O
intervention	NN	O	O
,	,	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
's	POS	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
18	CD	O	O
)	)	O	O
measured	VBN	O	O
results	NNS	O	O
showed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
improvement	NN	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
21	CD	O	O
)	)	O	O
(	(	O	O
time	NN	O	O
by	IN	O	O
treatment	NN	O	O
interaction	NN	O	O
)	)	O	O
:	:	O	O
anxiety	NN	o	O
levels	NNS	o	O
decreased	VBN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
QoL	NNP	o	O
and	CC	o	O
mood	NN	o	O
improved	VBN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
levels	NNS	O	O
of	IN	O	O
pain	NN	o	O
and	CC	o	O
stress	NN	o	O
decreased	VBN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Findings	NNP	O	O
indicate	VBP	O	O
IBD	NNP	p	O
patients	NNS	p	O
may	MD	O	O
benefit	VB	O	O
from	IN	O	O
relaxation	NN	i	O
training	NN	i	O
in	IN	O	O
their	PRP$	O	O
holistic	JJ	O	O
care	NN	O	O
.	.	O	O

New	NNP	O	O
studies	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
further	JJ	O	O
investigation	NN	O	O
of	IN	O	O
the	DT	O	O
subject	NN	O	O
are	VBP	O	O
warranted	VBN	O	O
.	.	O	O

A	DT	O	O
pilot	NN	O	O
study	NN	O	O
on	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
progressive	JJ	i	IE
muscle	NN	i	IE
relaxation	NN	i	IE
training	NN	i	IE
of	IN	O	O
patients	NNS	p	O
after	IN	p	O
stoma	NN	p	PC
surgery	NN	p	PC
.	.	O	O

Eighteen	JJ	p	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
undergone	JJ	p	O
stoma	NN	p	PC
surgery	NN	p	PC
were	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
their	PRP$	O	O
anxiety	NN	o	OME
level	NN	o	OME
and	CC	o	O
self-reported	JJ	o	OPH
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
(	(	o	OPH
QoL	NNP	o	OPH
)	)	o	OPH
on	IN	O	O
three	CD	O	O
occasions	NNS	O	O
;	:	O	O
namely	RB	O	O
,	,	O	O
immediately	RB	O	O
after	IN	O	O
surgery	NN	O	O
,	,	O	O
5	CD	O	O
weeks	NNS	O	O
after	IN	O	O
surgery	NN	O	O
,	,	O	O
and	CC	O	O
10	CD	O	O
weeks	NNS	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomised	VBN	O	O
into	IN	O	O
a	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
and	CC	O	O
an	DT	O	O
experimental	JJ	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
8	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
20-min	JJ	O	O
set	NN	O	O
of	IN	O	O
audiotaped	JJ	O	O
instructions	NNS	O	O
on	IN	O	O
progressive	JJ	i	IE
muscle	NN	i	IE
relaxation	NN	i	IE
training	NN	i	IE
(	(	i	IE
PMRT	NNP	i	IE
)	)	i	IE
was	VBD	O	O
given	VBN	O	O
to	TO	O	O
the	DT	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
for	IN	O	O
home	NN	O	O
practice	NN	O	O
.	.	O	O

Assessment	NNP	O	O
instructions	NNS	O	O
included	VBD	O	O
the	DT	O	O
Chinese	JJ	o	OME
State-Trait	NNP	o	OME
Anxiety	NNP	o	OME
Inventory	NNP	o	OME
(	(	o	OME
C-STAI	NNP	o	OME
)	)	o	OME
,	,	o	O
the	DT	o	OOt
Quality	NN	o	OPH
of	IN	o	OPH
Life	NNP	o	OPH
Index	NNP	o	OPH
for	IN	o	OPH
Colostomy	NNP	o	OPH
(	(	o	OPH
QoL-Colostomy	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
the	DT	o	O
Hong	NNP	o	OPH
Kong	NNP	o	OPH
Chinese	JJ	o	OPH
version	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
World	NNP	o	OPH
Health	NNP	o	OPH
Organisation	NNP	o	OPH
Quality	NNP	o	OPH
of	IN	o	OPH
Life	NNP	o	OPH
Scale	NNP	o	OPH
(	(	o	OOt
WHOQoL	NNP	o	OOt
)	)	o	OOt
.	.	O	O

Results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
both	DT	O	O
the	DT	O	O
C-STAI	NNP	o	OPH
score	NN	o	OPH
(	(	O	O
F	NNP	O	O
=	NNP	O	O
4.66	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
WHOQoL	NNP	o	OPH
score	NN	o	OPH
(	(	O	O
F	NNP	O	O
=	NNP	O	O
4.74	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
.	.	O	O

Among	IN	O	O
the	DT	O	O
domains	NNS	O	O
of	IN	O	O
WHOQoL	NNP	o	OOt
,	,	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
shown	VBN	O	O
in	IN	O	O
physical	JJ	O	O
health/independence	NN	O	O
and	CC	O	O
general	JJ	O	O
perception	NN	O	O
of	IN	O	O
QoL	NNP	o	OOt
,	,	O	O
with	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
demonstrating	VBG	O	O
better	JJR	O	O
functioning	NN	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
QoL-Colostomy	NNP	o	OPH
,	,	O	O
however	RB	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
control	NN	O	O
and	CC	O	O
experimental	JJ	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
PMRT	NNP	i	IE
could	MD	O	O
enhance	VB	O	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
and	CC	O	O
decrease	NN	O	O
state	NN	O	O
anxiety	NN	o	OME
in	IN	O	O
patients	NNS	p	O
after	IN	p	O
stoma	NN	p	PC
surgery	NN	p	PC
.	.	p	O

[	IN	O	O
The	DT	O	O
chemotherapy	NN	i	IPM
of	IN	O	O
advanced	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
.	.	O	O

A	DT	O	O
report	NN	O	O
on	IN	O	O
the	DT	O	O
first	JJ	O	O
600	CD	p	O
cases	NNS	p	O
in	IN	O	O
a	DT	O	O
cooperative	JJ	O	O
programme	NN	O	O
to	TO	O	O
carry	VB	O	O
out	RP	O	O
a	DT	O	O
systematic	JJ	O	O
study	NN	O	O
(	(	O	O
1974-1977	JJ	O	O
)	)	O	O
(	(	O	O
author	NN	O	O
's	POS	O	O
transl	NN	O	O
)	)	O	O
]	NN	O	O
.	.	O	O

The	DT	O	O
authors	NNS	O	O
explain	VBP	O	O
the	DT	O	O
objectives	NNS	O	O
and	CC	O	O
the	DT	O	O
structure	NN	O	O
of	IN	O	O
a	DT	O	O
programme	NN	O	O
evolved	VBN	O	O
for	IN	O	O
the	DT	O	O
methodic	JJ	O	O
study	NN	O	O
of	IN	O	O
advanced	JJ	p	PC
breast	NN	p	PC
cancers	NNS	p	PC
which	WDT	O	O
they	PRP	O	O
have	VBP	O	O
worked	VBN	O	O
out	RP	O	O
and	CC	O	O
carried	VBD	O	O
out	RP	O	O
in	IN	O	O
cooperation	NN	O	O
with	IN	O	O
the	DT	O	O
departments	NNS	O	O
of	IN	O	O
medicine	NN	O	O
in	IN	O	O
eight	CD	O	O
French	JJ	p	O
anticancer	NN	O	O
centres	NNS	O	O
.	.	O	O

They	PRP	O	O
analyse	VBP	O	O
the	DT	O	O
initial	JJ	O	O
phases	NNS	O	O
,	,	O	O
which	WDT	O	O
correspond	NN	O	O
to	TO	O	O
the	DT	O	O
three	CD	O	O
first	JJ	O	O
years	NNS	O	O
of	IN	O	O
work	NN	O	O
.	.	O	O

They	PRP	O	O
give	VBP	O	O
the	DT	O	O
state	NN	O	O
of	IN	O	O
the	DT	O	O
results	NNS	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
obtained	VBN	O	O
in	IN	O	O
603	CD	p	O
patients	NNS	p	O
using	VBG	O	O
three	CD	O	O
protocols	NNS	O	O
for	IN	O	O
treatment	NN	O	O
.	.	O	O

These	DT	O	O
consisted	VBN	O	O
of	IN	O	O
the	DT	O	O
administration	NN	O	O
in	IN	O	O
interrupted	JJ	O	O
doses	NNS	O	O
of	IN	O	O
chemotherapy	NN	i	IPM
which	WDT	O	O
consisted	VBD	O	O
of	IN	O	O
vincristine	NN	i	IPM
associated	VBN	O	O
for	IN	O	O
the	DT	O	O
one	CD	O	O
part	NN	O	O
with	IN	O	O
cyclophosphamide	NN	i	IPM
and	CC	O	O
5-fluoro-uracil	JJ	i	IPM
and	CC	O	O
on	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
with	IN	O	O
doxorubicine	NN	i	IPM
or/and	NN	O	O
with	IN	O	O
methotrexate	NN	i	IPM
.	.	O	O

From	IN	O	O
this	DT	O	O
study	NN	O	O
there	RB	O	O
emerged	VBD	O	O
the	DT	O	O
value	NN	O	O
of	IN	O	O
combined	JJ	O	O
therapy	NN	O	O
using	VBG	O	O
doxorubicine	NN	i	IPM
as	IN	O	O
much	JJ	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
frequency	NN	O	O
with	IN	O	O
which	WDT	O	O
results	NNS	o	OPH
better	JJR	O	O
than	IN	O	O
50	CD	O	O
%	NN	O	O
were	VBD	O	O
obtained	VBN	O	O
(	(	O	O
in	IN	O	O
a	DT	O	O
randomised	JJ	O	O
trial	NN	O	O
)	)	O	O
as	IN	O	O
by	IN	O	O
their	PRP$	O	O
quality	NN	o	OOt
,	,	O	O
which	WDT	O	O
was	VBD	O	O
made	VBN	O	O
clear	JJ	O	O
in	IN	O	O
an	DT	O	O
important	JJ	O	O
series	NN	O	O
of	IN	O	O
240	CD	O	O
cases	NNS	O	O
.	.	O	O

They	PRP	O	O
point	VBP	O	O
out	RP	O	O
the	DT	O	O
conditions	NNS	O	O
required	VBN	O	O
to	TO	O	O
initiate	VB	O	O
the	DT	O	O
place	NN	O	O
of	IN	O	O
such	PDT	O	O
a	DT	O	O
scheme	NN	O	O
in	IN	O	O
all	DT	O	O
complex	JJ	O	O
therapy	NN	O	O
which	WDT	O	O
aims	VBZ	O	O
as	RB	O	O
much	JJ	O	O
at	IN	O	O
palliation	NN	O	O
as	IN	O	O
at	IN	O	O
cure	NN	O	O
,	,	O	O
and	CC	O	O
point	VB	O	O
out	RP	O	O
how	WRB	O	O
important	JJ	O	O
it	PRP	O	O
is	VBZ	O	O
to	TO	O	O
be	VB	O	O
methodical	JJ	O	O
in	IN	O	O
the	DT	O	O
application	NN	O	O
of	IN	O	O
chemotherapy	NN	i	IPM
in	IN	O	O
order	NN	O	O
to	TO	O	O
ensure	VB	O	O
its	PRP$	O	O
development	NN	O	O
as	IN	O	O
an	DT	O	O
anticancer	NN	O	O
therapy	NN	O	O
.	.	O	O

Serum	NNP	O	O
biochemical	JJ	O	O
characteristics	NNS	O	O
of	IN	O	O
Beluga	NNP	p	O
,	,	p	O
Huso	NNP	p	O
huso	NN	p	O
(	(	p	O
L.	NNP	p	O
)	)	p	O
,	,	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
blood	NN	O	O
sampling	NN	O	O
after	IN	O	O
clove	NN	O	O
powder	NN	O	O
solution	NN	O	O
exposure	NN	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
anesthesia	NN	O	O
on	IN	O	O
serum	NN	O	O
parameters	NNS	O	O
,	,	O	O
Beluga	NNP	p	O
,	,	p	O
Huso	NNP	p	O
huso	NN	p	O
(	(	p	O
L.	NNP	p	O
)	)	p	O
were	VBD	O	O
blood-sampled	JJ	O	O
immediately	RB	O	O
without	IN	O	O
anesthesia	NN	i	IPH
(	(	O	O
control	NN	O	O
)	)	O	O
or	CC	O	O
subjected	VBN	O	O
to	TO	O	O
following	VBG	O	O
anesthesia	JJ	i	IPH
procedure	NN	O	O
:	:	O	O
40	CD	O	O
,	,	O	O
120	CD	O	O
,	,	O	O
and	CC	O	O
240	CD	O	O
s	NN	O	O
exposure	NN	O	O
to	TO	O	O
3,000	CD	O	O
,	,	O	O
700	CD	O	O
,	,	O	O
and	CC	O	O
500	CD	O	O
mg	NN	O	O
l??	NN	O	O
clove	NN	i	O
solution	NN	i	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Blood	NN	O	O
samples	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
after	IN	O	O
these	DT	O	O
periods	NNS	O	O
,	,	O	O
when	WRB	O	O
fish	NN	p	O
were	VBD	O	O
immobile	JJ	O	O
and	CC	O	O
reached	VBD	O	O
stage	NN	O	O
4	CD	O	O
anesthesia	NN	O	O
.	.	O	O

Results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
cortisol	NN	o	O
and	CC	o	O
glucose	JJ	o	O
levels	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
high	JJ	O	O
in	IN	O	O
700	CD	O	O
and	CC	O	O
500	CD	O	O
but	CC	O	O
not	RB	O	O
3,000	CD	O	O
mg	NNS	O	O
l??	JJ	O	O
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
control	VB	O	O
.	.	O	O

Serum	NNP	o	O
lactate	NN	o	O
levels	NNS	o	O
were	VBD	O	O
significantly	RB	O	O
high	JJ	O	O
in	IN	O	O
500	CD	O	O
mg	NNS	O	O
l??	JJ	O	O
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
control	VB	O	O
group	NN	O	O
.	.	O	O

Lactate	NNP	o	O
levels	NNS	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
differed	VBN	O	O
between	IN	O	O
control	NN	O	O
,	,	O	O
3,000	CD	O	O
,	,	O	O
and	CC	O	O
700	CD	O	O
mg	NN	O	O
l??	NN	O	O
groups	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
serum	NN	o	O
levels	NNS	o	O
of	IN	o	O
cholesterol	NN	o	O
,	,	o	O
total	JJ	o	O
protein	NN	o	O
,	,	o	O
lactate	JJ	o	O
dehydrogenase	NN	o	O
,	,	o	O
aspartate	JJ	o	O
aminotransferase	NN	o	O
,	,	o	O
alanine	JJ	o	O
aminotransferase	NN	o	O
,	,	o	O
Na?	NNP	o	O
,	,	o	O
Cl?	NNP	o	O
,	,	o	O
K?	NNP	o	O
,	,	o	O
and	CC	o	O
Ca??	NNP	o	O
.	.	O	O

Results	NNP	O	O
suggest	VBP	O	O
that	IN	O	O
rapid	JJ	O	O
anesthesia	NN	O	O
with	IN	O	O
higher	JJR	O	O
dose	NN	O	O
is	VBZ	O	O
better	JJR	O	O
than	IN	O	O
slow	JJ	O	O
anesthesia	NN	O	O
with	IN	O	O
lower	JJR	O	O
dose	NN	O	O
for	IN	O	O
blood	NN	O	O
sampling	NN	O	O
in	IN	O	O
Beluga	NNP	p	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
low-dose	JJ	O	O
aspirin	NN	i	IPM
on	IN	O	O
clinic	NN	o	OPH
and	CC	o	OPH
ambulatory	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
in	IN	O	O
treated	JJ	p	O
hypertensive	JJ	p	PC
patients	NNS	p	O
.	.	O	O

Collaborative	NNP	O	O
Group	NNP	O	O
of	IN	O	O
the	DT	O	O
Primary	NNP	O	O
Prevention	NNP	O	O
Project	NNP	O	O
(	(	O	O
PPP	NNP	O	O
)	)	O	O
--	:	O	O
Hypertension	NNP	O	O
study	NN	O	O
.	.	O	O

Nonsteroidal	NNP	O	O
antiinflammatory	JJ	O	O
drugs	NNS	O	O
may	MD	O	O
affect	VB	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
BP	NNP	o	OPH
)	)	o	OPH
control	NN	o	OPH
in	IN	O	O
hypertensive	JJ	p	O
patients	NNS	p	O
receiving	VBG	p	O
drug	NN	p	O
treatment	NN	p	O
,	,	O	O
but	CC	O	O
data	NNS	O	O
on	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
low-dose	JJ	O	O
aspirin	NNS	i	IPM
are	VBP	O	O
scanty	RB	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
assessed	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
chronic	JJ	O	O
treatment	NN	O	O
with	IN	O	O
low	JJ	O	O
doses	NNS	O	O
of	IN	O	O
aspirin	NN	i	IPM
(	(	O	O
100	CD	O	O
mg/day	NN	O	O
)	)	O	O
on	IN	O	O
clinic	NN	o	OPH
and	CC	o	OPH
ambulatory	JJ	o	OPH
systolic	NN	o	OPH
(	(	o	OPH
SBP	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
diastolic	JJ	o	OPH
(	(	o	OPH
DBP	NNP	o	OPH
)	)	o	OPH
BP	NNP	o	OPH
in	IN	O	O
hypertensives	NNS	O	O
on	IN	O	O
chronic	NN	O	O
,	,	O	O
stable	JJ	O	O
antihypertensive	JJ	O	O
therapy	NN	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
the	DT	O	O
framework	NN	O	O
of	IN	O	O
the	DT	O	O
Primary	NNP	O	O
Prevention	NNP	O	O
Project	NNP	O	O
(	(	O	O
PPP	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
factorial	JJ	O	O
trial	NN	O	O
on	IN	O	O
the	DT	O	O
preventive	JJ	O	O
effect	NN	O	O
of	IN	O	O
aspirin	NN	i	IPM
or	CC	O	O
vitamin	NN	i	IPM
E	NN	i	IPM
in	IN	O	O
people	NNS	p	O
with	IN	p	O
one	CD	p	O
or	CC	p	O
more	JJR	p	O
cardiovascular	JJ	p	PC
risk	NN	p	PC
factors	NNS	p	PC
.	.	O	O

Fifteen	NNP	p	O
Italian	JJ	p	O
hypertension	NN	p	O
units	NNS	p	O
studied	VBD	p	O
142	CD	p	PSS
hypertensive	JJ	p	O
patients	NNS	p	O
(	(	p	O
76	CD	p	PSS
men	NNS	p	PSE
,	,	p	O
66	CD	p	PSS
women	NNS	p	PSE
;	:	p	O
mean	JJ	p	O
age	NN	p	O
59	CD	p	PA
+/-	JJ	p	PA
5.9	CD	p	PA
years	NNS	p	PA
)	)	p	O
treated	VBD	p	O
with	IN	p	O
different	JJ	p	O
antihypertensive	JJ	p	O
drugs	NNS	p	O
:	:	O	O
71	CD	O	O
patients	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
aspirin	VB	i	IPM
and	CC	O	O
71	CD	O	O
served	VBD	O	O
as	IN	O	O
controls	NNS	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
underwent	VBD	O	O
a	DT	O	O
clinic	JJ	o	OPH
BP	NNP	o	OPH
evaluation	NN	O	O
with	IN	O	O
an	DT	O	O
automatic	JJ	O	O
sphygmomanometer	NN	O	O
and	CC	O	O
a	DT	O	O
24-h	JJ	o	OPH
ambulatory	NN	o	OPH
BP	NNP	o	OPH
monitoring	NN	o	OPH
,	,	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
3	CD	O	O
months	NNS	O	O
of	IN	O	O
aspirin	JJ	i	IPM
treatment	NN	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
the	DT	O	O
changes	NNS	O	O
in	IN	O	O
clinic	JJ	o	OPH
SBP	NNP	o	OPH
and	CC	o	OPH
DBP	NNP	o	OPH
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
different	JJ	O	O
in	IN	O	O
treated	JJ	O	O
and	CC	O	O
untreated	JJ	O	O
subjects	NNS	O	O
.	.	O	O

Ambulatory	NNP	o	OPH
SBP	NNP	o	OPH
and	CC	o	OPH
DBP	NNP	o	OPH
after	IN	O	O
3	CD	O	O
months	NNS	O	O
of	IN	O	O
aspirin	JJ	i	IPM
treatment	NN	O	O
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
baseline	VB	O	O
:	:	O	O
deltaSBP	NN	O	O
-0.5	NN	O	O
mmHg	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NNS	O	O
[	VBP	O	O
CI	NNP	O	O
]	NN	O	O
from	IN	O	O
-1.9	NN	O	O
to	TO	O	O
+2.9	VB	O	O
mm	JJ	O	O
Hg	NNP	O	O
)	)	O	O
and	CC	O	O
deltaDBP	JJ	O	O
-1.1	NNP	O	O
mm	NN	O	O
Hg	NNP	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
from	IN	O	O
-2.5	NNP	O	O
to	TO	O	O
+0.3	VB	O	O
mm	JJ	O	O
Hg	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
pattern	NN	O	O
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

No	DT	O	O
interaction	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
aspirin	NN	i	IPM
and	CC	O	O
the	DT	O	O
most	RBS	O	O
used	JJ	O	O
antihypertensive	JJ	O	O
drug	NN	O	O
classes	NNS	O	O
(	(	O	O
angiotensin	IN	O	O
converting	VBG	O	O
enzyme	JJ	O	O
inhibitors	NNS	O	O
and	CC	O	O
calcium	NN	O	O
antagonists	NNS	O	O
)	)	O	O
.	.	O	O

Despite	IN	O	O
the	DT	O	O
relatively	RB	O	O
small	JJ	O	O
sample	NN	O	O
size	NN	O	O
our	PRP$	O	O
results	NNS	O	O
seem	VBP	O	O
to	TO	O	O
exclude	VB	O	O
any	DT	O	O
significant	JJ	O	O
influence	NN	O	O
of	IN	O	O
low-dose	JJ	O	O
aspirin	NN	i	IPM
on	IN	O	O
BP	NNP	o	OPH
control	NN	O	O
in	IN	O	O
hypertensives	NNS	O	O
under	IN	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
cognitive-behavioral	JJ	i	IPS
therapy	NN	i	IPS
versus	NN	O	O
treatment	NN	i	IC
as	IN	i	IC
usual	JJ	i	IC
for	IN	O	O
anxiety	NN	p	PC
in	IN	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
:	:	O	O
a	DT	O	O
randomized	NN	O	O
,	,	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
examine	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
a	DT	O	O
modular	JJ	O	O
cognitive-behavioral	JJ	i	IPS
therapy	NN	i	IPS
(	(	i	IPS
CBT	NNP	i	IPS
)	)	i	IPS
protocol	VBP	O	O
relative	JJ	O	O
to	TO	O	O
treatment	NN	i	IC
as	IN	i	IC
usual	JJ	i	IC
(	(	i	O
TAU	NNP	i	O
)	)	i	O
among	IN	O	O
children	NNS	p	O
with	IN	p	O
high-functioning	JJ	p	PC
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
(	(	p	PC
ASD	NNP	p	PC
)	)	p	PC
and	CC	p	O
clinically	RB	p	PC
significant	JJ	p	PC
anxiety	NN	p	PC
.	.	O	O

METHOD	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
45	CD	p	PSS
children	NNS	p	O
(	(	p	O
7-11	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
)	)	p	O
with	IN	p	O
high-functioning	JJ	p	PC
ASD	NNP	p	PC
and	CC	p	O
clinically	RB	p	PC
significant	JJ	p	PC
anxiety	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
16	CD	O	O
sessions	NNS	O	O
of	IN	O	O
weekly	JJ	O	O
CBT	NNP	i	IE
or	CC	O	O
TAU	NNP	i	IC
for	IN	O	O
an	DT	O	O
equivalent	JJ	O	O
duration	NN	O	O
.	.	O	O

After	IN	O	O
screening	VBG	O	O
,	,	O	O
assessments	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
post-treatment	JJ	O	O
,	,	O	O
and	CC	O	O
3-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

Raters	NNPS	O	O
were	VBD	O	O
blind	RB	O	O
to	TO	O	O
treatment	NN	O	O
condition	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Youth	NNP	O	O
receiving	VBG	O	O
CBT	NNP	i	IC
showed	VBD	O	O
substantial	JJ	O	O
improvement	NN	O	O
relative	NN	O	O
to	TO	O	O
TAU	VB	i	IC
on	IN	O	O
primary	JJ	o	OME
anxiety	NN	o	OME
outcomes	NNS	o	OME
.	.	O	O

Of	IN	O	O
24	CD	O	O
children	NNS	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
CBT	NNP	i	IE
arm	NN	O	O
,	,	O	O
18	CD	O	O
(	(	O	O
75	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
treatment	NN	O	O
responders	NNS	O	O
,	,	O	O
versus	IN	O	O
only	RB	O	O
3	CD	O	O
of	IN	O	O
21	CD	O	O
children	NNS	O	O
(	(	O	O
14	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
TAU	NNP	i	IC
arm	NN	O	O
.	.	O	O

Gains	NNS	O	O
were	VBD	O	O
generally	RB	O	O
maintained	VBN	O	O
at	IN	O	O
3-month	JJ	O	O
follow-up	NN	O	O
for	IN	O	O
CBT	NNP	i	IC
responders	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Relative	NNP	O	O
to	TO	O	O
usual	JJ	O	O
care	NN	O	O
,	,	O	O
CBT	NNP	i	IE
adapted	VBD	O	O
for	IN	O	O
anxious	JJ	O	O
youth	NN	O	O
with	IN	O	O
high-functioning	JJ	O	O
ASD	NNP	O	O
demonstrates	VBZ	O	O
large	JJ	O	O
effects	NNS	O	O
in	IN	O	O
reducing	VBG	O	O
anxiety	NN	o	OME
symptoms	NNS	o	OME
.	.	O	O

This	DT	O	O
study	NN	O	O
contributes	VBZ	O	O
to	TO	O	O
the	DT	O	O
growing	VBG	O	O
literature	NN	O	O
supporting	VBG	O	O
adapted	VBN	O	O
CBT	NNP	i	IE
approaches	NNS	O	O
for	IN	O	O
treating	VBG	O	O
anxiety	NN	O	O
in	IN	O	O
youth	NN	O	O
with	IN	O	O
ASD	NNP	O	O
.	.	O	O

Oral	JJ	O	O
ciprofloxacin	NN	i	IPM
vs.	FW	O	O
intramuscular	JJ	O	O
ceftriaxone	NN	i	IPM
as	IN	O	O
empiric	JJ	O	O
treatment	NN	O	O
of	IN	O	O
acute	JJ	p	O
invasive	JJ	p	O
diarrhea	NN	p	O
in	IN	p	O
children	NNS	p	O
.	.	O	O

BACKGROUND	NNP	O	O
Acute	NNP	O	O
invasive	JJ	O	O
diarrhea	NN	O	O
is	VBZ	O	O
a	DT	O	O
potentially	RB	O	O
serious	JJ	O	O
condition	NN	O	O
in	IN	O	O
children	NNS	p	O
.	.	O	O

Because	IN	O	O
of	IN	O	O
the	DT	O	O
increasing	VBG	O	O
resistance	NN	O	O
of	IN	O	O
enteric	JJ	O	O
pathogens	NNS	O	O
to	TO	O	O
commonly	RB	O	O
used	JJ	O	O
oral	JJ	O	O
antibiotics	NNS	O	O
,	,	O	O
intramuscular	JJ	O	O
ceftriaxone	NN	i	IPM
has	VBZ	O	O
become	VBN	O	O
the	DT	O	O
routine	JJ	O	O
drug	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
acute	JJ	O	O
invasive	JJ	O	O
diarrhea	NN	O	O
requiring	VBG	O	O
an	DT	O	O
emergency	NN	O	O
visit	NN	O	O
in	IN	O	O
southern	JJ	O	O
Israel	NNP	O	O
.	.	O	O

The	DT	O	O
inconvenience	NN	O	O
of	IN	O	O
this	DT	O	O
parenteral	JJ	O	O
regimen	NNS	O	O
created	VBD	O	O
an	DT	O	O
increased	VBN	O	O
need	NN	O	O
for	IN	O	O
oral	JJ	O	O
pediatric	JJ	O	O
formulations	NNS	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
invasive	JJ	O	O
diarrhea	NN	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
a	DT	O	O
suspension	NN	O	O
formulation	NN	O	O
of	IN	O	O
ciprofloxacin	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
acute	JJ	p	PC
invasive	JJ	p	PC
diarrhea	NN	p	PC
in	IN	p	O
infants	NNS	p	O
and	CC	p	O
children	NNS	p	O
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
From	NNP	O	O
July	NNP	O	O
1996	CD	O	O
through	IN	O	O
December	NNP	O	O
1997	CD	O	O
,	,	O	O
201	CD	p	O
evaluable	JJ	p	O
children	NNS	p	O
ages	VBZ	p	PA
6	CD	p	PA
months	NNS	p	PA
to	TO	p	PA
10	CD	p	PA
years	NNS	p	PA
(	(	p	PA
35	CD	p	PA
%	NN	p	PA
<	CC	p	PA
1	CD	p	PA
year	NN	p	PA
;	:	p	PA
70	CD	p	PA
%	NN	p	PA
<	JJ	p	PA
3	CD	p	PA
years	NNS	p	PA
)	)	p	PA
presenting	VBG	p	O
with	IN	p	O
acute	JJ	p	O
invasive	JJ	p	O
diarrhea	NN	p	O
at	IN	p	O
the	DT	p	O
Pediatric	NNP	p	O
Emergency	NNP	p	O
Room	NNP	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
ciprofloxacin	NN	i	IPM
suspension	NN	O	O
(	(	O	O
10	CD	O	O
mg/kg	NN	O	O
twice	RB	O	O
a	DT	O	O
day	NN	O	O
+	NNP	O	O
im	NN	O	O
placebo	NN	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
95	CD	O	O
)	)	O	O
or	CC	O	O
im	VB	O	O
ceftriaxone	NN	i	IPM
(	(	O	O
50	CD	O	O
mg/kg/day	NN	O	O
+	NNP	O	O
placebo	NN	O	O
suspension	NN	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
106	CD	O	O
)	)	O	O
for	IN	O	O
3	CD	O	O
days	NNS	O	O
in	IN	O	O
a	DT	O	O
double	JJ	O	O
blind	NN	O	O
manner	NN	O	O
.	.	O	O

Stool	NNP	o	OPH
cultures	NNS	o	OPH
for	IN	o	OPH
Shigella	NNP	o	OPH
,	,	o	O
Salmonella	NNP	o	OPH
,	,	o	O
Campylobacter	NNP	o	OPH
spp	NN	o	OPH
.	.	o	O

and	CC	o	O
diarrheagenic	JJ	o	OPH
Escherichia	NNP	o	OPH
coli	NNS	o	OPH
were	VBD	O	O
obtained	VBN	O	O
on	IN	O	O
Days	NNP	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
4	CD	O	O
to	TO	O	O
5	CD	O	O
and	CC	O	O
21	CD	O	O
+/-	JJ	O	O
5	CD	O	O
.	.	O	O

Clinical	JJ	o	OOt
response	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
were	VBD	O	O
assessed	VBN	O	O
on	IN	O	O
Days	NNP	O	O
1	CD	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
4	CD	O	O
to	TO	O	O
5	CD	O	O
and	CC	O	O
21	CD	O	O
+/-	JJ	O	O
5	CD	O	O
.	.	O	O

RESULTS	NNP	O	O
We	PRP	O	O
isolated	VBD	O	O
127	CD	O	O
pathogens	NNS	O	O
from	IN	O	O
121	CD	O	O
(	(	O	O
60	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
:	:	O	O
73	CD	O	O
(	(	O	O
57	CD	O	O
%	NN	O	O
)	)	O	O
Shigella	NNP	O	O
;	:	O	O
23	CD	O	O
(	(	O	O
18	CD	O	O
%	NN	O	O
)	)	O	O
Salmonella	NNP	O	O
;	:	O	O
18	CD	O	O
(	(	O	O
14	CD	O	O
%	NN	O	O
)	)	O	O
E.	NNP	O	O
coli	NNS	O	O
;	:	O	O
and	CC	O	O
13	CD	O	O
(	(	O	O
10	CD	O	O
%	NN	O	O
)	)	O	O
Campylobacter	NNP	O	O
.	.	O	O

Overall	NNP	O	O
bacteriologic	JJ	O	O
eradication	NN	O	O
on	IN	O	O
Day	NNP	O	O
4	CD	O	O
to	TO	O	O
5	CD	O	O
was	VBD	O	O
99	CD	O	O
%	NN	O	O
for	IN	O	O
Shigella	NNP	O	O
,	,	O	O
77	CD	O	O
%	NN	O	O
for	IN	O	O
Salmonella	NNP	O	O
and	CC	O	O
77	CD	O	O
%	NN	O	O
for	IN	O	O
Campylobacter	NNP	O	O
,	,	O	O
with	IN	O	O
no	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

Clinical	JJ	o	OOt
cure	NN	o	OOt
or	CC	o	OOt
improvement	NN	o	OOt
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
100	CD	O	O
and	CC	O	O
99	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
ciprofloxacin	NN	i	IPM
and	CC	O	O
ceftriaxone	NN	i	IPM
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Serum	NNP	O	O
ciprofloxacin	NN	i	IPM
values	NNS	O	O
determined	VBN	O	O
on	IN	O	O
Day	NNP	O	O
3	CD	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
were	VBD	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
patients	NNS	O	O
than	IN	O	O
were	VBD	O	O
the	DT	O	O
MIC50	NNP	O	O
and	CC	O	O
MIC90	NNP	O	O
values	NNS	O	O
for	IN	O	O
the	DT	O	O
Shigella	NNP	O	O
and	CC	O	O
Salmonella	NNP	O	O
spp	NN	O	O
.	.	O	O

isolated	VBN	O	O
.	.	O	O

Possible	JJ	O	O
drug-related	JJ	O	O
adverse	JJ	o	OA
events	NNS	o	OA
occurred	VBD	O	O
in	IN	O	O
13	CD	O	O
patients	NNS	O	O
[	JJ	O	O
ciprofloxacin	NN	i	IPM
,	,	O	O
8	CD	O	O
(	(	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
ceftriaxone	NN	i	IPM
,	,	O	O
5	CD	O	O
(	(	O	O
4.7	CD	O	O
%	NN	O	O
)	)	O	O
]	NN	O	O
and	CC	O	O
were	VBD	O	O
mild	NNS	O	O
and	CC	O	O
transient	NN	O	O
.	.	O	O

Joint	JJ	o	OPH
examination	NN	o	OPH
was	VBD	O	O
normal	JJ	O	O
during	IN	O	O
and	CC	O	O
after	IN	O	O
completion	NN	O	O
of	IN	O	O
therapy	NN	O	O
in	IN	O	O
all	DT	O	O
patients	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Oral	NNP	O	O
ciprofloxacin	NN	i	IPM
was	VBD	O	O
as	IN	O	O
safe	JJ	o	OOt
and	CC	O	O
effective	JJ	o	OOt
as	IN	O	O
intramuscular	JJ	O	O
ceftriaxone	NN	i	IPM
for	IN	O	O
the	DT	O	O
empiric	JJ	O	O
treatment	NN	O	O
of	IN	O	O
acute	JJ	O	O
invasive	JJ	O	O
diarrhea	NN	O	O
in	IN	O	O
ambulatory	JJ	p	PC
pediatric	JJ	p	PC
patients	NNS	p	PC
requiring	VBG	p	PC
an	DT	p	PC
emergency	NN	p	PC
room	NN	p	PC
visit	NN	p	PC
.	.	p	O

